<SEC-DOCUMENT>0000721371-22-000133.txt : 20221104
<SEC-HEADER>0000721371-22-000133.hdr.sgml : 20221104
<ACCEPTANCE-DATETIME>20221104091157
ACCESSION NUMBER:		0000721371-22-000133
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221104
DATE AS OF CHANGE:		20221104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		221360418

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:964ac801-dd50-4cbf-978f-cd662ea3a8c6,g:8bda5b56-43aa-4d85-9f5e-cb52b0901382,d:bd18cf751e3b4588bcfe40175c3f40a1--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:cah="http://www.cardinal.com/20220930" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF8yLTEtMS0xLTIwMDU3MQ_707cb9e9-547c-460b-9686-655d718a3435">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF8zLTEtMS0xLTIwMDU3MQ_958eec4f-0854-4d07-a3d4-2ffce74762da">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF80LTEtMS0xLTIwMDU3MQ_2f62f0e9-6943-43be-9014-e8e8e74e8805">2023</ix:nonNumeric><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF81LTEtMS0xLTIwMDU3MQ_83bfba54-ff85-4347-89e2-56b6948fc4f8">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF82LTEtMS0xLTIwMDU3MQ_ab423f01-4e9c-4a9a-839a-e5397140d43d">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97b6bf5e281846449637b671f8c5ea5f_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic9365f443f224be298ffcc176e64bb3d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id865979318b34ac9a0006dc78693a91a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61aa9535a0c549598a0d82a3c9b83b9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebbccb601ed947409b53296af5ef77fe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff6a8fdb0634005af68bc1212ab0bbe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612187032ec943d394d68353bc74417b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a42960e2e7c47b3868bbc551995df2d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698aacd651704977bb16df51d8070a30_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18abcc7f15c143aab18a99234cb10114_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6785c932a3874568bb05dfea04d9946b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19650c5a913416ca6588da34a348f22_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib26655c3a88e4720ab7d8bc05312c1b8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad5885e711d42da835169aa6f388325_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e44ef25f8d4bd2bcd0d9afdb11ce46_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3061556bb3664f40a526ed65a094ef2e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a06e509abb14275bd46ec4afb985d35_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758e3844f8bd47929282bc88703ea8f0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf460939e6f142618d8200a4e95a4733_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc85debed74f4b3faea2295133b498fa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15ca96c683e4ba6865784ead9adbc78_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcede8d084d432d9ea4736241a37ba4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie41d7fe9babb47ad971ea568ec44ee4c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i853ff6add89c4a1ea84c989f618420fb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490000f10c0b4b0682cb24d52cb388ad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc43915a36234990a428483dd2251e18_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie32a5bd181674aac970917c2db9cf482_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50701f17cc6d42238115a15492c656da_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa1095ca2d145a488a40d99cf500cbd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73291183b5c94c569731d6000358a035_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70aa8ba2fa76462a98de9c2a2a3b3eab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8df42a7b9384d7ba6a2b613756fc333_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6f5954a39f4eaab401f0922f87e2b2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7336a5c8dffa4fed905779c7906e0698_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4c7a1de55d4507ad5cbd581472af6f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06c8e71b77e84415aa0fb3cf24c26850_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cad212f102146228e0cd765ec3011f8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4f963e1258409697ad8f442ba79dc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be56105efe44fd58a9ef7c7851443fb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056167140f4147eca75967688b8394b6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a3dd894882408790e569ecd7a0a0f6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a322d3b1b71496d949f588cbc3e8c44_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7138c986208346caab693c394d3fc544_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6fb2d9aad92e4c598b91935a092f4aea_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fbcc66fb7f548ae9276527dd4263120_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bdbb7b08c494b6ea6bebbc41a301248_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5754d58acfdb4215a3917a18dd269e93_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec2ce0031f949829f8cff3fae7f33b8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c74d76f8974daeb64325a492d7cb0c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5001b8fecb8f4da89f5a3a06c330244d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2b097d758b45aa95ea584e855a2631_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e87b70e3bf41fa8effe5bef9f99d54_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b18dbf515f4767a1d1688c18c6b7a1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fae5e1f8744690836ce67e2c6432cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8b6ae0c11d4c79addc75f5d463aad6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b66144fc554632a9c5a93bee338b1d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd0b96897d1470fb2329660c7d50e7d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2297365bf0cb4e03a98dbbb10ac1c343_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b8e59737824266b20b0bb162a7f6fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f6b2710bce442e9c8a8211ae3d15b6_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a25416abfca4ca5a2c8a79563abdbf6_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb927b476ad43678e84b8626a1dccd8_I20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="states"><xbrli:measure>cah:states</xbrli:measure></xbrli:unit><xbrli:unit id="numberofusterritories"><xbrli:measure>cah:numberOfUSTerritories</xbrli:measure></xbrli:unit><xbrli:context id="id0676373b4634242b6227fe4aaa7279e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78dcc5cdb1a34a3688e6c1ce718bb3d4_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad2e4f4027b649c8b68073da27cc75ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a78fb2810d4d5cb0d5270aa7494bd0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d26088d8851461e886dd938e1e01e06_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c064b32b7241f5861b32d00930b148_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:NativeAmericanTribesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2674d9c4424aee92b083b06676b132_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c2e07a1122434fb48591c34c3b03e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if117a27e06074dd49394d4673002a60d_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i32f85e3cb646437cb5f56dcc696128e6_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12caa08ddee14ac2a252cf36f1b23ea5_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i4a355aa72fe54940911ec0fc9eec1d71_I20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de11675da4a46d1a1dd19d98e7d028f_D20221103-20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eadbc725e9d4be693afcd2438eb9445_I20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f3e424f456485faa3f18f61dbada6c_D20221103-20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad30b04476e408b9b94106e5ec72041_D20210731-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89257f0029142808d8e517babd2e9ce_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efb723c71ca43158a719af61d57c9fe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b381f73ed74b7c87202faa366ced15_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63acc3676d524a4cb1fe19ba5584d6a9_D20220701-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5cab62da2c411d9384568354fcbb20_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f63075f2d6941f88610dca064275c22_D20221001-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:GoodwillImpairmentMedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2647f5df574a4790a972ae81d73483a7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838c37506e6a4118b13af6b0e18e635e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a6ab707b7b48c3900375ae0fdf5bd0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4747655b789c466c9d320622352b10eb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i112c682ae8824132a82e463e2829fbde_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i409e7ac6eece4672b979373d4beb255a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a28758bc65a4cb4af33498d26db24ac_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49aba128f32b4dab86cb347514750422_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d65960fd135483bb22e0f9214f5cc93_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5307df37214cb5856b80573d7cd236_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387ff4bbab2845dabaeeca1215e98d4f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5379f66427748ca8c43f633f07433f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ffadf1769b4b338c57b958d74314c6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ccafc16fb54194a171620229fdbe11_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e85c09481f4f09a7ccf2fe64711f33_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65825c4d85ac4f8d93a497d87be20ab0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdecbea244440c2ba6bf56b66b21f7d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c072105cd740018a1c9aeea1081994_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03dbc97b506740c1ab99758d71d8644a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e88d2441654c87afe085d4a0348bb9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9127505057a74be592b08798b91f4df4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09ef0c511ae4237af07d4b591d9c579_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b51adfb3de843dc981ee6f67bb7126c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9bf46791af4b50b139fbccfcf7acb6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i804fad5b06b0439c81e19646ddce2790_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8fa2946d75244f5af4e048c4b6f80f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad50074ece84ece82376c3fa9fb7b8b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1f58cfa53748e180e4ce356b89feb0_D20211004-20211004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5566f30ebc41c9a4c5aa210ea0d0a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0da40648754f7e8ebf900b3a6b20a7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bca371c3eb7478a9a9c71b3235bd9da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892094d14d894e958f90124c7fa6d265_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7de5f4005fe40ad951ccbaf90fed316_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b8399010484b6095659918a1811fbe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d06169bd4ac4fe1b8c2bc2c47eb44f6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i518c9f6c90a440a9b3e29e04e98d1fe2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ce1edc4ddb41989ad743f2322d6d0e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49d63915083840a09569f5e9570a4c80_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i855d5c9c3f5e4418855a7294a17541ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3044261be5249d9833e8961865fb32f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbb9c3f242b449a93c375031cccfb0a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9ffb10cd2a4f23ae074893f97a8ac8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50162f37f7b7432489740885c70a6401_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e9a4dc61694a2cbe868bd038d8e96a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2f856b81cd0b4febbaa82e7ba3b7de3e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb884cfea93c4a6b9776a6eb15f99801_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98a9f7800324334933b05a45c7c1081_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6964ebf21c6641d8a7d3c962e30215fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd40bf9e64d4e28aba32338f5e1c3f3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab13212bf3f64da69caee3d568418629_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23cd6cc579e4db1ac1517955232ea9e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871bd2199ae14c3d8b2d85b00fa634dd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if915e60e430a448e95ac1d3210262b21_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae83bd29fad7455f842d7e87a827912f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9bf49c924d4d84898b126cd4f6a3ff_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015c85ec14f2406f8e7dffe472b4851c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ff688f93904d2baa8f773161063474_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b65aec35854386926330a8514839c9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195c3e4a70d140e6a8c0d6fbd576c739_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d7926d786e4e449517abc30d8e145f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2160ad80e344e7a85fc8a96deb9476c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81002aafca94fc2b38566fff63f36b6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28f690daefd04e45ba22e43204d3f8ce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a03688720b448f29df8a3a0536629e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ead376383b64ae98d667697c55cf194_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8d1a31b74a43529c08389b432be66a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c33230a00c486e83ac2a0e6d04febe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b600072fc640a2accf8530d5da12dc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ad627a1ffc43319b21b5b9c5ec5da3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ab637b9b2d4e64a547c5de3c7224a8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reportable_segments"><xbrli:measure>cah:Reportable_Segments</xbrli:measure></xbrli:unit><xbrli:context id="ic4a1eacea71a4285aadeba26a17758a0_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7555e89f9a44c0be6b8791b103af9c_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea97411b6d7641378c9eb6b952443d0d_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f28dc925abc41bb8cf3ce6828882c78_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b0209d5fc294341b06b2c8dbf923e09_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1fe6789c734a7cb6a29d3d8764b93b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ada8d3d750f4d05bd88fb3b24af4514_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8eb22db75ac48e3948c5833cc36811c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217061d4807f455b88c7f795a4fa433d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN184NA_2bd5824e-ce5a-4493-bb1a-91ea8ee2bcd7">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6M2Q2MWI3NWNlMjFkNDI1ODk4Njc2NzhmNDY1ZjI4ZjQvdGFibGVyYW5nZTozZDYxYjc1Y2UyMWQ0MjU4OTg2NzY3OGY0NjVmMjhmNF8wLTAtMS0xLTIwMDU3MQ_c14b92e0-58ea-4672-abfa-2e8b115f481c">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xMjE_0f4b3615-524b-4869-b250-14439af82a7e">September&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NDAzOGU0OTg3NmViNGEzMjljYTVkNDI3YTE3NzExYmEvdGFibGVyYW5nZTo0MDM4ZTQ5ODc2ZWI0YTMyOWNhNWQ0MjdhMTc3MTFiYV8wLTAtMS0xLTIwMDU3MQ_592ba409-54a0-4856-90d0-687502c296fb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA4_ab80a66d-59fc-4b7a-8a87-a51828473600">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTAx_a980a02d-7eb4-4315-bd66-8d6b47d53ef8">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:566.25pt"><tr><td style="width:1.0pt"></td><td style="width:145.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:31.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8wLTAtMS0xLTIwMDU3MQ_dbe1053f-0163-4994-8958-d2dd87e43014">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8wLTYtMS0xLTIwMDU3MQ_e13cfe86-2969-4b0b-a54a-2a29f54c3547">31-0958666</ix:nonNumeric></span></td></tr><tr style="height:23pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTAtMS0xLTIwMDU3MQ_0fca447a-5ae7-4228-83f6-1a0c763f0e3f">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTItMS0xLTIwMDU3MQ_fd6abb01-c2a3-4725-82f7-15784843696d">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTQtMS0xLTIwMDU3MQ_3f687937-d30f-490b-a253-ae6b5bd8b2fc">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTYtMS0xLTIwMDU3MQ_10cd1eda-2383-4cf0-9690-516ea9db4af5">43017</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTAy_f6cd2820-c33e-4bd3-a184-c81587a47138">614</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTAz_5405e9ef-1d8c-428a-800f-2860f9326c9e">757-5000</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:138.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6Mzk3Yzk5MjJkNzJmNGU1Yjg1ZjIxZDkzNTE4NjU0NmQvdGFibGVyYW5nZTozOTdjOTkyMmQ3MmY0ZTViODVmMjFkOTM1MTg2NTQ2ZF8yLTAtMS0xLTIwMDU3MQ_46672833-0e0c-43c9-8948-c5d56ead7792">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6Mzk3Yzk5MjJkNzJmNGU1Yjg1ZjIxZDkzNTE4NjU0NmQvdGFibGVyYW5nZTozOTdjOTkyMmQ3MmY0ZTViODVmMjFkOTM1MTg2NTQ2ZF8yLTEtMS0xLTIwMDU3MQ_f3359834-7a02-44d1-a0cd-0a1b99832da8">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6Mzk3Yzk5MjJkNzJmNGU1Yjg1ZjIxZDkzNTE4NjU0NmQvdGFibGVyYW5nZTozOTdjOTkyMmQ3MmY0ZTViODVmMjFkOTM1MTg2NTQ2ZF8yLTItMS0xLTIwMDU3MQ_62894aa7-319d-4c65-a775-ece94b3256bd">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA0_a1cc46b7-d565-42de-adfa-7f28b6fdfeb4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA1_5c2bee06-f18b-4013-9a00-f3c95ac2d58f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NWU4ZGVhMjgwYTc1NDAxODg3MmY2YWJkZWQ0ZGRiNjQvdGFibGVyYW5nZTo1ZThkZWEyODBhNzU0MDE4ODcyZjZhYmRlZDRkZGI2NF8wLTAtMS0xLTIwMDU3MQ_1cd5ba99-a21c-462e-b14a-e8a4247f1067">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NWU4ZGVhMjgwYTc1NDAxODg3MmY2YWJkZWQ0ZGRiNjQvdGFibGVyYW5nZTo1ZThkZWEyODBhNzU0MDE4ODcyZjZhYmRlZDRkZGI2NF8xLTQtMS0xLTIwMDU3MQ_63b96c89-889f-4492-aaa3-d0bcd7dcdad6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NWU4ZGVhMjgwYTc1NDAxODg3MmY2YWJkZWQ0ZGRiNjQvdGFibGVyYW5nZTo1ZThkZWEyODBhNzU0MDE4ODcyZjZhYmRlZDRkZGI2NF8yLTQtMS0xLTIwMDU3MQ_5855cab2-ef18-42cc-b66c-82c687a979d6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA2_42cf8aa6-d5c8-4ed0-b8de-50198ed8c394">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of October&#160;31, 2022, was the following: <ix:nonFraction unitRef="shares" contextRef="i97b6bf5e281846449637b671f8c5ea5f_I20221031" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xODk5_60864d3f-af1d-408c-9b04-612185d9edfb">262,134,053</ix:nonFraction>.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_7"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q1 Fiscal 2023 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_31">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_31">16</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_40">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_40">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_43">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_46">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_49">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_52">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_58">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_58">24</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_121">41</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_124">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_124">42</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_127">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_127">43</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2023 and fiscal 2022 and to FY23 and FY22 are to the fiscal years ending or ended June&#160;30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2022 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our &#8220;2022 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at September&#160;30, 2022 and June&#160;30, 2022, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three months ended September&#160;30, 2022 and 2021. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2022 Form 10-K. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended September&#160;30, 2022 increased 13 percent to $49.6 billion due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which primarily consisted of branded pharmaceutical sales to existing and net new customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(67)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP operating earnings decreased 67 percent to $137 million during the three months ended September&#160;30, 2022 primarily due to a $154&#160;million pre-tax non-cash goodwill impairment charge related to the Medical Segment and a decline in Medical segment profit. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_85">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the goodwill impairment charge. The decline in Medical segment profit was due to net inflationary impacts and an adverse impact from personal protective equipment, which included inventory charges as a result of our simplification strategy.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings decreased 20 percent to $423 million, primarily due to the decline in Medical segment profit discussed above.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.94&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.44</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $154 million related to the Medical segment recorded during the three months ended September&#160;30, 2022. For fiscal 2023, the net tax benefit related to this impairment charge is $12 million and is included in the annual effective tax rate. As a result, the amount of tax benefit for three months ended September&#160;30, 2022 increased approximately by an incremental $22 million and is expected to increase the provision for income taxes during the remainder of the fiscal year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, GAAP diluted EPS decreased 57 percent to $0.40 and non-GAAP diluted EPS decreased 7 percent to $1.20 due to the factors impacting GAAP and non-GAAP operating earnings discussed above, partially offset by favorable changes in discrete tax items and a lower share count as a result of share repurchases. In addition, the goodwill impairment charge related to the Medical segment had a $(0.44) per share after-tax impact on GAAP diluted EPS. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_85">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_100">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_100">7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.5 billion at September&#160;30, 2022 compared to $4.7 billion at June&#160;30, 2022. During the three months ended September&#160;30, 2022, net cash provided by operating activities was $23 million, which includes the impact of our second annual payment of $372&#160;million related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "Settlement Agreement"). See the Significant Developments in Fiscal 2023 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to the Settlement Agreement. In addition, we deployed cash of $1.0 billion for share repurchases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2023 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inflationary Impacts</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively affected by inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities and labor during the three months ended September&#160;30, 2022 and on a year-over-year basis.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these inflationary impacts to continue to adversely impact Medical segment profit in fiscal 2023 and beyond. In order to partially mitigate this impact, we have implemented certain price increases and we intend to implement additional price increases. We are also evolving our commercial contracting processes to provide us with greater pricing flexibility. These increased costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. In the event these costs decrease, the benefit to Medical segment profit will be delayed until the higher-cost inventory has moved through our supply chain. Our plans to continue to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent we anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To a lesser extent, inflationary impacts, primarily related to increased transportation and labor costs, also adversely affected Pharmaceutical segment profit during the three months ended September&#160;30, 2022. We expect these inflationary supply chain costs to continue to adversely impact Pharmaceutical segment profit in fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PPE Demand and Pricing</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. Demand for PPE fluctuated during fiscal 2022 resulting in variability in sales volumes, inventory levels and costs to manufacture and source these products. We expect demand for PPE to continue to fluctuate during the remainder of fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPE adversely impacted Medical segment revenue during the three months ended September&#160;30, 2022 and on a year-over-year basis, primarily due to declines in pricing and volumes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was adversely impacted during the three months ended September&#160;30, 2022 and on a year-over-year basis due to $18&#160;million of inventory charges related to our simplification strategy, which includes the impact from the sale of certain disposable gloves that are primarily utilized in non-healthcare industries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The demand and pricing for PPE is subject to risks and uncertainties, which may continue to impact Medical segment revenue, Medical segment profit and consolidated operating earnings during the remainder of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Medical Goodwill</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the adverse impact on our financial results from and the risks and uncertainties related to inflationary impacts and PPE demand and pricing, as well as increases in the risk-free interest rate, we performed interim goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (the &#8220;Medical Unit&#8221;) during the three months ended September&#160;30, 2022. This testing resulted in a pre-tax charge of $154 million, which is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This charge was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_85">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in key assumptions or a significant change in industry or economic trends during the remainder of fiscal 2023 could result in additional goodwill impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Shareholder Cooperation Agreement</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The evaluation and implementation of any actions recommended by the Business Review Committee and the Board may impact our financial position and results of operations during the remainder of fiscal 2023. In addition, during the three months ended September&#160;30, 2022, we incurred $6 million of expenses related to the negotiation and finalization of the Cooperation Agreement. We expect to incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee during the remainder of fiscal 2023. See "</span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_49">Risk Factors</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section for additional detail related to risks associated with the Cooperation Agreement. <br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20220930_g1.jpg" alt="cah-20220930_g1.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="cah-20220930_g2.jpg" alt="cah-20220930_g2.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:75.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,822&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment revenue increased during the three months ended September&#160;30, 2022 due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $5.9 billion and primarily consisted of branded pharmaceutical sales to existing and net new customers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue decreased during the three months ended September&#160;30, 2022 primarily due to lower sales within products and distribution, largely due to the impact of PPE pricing and volumes. The adverse impact of the prior-year divestiture of the Cordis business was mostly offset by sales growth in at-Home Solutions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased 13 percent to $48.0 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to the factors affecting the changes in revenue and gross margin.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20220930_g3.jpg" alt="cah-20220930_g3.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="cah-20220930_g4.jpg" alt="cah-20220930_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,614</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the three months ended September&#160;30, 2022 decreased primarily due to net inflationary impacts in the Medical segment and the divestiture of the Cordis business, partially offset by the performance of our generics program in the Pharmaceutical segment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 48 basis points during the three months ended September&#160;30, 2022 mainly due to changes in overall product mix, primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate. The performance of Medical segment products and distribution, which reflects increased costs due to net inflationary impacts, also had an adverse impact on gross margin rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General, and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,197</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, SG&amp;A expenses increased largely due to inflationary impacts, primarily related to increased transportation and labor costs, as well as other operating expenses.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we incurred $6 million of expenses related to the finalization of the Cooperation Agreement. See the Significant Developments in Fiscal 2023 and Trends section in this MD&amp;A for additional detail related to the Cooperation Agreement.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_115">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:75.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(67)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit increased during the three months ended September&#160;30, 2022, primarily due to the performance of our generics program and increased contribution from branded pharmaceutical and specialty pharmaceutical products. These factors were partially offset by inflationary impacts, primarily related to increased transportation and labor costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medical segment profit decreased during the three months ended September&#160;30, 2022, largely due to net inflationary impacts, which primarily related to increased transportation and commodities costs, partially offset by price increases. Medical segment profit was also adversely affected by the impact of PPE, which included inventory charges related to the sale of certain disposable gloves in connection with our simplification strategy.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three months ended September&#160;30, 2022 are due to the factors discussed in the Other Components of Consolidated Operating Earnings section that follows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin, and SG&amp;A expenses discussed previously, consolidated operating earnings were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:74.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September&#160;30, 2021, restructuring also included costs related to the divestiture of the Cordis business.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $71 million and $78 million for the three months ended September&#160;30, 2022 and 2021, respectively. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we recognized a $154 million pre-tax non-cash goodwill impairment related to the Medical segment, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_85">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022 and 2021, we recognized $21 million and $26 million, respectively, of estimated losses and legal defense costs associated with the inferior vena cava ("IVC") filter product liability claims. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we recognized income of $17 million for recoveries in class action antitrust lawsuits in which we were a class member.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings before income taxes was impacted by the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, interest expense decreased by 38 percent primarily due to increased interest income from cash and equivalents.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Early Extinguishment of Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September&#160;30, 2021, we recognized a $10 million loss in connection with the debt redemption as described further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_94">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2022 compared to the prior-year period was primarily due to tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items. The effective tax rate for the three months ended September 30, 2022 also includes the tax effect of the goodwill impairment charge described below. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we recognized a $154&#160;million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12 million for fiscal 2023. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September&#160;30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September&#160;30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September&#160;30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September&#160;30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations and cash requirements; tax payments; current and projected debt service requirements, dividends and share repurchases; and known opioid litigation settlement payments. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.5 billion at September&#160;30, 2022 compared to $4.7 billion at June&#160;30, 2022. During the three months ended September&#160;30, 2022, net cash provided by operating activities was $23 million, which includes the impact of our second annual payment of $372&#160;million related to the Settlement Agreement. For additional information, see Opioid Litigation Settlement Agreement section below. In addition, we deployed cash of $1.0 billion for share repurchases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at September&#160;30, 2022 included $561 million of cash held by subsidiaries outside of the United States. </span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at September&#160;30, 2022 include a $2.0 billion commercial paper program, backed by a&#160;$2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;September&#160;30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$5.3 billion at both September&#160;30, 2022 and June&#160;30, 2022. </span></div></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Litigation Settlement Agreement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $6.03 billion accrued at September&#160;30, 2022 related to certain opioid litigation, as further described within </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the payment amounts to be spread over 18 years. The effective date of the Settlement Agreement was April 2, 2022. During the three months ended September&#160;30, 2022, we made our second annual payment of $372&#160;million under the Settlement Agreement. We expect to make subsequent annual payments under the Settlement Agreement every July for the term of the Settlement Agreement. The amounts of these future payments may differ from the payments that we have already made. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the three months ended September&#160;30, 2022 and 2021 were $70 million and $67 million, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 10, 2022 and August 10, 2022, our Board of Directors approved a quarterly dividend of $0.4957 per share, or $1.98 per share on an annualized basis, which were paid on July 15, 2022 and October 17, 2022 to shareholders of record on July 1, 2022 and October 3, 2022, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we repurchased $1.0 billion of our common shares under an accelerated share repurchase ("ASR") program. We funded the ASR program with available cash. The ASR program is expected to conclude in the second quarter of fiscal 2023, which is expected to reduce the amount remaining under our existing share repurchase authorization to approximately $1.7 billion. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_109">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2022 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2022. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_28"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2022 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K and our other filings with the SEC since June 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Unit Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September&#160;30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September&#160;30, 2022 after recognizing the impairment charge was $6.7 billion, of which $1.8 billion was goodwill. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_85">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for further discussion.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider these assumptions to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2023 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products, increasing growth in certain strategic divisions within our Medical segment, and driving simplification efforts and cost optimization projects, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; the impact of the Cordis </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">divestiture; estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates (including potential tax reform); or a significant change in industry or economic trends. Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent or decrease the terminal growth rate by a hypothetical 1.75 percent, the fair value for the Medical Unit would have further decreased by approximately $300 million.</span></div></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs or income</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Shareholder cooperation agreement costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the new Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court or reimbursed by manufacturers. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.85pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2022, we incurred a one-time contingent attorneys' fee of $18 million related to the finalization of the settlement agreement (the &#8220;Settlement Agreement&#8221;) resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this fee was included in litigation recoveries or charges, net. Additionally, during fiscal 2022 our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits. This judgment was the result of an ordinary course intellectual property rights claim and, therefore, is not adjusted in calculating the litigation recoveries or charges, net adjustment. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">(Gain)/Loss on sale of equity interest in naviHealth</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> operating earnings excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, and (8) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ne</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth, each net of tax.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth divided by (earnings before income taxes adjusted for the ten items above). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.042%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/ (Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(67)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholder cooperation agreement costs </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.44</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">396</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.94&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $154 million related to the Medical segment.  For fiscal 2023, the net tax benefit related to this impairment charge is $12 million and is included in the annual effective tax rate. As a result, the amount of tax benefit for the three months ended September 30, 2022 increased approximately by an incremental $22 million and is expected to increase the provision for income taxes during the remainder of the fiscal year.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_40"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2022&#160;Form 10-K since the end of fiscal&#160;2022&#160;through&#160;September&#160;30, 2022.</span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September&#160;30, 2022. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September&#160;30, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended&#160;September&#160;30, 2022&#160;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the parties reached an agreement in principle to settle this matter and in October 2022, the court entered an order approving the settlement and dismissing the case. This settlement does not include any admission of liability. Under the settlement, Cardinal's director and officer's liability insurance carriers, on behalf of the defendants, will pay Cardinal $124 million, less approximately $31 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal expects to receive this payment during fiscal year 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the Risk Factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K and our filings with the SEC since June&#160;30, 2022. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business could be affected by activist shareholders.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors, among other things, (1) appointed four new independent directors, including a representative from Elliott , and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cooperation Agreement may create unintended consequences, such as creating uncertainty about our management or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. Additionally, implementing any actions recommended by the Business Review Committee and Board may be costly and time-consuming, may be disruptive to our ongoing business operations and may ultimately be unsuccessful. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that activist shareholders may, among other things, attempt to effect additional changes and exert influence over our Board of Directors and management or initiate a proxy contest, which may disrupt our operations by diverting the attention of management and the Board and be costly and time-consuming. Any such proxy contests, actions or requests, or the mere public presence of activist shareholders, may cause the market price for our shares to experience volatility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in the tax laws or challenges to our tax positions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission&#8217;s investigation into illegal state aid. In August 2022, the U.S. federal government enacted the Inflation Reduction Act, which imposed a 15 percent corporate minimum tax on certain large corporations and a 1 percent tax on share repurchases after December 31, 2022. These </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions may adversely impact our financial position and results of operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the accruals taken in connection with opioid-related lawsuits in fiscal years 2021 and 2020, we recorded net tax benefits of $228 million and $488 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment, and it is possible that they could be subject to challenges by the U.S. Internal Revenue Service ("IRS").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. tax law governing deductibility was changed by the Tax Act and the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2021, our provision for income taxes reflected a $424 million benefit from the tax benefits of a self-insurance pre-tax net operating loss carryback under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. Also, as a result of this net operating loss carryback, we received a U.S. federal income tax refund of $966 million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives&#8217; Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We responded to the letter. It is possible that the IRS could challenge our tax position with respect to this self-insurance loss. If these initiatives are successful, our effective tax rate could be adversely impacted. Additionally, laws governing insurance coverage vary by state and some state courts have interpreted laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. Tax laws are complex and subject to varying interpretations. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Proposed adjustments </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in ongoing audits may adversely affect our effective tax rate or tax payments.</span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_52"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:15.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share (2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(3)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aug 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sept 2022</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,987,022&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.74&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,986,815&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,988,359</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66.74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,986,815</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,943</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 775, 562 and 207 common shares purchased in July, August and September 2022, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On September 14, 2022, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $1.0 billion and received an initial delivery of 12.0 million common shares using a reference price of $66.74. The ASR program is expected to conclude in the second quarter of fiscal 2023. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_109">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 4, 2021, our Board of Directors approved a new $3.0 billion share repurchase program, which will expire on December 31, 2024. As of September 30, 2022, we have $1.9 billion authorized for share repurchases remaining under this program. The ASR program is expected to reduce the amount remaining under our existing share repurchase authorization to approximately $1.7 billion when concluded.</span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_55"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMi0xLTEtMS0yMDA1NzE_e5ed5148-09bd-4c32-b5ea-49aa34f603b0">49,603</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMi0zLTEtMS0yMDA1NzE_d7f3cf6c-68f8-44ba-9567-6f02c4e37d38">43,968</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMy0xLTEtMS0yMDA1NzE_2cb3b534-be03-4b79-93b4-cedc6ce688fa">47,989</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMy0zLTEtMS0yMDA1NzE_3b7a2d96-41c3-4a1d-913c-27cdadf291be">42,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNC0xLTEtMS0yMDA1NzE_5579cef1-0d32-4871-a93d-c4dadfdd0101">1,614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNC0zLTEtMS0yMDA1NzE_a5c29626-6bf1-4032-a7b1-ef27019419df">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNy0xLTEtMS0yMDA1NzE_11a56a55-6909-4a08-97f2-929c6f6a949e">1,197</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNy0zLTEtMS0yMDA1NzE_a4ec1650-d7ac-4e95-af7a-67f8a343091d">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOC0xLTEtMS0yMDA1NzE_61f8e507-4ed2-4295-959c-bd9e6e8996a3">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOC0zLTEtMS0yMDA1NzE_4f44f422-61e5-4e7d-b9e5-a4b2af985028">18</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOS0xLTEtMS0yMDA1NzE_c5994da5-7090-462d-8322-70e048b0d5f1">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOS0zLTEtMS0yMDA1NzE_4435b5d2-2671-44b3-98dd-bf54a5cde3f9">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTAtMS0xLTEtMjAwNTcx_ca548b5b-dc14-421b-af82-e73342587e03">153</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTAtMy0xLTEtMjAwNTcx_f5f64fd5-781e-434c-99ac-2381e13ea848">2</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTEtMS0xLTEtMjAwNTcx_5c6b8e55-67a4-4773-9585-9c2af807ed8b">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTEtMy0xLTEtMjAwNTcx_0337939b-9a4a-4025-93fa-4669adfe937b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTItMS0xLTEtMjAwNTcx_07d40fae-b28b-44d8-87e1-9ac389a9d386">137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTItMy0xLTEtMjAwNTcx_83b03f9f-eb3b-45ea-8a12-140814aa1ac1">415</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTQtMS0xLTEtMjAwNTcx_553a2fc1-0da7-4e26-9872-d85210a35a3e">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTQtMy0xLTEtMjAwNTcx_3278ed90-c59b-404f-b113-cb5ca7589720">4</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTUtMS0xLTEtMjAwNTcx_c6d1d272-4b32-4ffb-aeef-3ad4b945b7a1">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTUtMy0xLTEtMjAwNTcx_993fa472-09bf-40c9-a523-204801bfcc4e">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTYtMS0xLTEtMjAwNTcx_b69fe7c8-3bbb-47c0-a6b5-536a36334247">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTYtMy0xLTEtMjAwNTcx_2ecce1c7-e87e-49b9-99d8-2505a0dd9f4b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTctMS0xLTEtMjAwNTcx_1f75b542-3d10-49ad-a05e-19abe64641ec">110</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTctMy0xLTEtMjAwNTcx_dcc89a07-06b4-4a88-b91f-2f0ee9836312">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTktMS0xLTEtMjAwNTcx_fce2d702-9fc9-4f23-8033-20dc551bdd6d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTktMy0xLTEtMjAwNTcx_8da92d68-802c-4a28-a9c1-abb1d857a77d">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjAtMS0xLTEtMjAwNTcx_c553b429-dd4f-4f1c-8cc8-2e0641d78fb8">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjAtMy0xLTEtMjAwNTcx_cc1bcc6c-de9f-41d7-aaa1-1ef092b568c3">272</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjUtMS0xLTEtMjAwNTcx_571ce7b9-150a-4055-9030-297b7120a3fb">1</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjUtMy0xLTEtMjAwNTcx_e25be45a-c935-4f3c-b7f2-85ece05cd138">1</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings attributable to Cardinal Health, Inc. </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjYtMS0xLTEtMjAwNTcx_f519ad54-badb-408a-abb4-11394f8ce628">110</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjYtMy0xLTEtMjAwNTcx_5363e2ab-e8ac-4087-9d9b-d2f112beae1e">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjktMS0xLTEtMjAwNTcx_0a06cfe8-4570-42db-bace-80825d5a2a18">0.41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjktMy0xLTEtMjAwNTcx_237d3e02-ceec-4d4d-88b7-9b45e8508d68">0.94</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzAtMS0xLTEtMjAwNTcx_a2289947-bdaa-487b-8613-981fe659fc49">0.40</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzAtMy0xLTEtMjAwNTcx_f238dafa-79b2-4286-8063-e21371b1836a">0.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzMtMS0xLTEtMjAwNTcx_4e31e27f-d1da-48a2-846e-ed230b4a4f97">271</ix:nonFraction></span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzMtMy0xLTEtMjAwNTcx_7b4aa20a-758e-4611-a5fe-27bb66243b14">287</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzQtMS0xLTEtMjAwNTcx_41983acf-1981-4453-b77b-883937be6dbd">273</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzQtMy0xLTEtMjAwNTcx_dfe423b3-8f4f-4ee7-96f6-fa8c1b92d028">289</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzYtMS0xLTEtMjAwNTcx_e37d7db6-cb91-48df-809d-c3c067e7af62">0.4957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzYtMy0xLTEtMjAwNTcx_5a47f662-9d72-4bd2-9f05-75ebf16b13ba">0.4908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMi0xLTEtMS0yMDA1NzE_c553b429-dd4f-4f1c-8cc8-2e0641d78fb8">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMi0zLTEtMS0yMDA1NzE_cc1bcc6c-de9f-41d7-aaa1-1ef092b568c3">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNS0xLTEtMS0yMDA1NzE_fe47c038-0d36-4dd8-9dc7-b4bddba31d1a">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNS0zLTEtMS0yMDA1NzE_3832e17b-c4eb-4b8e-87c4-5c431d151aed">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNi0xLTEtMS0yMDA1NzE_4e40a5e9-10af-4af4-a4d6-f0e2b4b61abf">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNi0zLTEtMS0yMDA1NzE_f9dc2dca-b347-4e3f-9d3b-ab26171698e0">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNy0xLTEtMS0yMDA1NzE_543d22c4-8dc2-4632-8616-b161c93ba610">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNy0zLTEtMS0yMDA1NzE_b44df2e1-694d-45ce-9b44-c5a05c9436bf">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfOS0xLTEtMS0yMDA1NzE_7d115b6f-811e-4356-a172-720af493c3c4">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfOS0zLTEtMS0yMDA1NzE_fd2e2cf7-bf43-4d68-bf68-527e0b268ca2">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTEtMS0xLTEtMjAwNTcx_855e6acf-ffaf-4989-9031-fe272441fcf3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTEtMy0xLTEtMjAwNTcx_27a0d7f7-0a64-405d-8429-bbc3df3b1e73">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTMtMS0xLTEtMjAwNTcx_327209c7-dcd6-4407-ac04-8d7dcc186305">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTMtMy0xLTEtMjAwNTcx_8088d26d-8cc1-4189-aec3-275da1374e9f">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMy0xLTEtMS0yMDA1NzE_f702e366-da09-4837-b1bf-8a74d19881b7">3,492</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMy0zLTEtMS0yMDA1NzE_0c383993-3ba9-407c-b354-f9623e0471bf">4,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNC0xLTEtMS0yMDA1NzE_73d26048-3458-4985-a29f-f2d15b4a0e3c">11,039</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNC0zLTEtMS0yMDA1NzE_33d76212-e78e-41cd-b84c-a975c88bf099">10,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNS0xLTEtMS0yMDA1NzE_797373de-87eb-4bd1-977b-8518a9be1155">15,891</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNS0zLTEtMS0yMDA1NzE_bd6d4df4-eb4a-40b1-8f59-e83084eb9443">15,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNi0xLTEtMS0yMDA1NzE_2e7b39c6-e88f-4fd2-a1c5-b943b0101f17">2,274</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNi0zLTEtMS0yMDA1NzE_d01b082c-3c39-406d-902a-31133625b70f">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfOC0xLTEtMS0yMDA1NzE_1e7ee306-2eea-4978-af01-666acd998ea8">32,696</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfOC0zLTEtMS0yMDA1NzE_e32761c5-692d-4042-9836-8df0dca22b68">32,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTAtMS0xLTEtMjAwNTcx_cf357b03-7e29-4b4f-b329-d535ee4877b8">2,339</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTAtMy0xLTEtMjAwNTcx_fb89b407-91e6-4fd2-a155-ebf941400534">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTEtMS0xLTEtMjAwNTcx_e83b65a0-d477-4ff1-a7a5-ae7044d76299">7,367</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTEtMy0xLTEtMjAwNTcx_7171d65d-40a2-4cbb-b03b-be77970417b8">7,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTMtMS0xLTEtMjAwNTcx_fcd6453a-14de-4eb6-a105-3cccf02eb652">985</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTMtMy0xLTEtMjAwNTcx_3ff1e721-4b48-4ab1-ba49-b2361511171f">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTQtMS0xLTEtMjAwNTcx_8c5bbf96-e0ce-4170-8674-8c6ab146e2a2">43,387</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTQtMy0xLTEtMjAwNTcx_df853ee8-697c-4cb9-95d1-91eb97a897a8">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTgtMS0xLTEtMjAwNTcx_71452653-91d0-4169-bcf8-8f57c3c264f4">28,362</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTgtMy0xLTEtMjAwNTcx_a2ad989d-83a2-4f10-a5ad-0ff05592a38b">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTktMS0xLTEtMjAwNTcx_e9a7fed1-b9de-4515-99bf-dfa065a08448">578</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTktMy0xLTEtMjAwNTcx_88585c05-a233-4099-8cfa-80c05b03f7bc">580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjAtMS0xLTEtMjAwNTcx_25bff129-7328-47a8-8266-490215d2991e">2,619</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjAtMy0xLTEtMjAwNTcx_352aaa94-3a57-429a-98c0-be9657394a2a">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjItMS0xLTEtMjAwNTcx_9cff57b7-176f-4346-bab2-0882279243ff">31,559</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjItMy0xLTEtMjAwNTcx_a4c3cb5b-3c11-450d-b89e-d5cf198fb248">30,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjQtMS0xLTEtMjAwNTcx_f08f5cfa-c1a7-4afa-9f8d-9f7c67f9ae0d">4,689</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjQtMy0xLTEtMjAwNTcx_02d13acf-7b6a-44a3-9ee9-a221d35647ad">4,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjUtMS0xLTEtMjAwNTcx_2e149a1f-ab05-4bf3-b35c-a2b8f3ded21a">8,919</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjUtMy0xLTEtMjAwNTcx_adcc40ab-9f50-453f-bdf4-4b422f9caca2">9,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMTU_7752af60-73f8-4b36-b07c-07b3babe857a"><ix:nonFraction unitRef="shares" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMTU_7a197c2d-256d-4312-9521-d1d6f9e7c70e">500</ix:nonFraction></ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMzM_39945974-6cf7-4944-9166-35c48b5256d5"><ix:nonFraction unitRef="shares" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMzM_6f0b1ccc-210f-4f7c-a26f-25e7c8023811">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMS0xLTEtMjAwNTcx_9bdb4a2a-2bd4-41aa-a10f-00642f082bb5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMy0xLTEtMjAwNTcx_146cc186-5469-48bd-bf0d-40a8ee9a237f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMTU_015d676b-f495-4383-9b16-26499382c77d"><ix:nonFraction unitRef="shares" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMTU_eae56cd4-75a2-4f2d-8cfd-4e7ae0a833b2">755</ix:nonFraction></ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMzM_6815b59d-b787-46cf-a39d-f9a102c4a4f0"><ix:nonFraction unitRef="shares" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMzM_d2bb9aa8-39a0-4a36-b7ec-2dd34d6f8dd8">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">and June 30,2022</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMS0xLTEtMjAwNTcx_3d5c4578-2a21-4985-a6ec-d5e4454e7b64">2,576</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMy0xLTEtMjAwNTcx_2a0dc79c-fa21-41f1-aeaf-29c204cb874d">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzItMS0xLTEtMjAwNTcx_0ef0d726-c824-4c8a-8262-48e3678f56ae">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzItMy0xLTEtMjAwNTcx_847f041a-34cf-4681-91cc-f46beb8d3678">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares in treasury, at cost:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> <ix:nonFraction unitRef="shares" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246MzU4NzlkOTAyMGI4NGE0MGJkY2M4ZDhiNDk0MmUzZDVfNDA_a739e05c-f118-4ab9-8e5e-684d8ff4f069">65</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares and <ix:nonFraction unitRef="shares" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246MzU4NzlkOTAyMGI4NGE0MGJkY2M4ZDhiNDk0MmUzZDVfNTQ_56a5a3ed-7652-4136-9fb5-3499cbdd7a6a">54</ix:nonFraction> million shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> and June 30, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMS0xLTEtMjAwNTcx_9152b0b9-f072-4538-b98b-2c66dd407c02">3,880</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMy0xLTEtMjAwNTcx_338d0060-87bd-4b34-8945-d30cbdeda099">3,128</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzQtMS0xLTEtMjAwNTcx_0f83cc64-4050-4183-85f1-f7b099f0f1b4">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzQtMy0xLTEtMjAwNTcx_2fef7b1f-43f1-4982-baad-b9b2ee4707f4">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' deficit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzUtMS0xLTEtMjAwNTcx_bfe899fb-cd1a-409f-9a5b-794aabf9d29c">1,781</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzUtMy0xLTEtMjAwNTcx_70ab98bf-5a7f-41e2-be08-8dd97f39504b">709</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzYtMS0xLTEtMjAwNTcx_fff5ec79-6acb-433e-a1c0-6be0dee6fbc2">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzYtMy0xLTEtMjAwNTcx_080f7bc2-ccb1-4a1e-86c1-169f8c952f44">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzctMS0xLTEtMjAwNTcx_ea958139-5a83-40e5-abcb-705d76e2feeb">1,780</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzctMy0xLTEtMjAwNTcx_2bfa7df6-106c-4325-b6a1-9ce75c580c13">706</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzgtMS0xLTEtMjAwNTcx_7bdff1e5-ee27-48e8-833f-1b6e936dd447">43,387</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzgtMy0xLTEtMjAwNTcx_fb88b644-e42f-4389-a7ef-6589421a0176">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Equity/(Deficit)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:30.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.134%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity/(Deficit)</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings/(Accumulated Deficit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61aa9535a0c549598a0d82a3c9b83b9c_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xLTEtMS0yMDA1NzE_704958a2-ea7b-47f9-bc5f-259a21d719b9">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61aa9535a0c549598a0d82a3c9b83b9c_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0zLTEtMS0yMDA1NzE_9b22876b-34f1-4658-8836-4b5d93e0e1e8">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebbccb601ed947409b53296af5ef77fe_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy01LTEtMS0yMDA1NzE_253b3e2c-1d75-4c83-bdb7-259300a2bfad">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1ff6a8fdb0634005af68bc1212ab0bbe_I20220630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy03LTEtMS0yMDA1NzE_6aec8792-612e-478e-b731-6e0dca520684">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ff6a8fdb0634005af68bc1212ab0bbe_I20220630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy05LTEtMS0yMDA1NzE_ef6bf6ff-a17e-4fdf-ac4e-02faa344e9d5">3,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i612187032ec943d394d68353bc74417b_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xMS0xLTEtMjAwNTcx_b2357266-31de-4f36-aa9a-d068d8032156">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a42960e2e7c47b3868bbc551995df2d_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xMy0xLTEtMjAwNTcx_a8dbd1d6-6ecf-4741-b754-ad5bff2dd302">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xNS0xLTEtMjAwNTcx_78d89be1-678b-407d-90cd-29a091994143">706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNC01LTEtMS0yMDA1NzE_f519ad54-badb-408a-abb4-11394f8ce628">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNC0xMy0xLTEtMjAwNTcx_2d3444a8-b8f1-4988-9d73-0602a12a4eeb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNC0xNS0xLTEtMjAwNTcx_1a864a55-287e-4e70-8f13-19ea1b8f06fc">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i698aacd651704977bb16df51d8070a30_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNS0xMS0xLTEtMjAwNTcx_758ea2ed-9779-4fbd-8b27-44f4aedb7a9e">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNS0xNS0xLTEtMjAwNTcx_e2f35c61-651d-4e8b-acb9-54924e29c667">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interests</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNi0xMy0xLTEtMjI2Mjg4_b493e259-a8a6-43c2-828b-f12e5bb89477">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNi0xNS0xLTEtMjI3MTU0_8880761f-5549-448a-a5f2-a67b506a1c7c">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy0xLTEtMS0yMDA1NzE_d559330b-b3f7-42e1-bbf4-9537727c4da5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy0zLTEtMS0yMDA1NzE_93fb11ea-806c-46ef-bc92-5dbdc8a11e4d">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy03LTEtMS0yMDA1NzE_f15e7e96-1c5f-4c76-88c2-35b4ca7b1437">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy05LTEtMS0yMDA1NzE_709b64e0-1a77-414a-99d4-459b02f0f1ce">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy0xNS0xLTEtMjAwNTcx_24a16655-9d0d-42d6-8aaa-b233ede3e946">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC0zLTEtMS0yMDA1NzE_11df2373-5132-423d-85fb-5fb395ef394a">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC03LTEtMS0yMDA1NzE_e6fe17be-5e4a-49d2-806b-1c466310191a">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC05LTEtMS0yMDA1NzE_7e98c836-1409-439a-9c3f-22cfebdbfec1">800</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC0xNS0xLTEtMjAwNTcx_6e64d7c5-cfa1-474d-86cf-3ffaddf12b00">1,000</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18abcc7f15c143aab18a99234cb10114_D20220701-20220930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOS01LTEtMS0yMDA1NzE_ab67c76f-27b5-4430-b65d-a82bfb17300d">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOS0xNS0xLTEtMjAwNTcx_4ee00804-1aec-47b6-9c67-1b40e1acc330">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTAtMTMtMS0xLTIwMDU3MQ_a94fe0eb-af3d-4bf6-b63b-b8dcd848c1b9">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTAtMTUtMS0xLTIwMDU3MQ_fd9833f5-05d2-481b-b0b3-72aa0820e770">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6785c932a3874568bb05dfea04d9946b_I20220930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMS0xLTEtMjAwNTcx_635f2a01-b35e-40f6-bb81-7c5a8028f684">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6785c932a3874568bb05dfea04d9946b_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMy0xLTEtMjAwNTcx_d2231d66-603e-41ec-86ad-73b6a4f6a584">2,576</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib19650c5a913416ca6588da34a348f22_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItNS0xLTEtMjAwNTcx_fbdf7da9-9899-4713-8189-a294e91df0aa">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib26655c3a88e4720ab7d8bc05312c1b8_I20220930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItNy0xLTEtMjAwNTcx_a9e460d9-c9a2-429f-a7f8-328a453b4a04">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib26655c3a88e4720ab7d8bc05312c1b8_I20220930" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItOS0xLTEtMjAwNTcx_adb8dad9-cd6a-47c3-b933-d5e722a7911c">3,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icad5885e711d42da835169aa6f388325_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMTEtMS0xLTIwMDU3MQ_cd51abad-79c1-43a3-8756-80945e9fd948">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e44ef25f8d4bd2bcd0d9afdb11ce46_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMTMtMS0xLTIwMDU3MQ_dc160f7e-7f81-4160-83de-8a9d082f533c">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMTUtMS0xLTIwMDU3MQ_3f9874f7-3f6a-411f-8de0-6e359a5a8c60">1,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:29.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3061556bb3664f40a526ed65a094ef2e_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xLTEtMS0yMDA1NzE_0941e7c6-52d8-4a1b-8408-cc59d44760b7">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3061556bb3664f40a526ed65a094ef2e_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0zLTEtMS0yMDA1NzE_6ef3fdf7-7985-49fe-952c-0e646490e9c5">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a06e509abb14275bd46ec4afb985d35_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS01LTEtMS0yMDA1NzE_22f08986-3317-49ef-a8c4-62086d50fa47">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i758e3844f8bd47929282bc88703ea8f0_I20210630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS03LTEtMS0yMDA1NzE_8b6f1a1d-f67a-49e1-b294-fb25e2a60968">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i758e3844f8bd47929282bc88703ea8f0_I20210630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS05LTEtMS0yMDA1NzE_c55bbc24-507f-4676-a811-7743ec4e4b31">2,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf460939e6f142618d8200a4e95a4733_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xMS0xLTEtMjAwNTcx_1427a977-f713-4980-a18e-4d3ce2da9b03">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc85debed74f4b3faea2295133b498fa_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xMy0xLTEtMjAwNTcx_ac1701c9-819d-4e0f-b72b-f6985f39829f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15ca96c683e4ba6865784ead9adbc78_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xNS0xLTEtMjAwNTcx_b38dbcd0-b02a-4055-8595-dcd0043d2606">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMi01LTEtMS0yMDA1NzE_e8768bb5-0b45-4942-a374-d6dbe72500b6">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcede8d084d432d9ea4736241a37ba4_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMi0xMy0xLTEtMjAwNTcx_43062ea0-72ae-417e-ab3a-9167183ff4ca">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMi0xNS0xLTEtMjAwNTcx_e7039fd0-73e0-4c75-b2b1-71dbbf2720f4">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMy0xMS0xLTEtMjAwNTcx_bb44c101-3ca0-40f1-904e-1a00ddad98ea">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMy0xNS0xLTEtMjAwNTcx_56b7393d-2235-4ff9-8d8d-302ca8298bf0">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS0xLTEtMS0yMDA1NzE_9649e3dc-d781-4116-ba54-ad9d8a15d377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS0zLTEtMS0yMDA1NzE_7c5e5039-b175-4df6-a660-9494d0464110">40</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS03LTEtMS0yMDA1NzE_1a9b6e3d-56d8-4f44-bc4c-a66fd65d4eb3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS05LTEtMS0yMDA1NzE_2e7045ff-38c0-48b9-b5bc-bf16daca6762">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS0xNS0xLTEtMjAwNTcx_f31cd9ac-45d9-4b95-9842-f30edc4665c1">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi0zLTEtMS0yMDA1NzE_fc30785b-0d8d-46c6-8ed0-db0446314c7a">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi03LTEtMS0yMDA1NzE_d2befdd6-002f-4ca5-994f-e0dbe42d12a3">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi05LTEtMS0yMDA1NzE_557a2aa0-0405-4dab-8162-f44352a68b95">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi0xNS0xLTEtMjAwNTcx_c0234c45-2c5e-4729-b7f6-14759e1d1904">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie41d7fe9babb47ad971ea568ec44ee4c_D20210701-20210930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNy01LTEtMS0yMDA1NzE_5def6ab1-04fe-49bc-8fb2-121f078e4cab">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNy0xNS0xLTEtMjAwNTcx_1946f3ce-84d0-4717-a71e-ce1a0c778188">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bcede8d084d432d9ea4736241a37ba4_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfOC0xMy0xLTEtMjAwNTcx_c36d1634-9270-4c98-bcbf-adf20e3bd4e7">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfOC0xNS0xLTEtMjAwNTcx_7dda17a1-445a-4327-a559-949e0381b6bc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i853ff6add89c4a1ea84c989f618420fb_I20210930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMS0xLTEtMjAwNTcx_2fcf2c0e-0e65-4ced-b698-5599239edde3">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853ff6add89c4a1ea84c989f618420fb_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMy0xLTEtMjAwNTcx_09d31ef5-5540-497b-bc10-11dab6fed2c8">2,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490000f10c0b4b0682cb24d52cb388ad_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtNS0xLTEtMjAwNTcx_6c575bbb-619b-4c07-865c-fa63478e182e">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idc43915a36234990a428483dd2251e18_I20210930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtNy0xLTEtMjAwNTcx_ac706440-841d-4c13-ba6e-ba3488d787d4">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc43915a36234990a428483dd2251e18_I20210930" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtOS0xLTEtMjAwNTcx_2352266c-95fb-43ff-8907-53ff62308576">2,547</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie32a5bd181674aac970917c2db9cf482_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMTEtMS0xLTIwMDU3MQ_fd2b5a18-2675-4b5d-aec8-7f2afba587c8">61</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50701f17cc6d42238115a15492c656da_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMTMtMS0xLTIwMDU3MQ_2d965868-89f7-4bfe-ad78-aca4fb2d0984">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa1095ca2d145a488a40d99cf500cbd_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMTUtMS0xLTIwMDU3MQ_9b87f45f-bf0c-4f6e-a9ce-4c768a347709">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMy0xLTEtMS0yMDA1NzE_c553b429-dd4f-4f1c-8cc8-2e0641d78fb8">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMy0zLTEtMS0yMDA1NzE_cc1bcc6c-de9f-41d7-aaa1-1ef092b568c3">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNi0xLTEtMS0yMDA1NzE_a3c434de-b0b1-463d-bd8b-b398ddd4c865">171</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNi0zLTEtMS0yMDA1NzE_c87d0a11-91ee-4e42-a69f-fad2839c26c9">168</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOC0xLTEtMS0yMDA1NzE_2b2817e9-b858-4ff1-b138-78f7bc4732b8">153</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOC0zLTEtMS0yMDA1NzE_dbbe28b4-be37-440f-a45a-1de662075267">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOS0xLTEtMS0yMDA1NzE_e8daed7e-17d7-489e-a690-6af7bf2a44dc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOS0zLTEtMS0yMDA1NzE_b070260b-1701-41f8-a2b1-5f60f11d37c7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTAtMS0xLTEtMjAwNTcx_34fbafe2-4aa4-4e6f-902b-a840d3ad8eda">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTAtMy0xLTEtMjAwNTcx_258c1aa3-929d-4523-80fa-74dbb6a3c5e5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTEtMS0xLTEtMjAwNTcx_ab6f23c5-e691-4d0a-9e30-b1fa5faefb16">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTEtMy0xLTEtMjAwNTcx_de557848-1fea-47e9-a982-9169fe1b81ac">12</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTQtMS0xLTEtMjAwNTcx_7ce9e84d-0839-47e1-845e-5644ae187303">508</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTQtMy0xLTEtMjAwNTcx_097af0be-4466-498c-be11-96abbe672004">214</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTUtMS0xLTEtMjAwNTcx_14dc5996-2cd3-4434-b0ad-9997cd9ad4b3">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTUtMy0xLTEtMjAwNTcx_8fa1a487-5d5e-4538-8d79-faf23ada01dc">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTYtMS0xLTEtMjAwNTcx_b7074a62-26f3-4590-b99a-de7f341fa75c">1,234</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTYtMy0xLTEtMjAwNTcx_87bda266-46cb-4214-b4b9-a8dfcac4c736">292</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTctMS0xLTEtMjAwNTcx_c9417ce7-b07a-4320-9f87-bcdbee91e9ec">926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTctMy0xLTEtMjAwNTcx_7381aded-8c08-4101-b940-d65767cc3440">495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTgtMS0xLTEtMjAwNTcx_f563a5a8-8385-41d2-b97c-e255188a1aa5">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTgtMy0xLTEtMjAwNTcx_edffe64e-ecab-48f7-b989-a4afe319aac1">646</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjItMS0xLTEtMjAwNTcx_7ba81cd9-b51a-4c5a-a803-89fa37195890">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjItMy0xLTEtMjAwNTcx_b0e779ff-488c-4873-accd-6ccc27910bd5">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjMtMS0xLTEtMjAwNTcx_393372cf-071a-40d8-94a5-cfa5fbb53901">70</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjMtMy0xLTEtMjAwNTcx_e2d5e218-4853-4e23-8abf-d5da0805e4e0">67</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMS0xLTEtMjI0OTY1_f644e67f-ecd0-4a65-bd93-bb48eadfad88">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMy0xLTEtMjI0OTcz_6a49afc0-44dd-4d4c-9a24-7dd096a26c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMS0xLTEtMjAwNTcx_402508f8-266a-40e9-b4be-c8ded5e6e2d9">3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMy0xLTEtMjAwNTcx_005da0c0-87a5-4a69-99c7-a152843b8593">2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjUtMS0xLTEtMjAwNTcx_dd328fb2-3648-4610-883a-3ddbcfc7d5e6">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjUtMy0xLTEtMjAwNTcx_40c90970-b80d-4b09-94d6-e1ed86fc0c5e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjctMS0xLTEtMjAwNTcx_3793b85f-f42e-4b8e-b785-b0c5aa72f6aa">70</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjctMy0xLTEtMjAwNTcx_e46e3e2c-561e-4f33-9c1a-f9ca44de518b">862</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzItMS0xLTEtMjAwNTcx_3b78568b-cef9-42d9-9192-f77a4db8bda9">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzItMy0xLTEtMjAwNTcx_0e18231e-518d-453d-a0b3-765638a0da80">587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzQtMS0xLTEtMjAwNTcx_e65acef5-f9c7-49e7-8a24-3bf9db3f0533">14</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzQtMy0xLTEtMjAwNTcx_3f6e3901-c2df-486b-9cca-346645ec967e">28</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzUtMS0xLTEtMjAwNTcx_d85d8027-4d9c-4655-9c1b-027f94d5ee52">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzUtMy0xLTEtMjAwNTcx_f0b80edc-95b8-4052-888d-fa2778467318">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzYtMS0xLTEtMjAwNTcx_0db4a6f5-238a-4dc0-8e16-148de281e91d">1,000</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzYtMy0xLTEtMjAwNTcx_a9df66d9-0de2-475c-8527-85364d90e0b0">500</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzctMS0xLTEtMjAwNTcx_65f3313f-fded-4e72-8af7-734f859a1d57">1,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzctMy0xLTEtMjAwNTcx_f5d461b0-bfd7-44f6-b22e-fb2879077e8c">1,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzktMS0xLTEtMjAwNTcx_4d8882db-fadf-43e2-b98c-323eec03e700">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzktMy0xLTEtMjAwNTcx_36ef16d7-6482-400f-8788-89692d4cc688">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash reclassified from assets held for sale</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="cah:CashReclassifiedFromAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDAtMS0xLTEtMjAwNTcx_55418aa6-0e95-4785-aacf-9b9f06758d16">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="cah:CashReclassifiedFromAssetsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDAtMy0xLTEtMjAwNTcx_89a6fcb9-88aa-4f93-baca-b0d2a873431f">109</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDItMS0xLTEtMjAwNTcx_6ed926e5-4217-4730-baae-7c4b7662cb2a">1,225</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDItMy0xLTEtMjAwNTcx_d22125ef-a7fe-44b9-aff3-a6a24f8b2d82">944</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDMtMS0xLTEtMjAwNTcx_8ee909ab-b12e-472e-a13d-b17f9597be93">4,717</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15ca96c683e4ba6865784ead9adbc78_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDMtMy0xLTEtMjAwNTcx_90bb179e-fbf1-41d3-b2c3-581e10e16a79">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDQtMS0xLTEtMjAwNTcx_0d4e9caf-6bfd-4923-8996-3cd378fc4a0f">3,492</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa1095ca2d145a488a40d99cf500cbd_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDQtMy0xLTEtMjAwNTcx_7eabec17-6d9f-410b-9ec6-40b2b00299c6">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_76"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83Ni9mcmFnOjVhNGM4OWJiOWU3OTQwNTc5YTNhMmJlYzg0ZTRlMTEwL3RleHRyZWdpb246NWE0Yzg5YmI5ZTc5NDA1NzlhM2EyYmVjODRlNGUxMTBfMzEzMA_0bd52747-4f5f-4e66-9374-1267a28949d7" continuedAt="i0803d958a343485b927f9308622611f6" escape="true"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83Ni9mcmFnOjVhNGM4OWJiOWU3OTQwNTc5YTNhMmJlYzg0ZTRlMTEwL3RleHRyZWdpb246NWE0Yzg5YmI5ZTc5NDA1NzlhM2EyYmVjODRlNGUxMTBfMzEyNg_3cc0af61-54c6-46f0-87d5-f6be5f86a4d7" continuedAt="if44c2f19a22d48ec816b3186862f6181" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if44c2f19a22d48ec816b3186862f6181">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").</ix:continuation> </span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83Ni9mcmFnOjVhNGM4OWJiOWU3OTQwNTc5YTNhMmJlYzg0ZTRlMTEwL3RleHRyZWdpb246NWE0Yzg5YmI5ZTc5NDA1NzlhM2EyYmVjODRlNGUxMTBfMzEyMw_b823eec1-6192-49d9-8a47-66d603cff97e" continuedAt="i99b0444e7d3442e7a694b72c0308d246" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as </span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i0803d958a343485b927f9308622611f6"><ix:continuation id="i99b0444e7d3442e7a694b72c0308d246"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2022.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_79"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83OS9mcmFnOjE4ZjU4NTc4MGY1NDQyMTJiNjc1YzE5MGVjODY5NTc5L3RleHRyZWdpb246MThmNTg1NzgwZjU0NDIxMmI2NzVjMTkwZWM4Njk1NzlfNTc1_259a5622-a4e1-4904-a07d-5e4053d199ea" escape="true"><div style="text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i73291183b5c94c569731d6000358a035_D20210701-20220630" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83OS9mcmFnOjE4ZjU4NTc4MGY1NDQyMTJiNjc1YzE5MGVjODY5NTc5L3RleHRyZWdpb246MThmNTg1NzgwZjU0NDIxMmI2NzVjMTkwZWM4Njk1NzlfOTA_87e6989b-391e-4287-8efe-1ca13c6f0ecb">923</ix:nonFraction> million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_82"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RleHRyZWdpb246N2VjYmFjZTNlOTE1NDVjMWIxZDQ2OTU0OTIxZDA1ZjRfOTk3_ef61c98f-9c2b-4237-9650-b2231670a005" continuedAt="i65abe536cbe04886a1251fd77bb66791" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance </span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RleHRyZWdpb246N2VjYmFjZTNlOTE1NDVjMWIxZDQ2OTU0OTIxZDA1ZjRfMTAyMw_6dcd6080-66e6-4623-967b-bdcc866ac1af" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMi0xLTEtMS0yMDA1NzE_24055499-fc95-4a77-a53e-1bbdaff0dcd6">19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMi0zLTEtMS0yMDA1NzE_1c16554b-44b0-4812-8e68-6abdec23b5aa">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMy0xLTEtMS0yMDA1NzE_31e0a153-0dc8-4c5c-9178-c2b950e9a2b8">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMy0zLTEtMS0yMDA1NzE_20d1734a-22d1-4fce-bf40-4afd553e72b7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfNC0xLTEtMS0yMDA1NzE_61f8e507-4ed2-4295-959c-bd9e6e8996a3">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfNC0zLTEtMS0yMDA1NzE_4f44f422-61e5-4e7d-b9e5-a4b2af985028">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i65abe536cbe04886a1251fd77bb66791"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September&#160;30, 2021, restructuring also included costs related to the divestiture of the Cordis business.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RleHRyZWdpb246N2VjYmFjZTNlOTE1NDVjMWIxZDQ2OTU0OTIxZDA1ZjRfMTAwOA_bd483dce-7842-45b4-aa71-2b1d6ec01ce6" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70aa8ba2fa76462a98de9c2a2a3b3eab_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMS0xLTEtMS0yMDA1NzE_1aa25fd0-4705-401e-8c02-ba87f6f98a39">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8df42a7b9384d7ba6a2b613756fc333_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMS0zLTEtMS0yMDA1NzE_9bae4777-f35f-4bd6-91e0-4b7be3961e2b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMS01LTEtMS0yMDA1NzE_c2590a88-791b-4fb9-994e-59704a9de4f5">66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6f5954a39f4eaab401f0922f87e2b2_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMi0xLTEtMS0yMDA1NzE_fe4a4bb8-2f47-46c4-b90f-f44f669269ff">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7336a5c8dffa4fed905779c7906e0698_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMi0zLTEtMS0yMDA1NzE_730759ac-a6fc-4eae-8ec0-01df70e1021f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMi01LTEtMS0yMDA1NzE_6e59bd62-7021-4d18-a571-038989d7cd81">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd6f5954a39f4eaab401f0922f87e2b2_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMy0xLTEtMS0yMDA1NzE_bef50a5a-9d69-476a-b72b-50353a3278fe">11</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7336a5c8dffa4fed905779c7906e0698_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMy0zLTEtMS0yMDA1NzE_13d5c15c-714f-4cb7-a8b4-2425f41b8021">10</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMy01LTEtMS0yMDA1NzE_3297d4bd-4576-49c4-8248-b9c8ffe0a98b">21</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c4c7a1de55d4507ad5cbd581472af6f_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfNC0xLTEtMS0yMDA1NzE_f19e0cd1-e456-4ecb-b377-601a00b59018">65</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c8e71b77e84415aa0fb3cf24c26850_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfNC0zLTEtMS0yMDA1NzE_98e42593-d3ff-4b6e-8da6-742f771bd654">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfNC01LTEtMS0yMDA1NzE_086b3c12-844c-49dd-bd41-46a05f51a520">68</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_85"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjc0ODc3OTA3MjQxOA_e076bce8-baf1-4946-9132-3fce74451042" continuedAt="i01a158b52a2a43f6be56f94aa4f8ac86" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjc0ODc3OTA3MjQxOQ_e6adf1b4-6e9c-4158-b10b-b85396374fa1" continuedAt="i691db420f9584730a3600ab3a095d03c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"><tr><td style="width:1.0%"></td><td style="width:44.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cad212f102146228e0cd765ec3011f8_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMS0xLTEtMS0yMDA1NzE_5a795d40-b5f2-4c16-a18b-e6e2db53b0c1">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4f963e1258409697ad8f442ba79dc3_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMS0zLTEtMS0yMDA1NzE_8cafb136-50b9-4443-b276-265639bcbed2">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMS01LTEtMS0yMDA1NzE_fa18b809-fd49-4398-8dd6-c2474225fe1c">5,855</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be56105efe44fd58a9ef7c7851443fb_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMy0xLTEtMS0yMDA1NzE_2c789466-4179-4c53-800f-78380f7af8d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMy0zLTEtMS0yMDA1NzE_73ef3454-682b-4ffd-919d-0838b609dc94">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMy01LTEtMS0yMDA1NzE_41cff5ed-159e-4402-ba00-8f28d10dad36">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be56105efe44fd58a9ef7c7851443fb_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0xLTEtMS0yMTA3NzQ_02f8ad52-99dd-42c7-b06e-931810acb186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0zLTEtMS0yMTA3Nzg_1577684a-8074-4c6f-a629-d14c8003cdf4">154</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC01LTEtMS0yMTA3ODI_5b4400b0-b869-49a2-bfdf-7cce540e131e">154</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a3dd894882408790e569ecd7a0a0f6_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0xLTEtMS0yMDA1NzE_af51aeae-b2c0-44fa-8082-7dc97f00201b">2,673</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a322d3b1b71496d949f588cbc3e8c44_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0zLTEtMS0yMDA1NzE_c8c34d56-36b2-422b-9432-4255e90c6821">3,002</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC01LTEtMS0yMDA1NzE_f30c1041-9e32-4042-b408-6bca17e811d3">5,675</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i691db420f9584730a3600ab3a095d03c" continuedAt="ie0e72c545bbb424ebc6ec79e99fa2075">(1)</ix:continuation></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:continuation id="ie0e72c545bbb424ebc6ec79e99fa2075">At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="i9a322d3b1b71496d949f588cbc3e8c44_I20220930" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NjkxMA_679ab43b-ddbc-405e-ad9b-ce2e5ada753a">3.6</ix:nonFraction> billion</ix:continuation>.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of <ix:nonFraction unitRef="number" contextRef="i7138c986208346caab693c394d3fc544_D20220701-20220930" decimals="3" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzMwMQ_04cd1db4-79f3-4491-9b53-d67d13aca075">10.5</ix:nonFraction> percent and a terminal growth rate of <ix:nonFraction unitRef="number" contextRef="i7138c986208346caab693c394d3fc544_D20220701-20220930" decimals="3" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzMxNg_7b9d718d-4e0b-4e61-b740-5c5c2851560d">2</ix:nonFraction> percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjc0ODc3OTA3MTk3Ng_1577684a-8074-4c6f-a629-d14c8003cdf4">154</ix:nonFraction> million for the Medical Unit, which was recognized during the three months ended September&#160;30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i01a158b52a2a43f6be56f94aa4f8ac86"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September&#160;30, 2022 after recognizing the impairment charge was $<ix:nonFraction unitRef="usd" contextRef="i6fb2d9aad92e4c598b91935a092f4aea_I20220930" decimals="-6" name="us-gaap:AssetsNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzMzMg_1031c363-7368-40a2-8816-910d2b942b3a">6.7</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i6fb2d9aad92e4c598b91935a092f4aea_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzM1OA_5e98f5e8-477b-43ef-8262-065f5c3f098e">1.8</ix:nonFraction>&#160;billion was goodwill.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDgx_a00b6119-9df4-4344-b29c-85d6cb111174" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbcc66fb7f548ae9276527dd4263120_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMy0xLTEtMS0yMDA1NzE_be4f99cd-8646-4884-8148-d9fca893592c">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbcc66fb7f548ae9276527dd4263120_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMy01LTEtMS0yMDA1NzE_5262666b-67a8-412a-ab1d-f2992ceee174">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNC0xLTEtMS0yMDA1NzE_4c62a6a6-0dc5-46b5-8027-352e87f2cd38">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNC01LTEtMS0yMDA1NzE_52758476-574f-4b83-b45a-04cbe9d2a05f">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy0xLTEtMS0yMDA1NzE_1db54d90-3bbf-49f3-8473-4b585ff7366e">3,206</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy0zLTEtMS0yMDA1NzE_4e071840-c664-49fd-9281-ab88f8ca0552">2,157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy01LTEtMS0yMDA1NzE_0d6bb9d3-e266-41c7-9b72-983d3c7d7ff5">1,049</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1bdbb7b08c494b6ea6bebbc41a301248_D20220701-20220930" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy03LTEtMS0yMDA1NzE_b8f39b6d-9938-40fb-a6d0-41a9cb334849">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC0xLTEtMS0yMDA1NzE_f282b59f-9f5e-4d22-a5b4-adbef9d4762e">546</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC0zLTEtMS0yMDA1NzE_e36c1190-8d3b-489b-8b40-35da78c9389c">361</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC01LTEtMS0yMDA1NzE_4e3bb0f6-73a9-4e60-aecb-9322ebbcac72">185</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5754d58acfdb4215a3917a18dd269e93_D20220701-20220930" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC03LTEtMS0yMDA1NzE_ba27efa4-212d-4784-b4f3-cb7f8f4445ec">8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS0xLTEtMS0yMDA1NzE_a21ac8a7-98da-4081-b2ca-ccc05bfc85d5">1,037</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS0zLTEtMS0yMDA1NzE_28bf10ee-3327-476f-bb21-1088ad92d01e">590</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS01LTEtMS0yMDA1NzE_a03bbecc-c82e-4fc7-a2f7-5cd29c21b2ff">447</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ec2ce0031f949829f8cff3fae7f33b8_D20220701-20220930" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS03LTEtMS0yMDA1NzE_1859de81-e15b-4aa2-95d0-0b8f7b00dc15">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtMS0xLTEtMjAwNTcx_ebead3c5-d3f6-4952-b5cb-4d967e788ecf">4,789</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtMy0xLTEtMjAwNTcx_a3e82b81-47c9-492b-bf88-8317bb98a380">3,108</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtNS0xLTEtMjAwNTcx_950729b9-7752-40f1-a0f2-b19c81f9824f">1,681</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtNy0xLTEtMjAwNTcx_f901ef1d-ba41-4aab-9825-fdc22db54701">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTEtMS0xLTEtMjAwNTcx_4080695f-33ca-4856-8fee-1b7b41647d39">4,800</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTEtMy0xLTEtMjAwNTcx_e1d54057-1ae5-4238-9d3c-755e7e1aa701">3,108</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTEtNS0xLTEtMjAwNTcx_d621c9dd-03f2-4a89-a721-37fdd529ade3">1,692</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c74d76f8974daeb64325a492d7cb0c_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMy0xLTEtMS0yMDA1NzE_24f15e3b-abd9-40dc-bf5c-d3d980ef537f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c74d76f8974daeb64325a492d7cb0c_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMy01LTEtMS0yMDA1NzE_8a450642-fae2-4ea0-a523-5a7ee85f0bfd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNC0xLTEtMS0yMDA1NzE_696c93e4-4496-46e7-a830-94995942fed8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNC01LTEtMS0yMDA1NzE_a9c8800e-8795-4c83-b023-6eb6c76ee04d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5001b8fecb8f4da89f5a3a06c330244d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNy0xLTEtMS0yMDA1NzE_0b09730a-05cf-496d-b9d4-218ec46d812e">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5001b8fecb8f4da89f5a3a06c330244d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNy0zLTEtMS0yMDA1NzE_0c533d1b-1d57-41a1-837f-a5f6b6b5142c">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5001b8fecb8f4da89f5a3a06c330244d_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNy01LTEtMS0yMDA1NzE_81d63a91-af45-4b6b-9903-dddb6f786a6c">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2b097d758b45aa95ea584e855a2631_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOC0xLTEtMS0yMDA1NzE_455d5ea1-84f2-4a89-b659-4ea3cda7a909">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2b097d758b45aa95ea584e855a2631_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOC0zLTEtMS0yMDA1NzE_fcd89550-6e39-450a-b811-9bd5510ca871">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2b097d758b45aa95ea584e855a2631_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOC01LTEtMS0yMDA1NzE_a6eb9138-1d7e-4af4-9197-53c229386a60">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOS0xLTEtMS0yMDA1NzE_72893b2f-cf91-465b-872a-15745fba7e2d">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOS0zLTEtMS0yMDA1NzE_caea8c68-ffdc-44f2-8b3a-4736ea290f30">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOS01LTEtMS0yMDA1NzE_16849799-18ff-4bb2-93b7-0e2acbd5878d">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTAtMS0xLTEtMjAwNTcx_c942db14-3d0d-42e9-89bf-f289ca87c1e7">4,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTAtMy0xLTEtMjAwNTcx_6ef1251a-ba0b-49d5-88e6-1f23f0613595">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTAtNS0xLTEtMjAwNTcx_bfac82d0-3360-4418-856a-3cd6759dd472">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTEtMS0xLTEtMjAwNTcx_cdefbf51-6e23-4de2-bb7b-89862d2f8a6c">4,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTEtMy0xLTEtMjAwNTcx_e8309544-57a1-45e5-a3d3-94145076ec53">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTEtNS0xLTEtMjAwNTcx_2f90c030-ba88-4582-996e-d86492713998">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjYy_4e320dbf-7dad-4ab0-9f8f-e9a4d69cc539">71</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjY5_3e7d2ff0-a06f-486a-8c10-33c119e58cd3">78</ix:nonFraction> million for the three months ended September&#160;30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDMy_e3cbdb98-dd05-44e8-bdf6-e882c59c281f">212</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDM2_1e55baa8-1e65-4d37-8998-2f8ce439dcd9">258</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDQw_86456a4c-0dc7-4977-a2e2-7527f55bfe2a">233</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDQ0_5b7f2c13-ffd7-4f5d-8acf-8cb4fbbaa19f">206</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDUy_90855683-e106-4e82-ae9f-0033a5d3bd0c">174</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMjMxMg_7e3b195b-a9d3-4ccf-8cfc-f899ce843e6d" continuedAt="i01d6ee8788fd41fb89c9961cfd592c9f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTI2_2013c7e6-d8c6-43d2-bbd9-a8a31d07defa"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTI2_b7a03e0f-128b-4d3f-87c8-5c0efb00f536">5.3</ix:nonFraction></ix:nonFraction> billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTE5_8321ac99-3928-4e31-95a0-0e0466cf3923">28.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTI2_8becfc69-0dd0-4fc9-957d-bb1dace8fa28">27.1</ix:nonFraction> billion at September 30, 2022 and June 30, 2022, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we redeemed all outstanding $<ix:nonFraction unitRef="usd" contextRef="if2e87b70e3bf41fa8effe5bef9f99d54_D20210701-20210930" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTQ5NzU1ODE2MzI5_265027b9-2519-42b1-9c28-9c293d5880f4">572</ix:nonFraction> million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $<ix:nonFraction unitRef="usd" contextRef="if2e87b70e3bf41fa8effe5bef9f99d54_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTQ5NzU1ODE2NTc2_4f8bc9be-1754-4e6f-8752-e4ed4d55739e">10</ix:nonFraction>&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="ic8b18dbf515f4767a1d1688c18c6b7a1_I20220930" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTE5OA_c807ebf1-15bc-4f07-9483-0b91fc64e8c2">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i22fae5e1f8744690836ce67e2c6432cb_I20220930" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTIzOA_42c1d948-828a-4485-b434-5659abd2484f">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="ief8b6ae0c11d4c79addc75f5d463aad6_I20220930" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTI4Mw_a8f267fb-5c29-495b-a597-fb030c1956f6">1.0</ix:nonFraction> billion committed receivables sales facility. At September 30, 2022, we had <ix:nonFraction unitRef="usd" contextRef="i27b66144fc554632a9c5a93bee338b1d_I20220930" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTMzOA_e73f4fd5-1757-4223-9a7e-22b9aac61d10">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01d6ee8788fd41fb89c9961cfd592c9f">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.</ix:continuation> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="ibd18cf751e3b4588bcfe40175c3f40a1_97"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTQzNQ_082645ce-6fa5-4f16-8d16-1c140388237e" continuedAt="i97aea97007e14a23a0d76eda1bce8d7a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i3bd0b96897d1470fb2329660c7d50e7d_D20220701-20220930" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMjUz_bfee9e07-ad2d-4de1-9a9c-cb2e2655d8f6">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i2297365bf0cb4e03a98dbbb10ac1c343_I20220930" decimals="-6" name="cah:AggregateAnnualAssessment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzA5_aaba906f-9f8c-4c7f-bbe1-d3f3191effd9">100</ix:nonFraction> million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i64b8e59737824266b20b0bb162a7f6fd_D20210701-20210930" decimals="-6" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTkzNg_e8d5bc15-b8b5-49f2-949d-c64ffd44b501">41</ix:nonFraction> million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $<ix:nonFraction unitRef="usd" contextRef="id6f6b2710bce442e9c8a8211ae3d15b6_D20211001-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM2Mg_690f3231-96b3-4705-b198-475559a9748f">20</ix:nonFraction>&#160;million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $<ix:nonFraction unitRef="usd" contextRef="i2297365bf0cb4e03a98dbbb10ac1c343_I20220930" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM0OQ_04e37c55-052d-429a-8f94-62686d6c50c8">20</ix:nonFraction>&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i97aea97007e14a23a0d76eda1bce8d7a" continuedAt="ib5fe638910224169bc619a13feaa5840"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i3a25416abfca4ca5a2c8a79563abdbf6_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM3OA_49227bb0-31cd-4f9d-baaa-ccced99ca621">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include <ix:nonFraction unitRef="states" contextRef="ideb927b476ad43678e84b8626a1dccd8_I20221103" decimals="0" name="cah:SettlingStates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc0NTc4NA_14cbc7de-d414-4d28-8db7-1fa5f63424cc">46</ix:nonFraction> states, the District of Columbia and <ix:nonFraction unitRef="numberofusterritories" contextRef="ideb927b476ad43678e84b8626a1dccd8_I20221103" decimals="0" name="cah:SettlingUSTerritories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc0NTc5MA_8071340f-3377-41bd-875b-8406a6709ae4">5</ix:nonFraction> U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this Settlement Agreement, we will pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="id0676373b4634242b6227fe4aaa7279e_I20220930" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfOTU4Mg_eda76d46-4371-448a-b0db-63e598b3944c">6.0</ix:nonFraction>&#160;billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $<ix:nonFraction unitRef="usd" contextRef="i78dcc5cdb1a34a3688e6c1ce718bb3d4_I20220731" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc2NjgwMg_ae3b7ab0-101b-4857-bfb6-f9dce0b3a041">124</ix:nonFraction>&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="iad2e4f4027b649c8b68073da27cc75ac_I20220630" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzE0NjgyNTY2NzY2NQ_863b0712-edb2-4c0e-9b7b-5bff89a8f68c">160</ix:nonFraction>&#160;million to the State of Washington and its participating subdivisions and approximately $<ix:nonFraction unitRef="usd" contextRef="i39a78fb2810d4d5cb0d5270aa7494bd0_I20220630" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc2NjgyOA_1747006b-0b79-4bad-b15b-e0e8e9f5fae1">95</ix:nonFraction>&#160;million to the </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ib5fe638910224169bc619a13feaa5840" continuedAt="i8b83f4e270b4435ab110b7f9076cc64d"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of <ix:nonFraction unitRef="states" contextRef="i2d26088d8851461e886dd938e1e01e06_I20221031" decimals="0" name="cah:LossContingencyNumberOfEligibleStates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTMxOTQxMzk2MjQyOTc_6bb6deef-7af1-49ab-a3bb-3b614edf8b70">49</ix:nonFraction> states will then be subject to the Settlement Agreement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in resolution discussions with the Attorney General for the State of Alabama.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i05c064b32b7241f5861b32d00930b148_I20221031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTQyMg_c162eef2-7445-414f-901b-526a77b45186">136</ix:nonFraction>&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we made our second annual payment of $<ix:nonFraction unitRef="usd" contextRef="i5a2674d9c4424aee92b083b06676b132_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfODcyNTM_2c79c1e4-a579-4794-9c0c-b3bd33998517">372</ix:nonFraction>&#160;million under the Settlement Agreement. In total, we have $<ix:nonFraction unitRef="usd" contextRef="id0676373b4634242b6227fe4aaa7279e_I20220930" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTI2MjI_696e0685-758d-4fb1-9728-f7bba8d63fa0">6.03</ix:nonFraction>&#160;billion accrued at September&#160;30, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="if8c2e07a1122434fb48591c34c3b03e8_I20220930" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTI2NDk_0e78af67-3a1f-47fa-aa7f-c8ec10e6361b">608</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="if117a27e06074dd49394d4673002a60d_I20221031" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM5MQ_6392d90e-a7d1-4a2d-9609-95e74a21cea6">454</ix:nonFraction> lawsuits as of October, 2022. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="i32f85e3cb646437cb5f56dcc696128e6_I20221031" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTQ3NDA_6f5f7988-e313-4a2f-bef5-8ace79ace0a3">151</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving <ix:nonFraction unitRef="plaintiff" contextRef="i12caa08ddee14ac2a252cf36f1b23ea5_D20220701-20220731" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDczMTM0Mg_030fb0e3-8b77-480e-9da9-7fd66fe8448c">21</ix:nonFraction> plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September&#160;30, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 3, 2022, we are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i4a355aa72fe54940911ec0fc9eec1d71_I20221103" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTU4NDk_d989c952-014a-43f4-afe9-dad3a8528815">450</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i6de11675da4a46d1a1dd19d98e7d028f_D20221103-20221103" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTU5NzI_060deb77-ec30-4bbd-8700-afef64572f98">5,215</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of IVC filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="i1eadbc725e9d4be693afcd2438eb9445_I20221103" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTYxMjM_9c28a928-d402-41bb-b50a-a400dd09af77">7</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i91f3e424f456485faa3f18f61dbada6c_D20221103-20221103" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTYxNzc_3cfa57a2-b772-48ae-b319-e7d4d07ea5f0">8</ix:nonFraction> plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately <ix:nonFraction unitRef="lawsuit" contextRef="ibad30b04476e408b9b94106e5ec72041_D20210731-20210731" decimals="-2" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTYzNzc_609ce6f1-d790-41d1-b80c-691cc0ca1ff3">1,300</ix:nonFraction> product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, we had a total of $<ix:nonFraction unitRef="usd" contextRef="ie89257f0029142808d8e517babd2e9ce_I20220930" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTY2MDI_20e8d2fd-7dea-4e57-991d-f974bb77730f">527</ix:nonFraction>&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="i5efb723c71ca43158a719af61d57c9fe_I20220930" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTcwNTg_0ff918c0-0121-4895-aff1-dc53ce4168ba">1.07</ix:nonFraction>&#160;billion, net of estimated insurance </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i8b83f4e270b4435ab110b7f9076cc64d" continuedAt="icdb288e85ab446a286ffcd31a313c4d8"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icdb288e85ab446a286ffcd31a313c4d8">In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $<ix:nonFraction unitRef="usd" contextRef="ib3b381f73ed74b7c87202faa366ced15_D20221001-20221231" decimals="-6" name="cah:IncomefromSettlementsofClassActionLawsuits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc3MjQ1MA_8c235602-d7a1-4d73-8f06-3b752dfad1c6">66</ix:nonFraction> million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022.</ix:continuation></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_100"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzQ0MTA_cbddd5ce-c478-4b83-8b00-8c609d76bdb6" continuedAt="i219f3d7c5d314ea7a7c500bfc95ec010" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2MjQ_1577684a-8074-4c6f-a629-d14c8003cdf4">154</ix:nonFraction> million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $<ix:nonFraction unitRef="usd" contextRef="i63acc3676d524a4cb1fe19ba5584d6a9_D20220701-20230630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2Mzk_2c3308a2-a253-49cf-9903-5e0c51508fc9">12</ix:nonFraction>&#160;million for fiscal <ix:nonNumeric contextRef="i9d5cab62da2c411d9384568354fcbb20_D20220701-20220930" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2NjQ_f06fd986-b585-448a-8a0b-61ba626b2261">2023</ix:nonNumeric>.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September&#160;30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September&#160;30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i7f63075f2d6941f88610dca064275c22_D20221001-20230630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2NTc_a3322c78-b65f-407d-97c5-f4bb88ecc110">22</ix:nonFraction>&#160;million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September&#160;30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September&#160;30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, the effective tax rate was (<ix:nonFraction unitRef="number" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzE4OTY_6b2fa008-f7a7-4c7b-8d08-a1bcee9dbc91">0.7</ix:nonFraction>) percent and <ix:nonFraction unitRef="number" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzE5MTE_09b53d8e-d0e9-404a-850a-d9cef3e42807">26.3</ix:nonFraction> percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzIxODQ_37ada235-5f6f-451e-8db3-8ce31e171128">940</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzIxOTE_91f04c10-38d9-402a-b091-0e2e51ef2d61">943</ix:nonFraction> million of unrecognized tax benefits at September 30, 2022 and June&#160;30, 2022, respectively. Both the September 30, 2022 and June&#160;30, 2022 balances include $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzIyODI_27962e8b-085f-4b2e-a2a4-7a5df4315d46">858</ix:nonFraction> </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i219f3d7c5d314ea7a7c500bfc95ec010"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and June&#160;30, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI0MjY_cd012c71-2e20-424e-8e8a-dc3334d581b4">49</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI0MzM_ae459edf-aeb3-4eb3-aed1-03b86c020d79">48</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="i2647f5df574a4790a972ae81d73483a7_I20220930" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzMzMDI_1860afce-1b05-4076-8dfc-bb7570de186c">zero</ix:nonFraction> and a net decrease of $<ix:nonFraction unitRef="usd" contextRef="i838c37506e6a4118b13af6b0e18e635e_I20220930" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzMzMjc_de5f0d06-afd3-40d0-9e70-31a855b08be2">75</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years <ix:nonNumeric contextRef="if4a6ab707b7b48c3900375ae0fdf5bd0_D20220701-20220930" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzQ0MDI_1a281da7-f5fa-4532-a8fa-264891ae7f61">2016</ix:nonNumeric> through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i4747655b789c466c9d320622352b10eb_I20220930" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzM5Njc_54bdf021-ec18-4759-8f06-d677921c4666">77</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i112c682ae8824132a82e463e2829fbde_I20220630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzU0OTc1NTgxODQ0NQ_2b41e6fb-2331-4ff3-88e7-2b795da22158">75</ix:nonFraction> million at September&#160;30, 2022 and June&#160;30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="ibd18cf751e3b4588bcfe40175c3f40a1_103"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90ZXh0cmVnaW9uOjQxZTlmMzFjZGU0ZTRhMTU4MDljY2I2NDVmNzc2ZWRkXzEyMjI_98715589-da0e-40bd-a3e6-40e496122a14" continuedAt="i220d861fad1342ada4cd253d74203662" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements </span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90ZXh0cmVnaW9uOjQxZTlmMzFjZGU0ZTRhMTU4MDljY2I2NDVmNzc2ZWRkXzEyMzU_9ed9b4d9-ec60-4b8f-a17d-9b58adccd774" continuedAt="ibe6ddf02670f432e85cbcb643936b2d4" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409e7ac6eece4672b979373d4beb255a_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtMS0xLTEtMjAwNTcx_e1d7953c-bba7-4f26-9d59-159c9dc0b941">1,477</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a28758bc65a4cb4af33498d26db24ac_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtMy0xLTEtMjAwNTcx_0e93cd71-da80-4c2d-ac67-9e8830d8ae9a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aba128f32b4dab86cb347514750422_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtNS0xLTEtMjAwNTcx_d3c6c5f4-6e88-4eb0-805c-1bad4a7e7f81">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d65960fd135483bb22e0f9214f5cc93_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtNy0xLTEtMjAwNTcx_dbb360fc-071e-47c5-90a4-16a329136076">1,477</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409e7ac6eece4672b979373d4beb255a_I20220930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtMS0xLTEtMjAwNTcx_f96bd46b-697b-46f6-be5e-9018726a275e">88</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a28758bc65a4cb4af33498d26db24ac_I20220930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtMy0xLTEtMjAwNTcx_62fda9d5-9f35-4915-a64a-a2e56de727aa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aba128f32b4dab86cb347514750422_I20220930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtNS0xLTEtMjAwNTcx_cc70819f-838d-48d4-adeb-8ee72c133d44">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5307df37214cb5856b80573d7cd236_I20220930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtNy0xLTEtMjAwNTcx_db5265a4-8839-403d-a1d2-e5910a09781c">88</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409e7ac6eece4672b979373d4beb255a_I20220930" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtMS0xLTEtMjAwNTcx_2772ca72-b5d9-4253-8fa4-6019dd8a4654">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a28758bc65a4cb4af33498d26db24ac_I20220930" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtMy0xLTEtMjAwNTcx_d9f30c23-0c74-45b2-adb2-910129a78594">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aba128f32b4dab86cb347514750422_I20220930" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtNS0xLTEtMjAwNTcx_f86821b4-7571-4768-b083-2e1d26fb63ae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee5307df37214cb5856b80573d7cd236_I20220930" decimals="-6" sign="-" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtNy0xLTEtMjAwNTcx_e99dca6a-4f6c-4a5b-92cf-227a77a7916d">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387ff4bbab2845dabaeeca1215e98d4f_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtMS0xLTEtMjAwNTcx_403d5ebf-fd38-4b57-ae3e-135b0b3b8993">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5379f66427748ca8c43f633f07433f3_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtMy0xLTEtMjAwNTcx_7ec50c9d-f529-4f9d-89ab-09db2f30e8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ffadf1769b4b338c57b958d74314c6_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtNS0xLTEtMjAwNTcx_95c3db15-4ebf-45e3-a897-c5b33d4706e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ccafc16fb54194a171620229fdbe11_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtNy0xLTEtMjAwNTcx_3aa52770-13e5-4fa1-8968-b970da0a96c1">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387ff4bbab2845dabaeeca1215e98d4f_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtMS0xLTEtMjAwNTcx_2ee45f91-1bc5-4652-8249-b2f6f6f58491">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5379f66427748ca8c43f633f07433f3_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtMy0xLTEtMjAwNTcx_de280e7c-8349-40af-9201-00bbf979b699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ffadf1769b4b338c57b958d74314c6_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtNS0xLTEtMjAwNTcx_faba7c5d-44fa-4051-8293-2dffb7f6eba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e85c09481f4f09a7ccf2fe64711f33_I20220630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtNy0xLTEtMjAwNTcx_14db19ab-09aa-48f2-9731-9918c69c5b97">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387ff4bbab2845dabaeeca1215e98d4f_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtMS0xLTEtMjAwNTcx_fe984381-ad01-4977-b361-afff9c7552c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5379f66427748ca8c43f633f07433f3_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtMy0xLTEtMjAwNTcx_460c7c2d-8def-42c3-b106-b3e0b24ed54e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ffadf1769b4b338c57b958d74314c6_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtNS0xLTEtMjAwNTcx_ea5064de-a608-446e-ab64-cbfb5f657318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e85c09481f4f09a7ccf2fe64711f33_I20220630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtNy0xLTEtMjAwNTcx_d83b2516-b943-4619-8704-3a03231c63f1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i220d861fad1342ada4cd253d74203662"><ix:continuation id="ibe6ddf02670f432e85cbcb643936b2d4">(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_106"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzM4NDgyOTA3MDkwOTI_8a4e1574-778b-4cdc-9a70-0b15713cf667" continuedAt="i919d7e3adfcd40c1a686e3403da33374" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i919d7e3adfcd40c1a686e3403da33374" continuedAt="i01ee225c212941c6bd01d6a6c86c96ed"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September&#160;30, 2022 and 2021, there was <ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzMyODY_18475af6-1fa0-4762-a7db-98629fb3cd3c">no</ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September&#160;30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i65825c4d85ac4f8d93a497d87be20ab0_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzM1NjM_5db279b3-8a7a-4316-81b9-92cec317d22a">200</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8fdecbea244440c2ba6bf56b66b21f7d_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzM4NDgyOTA3MDkwOTU_d80bb0cd-65f9-43c2-9145-1ddad0439be2">100</ix:nonFraction> million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $<ix:nonFraction unitRef="usd" contextRef="ib2c072105cd740018a1c9aeea1081994_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzQ5NDc4MDIzMzM1ODk_c2c531af-a2c0-4e5d-b92f-17b4b27022ac">4</ix:nonFraction> million for the three months ended September&#160;30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $<ix:nonFraction unitRef="usd" contextRef="i03dbc97b506740c1ab99758d71d8644a_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzU3NTM_cea6ac7f-9d63-4618-a274-231c0df1ae19">22</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="i75e88d2441654c87afe085d4a0348bb9_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzU3Njc_a5e5e082-1a6c-4cfe-b887-41a2956da89c">5</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="i03dbc97b506740c1ab99758d71d8644a_D20220701-20220930" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzYwMzQ_59128fa3-aea8-4b24-821a-ab53339e18ae">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i75e88d2441654c87afe085d4a0348bb9_D20210701-20210930" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzYwNDE_04d863a5-cbe6-4e63-93e2-830909477447">6</ix:nonFraction>&#160;million during the three months ended September&#160;30, 2022 and 2021, respectively.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i01ee225c212941c6bd01d6a6c86c96ed"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="i9127505057a74be592b08798b91f4df4_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzQ5NDc4MDIzMzU4MTY_9703787d-9642-431d-85a8-080378481b3d">6</ix:nonFraction>&#160;million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzc3MTY_47f9b3ea-a885-4513-bec5-d51d8b067683" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09ef0c511ae4237af07d4b591d9c579_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzEtMS0xLTEtMjAwNTcx_5102cd9b-d882-416f-8c71-e04a7d1bc8e3">4,838</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b51adfb3de843dc981ee6f67bb7126c_I20220630" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzEtMy0xLTEtMjAwNTcx_db40a41f-b929-4663-9e08-714612e238fe">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzItMS0xLTEtMjAwNTcx_35d21790-a582-43e3-8adf-5559157ec35e">5,267</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzItMy0xLTEtMjAwNTcx_e7fac206-13b5-4edd-8f01-e5219aa763c7">5,315</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="ibd18cf751e3b4588bcfe40175c3f40a1_109"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzcyMw_d7c844a1-6960-4a01-a391-8b972cd04d7d" continuedAt="i99c31993d09c46278ef2cd55cf6e0ec8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit) </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="iad9bf46791af4b50b139fbccfcf7acb6_D20220701-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzE3MA_76d65e55-470e-46fc-9004-746bd3dd7af9">1.0</ix:nonFraction> billion. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i804fad5b06b0439c81e19646ddce2790_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEyNDM_36afa354-92da-496c-a392-af1f4faa584b">12.0</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i804fad5b06b0439c81e19646ddce2790_D20220701-20220930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEyNDk_8c6468a0-bf13-44f1-a710-68fbd3cc5877">66.74</ix:nonFraction>. The program is expected to conclude in the second quarter of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ib8fa2946d75244f5af4e048c4b6f80f0_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEyNjY_05f72c0c-f90f-4aa8-baa0-db4943003fa5">500</ix:nonFraction> million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i0ad50074ece84ece82376c3fa9fb7b8b_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEzMTk_a38c996f-0469-4492-a2a8-8d21ef5d8741">7.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ad50074ece84ece82376c3fa9fb7b8b_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0Xzc2OTY1ODEzOTYzMTU_3dd1ff93-86e2-4815-8c44-d837464c97d8">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd1f58cfa53748e180e4ce356b89feb0_D20211004-20211004" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0Xzc2OTY1ODEzOTYzMjM_e32070c8-4034-4b2b-b40d-6b8ce10deab8">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="ibd1f58cfa53748e180e4ce356b89feb0_D20211004-20211004" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0Xzc2OTY1ODEzOTYzMzE_17aa40f3-934d-4f9f-ba12-7001c0079438">2.0</ix:nonFraction>&#160;million common shares.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i99c31993d09c46278ef2cd55cf6e0ec8"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzcyMg_af864f57-510c-48db-a314-69a63cd78e66" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c5566f30ebc41c9a4c5aa210ea0d0a1_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzEtMS0xLTEtMjAwNTcx_cf0abaf5-c2db-430d-accf-49f39210ce2a">102</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e0da40648754f7e8ebf900b3a6b20a7_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzEtMy0xLTEtMjAwNTcx_3c3e0450-0ecb-46c2-b994-a1f3864e9b44">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bca371c3eb7478a9a9c71b3235bd9da_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzEtNS0xLTEtMjAwNTcx_20c6655c-5367-4f1c-b358-3ec53def3ec4">114</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzItMS0xLTEtMjAwNTcx_90002e1b-d774-4512-b055-d4d867a1189d">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i892094d14d894e958f90124c7fa6d265_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzItMy0xLTEtMjAwNTcx_af171695-b597-400a-91e6-e1857661a0fd">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i698aacd651704977bb16df51d8070a30_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzItNS0xLTEtMjAwNTcx_b363f34e-8bdf-4d9b-92d5-a7c38de37c78">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzMtMS0xLTEtMjAwNTcx_dcf7b61f-bc1e-45e5-b418-78fcc505f2b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i892094d14d894e958f90124c7fa6d265_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzMtMy0xLTEtMjAwNTcx_1487960b-bcab-43f5-979c-367ca406a1fb">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i698aacd651704977bb16df51d8070a30_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzMtNS0xLTEtMjAwNTcx_59cf2a77-69bf-483a-9bb2-0173dea56bec">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtMC0xLTEtMjMwOTE2L3RleHRyZWdpb246NzYzYzE4N2Y5YmVmNDQ3ZDg3OGJiZDIyNGE3NmRkNWNfMjc0ODc3OTA2OTU1Ng_9900cca2-bf8d-4abc-b48f-dc863229fc34">7</ix:nonFraction>&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtMS0xLTEtMjAwNTcx_57b47143-8794-4ef2-b427-fb53fbd68898">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i892094d14d894e958f90124c7fa6d265_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtMy0xLTEtMjAwNTcx_68d756b4-dbdb-449b-bcc6-1e742abdc97f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7de5f4005fe40ad951ccbaf90fed316_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtNS0xLTEtMjAwNTcx_690a28fd-8740-49c3-9614-95e768f33cb8">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2b8399010484b6095659918a1811fbe_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzUtMS0xLTEtMjAwNTcx_923ecbef-0cef-47fe-a2dd-c5b60cf7c70c">160</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d06169bd4ac4fe1b8c2bc2c47eb44f6_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzUtMy0xLTEtMjAwNTcx_48cda0e1-2532-4a2d-bba3-50f442522566">16</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i518c9f6c90a440a9b3e29e04e98d1fe2_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzUtNS0xLTEtMjAwNTcx_fd608725-86e4-4972-ade9-4553cc090371">176</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81ce1edc4ddb41989ad743f2322d6d0e_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzEtMS0xLTEtMjExOTg3_4464ff9d-51f1-443f-b9ad-3c7d702515aa">46</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49d63915083840a09569f5e9570a4c80_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzEtMy0xLTEtMjExOTg3_88850260-4f3a-4eac-af88-1f09021950b8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855d5c9c3f5e4418855a7294a17541ef_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzEtNS0xLTEtMjExOTg3_6013989c-e4d3-4746-8337-e49c77b9f797">34</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzItMS0xLTEtMjExOTg3_7c8d3aed-0a23-42f1-b0a1-00ce5ca492c5">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3044261be5249d9833e8961865fb32f_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzItMy0xLTEtMjExOTg3_c3faf665-b7e6-4026-ba9e-9aa8eae22c2a">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzItNS0xLTEtMjExOTg3_981c6332-a963-4901-9c8b-9d9291392bbd">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzMtMS0xLTEtMjExOTg3_ed1f44c5-b551-4502-8cf2-9be86739cae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3044261be5249d9833e8961865fb32f_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzMtMy0xLTEtMjExOTg3_1917d6f1-4f29-433d-a556-57bdedb0b6fb">1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzMtNS0xLTEtMjExOTg3_815fe4e8-3052-49bd-b961-538680850f12">1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzQtMS0xLTEtMjExOTg3_ef50170d-6d3d-4661-b19b-0430e223db35">25</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3044261be5249d9833e8961865fb32f_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzQtMy0xLTEtMjExOTg3_a7f0b749-12d5-446d-8acf-032c2aff5aa5">2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fbb9c3f242b449a93c375031cccfb0a_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzQtNS0xLTEtMjExOTg3_b3c5b265-5ad9-47fa-846a-48cdcc60e2df">27</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9ffb10cd2a4f23ae074893f97a8ac8_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzUtMS0xLTEtMjExOTg3_45df0160-7f7c-40f3-82f8-e832f6a9daf4">71</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50162f37f7b7432489740885c70a6401_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzUtMy0xLTEtMjExOTg3_c6d6f327-e3e8-46b3-8afb-682dee780073">10</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e9a4dc61694a2cbe868bd038d8e96a_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzUtNS0xLTEtMjExOTg3_a702da3e-e328-42d1-a794-7f1e50a0fd49">61</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_112"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzU3OA_c65ebfd2-55b1-4d6c-90c6-5b23262aa50d" continuedAt="i5272fbf7d32648669e182444c420a49f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings Per Share Attributable to Cardinal Health, Inc. </span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzU4NQ_f7ba8e12-23ee-4820-ac3e-38a09269957d" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzItMS0xLTEtMjAwNTcx_c282a7b5-f5b6-4607-ba0d-f5f4749d249b">271</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzItMy0xLTEtMjAwNTcx_dee91834-3820-48bf-a87f-b5e9357bb078">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzQtMS0xLTEtMjAwNTcx_0ab790e2-2f88-4861-96d5-4883239a71ea">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzQtMy0xLTEtMjAwNTcx_c54c84de-4021-4649-844f-04bdeb8fd969">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzUtMS0xLTEtMjAwNTcx_10571865-cd1c-4434-8638-8770772f4b73">273</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzUtMy0xLTEtMjAwNTcx_85995d90-cf6b-4ae6-8756-ead9ae0ba6e7">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5272fbf7d32648669e182444c420a49f">the three months ended September 30, 2022 and 2021 were <ix:nonFraction unitRef="shares" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="cah:Numberofsharesexcludedfromcalculationofdilutedshares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzMyMQ_3547cf7c-4fd6-4fa1-8805-c50d056445e6"><ix:nonFraction unitRef="shares" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="cah:Numberofsharesexcludedfromcalculationofdilutedshares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzMyMQ_f9f0605a-c627-4b37-b6d3-4bf52bef3eda">4</ix:nonFraction></ix:nonFraction> million</ix:continuation>.</span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_115"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MzY_831111f9-db03-475a-b455-0835b4f5d264" continuedAt="i76eaf5cede464c06b18666c3cb71da7d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzEwMg_29f01f1a-5eaa-430d-ae97-d186014f2ee5"><ix:nonFraction unitRef="segment" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzEwMg_546a5816-5f18-43cc-b25e-3a15cf7f1b26">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i76eaf5cede464c06b18666c3cb71da7d" continuedAt="i308c3dc7fdca4271b020d5174af3c8ff"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzI3NDg3NzkwNzY5MDk_0c790f17-517d-4834-af88-a9ab47e78974" continuedAt="icc5af0fc701b49ea9622746ad5859ec6" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f856b81cd0b4febbaa82e7ba3b7de3e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzItMS0xLTEtMjAwNTcx_4542e5a3-2df1-4f44-b3e5-64a60826ffb9">45,547</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb884cfea93c4a6b9776a6eb15f99801_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzItMy0xLTEtMjAwNTcx_f1c8b9ac-9d78-4ab2-be66-a7ec31d32de1">39,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98a9f7800324334933b05a45c7c1081_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzMtMS0xLTEtMjAwNTcx_b4a990f8-5cae-4fcd-baff-29b91b18f348">281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6964ebf21c6641d8a7d3c962e30215fc_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzMtMy0xLTEtMjAwNTcx_c5e180e0-4598-4eed-b6dc-de5cdb99547f">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd40bf9e64d4e28aba32338f5e1c3f3_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzQtMS0xLTEtMjAwNTcx_2525c37c-4ab4-4a27-907a-2138b040bab6">45,828</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab13212bf3f64da69caee3d568418629_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzQtMy0xLTEtMjAwNTcx_85d8a81b-d3b9-4de4-962d-9c7fce400a91">39,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23cd6cc579e4db1ac1517955232ea9e_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzUtMS0xLTEtMjAwNTcx_ba7e92f3-d646-4207-98fa-e2f07de02170">3,140</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871bd2199ae14c3d8b2d85b00fa634dd_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzUtMy0xLTEtMjAwNTcx_a89198d3-3922-43f9-9e82-7aa89dda44c1">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if915e60e430a448e95ac1d3210262b21_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzYtMS0xLTEtMjAwNTcx_afdba632-449d-4fe2-a87f-7c6945a68d9e">638</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae83bd29fad7455f842d7e87a827912f_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzYtMy0xLTEtMjAwNTcx_fbaa7c6c-2d62-413f-8f83-1875c079aacf">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9bf49c924d4d84898b126cd4f6a3ff_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzctMS0xLTEtMjAwNTcx_19fbb5fe-bb90-466f-bd7e-04fe79c1ca36">3,778</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015c85ec14f2406f8e7dffe472b4851c_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzctMy0xLTEtMjAwNTcx_1f789b55-122f-4e49-bf83-1d2e27358280">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzgtMS0xLTEtMjAwNTcx_9b8d9d7d-c1a3-4ccb-bccb-89fe7b0e3772">49,606</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzgtMy0xLTEtMjAwNTcx_0b0f55d3-231d-4d71-87a0-1b431fc0c70a">43,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65ff688f93904d2baa8f773161063474_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzktMS0xLTEtMjAwNTcx_57e55933-f3fd-4cf8-9469-998823bcdc02">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzktMy0xLTEtMjAwNTcx_0fec5bd6-9b21-4282-9010-f328f555dbea">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzEwLTEtMS0xLTIwMDU3MQ_e5ed5148-09bd-4c32-b5ea-49aa34f603b0">49,603</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzEwLTMtMS0xLTIwMDU3MQ_78173c52-9a43-4a20-b553-7ddf74b7b91b">43,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="icc5af0fc701b49ea9622746ad5859ec6" continuedAt="i8a35672aa8c14c2cbb70864a1dee6d3c">(5)</ix:continuation></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:continuation id="i8a35672aa8c14c2cbb70864a1dee6d3c">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments</ix:continuation>.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MzI_116aba3d-1cd4-42de-b125-8a25b0103e28" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b65aec35854386926330a8514839c9_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzItMS0xLTEtMjAwNTcx_d68d6649-da26-4106-93d4-fc4d2c510275">48,477</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195c3e4a70d140e6a8c0d6fbd576c739_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzItMy0xLTEtMjAwNTcx_79201032-f3e9-423a-b407-8a5cdd7f791a">42,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7926d786e4e449517abc30d8e145f_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzMtMS0xLTEtMjAwNTcx_cbb62fe0-9a32-4049-bb38-096eae655b74">1,129</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2160ad80e344e7a85fc8a96deb9476c_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzMtMy0xLTEtMjAwNTcx_0a4eea7e-221a-454d-ab9a-38cd9c8ad667">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzQtMS0xLTEtMjAwNTcx_9b8d9d7d-c1a3-4ccb-bccb-89fe7b0e3772">49,606</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzQtMy0xLTEtMjAwNTcx_8d59aa7a-e0f8-4239-af4a-5b6bca8bf2ae">43,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65ff688f93904d2baa8f773161063474_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzUtMS0xLTEtMjAwNTcx_57e55933-f3fd-4cf8-9469-998823bcdc02">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzUtMy0xLTEtMjAwNTcx_9f068f11-3995-483a-90c5-fd905b4a3662">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzYtMS0xLTEtMjAwNTcx_e5ed5148-09bd-4c32-b5ea-49aa34f603b0">49,603</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzYtMy0xLTEtMjAwNTcx_2210778b-0be5-4e0a-a007-ca0aee6387be">43,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2020 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i308c3dc7fdca4271b020d5174af3c8ff" continuedAt="i8fcc99b8f80349df8bd3589bc15364b4"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQzNzY_8713025a-3767-4808-a8d1-d33d8feeea20">6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQzODM_2562991e-7b23-43b1-8695-1e2c512afab1">7</ix:nonFraction> million for the three months ended September 30, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MjM_29715fe1-9bc1-4df8-b2c8-e977b36ccffa" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd40bf9e64d4e28aba32338f5e1c3f3_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzItMS0xLTEtMjAwNTcx_78436ec1-474e-4ab0-9c4f-840d57734d78">431</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab13212bf3f64da69caee3d568418629_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzItMy0xLTEtMjAwNTcx_36eb2741-4818-466d-94cb-35bdee8b6bcb">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad9bf49c924d4d84898b126cd4f6a3ff_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzMtMS0xLTEtMjAwNTcx_4923493d-efe4-4422-9eff-6ac0afcfa3ac">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015c85ec14f2406f8e7dffe472b4851c_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzMtMy0xLTEtMjAwNTcx_15d404aa-0b87-4eee-a64c-db4df7ba1f73">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzQtMS0xLTEtMjAwNTcx_5f172d0c-d9dc-443a-8e7c-ed1a5e75f6ae">423</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzQtMy0xLTEtMjAwNTcx_a6182ee9-d0b4-42ad-abad-bdcab699cad1">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65ff688f93904d2baa8f773161063474_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzUtMS0xLTEtMjAwNTcx_10afff6b-aff3-48ef-9aab-4962f20fce64">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzUtMy0xLTEtMjAwNTcx_0c7b00a8-fbac-4f40-8a45-8903aefda8dd">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzYtMS0xLTEtMjAwNTcx_07d40fae-b28b-44d8-87e1-9ac389a9d386">137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzYtMy0xLTEtMjAwNTcx_e3de778d-9ff3-40af-b63f-029c34b61e9f">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i8fcc99b8f80349df8bd3589bc15364b4"><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MzE_0c93bd15-49dc-424f-a330-fbeb9bbcfc1e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81002aafca94fc2b38566fff63f36b6_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzEtMS0xLTEtMjAwNTcx_48de397c-78ac-4350-87a3-66248ec27807">27,253</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f690daefd04e45ba22e43204d3f8ce_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzEtMy0xLTEtMjAwNTcx_8188d2b1-1b6e-4d80-86a7-9a4dd62491a7">26,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a03688720b448f29df8a3a0536629e2_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzItMS0xLTEtMjAwNTcx_bfabd72a-2cfb-41d2-8e21-33b4f321bc5f">11,338</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ead376383b64ae98d667697c55cf194_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzItMy0xLTEtMjAwNTcx_08ac1dc2-8184-437c-b830-ea8fbc327265">11,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8d1a31b74a43529c08389b432be66a_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzMtMS0xLTEtMjAwNTcx_ed279996-03c1-4272-a23c-c7c9b8021225">4,796</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c33230a00c486e83ac2a0e6d04febe_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzMtMy0xLTEtMjAwNTcx_9385c091-fec0-4f49-8c70-5168c3866802">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzQtMS0xLTEtMjAwNTcx_8c5bbf96-e0ce-4170-8674-8c6ab146e2a2">43,387</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id865979318b34ac9a0006dc78693a91a_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzQtMy0xLTEtMjAwNTcx_6d7e68bc-74ad-4cc6-8849-e44108178839">43,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_118"></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI0NDE_6d934825-2601-4e3a-b6ed-9e4c7312b269" continuedAt="i4a4c326771e14b739456fc485962ee8e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI0MTI_1c5210be-7dd6-4161-b47a-edec0c5e6f31" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzItMS0xLTEtMjAwNTcx_34519fee-67c4-444e-9987-44295c79cc84">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b600072fc640a2accf8530d5da12dc_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzItMy0xLTEtMjAwNTcx_74039a6b-1851-4cf4-866a-e801dc9617be">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzQtMS0xLTEtMjAwNTcx_6842f611-784f-47ba-89eb-16b109611558">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ad627a1ffc43319b21b5b9c5ec5da3_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzQtMy0xLTEtMjAwNTcx_687747d4-669c-4112-8ed7-f9c42902f344">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzUtMS0xLTEtMjAwNTcx_d9cecabb-0a38-467d-80aa-a4f72840f0ad">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzUtMy0xLTEtMjAwNTcx_ab45beb7-28ee-497b-b35c-d00a0544fe2b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI5MQ_0a9e02a8-d2c4-4fb9-8fb3-05a7532f7724">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzU0OTc1NTgxNjM0NA_85d4e2ca-823d-41dd-af35-b19fe4cd7998">4</ix:nonFraction> million for the three months ended September&#160;30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzQ2OQ_0b36de9d-5be5-4a37-8a57-277254c67674">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzIzODg_ed188e50-e518-46ca-9700-c3c6c9c2c667" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22ab637b9b2d4e64a547c5de3c7224a8_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzEtMS0xLTEtMjAwNTcx_07bbcd85-1433-4d20-b456-da557fdd8ef5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22ab637b9b2d4e64a547c5de3c7224a8_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzEtMy0xLTEtMjAwNTcx_c0255b58-ee0d-4255-9a19-2a2cf24f7d0f">46.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzItMS0xLTEtMjAwNTcx_62e4d12e-ec7b-4466-be89-0df030386d3e">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzItMy0xLTEtMjAwNTcx_ff491ad4-3674-4aa2-a4c5-032820eaf3c4">69.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzMtMS0xLTEtMjAwNTcx_bfe74c68-cfb4-4040-a2b5-eee1d575c43c">1.2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzMtMy0xLTEtMjAwNTcx_a74692a5-e5b2-40e3-9e69-8048ed3d24b4">49.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzQtMS0xLTEtMjAwNTcx_5acd6826-bfe5-493d-8e2b-ae5ba79c7033">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzQtMy0xLTEtMjAwNTcx_bae439b8-b497-4ee3-9bd1-9c5d4fa778b6">54.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzUtMS0xLTEtMjAwNTcx_930c826b-05eb-41d6-9dfa-4da3530afa4b">2.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzUtMy0xLTEtMjAwNTcx_77dc5995-cf46-48da-b837-e1443acf624b">59.43</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzgxNg_fd189f71-bd02-4058-b062-38b5949bc81b">119</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzg4OQ_29c70fc8-d21e-4f6f-944c-791096a01d7f">two years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="reportable_segments" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="0" name="cah:VestingPeriodinyearsforShares" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE2MTQ_37d10fac-6266-43b3-ac5d-0baa6ddc165a">three</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="ic4a1eacea71a4285aadeba26a17758a0_D20200701-20210630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3Nzc_799800f1-2d4d-4879-826e-03c5a0cd34e7"><ix:nonFraction unitRef="number" contextRef="i8c7555e89f9a44c0be6b8791b103af9c_D20190701-20200630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3Nzc_db54ca3f-d3d2-4a9b-b808-f01cc3d48616">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="iea97411b6d7641378c9eb6b952443d0d_D20200701-20210630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3ODM_34ecb77e-458a-46d3-b09f-8facb42a7e1c"><ix:nonFraction unitRef="number" contextRef="i9f28dc925abc41bb8cf3ce6828882c78_D20190701-20200630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3ODM_5dd068a3-80e2-4b9b-91d3-be61783516c3">240</ix:nonFraction></ix:nonFraction> percent of the target award amount for the fiscal 2020 and 2021 grants and <ix:nonFraction unitRef="number" contextRef="i1b0209d5fc294341b06b2c8dbf923e09_D20210701-20220630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTM_0f4a2e12-d05a-45cd-9e4d-4503341af023"><ix:nonFraction unitRef="number" contextRef="i1f1fe6789c734a7cb6a29d3d8764b93b_D20220701-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTM_189c78dd-b906-468a-9b88-cfd5cd861da9">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i2ada8d3d750f4d05bd88fb3b24af4514_D20210701-20220630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTk_1ae150bf-ffd7-4e5a-afa5-8ce6b0928c85"><ix:nonFraction unitRef="number" contextRef="ia8eb22db75ac48e3948c5833cc36811c_D20220701-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTk_77456e6f-d8e5-4e28-8741-ea07a276a7c3">234</ix:nonFraction></ix:nonFraction> percent for the fiscal 2022 and 2023 grants. Performance share </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i4a4c326771e14b739456fc485962ee8e"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI0MjQ_0b0e95d7-dd47-48fe-a339-409c7048ba71" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i217061d4807f455b88c7f795a4fa433d_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzEtMS0xLTEtMjAwNTcx_4dc86c00-157d-42a2-9480-9ff6f41fd73e">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i217061d4807f455b88c7f795a4fa433d_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzEtMy0xLTEtMjAwNTcx_051d538d-331e-4177-ab15-ab48cd69b67c">54.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzItMS0xLTEtMjAwNTcx_18237de7-cd46-48e4-9c01-7f70a242679d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzItMy0xLTEtMjAwNTcx_ff1932ad-72ef-4428-ad9c-89a654a4acde">76.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzMtMS0xLTEtMjAwNTcx_7fc4aeaa-547f-4ca9-bb6f-2b1fd33b5ca1">0.4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzMtMy0xLTEtMjAwNTcx_269305bd-31f9-4c0e-a551-1d4a02720060">59.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzQtMS0xLTEtMjAwNTcx_1bed27e2-95ac-416c-af4b-2261b14c1657">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzQtMy0xLTEtMjAwNTcx_f8690270-b62f-44fe-90a8-df342514a8e7">57.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzUtMS0xLTEtMjAwNTcx_1c449910-f5b0-4657-808a-20cafcf7413f">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzUtMy0xLTEtMjAwNTcx_725455b3-9ddf-4097-923d-2088343edb01">72.01</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzIyNjc_d5ee7db7-9370-452d-b325-09d734442ff5">28</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzIzNDA_b95a03a7-9d75-49a4-89f9-c8ec1dcfb91b">two years</ix:nonNumeric> if the performance goals are achieved.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">(incorporated by reference </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">to Exhibit 3.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">to Cardinal Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">'s Quarterly  Report on Form 10-Q filed on November 9, 2021, File No. 1-11373</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000096/exhibit10-1.htm">Cooperation Agreement, dated as of September 5, 2022, by and among Cardinal Health, Inc., Elliott Associates, L.P. and Elliott International, L.P. (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on September 6, 2022, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137122000127/exhibit101-10x4x2022.htm">Sixth Amendment to the Fourth Amended and Restated Receivables Purchase Agreement, dated September 30, 2022 (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on October 4, 2022, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q1_10qx093022xex3113.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q1_10qx093022xex3123.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q1_10qx093022xex3213.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a23q1_10qx093022xex9911.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:6.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_58">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_58">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_40">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_40">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_43">20</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_46">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_49">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_52">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_121">41</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_127">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd18cf751e3b4588bcfe40175c3f40a1_127">43</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="ibd18cf751e3b4588bcfe40175c3f40a1_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.005%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PATRICIA M. ENGLISH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patricia M. English</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2023 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a23q1_10qx093022xex3113.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8e52f9fcebcf492486f11bb004aec9bc_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a23q1_10qx093022xex3123.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic409121195cf44db9438f8662b6f2e53_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Patricia M. English, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PATRICIA M. ENGLISH</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia M. English</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a23q1_10qx093022xex3213.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if4f364b8871a4b3c958836683e9daa2b_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Patricia M. English, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended September 30, 2022 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;4, 2022 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PATRICIA M. ENGLISH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia M. English</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a23q1_10qx093022xex9911.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i685022d544c04179aa2296fe7b1f2ae5_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2022 (the &#8220;2022 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the Department of Justice which we believe concern our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the national settlement agreement to resolve the vast majority of opioid-related claims brought by states and other governmental entities, including the risk that the implementation and maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility of additional adverse impacts to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on ethylene oxide (&#34;EtO&#34;) to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience supply disruptions as a result of the Uyghur Forced Labor Prevention Act&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">certain risks arising from the ongoing COVID-19 pandemic&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2022 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cah-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:964ac801-dd50-4cbf-978f-cd662ea3a8c6,g:8bda5b56-43aa-4d85-9f5e-cb52b0901382-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>0000002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>0000008 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>0000009 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000010 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>0000011 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>0000012 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>0000013 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>0000015 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>0000016 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>0000017 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>0000018 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>0000019 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.cardinal.com/role/DivestituresTables">
        <link:definition>0000021 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>0000022 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>0000023 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>0000024 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>0000025 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>0000026 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>0000027 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>0000028 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>0000029 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000030 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetails" roleURI="http://www.cardinal.com/role/DivestituresDetails">
        <link:definition>0000031 - Disclosure - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>0000032 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>0000033 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarrativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails">
        <link:definition>0000034 - Disclosure - Restructuring and Employee Severance Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>0000035 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000036 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>0000037 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
        <link:definition>0000039 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000040 - Disclosure - Income Taxes Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000041 - Disclosure - Fair Value Measurements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000042 - Disclosure - Financial Instruments Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>0000043 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>0000044 - Disclosure - Shareholders' Equity Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000045 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>0000046 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>0000047 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000048 - Disclosure - Segment Information Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>0000049 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>0000050 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>0000051 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails">
        <link:definition>0000052 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyGeographicalSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails">
        <link:definition>0000053 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>0000054 - Disclosure - Share-Based Compensation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>0000055 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>0000056 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>0000057 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LossContingencyNumberOfEligibleStates" abstract="false" name="LossContingencyNumberOfEligibleStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_TerminalGrowthRateFairValueInput" abstract="false" name="TerminalGrowthRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePriceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_SettlingStates" abstract="false" name="SettlingStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicalSegmentDomain" abstract="true" name="MedicalSegmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NativeAmericanTribesMember" abstract="true" name="NativeAmericanTribesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_DiscountRateFairValueInput" abstract="false" name="DiscountRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_JudgmentForLostProfits" abstract="false" name="JudgmentForLostProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Numberofsharesexcludedfromcalculationofdilutedshares" abstract="false" name="Numberofsharesexcludedfromcalculationofdilutedshares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" abstract="true" name="BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A1BillionShareRepurchaseProgramMember" abstract="true" name="A1BillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicTable" abstract="true" name="SegmentRevenuebyGeographicTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthServicesMember" abstract="true" name="NuclearPrecisionHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePriceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicLineItems" abstract="true" name="SegmentRevenuebyGeographicLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_GoodwillImpairmentDomain" abstract="true" name="GoodwillImpairmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_GoodwillImpairmentMedicalUnitMember" abstract="true" name="GoodwillImpairmentMedicalUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LitigationTypeDomain" abstract="true" name="LitigationTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CashReclassifiedFromAssetsHeldForSale" abstract="false" name="CashReclassifiedFromAssetsHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PharmaceuticalSegmentDomain" abstract="true" name="PharmaceuticalSegmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_IncomefromSettlementsofClassActionLawsuits" abstract="false" name="IncomefromSettlementsofClassActionLawsuits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalSegmentAxis" abstract="true" name="PharmaceuticalSegmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_GoodwillImpairmentAxis" abstract="true" name="GoodwillImpairmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeSolutionsMember" abstract="true" name="CardinalHealthAtHomeSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicalUnitMember" abstract="true" name="MedicalUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicalSegmentAxis" abstract="true" name="MedicalSegmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SettlingUSTerritories" abstract="false" name="SettlingUSTerritories" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_A500MillionShareRepurchaseProgramMember" abstract="true" name="A500MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cah-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:964ac801-dd50-4cbf-978f-cd662ea3a8c6,g:8bda5b56-43aa-4d85-9f5e-cb52b0901382-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_da26343b-8c0e-4cef-a187-dd6fab4a7506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e812afe2-63d9-43ed-a264-3c3fdc49b0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_da26343b-8c0e-4cef-a187-dd6fab4a7506" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e812afe2-63d9-43ed-a264-3c3fdc49b0ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2469b762-4eaf-4680-96fb-fcd888f91409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_da26343b-8c0e-4cef-a187-dd6fab4a7506" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2469b762-4eaf-4680-96fb-fcd888f91409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b13596c9-500f-4c74-9783-1974651428af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_551696ec-a4aa-4a54-b37f-cc6be021dc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b13596c9-500f-4c74-9783-1974651428af" xlink:to="loc_us-gaap_Revenues_551696ec-a4aa-4a54-b37f-cc6be021dc6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_18103dea-3b71-43ca-83c6-1c02f26eba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b13596c9-500f-4c74-9783-1974651428af" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_18103dea-3b71-43ca-83c6-1c02f26eba5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd9f83ef-5b04-4e87-955f-c5439a0fcd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a7914b3d-55f1-45b9-8d1f-505face563a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd9f83ef-5b04-4e87-955f-c5439a0fcd9a" xlink:to="loc_us-gaap_OperatingIncomeLoss_a7914b3d-55f1-45b9-8d1f-505face563a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_02240ab7-0381-4b55-92bb-7420a5f3b855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd9f83ef-5b04-4e87-955f-c5439a0fcd9a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_02240ab7-0381-4b55-92bb-7420a5f3b855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f236ccc6-c42e-48dc-8cc2-18b7be806798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd9f83ef-5b04-4e87-955f-c5439a0fcd9a" xlink:to="loc_us-gaap_InterestExpense_f236ccc6-c42e-48dc-8cc2-18b7be806798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_da04f900-b09a-421b-9c93-330f975078df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd9f83ef-5b04-4e87-955f-c5439a0fcd9a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_da04f900-b09a-421b-9c93-330f975078df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_24f38e40-b7f9-41f0-9dce-f46e53a9f937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:to="loc_us-gaap_GrossProfit_24f38e40-b7f9-41f0-9dce-f46e53a9f937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fe350a68-db36-4e58-ac6f-ee991e257884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fe350a68-db36-4e58-ac6f-ee991e257884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0816b569-0d69-4089-abbb-e90ceeaaedb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:to="loc_us-gaap_RestructuringCharges_0816b569-0d69-4089-abbb-e90ceeaaedb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_26945b7f-b554-475a-bd23-928b0664ee0b" xlink:href="cah-20220930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_26945b7f-b554-475a-bd23-928b0664ee0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_1c55b895-5c48-44f5-b157-198fd8b20488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_1c55b895-5c48-44f5-b157-198fd8b20488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b86b85d1-ee4d-4e28-8c5a-fad70999657e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3be8694d-55d9-4d2e-813c-c58e12941580" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b86b85d1-ee4d-4e28-8c5a-fad70999657e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_476d715d-fb9c-4257-a967-5d32245f2920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3bbb889c-f38e-44de-8bb8-bdebe4062217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_476d715d-fb9c-4257-a967-5d32245f2920" xlink:to="loc_us-gaap_ProfitLoss_3bbb889c-f38e-44de-8bb8-bdebe4062217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d43659e2-5013-4a89-bfe4-bf13753605a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_476d715d-fb9c-4257-a967-5d32245f2920" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d43659e2-5013-4a89-bfe4-bf13753605a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_229d9cf9-577f-49c1-876d-fe875d8b75f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1c4f3ee1-e583-42be-b12a-1642c38120ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_229d9cf9-577f-49c1-876d-fe875d8b75f1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1c4f3ee1-e583-42be-b12a-1642c38120ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e0147679-c6c1-4db3-a506-c5ec2996ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_229d9cf9-577f-49c1-876d-fe875d8b75f1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e0147679-c6c1-4db3-a506-c5ec2996ceca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e970c0c6-9446-4661-b06f-bcb676126f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ada94eb5-3da1-48b9-be6f-2d1732f0c1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e970c0c6-9446-4661-b06f-bcb676126f2f" xlink:to="loc_us-gaap_ProfitLoss_ada94eb5-3da1-48b9-be6f-2d1732f0c1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c60b5b2b-c213-4d0d-9b2f-227e9263f317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e970c0c6-9446-4661-b06f-bcb676126f2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c60b5b2b-c213-4d0d-9b2f-227e9263f317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_292508e3-cd34-4377-82af-b871a542dd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_901b6f9a-5713-4808-83ba-72cf520f3625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_292508e3-cd34-4377-82af-b871a542dd25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_901b6f9a-5713-4808-83ba-72cf520f3625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9003a414-4536-43b3-a786-b6252260fc36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_292508e3-cd34-4377-82af-b871a542dd25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9003a414-4536-43b3-a786-b6252260fc36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_405c7c72-3269-48ae-a6bf-2c69bae6725c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6fa03959-d5a0-4432-b21e-872a77e97908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_405c7c72-3269-48ae-a6bf-2c69bae6725c" xlink:to="loc_us-gaap_StockholdersEquity_6fa03959-d5a0-4432-b21e-872a77e97908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b7c394d2-9ca8-4d47-825c-392bacff8a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_405c7c72-3269-48ae-a6bf-2c69bae6725c" xlink:to="loc_us-gaap_MinorityInterest_b7c394d2-9ca8-4d47-825c-392bacff8a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_57c92780-7e25-4434-93ae-0d2253a4d638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c15d9b8-caa9-43e9-9af3-0574a96d8195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_57c92780-7e25-4434-93ae-0d2253a4d638" xlink:to="loc_us-gaap_LiabilitiesCurrent_2c15d9b8-caa9-43e9-9af3-0574a96d8195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4d44d3b0-45be-4539-80c5-48eec7061828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_57c92780-7e25-4434-93ae-0d2253a4d638" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4d44d3b0-45be-4539-80c5-48eec7061828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_0a7ee3e7-d4ac-4d6d-8455-f31ff99c444d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_57c92780-7e25-4434-93ae-0d2253a4d638" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_0a7ee3e7-d4ac-4d6d-8455-f31ff99c444d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97ad2298-62b4-449b-a462-845121c32481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_57c92780-7e25-4434-93ae-0d2253a4d638" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97ad2298-62b4-449b-a462-845121c32481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_297655fe-25e2-4ce5-b2b4-1c7824c0b5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_21afc3c7-3fd1-4dde-afab-af21cf3deb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_297655fe-25e2-4ce5-b2b4-1c7824c0b5c7" xlink:to="loc_us-gaap_AccountsPayableCurrent_21afc3c7-3fd1-4dde-afab-af21cf3deb9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_06b7e45e-40af-40e3-8402-42a5f5d6bc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_297655fe-25e2-4ce5-b2b4-1c7824c0b5c7" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_06b7e45e-40af-40e3-8402-42a5f5d6bc05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e4ed24d-3594-4d9f-be79-452da118c095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_297655fe-25e2-4ce5-b2b4-1c7824c0b5c7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e4ed24d-3594-4d9f-be79-452da118c095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_47e31b97-f1e8-4cb5-b940-1e38c997fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_9348c12b-f003-40e6-948c-25725408242b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47e31b97-f1e8-4cb5-b940-1e38c997fe6e" xlink:to="loc_us-gaap_ReceivablesNetCurrent_9348c12b-f003-40e6-948c-25725408242b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d38190f-e0b5-49f8-bb21-e0caecd3a674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47e31b97-f1e8-4cb5-b940-1e38c997fe6e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d38190f-e0b5-49f8-bb21-e0caecd3a674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8aadbc5a-6f5b-4e10-a223-5279842de730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47e31b97-f1e8-4cb5-b940-1e38c997fe6e" xlink:to="loc_us-gaap_OtherAssetsCurrent_8aadbc5a-6f5b-4e10-a223-5279842de730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b8c8e7cc-c9bd-4123-ad19-a626c767579a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47e31b97-f1e8-4cb5-b940-1e38c997fe6e" xlink:to="loc_us-gaap_InventoryNet_b8c8e7cc-c9bd-4123-ad19-a626c767579a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e18773bf-2862-4707-bb29-5c0319516b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e63ffead-95d9-4b7a-aa43-de9ada2cd45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e18773bf-2862-4707-bb29-5c0319516b33" xlink:to="loc_us-gaap_PreferredStockValue_e63ffead-95d9-4b7a-aa43-de9ada2cd45d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dada555d-8c71-4852-a7c9-6bd6ddb69dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e18773bf-2862-4707-bb29-5c0319516b33" xlink:to="loc_us-gaap_CommonStockValue_dada555d-8c71-4852-a7c9-6bd6ddb69dbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a6aea8ad-365a-40c7-8dee-1fa1aac7d292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e18773bf-2862-4707-bb29-5c0319516b33" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a6aea8ad-365a-40c7-8dee-1fa1aac7d292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f917fbb0-6a06-4bf6-a184-b189f710e236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e18773bf-2862-4707-bb29-5c0319516b33" xlink:to="loc_us-gaap_TreasuryStockValue_f917fbb0-6a06-4bf6-a184-b189f710e236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e346a56f-f54a-42b5-8a2e-d1cd907f0ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e18773bf-2862-4707-bb29-5c0319516b33" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e346a56f-f54a-42b5-8a2e-d1cd907f0ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f229406b-2e47-49f9-a0a4-f23eec9591a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5ef4a2c0-6d4a-4402-a326-6af4d63a22cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f229406b-2e47-49f9-a0a4-f23eec9591a0" xlink:to="loc_us-gaap_AssetsCurrent_5ef4a2c0-6d4a-4402-a326-6af4d63a22cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b04c7811-2987-413d-9f1b-1642b8e6ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f229406b-2e47-49f9-a0a4-f23eec9591a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b04c7811-2987-413d-9f1b-1642b8e6ce05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_34f47438-d576-41c7-be0d-a215ad70c01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f229406b-2e47-49f9-a0a4-f23eec9591a0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_34f47438-d576-41c7-be0d-a215ad70c01c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_06aff464-b692-4137-9cf2-3c9b722c0881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f229406b-2e47-49f9-a0a4-f23eec9591a0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_06aff464-b692-4137-9cf2-3c9b722c0881" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6a64c9c-da7f-4595-a00f-1ce7d23f3015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_8fa3b1f9-6c9d-48b5-b6df-ef5057b9f81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6a64c9c-da7f-4595-a00f-1ce7d23f3015" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_8fa3b1f9-6c9d-48b5-b6df-ef5057b9f81d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f5f94192-5ae5-4c27-a965-4c798283ac17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6a64c9c-da7f-4595-a00f-1ce7d23f3015" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f5f94192-5ae5-4c27-a965-4c798283ac17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c82fada-817b-4615-b59d-0250d1fd01b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6a64c9c-da7f-4595-a00f-1ce7d23f3015" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c82fada-817b-4615-b59d-0250d1fd01b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_de91e9ce-f4bb-41e5-8aea-69a129035b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6a64c9c-da7f-4595-a00f-1ce7d23f3015" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_de91e9ce-f4bb-41e5-8aea-69a129035b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_71a4b7e7-325c-4017-b0b5-6d72cb4567d0" xlink:href="cah-20220930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e6a64c9c-da7f-4595-a00f-1ce7d23f3015" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_71a4b7e7-325c-4017-b0b5-6d72cb4567d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c311ede0-0d5a-4122-bc77-13924b68e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_ProfitLoss_c311ede0-0d5a-4122-bc77-13924b68e5cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_646476bf-7264-483b-bf3e-4cf1747d25a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_646476bf-7264-483b-bf3e-4cf1747d25a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2fffddce-05ac-4af0-97fa-de46209a3664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2fffddce-05ac-4af0-97fa-de46209a3664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c7cd533c-75b6-40e8-bd40-da5525cf2b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c7cd533c-75b6-40e8-bd40-da5525cf2b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e022b5f8-1625-4407-ac1f-678a8183c10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_ShareBasedCompensation_e022b5f8-1625-4407-ac1f-678a8183c10d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6db59e07-3eca-451a-abc4-88511d706384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6db59e07-3eca-451a-abc4-88511d706384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_30aec9d5-950b-4b02-9e8c-a6ddd0fdb1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_30aec9d5-950b-4b02-9e8c-a6ddd0fdb1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_22de5386-3f63-450e-abdd-2334ee65341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_22de5386-3f63-450e-abdd-2334ee65341f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0febc238-1ba2-4e29-89ad-1dc69ac51ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0febc238-1ba2-4e29-89ad-1dc69ac51ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d5bcd0fe-b369-4d8a-b6d2-421caf33628b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_acc656fa-0724-4489-bc95-ee85d3504931" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d5bcd0fe-b369-4d8a-b6d2-421caf33628b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd81f8e6-0734-47b9-aba0-3322a09b5544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_87954917-fd47-4f1e-8b93-9df5b0097246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd81f8e6-0734-47b9-aba0-3322a09b5544" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_87954917-fd47-4f1e-8b93-9df5b0097246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_241aba3f-e1c3-442b-a9ca-57c04cc97e4e" xlink:href="cah-20220930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd81f8e6-0734-47b9-aba0-3322a09b5544" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_241aba3f-e1c3-442b-a9ca-57c04cc97e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_5f0b353f-33e9-4f21-a266-eb316282e92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd81f8e6-0734-47b9-aba0-3322a09b5544" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_5f0b353f-33e9-4f21-a266-eb316282e92b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_97069191-bce9-497b-b685-4d720d6c63c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd81f8e6-0734-47b9-aba0-3322a09b5544" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_97069191-bce9-497b-b685-4d720d6c63c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7620f9-21be-4321-9c0b-2c5ac13c5208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_270762e9-62d4-4c44-942b-bc68680d19d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7620f9-21be-4321-9c0b-2c5ac13c5208" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_270762e9-62d4-4c44-942b-bc68680d19d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e4cfb6b-dabf-418e-9cd6-c9a7c6696f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7620f9-21be-4321-9c0b-2c5ac13c5208" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e4cfb6b-dabf-418e-9cd6-c9a7c6696f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91b85894-9a2c-462b-bfb2-08446c6bb6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7620f9-21be-4321-9c0b-2c5ac13c5208" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91b85894-9a2c-462b-bfb2-08446c6bb6df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79d0a71a-190b-4c97-a41e-c26e5a51d951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7620f9-21be-4321-9c0b-2c5ac13c5208" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79d0a71a-190b-4c97-a41e-c26e5a51d951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedFromAssetsHeldForSale_36d0de95-76b1-46cc-bc80-94318f29850c" xlink:href="cah-20220930.xsd#cah_CashReclassifiedFromAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7620f9-21be-4321-9c0b-2c5ac13c5208" xlink:to="loc_cah_CashReclassifiedFromAssetsHeldForSale_36d0de95-76b1-46cc-bc80-94318f29850c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_58afe70f-d196-4906-ba07-614d161f4002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c36d4c2d-48c2-41f9-8b95-f8438bdafe56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_58afe70f-d196-4906-ba07-614d161f4002" xlink:to="loc_us-gaap_SeveranceCosts1_c36d4c2d-48c2-41f9-8b95-f8438bdafe56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_6def8df1-0c58-4fc4-bd43-e7b34fc7e637" xlink:href="cah-20220930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_58afe70f-d196-4906-ba07-614d161f4002" xlink:to="loc_cah_FacilityExitAndOtherCosts_6def8df1-0c58-4fc4-bd43-e7b34fc7e637" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1025d030-7a65-4bea-9f2d-8d84c569e29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f860f56b-d4b2-422c-92a1-0ca533c10a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1025d030-7a65-4bea-9f2d-8d84c569e29f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f860f56b-d4b2-422c-92a1-0ca533c10a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f47e9dac-5710-4e58-a608-1cefc1baf2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1025d030-7a65-4bea-9f2d-8d84c569e29f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f47e9dac-5710-4e58-a608-1cefc1baf2cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7fbfa627-e435-4ee5-9cba-577a968b2dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c78d6bb2-cbb3-4780-b0b8-bf128e8ccce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7fbfa627-e435-4ee5-9cba-577a968b2dc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c78d6bb2-cbb3-4780-b0b8-bf128e8ccce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_22ada5ff-60f6-48b3-8a08-daff8ef3486c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7fbfa627-e435-4ee5-9cba-577a968b2dc1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_22ada5ff-60f6-48b3-8a08-daff8ef3486c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cah-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:964ac801-dd50-4cbf-978f-cd662ea3a8c6,g:8bda5b56-43aa-4d85-9f5e-cb52b0901382-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended" id="ia85227483c8e45d5a701abfabec236c7_CondensedConsolidatedStatementofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8d9d8725-d6bf-4cde-8b95-45117dd4f300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_CommonStockSharesIssued_8d9d8725-d6bf-4cde-8b95-45117dd4f300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f13a4e9-fe6e-4eda-8378-62a997c473d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f13a4e9-fe6e-4eda-8378-62a997c473d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5cec8493-34b7-4da3-b32d-20543234ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockShares_5cec8493-34b7-4da3-b32d-20543234ef85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_dcb182dc-1da6-48ed-8ddf-568046d6c9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockValue_dcb182dc-1da6-48ed-8ddf-568046d6c9ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0070757-db89-4399-8396-00c9a920f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_NetIncomeLoss_e0070757-db89-4399-8396-00c9a920f89b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8a5a7006-2951-45da-9e98-bff9c6bb2e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_ProfitLoss_8a5a7006-2951-45da-9e98-bff9c6bb2e88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d22a3ee1-7bb8-4797-b68b-dcbb5e32aa22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d22a3ee1-7bb8-4797-b68b-dcbb5e32aa22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_06b4b412-cb97-4b86-a7a5-0915eedeb167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_06b4b412-cb97-4b86-a7a5-0915eedeb167" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5ac9afe2-85cf-4144-a672-d61be163c101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5ac9afe2-85cf-4144-a672-d61be163c101" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5bb4b2cc-07b7-4346-b2dd-ec53267c695d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5bb4b2cc-07b7-4346-b2dd-ec53267c695d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_36cd31e6-2461-44f1-b6fc-26b69309eb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_36cd31e6-2461-44f1-b6fc-26b69309eb09" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_543c2fd2-7f97-4909-afde-d474fac16190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_543c2fd2-7f97-4909-afde-d474fac16190" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_f1196d98-1b15-4a84-a7f2-cccf1a83965e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_Dividends_f1196d98-1b15-4a84-a7f2-cccf1a83965e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_6e2314ff-ecb8-4c16-9ccc-e54a880f72ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockholdersEquityOther_6e2314ff-ecb8-4c16-9ccc-e54a880f72ef" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4dda6366-9e47-41ce-9c6c-e8aecd6d9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a2bd432-65cf-4904-bdeb-1e04dbdd8625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2339c8dd-25fd-4b32-9337-65080dffee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6117d3ae-d851-4457-b22f-f065e5e1ec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a846e708-52d5-4585-a00d-8d08cb9ffeb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:to="loc_us-gaap_EquityComponentDomain_a846e708-52d5-4585-a00d-8d08cb9ffeb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:to="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89011f21-56ad-4eab-bb67-c0f3f0b6386a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_CommonStockMember_89011f21-56ad-4eab-bb67-c0f3f0b6386a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_241b5c79-fd82-40d2-ae5c-c6d20cd3d857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_RetainedEarningsMember_241b5c79-fd82-40d2-ae5c-c6d20cd3d857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_094b4de6-ae3e-42f3-b612-70a1fc94d042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_TreasuryStockMember_094b4de6-ae3e-42f3-b612-70a1fc94d042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c914afa0-f966-4d37-9f45-ace62c30d018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c914afa0-f966-4d37-9f45-ace62c30d018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_57c80636-30ba-4845-ae38-86d66177e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_NoncontrollingInterestMember_57c80636-30ba-4845-ae38-86d66177e53d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended" id="i0a0646c4ad594e60afcb2423126d3b46_SegmentInformationTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_5470321d-80e2-4c7a-9755-bf34fd841296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_60e1db06-f7fd-4320-8589-00dbe68de0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_5470321d-80e2-4c7a-9755-bf34fd841296" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_60e1db06-f7fd-4320-8589-00dbe68de0b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_5470321d-80e2-4c7a-9755-bf34fd841296" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:to="loc_srt_ConsolidationItemsDomain_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e07353b8-7af0-4201-b9fe-87f8a57844a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:to="loc_srt_ConsolidationItemsDomain_e07353b8-7af0-4201-b9fe-87f8a57844a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:to="loc_us-gaap_SegmentDomain_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70a59f0b-7945-4e37-92e0-e0237477c996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:to="loc_us-gaap_SegmentDomain_70a59f0b-7945-4e37-92e0-e0237477c996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c250c616-743f-44ad-90c7-ce88522a5e3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:to="loc_us-gaap_SubsegmentsDomain_c250c616-743f-44ad-90c7-ce88522a5e3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5849bc36-2685-4687-ae80-af2833bd5fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:to="loc_us-gaap_SubsegmentsDomain_5849bc36-2685-4687-ae80-af2833bd5fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_08bc7cde-00ae-4bc8-8947-6d6146f1b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_08bc7cde-00ae-4bc8-8947-6d6146f1b7d1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#DivestituresDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DivestituresDetails" xlink:type="extended" id="i7721d00239db4fe78111d08dad32b435_DivestituresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_e91fa4af-62bb-40e3-9c8e-395fa649d665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_3f3de6e9-a8e2-45c3-a0ae-dfa665c58a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_e91fa4af-62bb-40e3-9c8e-395fa649d665" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_3f3de6e9-a8e2-45c3-a0ae-dfa665c58a4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_e91fa4af-62bb-40e3-9c8e-395fa649d665" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:href="cah-20220930.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:to="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5_default" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:to="loc_cah_CordisDivestitureDomain_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_cdcde7ba-f299-47c0-8e64-9d921a033ca4" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:to="loc_cah_CordisDivestitureDomain_cdcde7ba-f299-47c0-8e64-9d921a033ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_2276497b-d6cd-40ff-affe-b8ddeccfb9d8" xlink:href="cah-20220930.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_cdcde7ba-f299-47c0-8e64-9d921a033ca4" xlink:to="loc_cah_CordisDivestitureMember_2276497b-d6cd-40ff-affe-b8ddeccfb9d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i9619a41647c34aaba847a6906c4dccaf_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b5254e18-bc36-43d5-8998-8bbe33929646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b5254e18-bc36-43d5-8998-8bbe33929646" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_03cfe05f-2e48-4295-8021-e9a9faee2a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_RestructuringReserve_03cfe05f-2e48-4295-8021-e9a9faee2a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_9bef8b62-321a-4ad0-95c5-e816db6c04ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_RestructuringCosts_9bef8b62-321a-4ad0-95c5-e816db6c04ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_cc597416-e3f3-4d5b-9b2c-148db945c24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_PaymentsForRestructuring_cc597416-e3f3-4d5b-9b2c-148db945c24c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ce190ee6-f1d5-42ce-80ef-0ded602df159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b5254e18-bc36-43d5-8998-8bbe33929646" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6ed6813d-a028-4e2e-99a5-260c8fcd05de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6ed6813d-a028-4e2e-99a5-260c8fcd05de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_92f1748c-3397-4466-a47d-44d47394b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_92f1748c-3397-4466-a47d-44d47394b5ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_899d3d7d-a9e3-4926-bc99-4b9da952895f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:to="loc_us-gaap_FacilityClosingMember_899d3d7d-a9e3-4926-bc99-4b9da952895f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended" id="if4a62a4269ca41528349918738504473_RestructuringandEmployeeSeveranceNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_44b0ebef-fd2a-4f71-b3ba-898bce14cff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:to="loc_us-gaap_SeveranceCosts1_44b0ebef-fd2a-4f71-b3ba-898bce14cff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_714914e0-38ed-49cc-89eb-4caf29de7440" xlink:href="cah-20220930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:to="loc_cah_FacilityExitAndOtherCosts_714914e0-38ed-49cc-89eb-4caf29de7440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:to="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_346d091b-f03c-4a43-b56f-822b01a638aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:to="loc_us-gaap_RestructuringPlanDomain_346d091b-f03c-4a43-b56f-822b01a638aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9e113077-12dd-4e68-b9f9-1f97bf58235e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:to="loc_us-gaap_RestructuringPlanDomain_9e113077-12dd-4e68-b9f9-1f97bf58235e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="ib774f71a3c7749b0aab5618b15cbee77_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:to="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_912438d8-1fcf-4ae0-a896-50d178b41cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_Goodwill_912438d8-1fcf-4ae0-a896-50d178b41cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_021a4f84-7543-4911-8cf3-f966051a34ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_021a4f84-7543-4911-8cf3-f966051a34ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_78048d25-78b9-49aa-9653-d7f345595015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_78048d25-78b9-49aa-9653-d7f345595015" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4c3c95a7-224f-4395-b458-dfa8cf632f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b0f09430-c337-4a11-ad8b-19deb29fb08b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b0f09430-c337-4a11-ad8b-19deb29fb08b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7dfe8b84-d777-4de9-96b1-0847182ac54e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:to="loc_us-gaap_SegmentDomain_7dfe8b84-d777-4de9-96b1-0847182ac54e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:to="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_50e13d2e-9235-4f42-b24f-f7b318635244" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:to="loc_cah_PharmaceuticalMember_50e13d2e-9235-4f42-b24f-f7b318635244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bab47b14-6489-4640-984d-a4a08e545387" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:to="loc_cah_MedicalMember_bab47b14-6489-4640-984d-a4a08e545387" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i85519e50e83f420e8d5917e348017b7a_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_dad89d54-1c53-41ec-99d9-5aae2fe51667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07573f97-7126-42bd-9aad-4a826879451e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_dad89d54-1c53-41ec-99d9-5aae2fe51667" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07573f97-7126-42bd-9aad-4a826879451e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_dad89d54-1c53-41ec-99d9-5aae2fe51667" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fb93dac8-67b6-49d6-bf3e-93b0a76497db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fb93dac8-67b6-49d6-bf3e-93b0a76497db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7c072b5a-f7dc-4e0f-ac8c-04fd32977423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7c072b5a-f7dc-4e0f-ac8c-04fd32977423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_6a671ad7-67f2-4511-8629-234ccc1e3a5d" xlink:href="cah-20220930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7c072b5a-f7dc-4e0f-ac8c-04fd32977423" xlink:to="loc_cah_IPRDTrademarksandOtherMember_6a671ad7-67f2-4511-8629-234ccc1e3a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2718a098-bfea-4e09-9ed4-8506c99e7f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2718a098-bfea-4e09-9ed4-8506c99e7f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d1a975ec-643c-4845-9f12-bf9817d3eec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d1a975ec-643c-4845-9f12-bf9817d3eec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5049747-6081-4df0-bb2e-414ccf4bb2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5049747-6081-4df0-bb2e-414ccf4bb2c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e0ebdf68-ba3b-40a6-924f-b8169ffa8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e0ebdf68-ba3b-40a6-924f-b8169ffa8b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_483f9b64-0c77-4080-bb62-b896a1501224_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_483f9b64-0c77-4080-bb62-b896a1501224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5d4afed0-1e71-4eef-b3fd-69a3066fc120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5d4afed0-1e71-4eef-b3fd-69a3066fc120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_52b23549-4a78-4ebb-9028-51176e1eb227" xlink:href="cah-20220930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:to="loc_cah_TrademarksAndPatentsMember_52b23549-4a78-4ebb-9028-51176e1eb227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1a26d55c-7dce-42a2-a64b-2e9066a6d078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1a26d55c-7dce-42a2-a64b-2e9066a6d078" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="ib6b6708affc045b78b892b925e59c112_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_3cedd16a-4527-4bc5-9617-8c4c71370733" xlink:href="cah-20220930.xsd#cah_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_cah_DiscountRateFairValueInput_3cedd16a-4527-4bc5-9617-8c4c71370733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_b71f3401-600d-4a61-967e-c8f908488820" xlink:href="cah-20220930.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_b71f3401-600d-4a61-967e-c8f908488820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b5714540-0534-4e29-a433-491eff023043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b5714540-0534-4e29-a433-491eff023043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_08ce6472-6374-4a80-91d4-ab71fb16eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_AssetsNet_08ce6472-6374-4a80-91d4-ab71fb16eca2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_21769695-b8ff-4373-98db-eb6b23bb518d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_Goodwill_21769695-b8ff-4373-98db-eb6b23bb518d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_731270d2-914b-4034-8687-6e0f646c957f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:to="loc_us-gaap_SegmentDomain_731270d2-914b-4034-8687-6e0f646c957f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_268ef1eb-888d-4b88-a6a5-dba518ff2ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:to="loc_us-gaap_SegmentDomain_268ef1eb-888d-4b88-a6a5-dba518ff2ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_5ebb14d0-0a33-4c36-9a28-e170ea3e6dda" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_268ef1eb-888d-4b88-a6a5-dba518ff2ffe" xlink:to="loc_cah_MedicalMember_5ebb14d0-0a33-4c36-9a28-e170ea3e6dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:to="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_26c93550-799b-40b5-98c7-6fa6b4ecd903_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:to="loc_us-gaap_ReportingUnitDomain_26c93550-799b-40b5-98c7-6fa6b4ecd903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_25c6b1f3-d8c6-4b73-9c42-e6cab05f419b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:to="loc_us-gaap_ReportingUnitDomain_25c6b1f3-d8c6-4b73-9c42-e6cab05f419b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_d39c45ab-9112-476b-b45e-3a8ae1330e99" xlink:href="cah-20220930.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_25c6b1f3-d8c6-4b73-9c42-e6cab05f419b" xlink:to="loc_cah_MedicalUnitMember_d39c45ab-9112-476b-b45e-3a8ae1330e99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended" id="i01133490d36342fcbf94d163cae06833_LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fe280ae0-f9d7-4ebb-9032-954d2c63acd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fe280ae0-f9d7-4ebb-9032-954d2c63acd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_daf6c3d0-5978-4fb3-8ad0-ce7f7103d122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_daf6c3d0-5978-4fb3-8ad0-ce7f7103d122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_58b2923b-1cf7-4fd8-946e-33dcfc20f547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_58b2923b-1cf7-4fd8-946e-33dcfc20f547" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0fd4ca1c-f402-48eb-81b7-cc18450b7f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0fd4ca1c-f402-48eb-81b7-cc18450b7f45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_780316d7-4e1d-4ce0-a458-3d8a801f9d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_780316d7-4e1d-4ce0-a458-3d8a801f9d64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_f200367f-9aa2-4736-9345-5b14bbd23e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_OtherShortTermBorrowings_f200367f-9aa2-4736-9345-5b14bbd23e64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1567a8c9-e976-4bf6-831d-076b1169bbc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:to="loc_us-gaap_CreditFacilityDomain_1567a8c9-e976-4bf6-831d-076b1169bbc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:to="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8e8acd46-60b9-443c-9e07-b0fab92081ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:to="loc_us-gaap_CommercialPaperMember_8e8acd46-60b9-443c-9e07-b0fab92081ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_59890009-ee1b-48af-81eb-336ba4a70121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_59890009-ee1b-48af-81eb-336ba4a70121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_20114a0a-06cd-4a0c-b245-cf1e2842b0ce" xlink:href="cah-20220930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_20114a0a-06cd-4a0c-b245-cf1e2842b0ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_45d00340-8907-49fc-adab-534fe44470e2" xlink:href="cah-20220930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_20114a0a-06cd-4a0c-b245-cf1e2842b0ce" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_45d00340-8907-49fc-adab-534fe44470e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_464ba6cf-1276-430a-b117-5ed41a3a3e44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_464ba6cf-1276-430a-b117-5ed41a3a3e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_59c8aaa2-f62c-404f-847f-ffe8a5e64a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_59c8aaa2-f62c-404f-847f-ffe8a5e64a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_17687641-087e-468a-99d7-632d83d00490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_17687641-087e-468a-99d7-632d83d00490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_439603b3-ecf5-4b2b-82a5-2bfd3b3f1d73" xlink:href="cah-20220930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_439603b3-ecf5-4b2b-82a5-2bfd3b3f1d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_c30366fa-d899-4a31-9465-3741ddb7d24d" xlink:href="cah-20220930.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:to="loc_cah_A2.616Notesdue2022Member_c30366fa-d899-4a31-9465-3741ddb7d24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ea3ee7f5-cde2-45d6-8538-b191e368a362_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:to="loc_us-gaap_VariableRateDomain_ea3ee7f5-cde2-45d6-8538-b191e368a362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8bd1e17f-38cf-49b5-859e-60a28aa59054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:to="loc_us-gaap_VariableRateDomain_8bd1e17f-38cf-49b5-859e-60a28aa59054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9fd6a358-3f9b-433a-8ada-5423605eb505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9fd6a358-3f9b-433a-8ada-5423605eb505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8126e665-8bc2-4b27-9423-b251940124c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8126e665-8bc2-4b27-9423-b251940124c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef29c226-13fb-4862-9773-b628a4d2b10f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:to="loc_srt_RangeMember_ef29c226-13fb-4862-9773-b628a4d2b10f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f65a9c6a-1680-4b56-a4ac-fbef7f736046" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:to="loc_srt_RangeMember_f65a9c6a-1680-4b56-a4ac-fbef7f736046" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended" id="i5bc5dfa11f234a30af11e3d054137ee0_CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_38a17058-f95a-43d2-99bf-08cdd6bf7367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_38a17058-f95a-43d2-99bf-08cdd6bf7367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_3b148519-57af-4306-ae5d-5c8678a588c4" xlink:href="cah-20220930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_LossContingencyLawsuitsNumber_3b148519-57af-4306-ae5d-5c8678a588c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_3d991efa-51a1-4a49-9449-da1d7024c547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LitigationReserve_3d991efa-51a1-4a49-9449-da1d7024c547" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_170f5d41-f163-4a51-b96a-54383e420223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_170f5d41-f163-4a51-b96a-54383e420223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_8f16fb45-4df4-40e6-8ea6-b71171ba2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_8f16fb45-4df4-40e6-8ea6-b71171ba2df7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_729adc6d-cb9d-4d52-af63-6630ffbc1dc1" xlink:href="cah-20220930.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_AggregateAnnualAssessment_729adc6d-cb9d-4d52-af63-6630ffbc1dc1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_4dc5f4a7-eab7-4b4b-829a-54266f2ce797" xlink:href="cah-20220930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_4dc5f4a7-eab7-4b4b-829a-54266f2ce797" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e43fe893-c8f8-4899-a4c3-f5d3895a5dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e43fe893-c8f8-4899-a4c3-f5d3895a5dc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_76b61059-6654-42b7-a86e-4125b44a36cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_76b61059-6654-42b7-a86e-4125b44a36cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_0683d0e7-9eb1-4180-93ae-90ec963849d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_0683d0e7-9eb1-4180-93ae-90ec963849d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_9d44e8b2-bbf5-4a56-80d9-d1b0cc276bb1" xlink:href="cah-20220930.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_JudgmentForLostProfits_9d44e8b2-bbf5-4a56-80d9-d1b0cc276bb1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_e1f238d9-9482-4745-92d6-65bd4c04e006" xlink:href="cah-20220930.xsd#cah_SettlingStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_SettlingStates_e1f238d9-9482-4745-92d6-65bd4c04e006" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_71044a16-f4f0-4873-b3c8-39244d370bd4" xlink:href="cah-20220930.xsd#cah_SettlingUSTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_SettlingUSTerritories_71044a16-f4f0-4873-b3c8-39244d370bd4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_f0b26adb-19d7-422b-8a07-54cbeff6d265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_f0b26adb-19d7-422b-8a07-54cbeff6d265" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_8d359897-91ce-4d09-b4bf-8085c9eb5d09" xlink:href="cah-20220930.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_8d359897-91ce-4d09-b4bf-8085c9eb5d09" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_7b65dba7-f3b5-417f-bd41-513122c38d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_7b65dba7-f3b5-417f-bd41-513122c38d24" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyNumberOfEligibleStates_8536f454-3d6f-4ad3-8850-bbf1a993c996" xlink:href="cah-20220930.xsd#cah_LossContingencyNumberOfEligibleStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_LossContingencyNumberOfEligibleStates_8536f454-3d6f-4ad3-8850-bbf1a993c996" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_a40bf5c5-5f3c-47dc-bbc5-88f9d36eb25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_a40bf5c5-5f3c-47dc-bbc5-88f9d36eb25e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:href="cah-20220930.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_9b8cc954-c698-4b1b-8883-f350a03b4a7c_default" xlink:href="cah-20220930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:to="loc_cah_LitigationTypeDomain_9b8cc954-c698-4b1b-8883-f350a03b4a7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:href="cah-20220930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:to="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_018a8dad-37b7-4eb8-a872-76aa11f2933e" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:to="loc_cah_ClassActionLawsuitsMember_018a8dad-37b7-4eb8-a872-76aa11f2933e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_16a24596-490a-4203-b6e6-e32871bb2449" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_16a24596-490a-4203-b6e6-e32871bb2449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_4cac7405-a186-4ce2-b420-b3efe2d720f8_default" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:to="loc_cah_PlaintiffTypeDomain_4cac7405-a186-4ce2-b420-b3efe2d720f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:to="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_a49fc956-ad80-4d15-8230-51ce41fb59bc" xlink:href="cah-20220930.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:to="loc_cah_PrivatePartiesMember_a49fc956-ad80-4d15-8230-51ce41fb59bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_edc32f24-b45f-40d3-b85b-6139c31c7d23" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:to="loc_cah_ClassActionLawsuitsMember_edc32f24-b45f-40d3-b85b-6139c31c7d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_f074f250-f0a8-4d4b-b28a-a69652c62e44_default" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:to="loc_cah_OpioidLitigationDomain_f074f250-f0a8-4d4b-b28a-a69652c62e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6824013f-c98a-44c2-9e03-93a5f04091a2" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:to="loc_cah_OpioidLitigationDomain_6824013f-c98a-44c2-9e03-93a5f04091a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_dadc14fe-1549-43f6-9b97-d264cc2679da" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_6824013f-c98a-44c2-9e03-93a5f04091a2" xlink:to="loc_cah_TotalOpioidLitigationMember_dadc14fe-1549-43f6-9b97-d264cc2679da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:to="loc_srt_SegmentGeographicalDomain_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:to="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_ad9a1d1c-90e7-48b2-b698-c23650073fca" xlink:href="cah-20220930.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_cah_AlamedaCountyMember_ad9a1d1c-90e7-48b2-b698-c23650073fca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_2822d88e-2a4a-4974-809d-16bef18c3a71" xlink:href="cah-20220930.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_cah_OtherJurisdictionsMember_2822d88e-2a4a-4974-809d-16bef18c3a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_dadd4065-f896-4dcd-84ac-9e74871b1552" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_WV_dadd4065-f896-4dcd-84ac-9e74871b1552" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_e47a8a56-0af5-4958-9071-15346dbc38a1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_OK_e47a8a56-0af5-4958-9071-15346dbc38a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_a75409e7-03e5-4ba6-854a-7c5a1ef3a6d0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_WA_a75409e7-03e5-4ba6-854a-7c5a1ef3a6d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_d2d3ef52-7af2-4c7b-b342-a17c4a601a36" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_GA_d2d3ef52-7af2-4c7b-b342-a17c4a601a36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember_727324e8-c753-4cc1-8a36-dc715cba2fdd" xlink:href="cah-20220930.xsd#cah_NativeAmericanTribesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_cah_NativeAmericanTribesMember_727324e8-c753-4cc1-8a36-dc715cba2fdd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:to="loc_srt_RangeMember_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:to="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_85d14de8-d4fd-4627-abb9-bae20a8883b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:to="loc_srt_MinimumMember_85d14de8-d4fd-4627-abb9-bae20a8883b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_84330f5a-064e-4ca5-9c0b-1f03a2eee4a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:to="loc_srt_MaximumMember_84330f5a-064e-4ca5-9c0b-1f03a2eee4a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_9db58ccd-f033-4166-89b9-819f08fec6eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_9db58ccd-f033-4166-89b9-819f08fec6eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_499ea32f-94e3-44d8-bc1d-677d241e26e5" xlink:href="cah-20220930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:to="loc_cah_OpioidLawsuitsMember_499ea32f-94e3-44d8-bc1d-677d241e26e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_00c0fe68-8d3e-4098-91e7-300aa730a599" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_00c0fe68-8d3e-4098-91e7-300aa730a599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c1dde3b-818e-428c-a60d-18aef6564345_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c1dde3b-818e-428c-a60d-18aef6564345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b8a085fd-94bc-4d4c-8ff3-7bcf1641908b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:to="loc_srt_NameOfMajorCustomerDomain_b8a085fd-94bc-4d4c-8ff3-7bcf1641908b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_03e269c5-fa27-4e52-a8c5-e93f47dc9d51" xlink:href="cah-20220930.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b8a085fd-94bc-4d4c-8ff3-7bcf1641908b" xlink:to="loc_cah_CVSHealthMember_03e269c5-fa27-4e52-a8c5-e93f47dc9d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_47e69d2a-06f0-44b0-b092-b7eb9674ea65_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:to="loc_srt_LitigationCaseTypeDomain_47e69d2a-06f0-44b0-b092-b7eb9674ea65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:to="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_2553998c-4dba-4f61-ab41-f489f8f2afb5" xlink:href="cah-20220930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_OpioidLawsuitsMember_2553998c-4dba-4f61-ab41-f489f8f2afb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_03f252c7-e7f6-4fb0-a1ce-9776be50f811" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_ClassActionLawsuitsMember_03f252c7-e7f6-4fb0-a1ce-9776be50f811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_a34945fa-681b-459f-bbff-c566d6b7b470" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_a34945fa-681b-459f-bbff-c566d6b7b470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_ea96699e-30a6-48ba-9b76-0c4157f8126a" xlink:href="cah-20220930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_ea96699e-30a6-48ba-9b76-0c4157f8126a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c71a5c71-1f5d-44af-af24-d00b4ff75cc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c71a5c71-1f5d-44af-af24-d00b4ff75cc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dba265f1-a648-4903-8de5-3766fef09277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dba265f1-a648-4903-8de5-3766fef09277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ee1d0741-6e2b-4628-b6be-2bd319d2cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dba265f1-a648-4903-8de5-3766fef09277" xlink:to="loc_us-gaap_SubsequentEventMember_ee1d0741-6e2b-4628-b6be-2bd319d2cf6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a6763a03-ee21-418b-ae8b-e3c316d04ac8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a6763a03-ee21-418b-ae8b-e3c316d04ac8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3ae9ed2b-5e55-44ca-8591-119ee90b7570" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3ae9ed2b-5e55-44ca-8591-119ee90b7570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c53edacc-131b-450b-a9c2-cf22b55b0723" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3ae9ed2b-5e55-44ca-8591-119ee90b7570" xlink:to="loc_srt_ScenarioForecastMember_c53edacc-131b-450b-a9c2-cf22b55b0723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_63909bb9-09ac-4b6a-8a99-26924c85206d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_63909bb9-09ac-4b6a-8a99-26924c85206d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_163f6b81-fd0b-4a77-84de-8b26709382d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_163f6b81-fd0b-4a77-84de-8b26709382d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_b6052862-8a56-4c9a-b675-0cfcbdd23fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_163f6b81-fd0b-4a77-84de-8b26709382d8" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_b6052862-8a56-4c9a-b675-0cfcbdd23fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_09f587c5-329a-45cd-8b0f-1a85badb702c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:to="loc_us-gaap_SegmentDomain_09f587c5-329a-45cd-8b0f-1a85badb702c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_896264e8-eadb-4c55-8918-75d026cce448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:to="loc_us-gaap_SegmentDomain_896264e8-eadb-4c55-8918-75d026cce448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_2fd23223-2658-4b32-9454-a6359162495a" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_896264e8-eadb-4c55-8918-75d026cce448" xlink:to="loc_cah_PharmaceuticalMember_2fd23223-2658-4b32-9454-a6359162495a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ib2e662378146471b980cf3218c4baf0b_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4eaaae45-f1ea-45e3-b6f3-bf4db4988f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4eaaae45-f1ea-45e3-b6f3-bf4db4988f0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_012a660f-977f-4485-8476-2df0f6ffb92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_012a660f-977f-4485-8476-2df0f6ffb92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2cdc534a-0581-4d93-a5a7-20495470dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2cdc534a-0581-4d93-a5a7-20495470dcb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0fcb1208-5117-4860-ae4f-a504f0c1ac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0fcb1208-5117-4860-ae4f-a504f0c1ac2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_230fbba8-e4c1-49d6-818b-89300268825d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_230fbba8-e4c1-49d6-818b-89300268825d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6ce08036-2e87-4adf-abce-65cabe384ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6ce08036-2e87-4adf-abce-65cabe384ca7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_143462a3-34e8-4efd-8131-ef83c6ec7d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_OpenTaxYear_143462a3-34e8-4efd-8131-ef83c6ec7d1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_bc649f05-a8b8-417c-b219-23173e6b2cff" xlink:href="cah-20220930.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_cah_IndemnificationReceivable_bc649f05-a8b8-417c-b219-23173e6b2cff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d760b046-c6b0-47b8-baf5-48c3d32f3962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d760b046-c6b0-47b8-baf5-48c3d32f3962" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:href="cah-20220930.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_0bec35f1-9848-4f2d-9c4a-013d9df4210f_default" xlink:href="cah-20220930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:to="loc_cah_TaxMatterDomain_0bec35f1-9848-4f2d-9c4a-013d9df4210f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_d8f71994-666d-4591-a83a-c2a5f0ecb550" xlink:href="cah-20220930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:to="loc_cah_TaxMatterDomain_d8f71994-666d-4591-a83a-c2a5f0ecb550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_b016c2dc-d46c-41ab-acf9-42e4a4acc1a8" xlink:href="cah-20220930.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_d8f71994-666d-4591-a83a-c2a5f0ecb550" xlink:to="loc_cah_CareFusionMember_b016c2dc-d46c-41ab-acf9-42e4a4acc1a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_7489877d-b143-48cd-aa41-66e87b747a8c_default" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:to="loc_cah_OpioidLitigationDomain_7489877d-b143-48cd-aa41-66e87b747a8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_d160ac32-8eef-4e2b-894d-5d9c937aa4f4" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:to="loc_cah_OpioidLitigationDomain_d160ac32-8eef-4e2b-894d-5d9c937aa4f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_aba1ed75-837c-440c-966f-1c41e3d95db3" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_d160ac32-8eef-4e2b-894d-5d9c937aa4f4" xlink:to="loc_cah_TotalOpioidLitigationMember_aba1ed75-837c-440c-966f-1c41e3d95db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3438e296-3d04-4375-b06c-511aab3590e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3438e296-3d04-4375-b06c-511aab3590e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d873722-8e47-45d1-b2b4-283bc6c66de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d873722-8e47-45d1-b2b4-283bc6c66de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c4126f0f-7fe6-45a6-ba5f-2b667d52728e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c4126f0f-7fe6-45a6-ba5f-2b667d52728e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_40a85828-4d84-4635-87d8-ccf687f84281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_40a85828-4d84-4635-87d8-ccf687f84281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b64e4972-c311-4b49-a7c7-8e65c05c664e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_40a85828-4d84-4635-87d8-ccf687f84281" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b64e4972-c311-4b49-a7c7-8e65c05c664e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bcf15956-0e0f-4024-8c6d-b7fb12eeef90_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:to="loc_srt_RangeMember_bcf15956-0e0f-4024-8c6d-b7fb12eeef90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:to="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f1bdd811-fd79-4b84-9332-f42776b41bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:to="loc_srt_MinimumMember_f1bdd811-fd79-4b84-9332-f42776b41bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_15fe2a4b-ada4-403c-801a-bc3fa6e1e6f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:to="loc_srt_MaximumMember_15fe2a4b-ada4-403c-801a-bc3fa6e1e6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f2b74685-c4de-423c-98d7-8cc1721a9d20_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f2b74685-c4de-423c-98d7-8cc1721a9d20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_957b844c-caba-486c-bad6-c138299585eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:to="loc_srt_ScenarioUnspecifiedDomain_957b844c-caba-486c-bad6-c138299585eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_58e8df44-3957-4721-8fe9-b3ed61ed9a24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_957b844c-caba-486c-bad6-c138299585eb" xlink:to="loc_srt_ScenarioForecastMember_58e8df44-3957-4721-8fe9-b3ed61ed9a24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:href="cah-20220930.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_e93fcb77-8394-4597-b3e6-a538d09941cb_default" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:to="loc_cah_CordisDivestitureDomain_e93fcb77-8394-4597-b3e6-a538d09941cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_3198a0a7-f334-4d13-be5d-21d2a5db3807" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:to="loc_cah_CordisDivestitureDomain_3198a0a7-f334-4d13-be5d-21d2a5db3807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_8c6a8b3f-61e0-4292-8e71-728f6c12bab3" xlink:href="cah-20220930.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_3198a0a7-f334-4d13-be5d-21d2a5db3807" xlink:to="loc_cah_CordisDivestitureMember_8c6a8b3f-61e0-4292-8e71-728f6c12bab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f35f2f2c-77d3-4339-96bf-611d6f4a67d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:to="loc_us-gaap_SegmentDomain_f35f2f2c-77d3-4339-96bf-611d6f4a67d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_535741c6-c321-4358-a9ec-d2cd2709f454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:to="loc_us-gaap_SegmentDomain_535741c6-c321-4358-a9ec-d2cd2709f454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c7b90065-e118-43f0-8360-6deab1dd137e" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_535741c6-c321-4358-a9ec-d2cd2709f454" xlink:to="loc_cah_MedicalMember_c7b90065-e118-43f0-8360-6deab1dd137e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_e0e00bb3-77c1-4259-aa17-b90d2b0d034c_default" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:to="loc_cah_GoodwillImpairmentDomain_e0e00bb3-77c1-4259-aa17-b90d2b0d034c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_b3f3c01a-f1e3-41cc-99cf-4b7306e2f1b7" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:to="loc_cah_GoodwillImpairmentDomain_b3f3c01a-f1e3-41cc-99cf-4b7306e2f1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentMedicalUnitMember_69c51c16-51b3-4c03-9463-05e255d2525a" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentMedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_b3f3c01a-f1e3-41cc-99cf-4b7306e2f1b7" xlink:to="loc_cah_GoodwillImpairmentMedicalUnitMember_69c51c16-51b3-4c03-9463-05e255d2525a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_404ef8b3-c811-436e-91a2-2b0294fb1b1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_404ef8b3-c811-436e-91a2-2b0294fb1b1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_96cb3938-9c17-4aef-a291-d8b93477ec69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_96cb3938-9c17-4aef-a291-d8b93477ec69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_134cf63d-7c41-4b41-80c5-5e694593ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_96cb3938-9c17-4aef-a291-d8b93477ec69" xlink:to="loc_us-gaap_SubsequentEventMember_134cf63d-7c41-4b41-80c5-5e694593ecab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i5831e34b583e4c76a9c5d8d534d0eb44_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9b1a9c5-34cf-465b-9faa-cf28574841ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9b1a9c5-34cf-465b-9faa-cf28574841ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64d3cfe0-ecb3-4a46-9d82-d3ffb6b1cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64d3cfe0-ecb3-4a46-9d82-d3ffb6b1cbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6658d180-fc69-449c-b124-0db824d0558e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6658d180-fc69-449c-b124-0db824d0558e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_7d3294d7-f1b9-44e3-9b91-f683bfc7dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_7d3294d7-f1b9-44e3-9b91-f683bfc7dccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76876726-a914-4e91-9eb0-693f6a5bb74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76876726-a914-4e91-9eb0-693f6a5bb74e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_342662bd-e15e-441c-8b53-0cfaee7271fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_63198e25-1111-4c75-b6a8-b1e5f4c00b37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_63198e25-1111-4c75-b6a8-b1e5f4c00b37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0cae14b-53c1-4609-9887-79c8c72dff77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0cae14b-53c1-4609-9887-79c8c72dff77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_154f6114-ea17-4e8c-bb8b-622dde07ad12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0cae14b-53c1-4609-9887-79c8c72dff77" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_154f6114-ea17-4e8c-bb8b-622dde07ad12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37866e23-6bc6-4098-ad9f-4b8bc2a46338_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37866e23-6bc6-4098-ad9f-4b8bc2a46338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_85edfd51-7f62-4f7f-8228-4701b40dd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_85edfd51-7f62-4f7f-8228-4701b40dd1da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5279ce3f-130d-4690-beac-4f6c98131f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5279ce3f-130d-4690-beac-4f6c98131f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0c731a87-70c5-464f-a2b2-c297848ba70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0c731a87-70c5-464f-a2b2-c297848ba70f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_fc3d8300-3e47-443d-8c5b-f1a5149b24e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_fc3d8300-3e47-443d-8c5b-f1a5149b24e9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ieff0237b7e11447f8e535d67fbd0e886_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e7ab71e5-147e-4b57-99b7-8eb2a932d5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e7ab71e5-147e-4b57-99b7-8eb2a932d5b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_955c4ad9-d2fb-4cc6-a4b4-f3900941df56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_955c4ad9-d2fb-4cc6-a4b4-f3900941df56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_9be5a050-36ec-47d0-9d14-d084bf391fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_9be5a050-36ec-47d0-9d14-d084bf391fb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_11a79878-250f-4efb-8a7e-f6de47c4c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_11a79878-250f-4efb-8a7e-f6de47c4c759" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_85919b8d-c277-4fdb-965e-62ee2817f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_85919b8d-c277-4fdb-965e-62ee2817f40e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_13c954d9-0b43-4ba3-ab62-1be3e3e7210f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_13c954d9-0b43-4ba3-ab62-1be3e3e7210f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d499058d-aedf-4d36-883f-c78ecfba41e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d499058d-aedf-4d36-883f-c78ecfba41e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fdd286e7-fd30-4626-bf59-2fdfea7ca3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fdd286e7-fd30-4626-bf59-2fdfea7ca3ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_0d4379e1-92af-4814-a099-3cd7d45cda4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fdd286e7-fd30-4626-bf59-2fdfea7ca3ad" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_0d4379e1-92af-4814-a099-3cd7d45cda4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d59e316b-06a7-4f43-8998-ade76ff9cc73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:to="loc_us-gaap_HedgingDesignationDomain_d59e316b-06a7-4f43-8998-ade76ff9cc73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:to="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bc08e45c-cb70-4e73-9441-8b676afdde8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bc08e45c-cb70-4e73-9441-8b676afdde8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a70076ba-d8f1-4666-bf27-88ce6571417a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:to="loc_us-gaap_NondesignatedMember_a70076ba-d8f1-4666-bf27-88ce6571417a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_eafc15bc-4e52-46cc-9d05-85ff3c580dcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_eafc15bc-4e52-46cc-9d05-85ff3c580dcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3afe03ad-6812-4feb-87a2-999310a36254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3afe03ad-6812-4feb-87a2-999310a36254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_02c3c9d3-380f-495a-ad83-475914c5d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3afe03ad-6812-4feb-87a2-999310a36254" xlink:to="loc_us-gaap_FairValueHedgingMember_02c3c9d3-380f-495a-ad83-475914c5d9a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d943ec15-b684-4325-89ed-e5bee1e06ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d943ec15-b684-4325-89ed-e5bee1e06ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_99843438-c179-474a-92d0-0d2c5cdcf9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:to="loc_us-gaap_InterestRateSwapMember_99843438-c179-474a-92d0-0d2c5cdcf9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_27987426-ed8d-4cfd-aa6b-92a93fcb0114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:to="loc_us-gaap_CashFlowHedgingMember_27987426-ed8d-4cfd-aa6b-92a93fcb0114" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i15aff28a754b423389f89fb9e0f04ef9_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_034cb2df-1d98-4a4a-b409-df663a599003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:to="loc_us-gaap_DebtInstrumentFairValue_034cb2df-1d98-4a4a-b409-df663a599003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_5aaef7fc-46ae-40a5-a3f3-0ee03758a4ac" xlink:href="cah-20220930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_5aaef7fc-46ae-40a5-a3f3-0ee03758a4ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bf796cf-268f-4b44-bc2f-ce32a5e15666_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4bf796cf-268f-4b44-bc2f-ce32a5e15666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8118a82b-a0e0-484c-88a1-61917208bd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8118a82b-a0e0-484c-88a1-61917208bd0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_74b0c436-db24-441f-b937-887e90727645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8118a82b-a0e0-484c-88a1-61917208bd0c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_74b0c436-db24-441f-b937-887e90727645" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="id205123116534ce182ab27b3161a9f73_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af6dd79c-c219-40ae-b7b8-07f56d49f3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af6dd79c-c219-40ae-b7b8-07f56d49f3d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f1f145dd-150d-415e-b7b8-e05ce07fa119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f1f145dd-150d-415e-b7b8-e05ce07fa119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_040eff69-907f-4fe5-ae1e-0537dd515a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_040eff69-907f-4fe5-ae1e-0537dd515a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d19c5c71-4928-40dc-a193-62fbc3d2204f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d19c5c71-4928-40dc-a193-62fbc3d2204f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c0e6e3ff-2e58-4b21-b265-85f83750145e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c0e6e3ff-2e58-4b21-b265-85f83750145e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3eb421e3-0b0d-4f03-89fa-c92a3d58015f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3eb421e3-0b0d-4f03-89fa-c92a3d58015f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_79296c7d-0b63-4e15-89bd-13fc6271ca88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3eb421e3-0b0d-4f03-89fa-c92a3d58015f" xlink:to="loc_us-gaap_SubsequentEventMember_79296c7d-0b63-4e15-89bd-13fc6271ca88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5a984a1-af0d-4e63-8867-7fa9647b7088_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:to="loc_us-gaap_EquityComponentDomain_b5a984a1-af0d-4e63-8867-7fa9647b7088_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9255ed27-e9f0-4537-886d-54fdc4e61f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:to="loc_us-gaap_EquityComponentDomain_9255ed27-e9f0-4537-886d-54fdc4e61f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d34be578-aea7-4404-b657-fd0a49a28f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9255ed27-e9f0-4537-886d-54fdc4e61f57" xlink:to="loc_us-gaap_TreasuryStockMember_d34be578-aea7-4404-b657-fd0a49a28f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_271f556e-293f-4000-8939-0f5c677afbdd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:to="loc_srt_RangeMember_271f556e-293f-4000-8939-0f5c677afbdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a1129d1-c5ff-4296-b4f5-3f54d42e7fe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:to="loc_srt_RangeMember_1a1129d1-c5ff-4296-b4f5-3f54d42e7fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5fe889db-c49f-4faf-ba34-c6183f86f2ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a1129d1-c5ff-4296-b4f5-3f54d42e7fe3" xlink:to="loc_srt_MinimumMember_5fe889db-c49f-4faf-ba34-c6183f86f2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972dda97-99d6-46e1-9bd8-8d7ac26f393a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972dda97-99d6-46e1-9bd8-8d7ac26f393a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe0f970-14d9-4e4b-95c5-83d97db5f1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe0f970-14d9-4e4b-95c5-83d97db5f1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7a2456d9-3fb8-435f-9fa2-1e099d08e4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe0f970-14d9-4e4b-95c5-83d97db5f1f4" xlink:to="loc_us-gaap_PerformanceSharesMember_7a2456d9-3fb8-435f-9fa2-1e099d08e4b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_354d63e0-9225-4171-aa05-4ca978fc15eb_default" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_354d63e0-9225-4171-aa05-4ca978fc15eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_1a04451c-ac40-4209-a17b-0e27b905833a" xlink:href="cah-20220930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_1a04451c-ac40-4209-a17b-0e27b905833a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember_22ca6d97-42e9-44a4-904f-c0ddd9e260ea" xlink:href="cah-20220930.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:to="loc_cah_A1BillionShareRepurchaseProgramMember_22ca6d97-42e9-44a4-904f-c0ddd9e260ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i5fffb515f7944f08a693298f50becb71_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_52451b18-cd1c-4781-bfb0-08cad596b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_52451b18-cd1c-4781-bfb0-08cad596b16c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce38ff66-b39b-46b2-8612-2d2747b478c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce38ff66-b39b-46b2-8612-2d2747b478c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c56d3eb-1604-4b68-bdf0-3d075dc7655e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c56d3eb-1604-4b68-bdf0-3d075dc7655e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bd42eb9a-4a17-4754-9f36-8adb522168de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bd42eb9a-4a17-4754-9f36-8adb522168de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05aec8e-2feb-448b-9a38-f1cedef89d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05aec8e-2feb-448b-9a38-f1cedef89d39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39119b0e-48b6-4f40-9041-7f022dec147b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_0a3da7c4-7c68-457a-9778-71c4a14f6d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_0a3da7c4-7c68-457a-9778-71c4a14f6d4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_52451b18-cd1c-4781-bfb0-08cad596b16c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6bc0b48d-661e-4cde-944a-23b28146c3af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:to="loc_us-gaap_EquityComponentDomain_6bc0b48d-661e-4cde-944a-23b28146c3af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:to="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_65f60d4a-5d25-4463-9bf9-ca793e84e87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_65f60d4a-5d25-4463-9bf9-ca793e84e87d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_994096b5-53b7-469e-8557-d926e2770599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_994096b5-53b7-469e-8557-d926e2770599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7d5bdd0c-1702-4d78-94a0-1eb80e808959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7d5bdd0c-1702-4d78-94a0-1eb80e808959" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5465e975-6dc8-4916-9836-b8022749af4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5465e975-6dc8-4916-9836-b8022749af4a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="ic2cef1756110412a8a1243f288f0096c_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_280c4e32-e6a7-45dd-92b9-733202d89f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:to="loc_us-gaap_LitigationReserve_280c4e32-e6a7-45dd-92b9-733202d89f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5cdc11ee-8f89-4414-a587-ccbc0fd3c3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5cdc11ee-8f89-4414-a587-ccbc0fd3c3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:to="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:to="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_c29e279f-93b8-43cb-94c4-0aa715e9b267_default" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:to="loc_cah_OpioidLitigationDomain_c29e279f-93b8-43cb-94c4-0aa715e9b267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_bd7c9db1-1c00-48bf-bc71-68968b18eb45" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:to="loc_cah_OpioidLitigationDomain_bd7c9db1-1c00-48bf-bc71-68968b18eb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_066965f2-6c8f-4c49-8501-485103b31150" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_bd7c9db1-1c00-48bf-bc71-68968b18eb45" xlink:to="loc_cah_TotalOpioidLitigationMember_066965f2-6c8f-4c49-8501-485103b31150" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="ia4d164b81e204e47894380bbb84cb17c_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e80aed00-6709-43c0-a0e6-95bd494edebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7903e504-89e3-40db-b28c-c270e125bd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e80aed00-6709-43c0-a0e6-95bd494edebd" xlink:to="loc_us-gaap_Revenues_7903e504-89e3-40db-b28c-c270e125bd07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e80aed00-6709-43c0-a0e6-95bd494edebd" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6393481e-a14d-4fad-b710-eed563fcd166_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:to="loc_us-gaap_SubsegmentsDomain_6393481e-a14d-4fad-b710-eed563fcd166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:to="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_faa6d23e-4c52-44e5-9491-3f1afef6bd28" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_faa6d23e-4c52-44e5-9491-3f1afef6bd28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_33a02e47-86e6-4132-b98c-3fdc789b4fcc" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_33a02e47-86e6-4132-b98c-3fdc789b4fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_5753776b-d85b-4534-80ca-b691503879be" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_MedicaldistributionandproductsMember_5753776b-d85b-4534-80ca-b691503879be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember_452b2a3f-6214-46b5-b802-349e4c3681e7" xlink:href="cah-20220930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_CardinalHealthAtHomeSolutionsMember_452b2a3f-6214-46b5-b802-349e4c3681e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:to="loc_srt_ConsolidationItemsDomain_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:to="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_586b2e92-6a70-4720-b6ff-c0f02c2fa9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:to="loc_us-gaap_OperatingSegmentsMember_586b2e92-6a70-4720-b6ff-c0f02c2fa9bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_fb00a924-a905-4f1f-b685-7b8ac86550d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_fb00a924-a905-4f1f-b685-7b8ac86550d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_450e7469-e245-443d-88db-8153d3f7388c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:to="loc_us-gaap_SegmentDomain_450e7469-e245-443d-88db-8153d3f7388c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:to="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_317b0169-74d6-40ce-9024-bb4587fe8ced" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:to="loc_cah_PharmaceuticalMember_317b0169-74d6-40ce-9024-bb4587fe8ced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_6eb163a5-3c7f-4815-9335-91255ce12342" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:to="loc_cah_MedicalMember_6eb163a5-3c7f-4815-9335-91255ce12342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e9048fa0-8b4c-4981-a211-fac811ebc5c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:to="loc_us-gaap_EquityComponentDomain_e9048fa0-8b4c-4981-a211-fac811ebc5c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8b078fe-1154-4124-b3b9-f1e2d8a2d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:to="loc_us-gaap_EquityComponentDomain_f8b078fe-1154-4124-b3b9-f1e2d8a2d76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_a0a54185-1ce4-432a-bed3-2bfdf36720e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8b078fe-1154-4124-b3b9-f1e2d8a2d76a" xlink:to="loc_us-gaap_TreasuryStockMember_a0a54185-1ce4-432a-bed3-2bfdf36720e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="i1e20f524801f4405abc5a5e67acdabd0_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5bd7964f-05fa-49f9-a0c9-2d37286c1969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_634b6355-239c-418a-8e57-a9a2769e93ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5bd7964f-05fa-49f9-a0c9-2d37286c1969" xlink:to="loc_us-gaap_OperatingIncomeLoss_634b6355-239c-418a-8e57-a9a2769e93ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5bd7964f-05fa-49f9-a0c9-2d37286c1969" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:to="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:to="loc_srt_ConsolidationItemsDomain_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:to="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_80bb2cfd-e0b7-4d5a-908f-eb2aa18b7e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:to="loc_us-gaap_OperatingSegmentsMember_80bb2cfd-e0b7-4d5a-908f-eb2aa18b7e08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f64cc75c-914c-48fd-9f72-a840dedfd573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f64cc75c-914c-48fd-9f72-a840dedfd573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d659ddaf-a4ca-4f13-be77-f8f4e0289371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:to="loc_us-gaap_SegmentDomain_d659ddaf-a4ca-4f13-be77-f8f4e0289371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:to="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_fdac9ec9-cd05-41dc-b252-4baa6c4c74ba" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:to="loc_cah_PharmaceuticalMember_fdac9ec9-cd05-41dc-b252-4baa6c4c74ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_0a6a8f69-b922-4e49-b08f-a6461b5a3a36" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:to="loc_cah_MedicalMember_0a6a8f69-b922-4e49-b08f-a6461b5a3a36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i59ac7c098038489d8032fab41ffa51a4_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d0417443-be3a-4e8a-8225-fff16a4ebf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_df392adb-4911-43ba-b8ea-a1a02dcae9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0417443-be3a-4e8a-8225-fff16a4ebf1b" xlink:to="loc_us-gaap_Assets_df392adb-4911-43ba-b8ea-a1a02dcae9b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0417443-be3a-4e8a-8225-fff16a4ebf1b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:to="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5269e093-a2ce-45b2-9b2d-f44cd79716f0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:to="loc_srt_ConsolidationItemsDomain_5269e093-a2ce-45b2-9b2d-f44cd79716f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:to="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9345e4b9-e3af-4f1b-a885-8443a0187365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:to="loc_us-gaap_OperatingSegmentsMember_9345e4b9-e3af-4f1b-a885-8443a0187365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d718fde1-dd51-478a-ace0-f29549c137ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d718fde1-dd51-478a-ace0-f29549c137ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_205fe949-f4e8-41ec-a920-e98f843d5586_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:to="loc_us-gaap_SegmentDomain_205fe949-f4e8-41ec-a920-e98f843d5586_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:to="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_18971703-6b15-4feb-93eb-c2ba58f7aef6" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:to="loc_cah_PharmaceuticalMember_18971703-6b15-4feb-93eb-c2ba58f7aef6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c02459da-65e2-4f70-bd9e-70e75eb17461" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:to="loc_cah_MedicalMember_c02459da-65e2-4f70-bd9e-70e75eb17461" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended" id="i8ad18000b5ac438e81b0296f40767c04_SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_457b66d8-22ec-4b6e-ab1f-cc4f6cf7bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_57f4e849-97e1-4e6c-98ca-5ba2299c472d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_457b66d8-22ec-4b6e-ab1f-cc4f6cf7bf78" xlink:to="loc_us-gaap_Revenues_57f4e849-97e1-4e6c-98ca-5ba2299c472d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_457b66d8-22ec-4b6e-ab1f-cc4f6cf7bf78" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:href="cah-20220930.xsd#cah_MedicalSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_1752bec0-b05d-4c73-92c7-bf2a40510d0d_default" xlink:href="cah-20220930.xsd#cah_MedicalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:to="loc_cah_MedicalSegmentDomain_1752bec0-b05d-4c73-92c7-bf2a40510d0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_34a5d235-d2af-4efa-b2ed-3310e49d9166" xlink:href="cah-20220930.xsd#cah_MedicalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:to="loc_cah_MedicalSegmentDomain_34a5d235-d2af-4efa-b2ed-3310e49d9166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_8aa4d485-39f6-4987-823f-2ca808ec5e49" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MedicalSegmentDomain_34a5d235-d2af-4efa-b2ed-3310e49d9166" xlink:to="loc_cah_MedicaldistributionandproductsMember_8aa4d485-39f6-4987-823f-2ca808ec5e49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_6784efbc-e978-4a04-bdd6-995f8c0ec99f_default" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:to="loc_cah_PharmaceuticalSegmentDomain_6784efbc-e978-4a04-bdd6-995f8c0ec99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:to="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_968f2d6a-421d-4a7b-a8f4-20bd77b1c748" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_968f2d6a-421d-4a7b-a8f4-20bd77b1c748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_07e8dc24-747a-4c4b-837e-d6e2b7d352db" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_07e8dc24-747a-4c4b-837e-d6e2b7d352db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3bd476a9-3cef-43fd-b357-6a3d35f190a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:to="loc_srt_ConsolidationItemsDomain_3bd476a9-3cef-43fd-b357-6a3d35f190a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:to="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0f2749b8-be99-4247-a2d4-190b5b17939d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:to="loc_us-gaap_OperatingSegmentsMember_0f2749b8-be99-4247-a2d4-190b5b17939d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c33fccbf-29ab-4176-88aa-83a387eb9224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c33fccbf-29ab-4176-88aa-83a387eb9224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_94521b0e-4be1-474c-b38f-e8bd012693e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:to="loc_us-gaap_SegmentDomain_94521b0e-4be1-474c-b38f-e8bd012693e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:to="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_e54e0a74-6606-4888-a735-642ad0c09f3e" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:to="loc_cah_PharmaceuticalMember_e54e0a74-6606-4888-a735-642ad0c09f3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_49b0e090-0c1d-49ee-aa13-05dced4e91bc" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:to="loc_cah_MedicalMember_49b0e090-0c1d-49ee-aa13-05dced4e91bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_7d56316f-2516-4b01-9ecf-8e6190863404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:to="loc_us-gaap_SubsegmentsDomain_7d56316f-2516-4b01-9ecf-8e6190863404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:to="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_50aa2ee9-4624-403a-aa82-d2a371e1aad7" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:to="loc_cah_MedicaldistributionandproductsMember_50aa2ee9-4624-403a-aa82-d2a371e1aad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_7f516739-65a1-4835-8739-88c1368033d2" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_7f516739-65a1-4835-8739-88c1368033d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_73fea3c3-5805-4aee-975b-d82835ff23a9" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_73fea3c3-5805-4aee-975b-d82835ff23a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_ef70db7b-21b2-49d6-a34e-3ce2a3115e96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_ef70db7b-21b2-49d6-a34e-3ce2a3115e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_7f493ebf-febd-4a86-af47-b7eff8ccca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_7f493ebf-febd-4a86-af47-b7eff8ccca0d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended" id="i9e3db7e325174ef083913385cd0fc228_SegmentInformationRevenuebyGeographicalSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_f82899b6-2267-45d3-850b-f7ad1d14490b" xlink:href="cah-20220930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_522dbdcd-5bef-448e-a3ec-ea4a8725c219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_f82899b6-2267-45d3-850b-f7ad1d14490b" xlink:to="loc_us-gaap_Revenues_522dbdcd-5bef-448e-a3ec-ea4a8725c219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:href="cah-20220930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_f82899b6-2267-45d3-850b-f7ad1d14490b" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:to="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_64b5b855-b9bc-474d-b503-62baf4843689_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:to="loc_srt_ConsolidationItemsDomain_64b5b855-b9bc-474d-b503-62baf4843689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3a6e68b7-4464-41ec-92db-ce814c24d5ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:to="loc_srt_ConsolidationItemsDomain_3a6e68b7-4464-41ec-92db-ce814c24d5ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4f5dd44e-98d8-473b-addd-59d8b3a5e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3a6e68b7-4464-41ec-92db-ce814c24d5ed" xlink:to="loc_us-gaap_OperatingSegmentsMember_4f5dd44e-98d8-473b-addd-59d8b3a5e86d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_92928213-c2ed-4696-ba7f-b021930dd89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingSegmentsMember_4f5dd44e-98d8-473b-addd-59d8b3a5e86d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_92928213-c2ed-4696-ba7f-b021930dd89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:to="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_890e7835-db86-4a20-97fd-7132216eaf92_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:to="loc_srt_SegmentGeographicalDomain_890e7835-db86-4a20-97fd-7132216eaf92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:to="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bd449bd7-4e5b-4111-9875-012d7c40e5df" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:to="loc_country_US_bd449bd7-4e5b-4111-9875-012d7c40e5df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_395f267d-eb72-440e-86a0-882a54845066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:to="loc_us-gaap_NonUsMember_395f267d-eb72-440e-86a0-882a54845066" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i052dc14ec7bd43e99eefccb83250942c_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1aea6c9c-eded-4df2-8431-0054f2c16972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1aea6c9c-eded-4df2-8431-0054f2c16972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_956341e5-a8da-410c-a7db-1de4829d47c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_956341e5-a8da-410c-a7db-1de4829d47c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_874a7df8-90d0-4bc2-95af-4f27604fae9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_874a7df8-90d0-4bc2-95af-4f27604fae9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b4501ac-f556-45fd-83bc-e03ceac57921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b4501ac-f556-45fd-83bc-e03ceac57921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e966495f-ec19-4339-b161-c924dcf24ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e966495f-ec19-4339-b161-c924dcf24ec9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_e3000393-fe98-49a5-9c83-04935cb22cdd" xlink:href="cah-20220930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_cah_VestingPeriodinyearsforShares_e3000393-fe98-49a5-9c83-04935cb22cdd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:to="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efc3619c-f650-49bb-90f1-480db65ca839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efc3619c-f650-49bb-90f1-480db65ca839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3574eeca-777e-4b57-853b-fc2b1041b9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3574eeca-777e-4b57-853b-fc2b1041b9eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9104f09c-6838-4c7b-a8cd-fcc265ef4f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:to="loc_us-gaap_PerformanceSharesMember_9104f09c-6838-4c7b-a8cd-fcc265ef4f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:to="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e5cb456-fc87-448e-90bc-e5d970248e57_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:to="loc_srt_RangeMember_3e5cb456-fc87-448e-90bc-e5d970248e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:to="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_10fdaf9a-6bb7-42fa-aa21-598bd08b2f31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:to="loc_srt_MinimumMember_10fdaf9a-6bb7-42fa-aa21-598bd08b2f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ceaef69d-3f0f-44da-8db1-734630fe821a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:to="loc_srt_MaximumMember_ceaef69d-3f0f-44da-8db1-734630fe821a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="ic8c29d70651a4fb094821054852aa7a3_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e0eb56b-9788-46a0-bc0d-dc6a5b20117a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4d02bfdf-3c0a-4b12-aa4f-d814988f38b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e0eb56b-9788-46a0-bc0d-dc6a5b20117a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4d02bfdf-3c0a-4b12-aa4f-d814988f38b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e0eb56b-9788-46a0-bc0d-dc6a5b20117a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:to="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe4a951-f68c-4982-8226-58314b5d80f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe4a951-f68c-4982-8226-58314b5d80f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c6f538c0-31f1-4381-84ef-5199632ba05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c6f538c0-31f1-4381-84ef-5199632ba05f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cd5d6c17-bc46-4753-bfaf-bb79277be280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:to="loc_us-gaap_PerformanceSharesMember_cd5d6c17-bc46-4753-bfaf-bb79277be280" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="ie25ad4f6604a4eb783fa2324b64ff653_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_248d21ad-c0c4-4bd9-b7ac-a9079a4ab97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_248d21ad-c0c4-4bd9-b7ac-a9079a4ab97d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ed926f0-9ec1-4209-a19d-e8c37207db94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ed926f0-9ec1-4209-a19d-e8c37207db94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f57bce6b-fc9c-4e0f-8ee1-8994b04c85b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f57bce6b-fc9c-4e0f-8ee1-8994b04c85b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e938bea7-c716-4374-bb29-92ea5813ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e938bea7-c716-4374-bb29-92ea5813ea49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_860e4f35-9479-480a-9dea-f887ac0b0e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_860e4f35-9479-480a-9dea-f887ac0b0e3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f26ec16a-e811-4871-a07d-3b77d90d37a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_451c3808-91ff-42e6-b802-d77f156e4ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_451c3808-91ff-42e6-b802-d77f156e4ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb71942-13f8-49b5-87e6-469787948e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb71942-13f8-49b5-87e6-469787948e4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa396121-d1e0-4358-a581-780c5b4eb893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa396121-d1e0-4358-a581-780c5b4eb893" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9885d64-d848-4ce7-8b11-cef72acc4015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9885d64-d848-4ce7-8b11-cef72acc4015" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fddd60c5-73f4-4b6f-a7bf-7d8befc1aa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:to="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05b60027-fdd6-458b-969a-478211046552_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05b60027-fdd6-458b-969a-478211046552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bd7a802-406e-4e39-a67d-a0ef91c6a06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bd7a802-406e-4e39-a67d-a0ef91c6a06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7544c3b8-01b4-47b1-ad5b-74dd4f46d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bd7a802-406e-4e39-a67d-a0ef91c6a06d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7544c3b8-01b4-47b1-ad5b-74dd4f46d3ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="i3c799e5c84c84ed4a2eb036070631700_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_630844cf-6228-4896-8674-6771d27de8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_630844cf-6228-4896-8674-6771d27de8bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa795a42-f03d-408a-9c8a-4a6652abe100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa795a42-f03d-408a-9c8a-4a6652abe100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19a168ac-bb67-4124-9cfa-24a44cd8119b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19a168ac-bb67-4124-9cfa-24a44cd8119b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_65625f7b-f871-416b-bee1-e52fc77a7dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_65625f7b-f871-416b-bee1-e52fc77a7dd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca43b552-7cd7-416d-8834-f0bbd87c0b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca43b552-7cd7-416d-8834-f0bbd87c0b98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c9054df6-cd8f-4989-b3fc-0a15424b26e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f222ec3-2d66-42be-820a-fc532579e395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f222ec3-2d66-42be-820a-fc532579e395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a758fac-b276-46bd-9d13-2c8d7249c107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a758fac-b276-46bd-9d13-2c8d7249c107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c2aae8-9489-47fe-9cc4-54baa82b30d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c2aae8-9489-47fe-9cc4-54baa82b30d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365f6d9e-1f1b-4b80-a422-3ba80627c0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365f6d9e-1f1b-4b80-a422-3ba80627c0e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45a69ca-a7be-41c6-b274-409a8988ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9ff9359b-e2f2-4904-808d-f17d9bd965a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9ff9359b-e2f2-4904-808d-f17d9bd965a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69c1002a-a1db-4990-8afb-822683b3ab85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69c1002a-a1db-4990-8afb-822683b3ab85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:to="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d571fd98-b19a-45bf-8e81-6f055a3ab34f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d571fd98-b19a-45bf-8e81-6f055a3ab34f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80842c22-40ca-4f97-92f1-0a2a6fa80896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80842c22-40ca-4f97-92f1-0a2a6fa80896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9590f57a-8e76-4c29-82d6-bf40d969c27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80842c22-40ca-4f97-92f1-0a2a6fa80896" xlink:to="loc_us-gaap_PerformanceSharesMember_9590f57a-8e76-4c29-82d6-bf40d969c27a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cah-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:964ac801-dd50-4cbf-978f-cd662ea3a8c6,g:8bda5b56-43aa-4d85-9f5e-cb52b0901382-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9df3ff87-3d44-4fd2-a93b-53f6e8e78647_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified to earnings</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_fd799174-c2b3-4608-a83e-afc5f23b0ef9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_00208477-004d-4dc1-a72a-ee40a01c2827_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3dea4a41-69b4-4c24-a0a9-4e3061a1e38a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_36992537-94a3-4b9c-b430-8cfb330a9b82_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_e4fe98dd-e7df-4c35-b840-82c51befdddc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_0e4cc048-8577-41b7-944a-41261b5a8145_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6ca98c41-264e-4071-8306-850808ed3e41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_70521405-187a-4366-ac3c-724bc828fc59_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_3a284b6e-edee-48f1-8c4e-10a16439d293_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_424aacde-8172-4280-bf66-1b1c353f16e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ab1d7758-ba22-424a-8808-1225ec715e55_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_fc28a998-f98c-49fb-93c0-935cd9a397af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_123a35f1-14f3-4d33-8544-e6a8579b7c32_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_11aa3c6d-c33f-4565-9d1b-453190873b91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_2cf35769-ed7a-4fa9-b2ac-58e8d0374845_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_15ed8e8c-bf4f-4e8b-9add-345f1758d29c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalSegmentAxis_97385db5-80e5-41d9-8974-fcdae0856fb7_terseLabel_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:label id="lab_cah_MedicalSegmentAxis_label_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:label id="lab_cah_MedicalSegmentAxis_documentation_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis" xlink:href="cah-20220930.xsd#cah_MedicalSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalSegmentAxis" xlink:to="lab_cah_MedicalSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_c79d3343-e8e3-4e16-9ad9-625bf10c0fdf_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_3273e960-ea72-43cd-9a41-3fbb67b479a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_af10a430-a0f1-41cf-b32d-ac997cd291f2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_a7c2db68-0efc-4405-bdbc-2e3084afa5af_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20220930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_7935d1d6-4379-447e-aae9-0522cad4de6a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_08183fae-6237-4bdf-8467-034a2008a290_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_42088fb2-f224-4a54-bc16-db5207345231_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c75aef6b-17d0-49d5-9168-85a9bd19f0be_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_d9ecfd9c-b86f-4992-a774-2f033bfe7e14_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_76fd285b-653f-45fd-a89e-6746b64ae73b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a760d5e2-43ea-4e51-82d1-47833ea41ce4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_540648f0-af72-4075-86dd-918f827f1799_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_a7a17d9e-1422-40b5-9ab6-f1500c96521b_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthServicesMember" xlink:to="lab_cah_NuclearPrecisionHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5e9e5592-cb18-4bf9-84aa-b8e2ad673481_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9198e505-c07a-48ea-b637-3b97589c181a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings/(Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6d28b1a3-1a29-4d3c-ab1d-ca04de36ae20_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5cfa0cce-d47c-4c83-a4f3-08fa4420133f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1fe051c6-e2a2-4402-9b3b-d6639c9915a8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_c99e0f61-bd44-4c25-af38-9c3c1cd0a57e_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WV_a614288c-2cd8-4755-b3b1-050766b25962_terseLabel_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:label id="lab_stpr_WV_label_en-US" xlink:label="lab_stpr_WV" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEST VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_f85d52a3-1b6d-4db9-be0c-bb92000ace60_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_50c3ad80-1628-4553-b1c8-f2f0d48f24ee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1d07c301-6690-4660-a53d-55f5e38d61e3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_8b5eff45-36ce-48d8-bb7e-a2cf9b6a5c34_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f1e9fd66-76f3-4437-aea6-fb8798a86f10_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_7eaa61a9-ed32-4882-ac7d-254c4cbce199_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a3922ee3-3a7b-43cb-9890-9e75e5b0bea8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_989f51c9-f072-496c-8e6a-849fc05403d9_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20220930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_ed43f4ce-3d66-41f7-b2ed-5f8c044b58ed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5359fd9e-178a-4819-b2fa-26dcea1fcd4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_df3e010d-eafe-4d58-af65-f6f7701bf3e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_78506252-797e-4ce5-9aae-c2f1cfe9687c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_1056b828-4184-4a18-8ab4-c47ca358b15e_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20220930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_c676868d-9018-4665-b05e-6355ecc2803b_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_af8e72fb-07d8-4570-8c56-aee9f0cafe4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7efef8f0-42fc-46e6-b3ef-46f9b7f4f86d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0537250d-0e5a-4457-9cd5-b9dc6956bc6c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_84331ecd-a7c7-49f7-a62d-e81c1006a5af_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_e2b45357-2b41-42ec-a312-8d0dfa7641d2_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20220930.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4b457e0d-5a5c-4962-b886-d7e0c617acdb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_d0ec9288-243d-48f6-a14a-2832bcbc84df_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_a2673cc9-ede9-41c5-aa81-eb25f090c6b5_terseLabel_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program</link:label>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A1BillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1 billion share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember" xlink:href="cah-20220930.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A1BillionShareRepurchaseProgramMember" xlink:to="lab_cah_A1BillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_343c5e2c-4f81-46ea-8763-c7f4c3108143_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax withholdings from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20220930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_55b05915-ba1a-4d1e-87fa-bd832bc63ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_f7ce07e1-8100-4de5-8a5c-5086e29f07ad_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_aecd810e-04e3-44d5-a034-c69654c0d7a1_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a22fb329-9786-4551-ad2d-0ab46c780670_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c72118d5-b0d6-403b-afcb-6589b6a53bfa_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8fa77df-5af4-4763-a7b4-09aeaa7855ec_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5d6c361a-1ff9-4d0a-bea4-19b8f8bb8baf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6c5759-9edf-4692-9238-88a84bb8d9a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingUSTerritories_5e4780cc-6c4b-4cf6-97ea-a93940c26598_terseLabel_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_label_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:label id="lab_cah_SettlingUSTerritories_documentation_en-US" xlink:label="lab_cah_SettlingUSTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling U.S Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories" xlink:href="cah-20220930.xsd#cah_SettlingUSTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingUSTerritories" xlink:to="lab_cah_SettlingUSTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_1df42841-68c9-4d28-a041-c29a2b38375b_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6f1032cb-21fe-4748-9a92-8eaad8250aa4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_73e93fd4-29e0-4844-807e-37c2b65a2057_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83eb9b97-4156-4b0c-ad8f-1da0f6470c7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f4fdc665-8618-4811-976c-3c32eb444f4d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_180d2dca-30db-4fbe-a883-26f3f5b3c74d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d574acc2-dee4-483a-b6e3-a27941ef4c59_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_80562e67-78c1-4467-bc71-b4178b1f930b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_df16f2c8-17e9-4682-8f4b-89743c3bb7f9_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_55af07d7-d5b4-4a38-b982-de0f5a7f7e6b_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b290724-516b-4ee4-8dc8-283ed57f1500_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4798ef35-99af-4103-8dcb-65b48b44a9e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f94eec2f-9ab3-4df1-aee6-ab7572fdcc17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1cf22176-3e2f-4579-b56f-5aa36c14efc2_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_76db8ba3-9f8e-4c45-9a95-71c784c40167_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0cdc07d2-1d43-4df3-9e0f-8fcc19604de4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_e17afbf1-91b9-420d-b9d7-6a32db37fc33_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20220930.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_745940d8-8e7a-40d9-a43d-150d3cb2aa4e_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20220930.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_446ea93a-5980-4b08-9612-a8708a9d0f54_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20220930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_85bff5bb-dd6a-4627-a47a-3c955252427f_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a729d81a-13da-46b9-8e80-085e04e1b4d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_ecad3a3c-1e3e-4c89-b078-9c81b5189e62_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_02cca529-5673-4802-9c71-169e0a75634e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_446cfbf8-69e4-4b3b-a902-f19d85a809b0_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_eb7cc6b2-0e59-4b47-a0ff-d2fab238d6c8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_c4b6036a-ef22-4979-9bfd-e0bee561e086_terseLabel_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="cah-20220930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_335a3781-55b5-400d-a8ba-aecbcb0bf0c4_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20220930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_f7a76f83-20fc-4733-9829-f4696dfafc27_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember" xlink:href="cah-20220930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeSolutionsMember" xlink:to="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e0836a7d-9249-4ab5-9fe6-d0ec79056068_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3b969f6e-e80f-41be-918c-720975b52f07_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_54084f77-9a9a-46f4-a464-b6d56158216f_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_c0ed4804-f859-4a00-9a0b-7eee2e845131_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable" xlink:href="cah-20220930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicTable" xlink:to="lab_cah_SegmentRevenuebyGeographicTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ce63f496-72c8-496a-a5d6-b30a55831d41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_727414d0-447d-4a6c-9482-f36e101ef527_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6ed4bc85-c428-4f73-ba6c-65a83b496de5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_cd9c2969-d808-4a60-bf4a-95c917d94c16_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_40241155-3083-46b0-ba16-8facfc53fac2_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_d7f3fb1d-7045-44d6-9f04-23bf550854a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_389e9d0f-9e60-4e32-9241-be807becb375_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ca351d8-13db-4401-b033-eaab460beafa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_487fb11a-48eb-476c-a17f-6bdb768c68fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedFromAssetsHeldForSale_08d8d9f1-38c7-437d-a9c3-7ed956363d7d_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedFromAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Assets Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedFromAssetsHeldForSale_label_en-US" xlink:label="lab_cah_CashReclassifiedFromAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified from Assets Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedFromAssetsHeldForSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedFromAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified from Assets Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedFromAssetsHeldForSale" xlink:href="cah-20220930.xsd#cah_CashReclassifiedFromAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedFromAssetsHeldForSale" xlink:to="lab_cah_CashReclassifiedFromAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_29154a91-4844-49b4-b351-5c3d9fc096cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_413b612f-974a-4891-8353-293258478a79_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3ec3069d-f6e5-4c82-8ccc-692e6c8f9e0d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_bc7b6e40-dfe5-4bf2-b66d-1f249c5ab3d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f8a909be-3ab6-4f46-b2d9-001feec664bc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e903c5ee-2830-4f62-b532-49a54d090ce1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e7dd6b51-75c9-42f2-ad55-8762050a4d4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_60ded8f6-0fca-4bf9-89b7-dcd58025a75b_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20220930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_a540397d-2abf-4462-a264-87c0fc192ca4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentAxis_2697bf91-d683-4a31-b98e-ef67db72c965_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_label_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentAxis" xlink:to="lab_cah_GoodwillImpairmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_237c9825-2004-4da5-b465-dc5de961c685_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_dac2e337-b046-4a32-9e1d-4d4215a6da3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_bf863299-7eb7-457b-a169-2c53a95247db_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5be01e26-1fb2-4bac-8662-1a56ccc00090_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3d38b082-e3fc-40c3-bf35-a513111f9ecf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f0281e5-0530-4a6c-90bf-9d8e3564388f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_fb8d9a5e-caf2-462b-a5c7-c034558a05a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_55728563-7b67-443a-909f-4473b64bdbe7_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Early Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_4ffd8f78-a36a-483a-897c-b5733639198d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_731ccbbf-9d27-49c7-8965-c09af0634211_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_77e2a430-e979-4ceb-9b5a-29d61e30c4f4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_171b67d7-5ac5-47bb-bb60-a2170c71523a_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_465a8386-2ee0-49a5-ab42-35c06caf37bb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_a373efe8-0667-4511-85ea-17e923c39c88_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7cbff032-d0e1-4538-9db0-447fffb45eb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_122aba06-271a-4faf-8abf-60f76785a54a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_0f22b23e-2eb0-48e3-b397-f2dc49a2d488_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a19781e1-2f1e-4678-a45d-8dab0b565f38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_5b9806b1-550a-4dbf-884a-a7d4d516d6e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_19257aca-b1e5-4523-ac2a-50d78a468f2d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ceeef58-7146-4bba-a29f-036536d38faa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dde47efe-fe07-4b29-b7da-f54e459e5a64_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd30ed09-b4b5-40fa-a5f2-530af8c9c4cf_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_112d6965-6359-4eba-90b3-33823a2f6f6c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e7f2238-e3b2-44e2-9a69-90aad051fda2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_365ff82b-b16b-409a-b99d-9255855b0310_terseLabel_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_label_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_documentation_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput" xlink:href="cah-20220930.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TerminalGrowthRateFairValueInput" xlink:to="lab_cah_TerminalGrowthRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1c8b9e33-c0ad-46ce-9a29-351c8eeb667a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_34322be7-1757-49ca-9276-92076d74f979_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f71ada78-ba06-4f3b-9142-1f0d9e61f7f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_25c14648-25f9-429e-9fc4-5fa1c45ed57d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8016fd5-bb3a-4f03-b729-d13924de50d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3ce26713-19d1-46b8-9c79-775a5e1d03f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1d3963c2-16c0-439a-831a-5cce27e13da4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f638eace-1d8f-43a1-9520-c7b7f411eb93_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dc77677b-82d6-44ea-b62f-9b230ca47637_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_5e4f0314-7904-45c5-a73a-3db74c39a2d8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_e7ebf2b1-fc86-430f-9931-5f00543629f5_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20220930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b80236a5-7c9b-46be-b0de-53ff5951b55f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentMedicalUnitMember_2043a182-14c9-45c9-81de-1b48566e846a_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentMedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentMedicalUnitMember_label_en-US" xlink:label="lab_cah_GoodwillImpairmentMedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment - Medical Unit [Member]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentMedicalUnitMember_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentMedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment - Medical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentMedicalUnitMember" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentMedicalUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentMedicalUnitMember" xlink:to="lab_cah_GoodwillImpairmentMedicalUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_be6dc1fc-6538-48e1-b02b-12511d159c18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ff06346a-d91b-4cd8-8b26-2c08b2e3ac03_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_13f312ec-023e-43fe-978b-df1b46f29282_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e76590a5-f0f9-4435-8c6d-41eff77e59b5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_86731ae6-61f9-4468-af7c-062dce961fc9_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20220930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_JudgmentForLostProfits_7bba9c28-9e0e-4802-8a66-17a759ae8f42_terseLabel_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_label_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_documentation_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits" xlink:href="cah-20220930.xsd#cah_JudgmentForLostProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_JudgmentForLostProfits" xlink:to="lab_cah_JudgmentForLostProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_5deeb0fb-eba2-4d10-b138-fbebfd6e67cf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8db2699b-0858-4763-908a-6e4f689de515_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3e3e306b-d88b-4cac-89da-3fd5d4df70a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_b59e0144-bf79-41c6-836b-1f5fe868ec53_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_98a2fbf9-5d3e-4abf-ae3c-1382b449108e_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_374d6232-e5c3-467d-966d-ea02b4f091c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0197bce9-6fae-4393-8a74-b5ed76a3d830_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_3dfd8a32-4266-480e-8a7c-6b57b69124bc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_f6922d91-1fc7-4cf8-ab84-bdcc90552470_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20220930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_51e538bb-d1c7-4f2c-91ae-9481a9522e68_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8716ae1b-ed92-45bf-ae14-e0acc29e1201_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_6a5e9654-fcd4-42bc-b2cb-6eb0d65f5f3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8925c49e-1872-401b-b509-bf4fa661fb3e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_c2cdca73-bee2-4b38-961d-605f7b6e0446_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_4782072b-853f-4591-81f4-e26fb1de85e3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_71bdacb7-38e7-42d2-b2d6-c4334dcb1e14_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_b7aa3afb-71be-4cee-bbf8-1e39344e64bb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9aebaf4c-fe8a-4d14-b88d-2d8c3020c3ad_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c959e894-81b2-45a9-ae0d-37f61e9a2487_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_910036ba-64e7-4cb3-a0d4-39b4aab4f917_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_66ccd887-dd50-42d3-a832-cdf8942450b2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb59e403-03bf-4cca-b7c8-f2bd9e644a26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_d87adc2e-4ee6-4579-b159-1d16a75ed306_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20220930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97d9f7a5-3e0e-4ee4-94c6-86f43e896b5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ba103a60-f29b-450e-ad71-b2a6226f00cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e61702b4-698c-4721-a0fc-3dff88f16d9d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_d7336c2a-989f-43e4-842b-5303e60afda7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_fd06f90e-9974-4f9e-9612-8b14d317516f_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_42cbd1ee-6655-4129-8bb5-63b4a9556858_terseLabel_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:href="cah-20220930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:to="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6d59ca4f-ffc8-446b-9a73-d672ab92c37a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_b9f07d7b-2e01-4462-97a8-4db276e81e90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_169203e5-fe81-4fa2-8cb7-45f529e1725b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c66f9e82-b2e4-486f-92a2-87891b9cfc1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fee947c3-e677-4989-87fd-697e0e967076_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalSegmentDomain_d6c451a6-3ab0-4862-8671-99390e86396b_terseLabel_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Domain]</link:label>
    <link:label id="lab_cah_MedicalSegmentDomain_label_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Domain]</link:label>
    <link:label id="lab_cah_MedicalSegmentDomain_documentation_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Medical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain" xlink:href="cah-20220930.xsd#cah_MedicalSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalSegmentDomain" xlink:to="lab_cah_MedicalSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_dfad1355-74a8-4500-853a-b1d2b2efc736_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock plans activity, net of shares withheld for employee taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_23d3a129-33fe-47d8-9821-945929929460_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_003675e7-cd40-4caf-a5e4-1c5d316e52ae_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_9abc24b5-d4ad-4dfa-8550-bfc39f83d131_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_80530f57-fa8c-4ebe-b097-f43075303f6e_terseLabel_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_label_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_IncomefromSettlementsofClassActionLawsuits_documentation_en-US" xlink:label="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:href="cah-20220930.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IncomefromSettlementsofClassActionLawsuits" xlink:to="lab_cah_IncomefromSettlementsofClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7a21d787-e94d-4151-ab05-bdd409b27101_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dd9505cf-cdea-4efc-a659-34861eb273bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_b26bbba1-54f8-4514-b25d-782b784c89ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_61193f5f-d7cb-4466-bd5d-7315461f2e52_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_eaf385ce-d420-4779-86c8-2bf0eb43720c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_edd8f980-40f5-4a78-81ea-7ff75d376039_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_2d506dbd-49ad-45ec-885c-6891d3ff9923_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20220930.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_433dbe53-fc95-400b-9680-84b2e4bfbfb1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_95b52b6b-bb7b-4b6a-8621-bcae31c6e76b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_41ea4586-b657-4e9e-9773-f49a117870dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ef6f3e62-3208-4f2e-ac37-5e7f4f54e718_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (using cost method), shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_709c1755-88f9-4309-937a-d90d5ded233b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, 2 and 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:to="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33fc2677-67f7-4dbb-94d2-6cac2c55a35d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_030f2a5f-e811-4063-b5dd-456f10401de8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_053fea3c-6fdd-4b76-8cb3-ea15d3159d84_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_15634728-44f9-42d0-a792-45faf4b9feb3_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SettlingStates_713c861c-6154-4d1b-8c7d-40f6a426a5e4_terseLabel_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_label_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:label id="lab_cah_SettlingStates_documentation_en-US" xlink:label="lab_cah_SettlingStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settling States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates" xlink:href="cah-20220930.xsd#cah_SettlingStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SettlingStates" xlink:to="lab_cah_SettlingStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e3a7eb-107b-40d5-81c7-662a1b6d5240_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_955a30b4-2ca7-45ea-9ef0-3573c6fc3267_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_fff34346-dc83-45d1-b90d-0db50ae52f9c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f756362b-d490-4e33-a798-ec8d6cf5e93b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_3add0af8-1fe4-456e-8afe-372ec3ee6e34_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_c1853a23-bb55-41c6-be0f-53810f3dda27_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b1c21749-7c8f-4147-bd42-a06fbe59bab7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bd13a57b-4996-4fd8-ac58-1119bafa3fb8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_715b4fcb-4dd8-4325-be9b-b060fc39fe25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_2a6066a3-ff92-468f-b19b-37348fa0524a_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_190a8e8e-48fe-442a-a52e-c565b16eabdf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3c6d0da2-3f96-4a51-a761-eab7cf87de24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f8c51ff-da00-4f8e-beb5-ded43003cf0b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_386359f7-8430-43dc-8e23-ccb953117235_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_8d365974-654b-4765-a1d0-03480ff89384_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets Held-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d18f81e1-ce4e-4f63-aa56-5053f34126fc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_27726bdd-e21f-494f-82f3-f53714fd7205_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Lived Assets Held-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b75c8aac-d8b7-4f61-b81d-40ef60877f0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_56e26937-ae34-447f-a906-48b47049019f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5bba14c4-606a-4b2d-b954-9202c6e9bb00_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_aeaf6a4b-f0c3-4ddc-9cff-0cd12378ebe2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyNumberOfEligibleStates_6953dbfe-311c-4342-b59e-317501801d12_terseLabel_en-US" xlink:label="lab_cah_LossContingencyNumberOfEligibleStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Eligible States</link:label>
    <link:label id="lab_cah_LossContingencyNumberOfEligibleStates_label_en-US" xlink:label="lab_cah_LossContingencyNumberOfEligibleStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Eligible States</link:label>
    <link:label id="lab_cah_LossContingencyNumberOfEligibleStates_documentation_en-US" xlink:label="lab_cah_LossContingencyNumberOfEligibleStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Eligible States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyNumberOfEligibleStates" xlink:href="cah-20220930.xsd#cah_LossContingencyNumberOfEligibleStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyNumberOfEligibleStates" xlink:to="lab_cah_LossContingencyNumberOfEligibleStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1cdb472e-8a1e-4cc9-82f9-229ac3f2211e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_43c8db27-4758-4ef4-898f-8518ab72cba9_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20220930.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_b999b64f-71a0-4f3d-b9a3-1d15d61fb090_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20220930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_72029dcb-1847-4e31-9a0c-68963bf6d9ab_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b3e227d1-a9b5-4f66-bbbe-48b9c5b44f1a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b70a668d-c952-4d52-b485-ed89f392563d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_889c3fb8-0816-4407-899a-80dee7c1fb33_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c77e3fe7-e196-4395-bb4a-eb18697b2500_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c52d3570-74bf-421d-a803-c2c67f27498d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8d01bd08-0575-4d7b-a0ee-6afee87e5ffa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_05249551-bbae-480a-939c-183b2a0c301f_terseLabel_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:href="cah-20220930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_14aff711-4b7a-4497-bbac-fae1bfaaa910_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_bde11beb-03fe-4363-b663-140bbb9db5fb_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20220930.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_6619921c-69f7-464d-a4a9-c26f2f366af5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentDomain_e5099eff-e6be-43ca-84da-bd67da7567ac_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_label_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentDomain" xlink:to="lab_cah_GoodwillImpairmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_755d2431-d466-4bd8-90f0-9dbd2ec51368_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LitigationTypeDomain_808ad6ad-4c74-4e13-89d7-39d024fd05c3_terseLabel_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_label_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_documentation_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Litigation Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain" xlink:href="cah-20220930.xsd#cah_LitigationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LitigationTypeDomain" xlink:to="lab_cah_LitigationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5e450500-d71c-40d5-b1f6-6fb7d5e9b6c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_5ee6f558-ed57-46f7-ab37-a65cdc0b742d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_b1d471f1-e62d-4a21-b7e7-f844db009625_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_05d6c32a-a314-41bd-a14e-e459e748d572_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_afcde21b-e4aa-4365-8e3f-70f55b43d42f_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_7eedd74e-ca39-4c6c-9d8d-c5121c56143b_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c7068bb1-5c80-4d39-8d1e-e5fd0aaaecb1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_44bbfbd6-e50a-4b1d-88fb-8b98efdab6b4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5513e66d-0cc8-409a-9b64-2bd32459742f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f00ca62e-c119-4368-9f82-05532aac03e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_88181fdb-2c44-4f6b-bad1-6d08ea33454e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_097af680-6865-4d6d-b7c8-cd2ee79ff5e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8cba0224-c31d-4903-98a6-f69282fae1b8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3723ff4a-5ebb-400a-9aa3-7614714c8db4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_369af445-2f08-4601-9ff7-032e33c1acb7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_d7010b77-dc32-4c25-921a-270d5ca25513_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ba899397-34fc-4c43-869d-27a233e868a4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_a906659c-5046-4f8d-91dd-a53f99322749_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40fdea89-d4fe-4852-90eb-6b43ca8afbce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84895510-698f-4845-8ecb-e73e663d1501_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_962c1232-5d5b-4594-a9c7-43bc95fdf6bf_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_e2b07bad-0bfb-4123-8afa-0e8c7e6336ce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitMember_4b0e698f-0a33-4a0a-b386-3c7aa29bc865_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitMember_label_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember" xlink:href="cah-20220930.xsd#cah_MedicalUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitMember" xlink:to="lab_cah_MedicalUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9086362e-61dc-4fc7-a4bf-00b2989a861e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_c03aa9c3-c602-4c51-b376-ea13d3c7545b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_43eca15f-8f6d-441d-990a-68d9c52a9083_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0a00f656-8487-4a21-b4b7-0c34621b029a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2079427d-e74e-4a75-80df-d9d831e291d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11dbd479-29c3-4e1f-9642-9795e9e77944_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56fff01f-61ed-461c-ae25-84284b932d40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_8578cd66-a87c-4902-bdd9-528d53be270f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a452e3dc-7c5b-424d-8b2d-9fb64a5aca03_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_95f3735b-aa62-461e-9a75-8555e0ff9d2c_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55867a54-c742-4ea3-a50b-4c86fe15fb7b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da808c51-f291-4d96-b101-a2a791428da9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f818cdf2-f1f8-4531-b4ea-45df84a43f14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4c5865ab-79b2-4647-884a-41653900bf2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_88771aca-d638-460c-b872-995442578d03_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_59e5c106-5b67-4c96-a5e0-edf589e03813_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_9e7734c9-5f59-4469-8385-bfb2651f67a9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_953a361e-9ecf-48b8-abc3-39f43ca798b4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91a47fd1-d488-4095-9d76-892ed5a140d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7366f815-c8ef-48a2-84b5-a3fd633a1cef_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2d3cb323-d03f-40c3-9ed2-feb8208848a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a655f40e-b1d9-48ec-a6f3-832650150535_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_065c099a-fedb-4983-be8f-0f57380bc8c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63f7f7db-a968-4d4e-ae8f-e6a153eb4a8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_9474b09f-8fe8-4faa-aa00-03756daf4f5c_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c4b8a2d5-f1ce-413f-8983-de50145a721a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0113b9a6-bb65-40a8-8c94-5b94f35c7343_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_1cfad8d3-ac7d-4ebe-ad17-a78b9840dae4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_a3ac04c5-7c8b-4c6f-b27a-ad1a2ff998ec_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_35d2ab37-e92a-41c0-bf9a-8e686733f4d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d0db2be5-cdc6-42a0-82a9-2dfb6089c1dc_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_68b3417f-3240-4bef-b975-2f80cef8dda4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_446e9e2e-3c02-4f80-ad1c-8304572c3ab6_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_label_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_documentation_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalSegmentAxis" xlink:to="lab_cah_PharmaceuticalSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_e84f0cc6-de9c-4771-b1cf-518ae8c9199e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1ae393a6-7efc-444b-a8a9-0ef6537739a5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8edacd1a-a2f4-4c9d-b79d-0b0134e68ad2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b31f068a-aa5a-4370-9d79-1e0523421c46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_e003cfb0-0940-4f43-8127-a45252cca0e3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b0170118-bdf5-4675-b97b-a05995423e62_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_d4a3bce4-44a5-409f-8860-c6b69a4bf94e_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_f8394f0b-8361-4f9c-84b2-c0aa0cc10eab_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_74a1a6b3-f8fd-40ca-91a0-e8a045510e74_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_28a7f4bb-8057-4107-af1a-d9449d6a4bab_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_c7cc75b0-b9e1-498f-8d96-35e4262c9c23_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_20a7140b-1e5b-40e9-8499-3b0d925952cf_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ab71c018-73f4-48d9-b9ea-f9a7cc7c5271_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_b8f4ff15-a362-4499-97f3-7eb8c07687fd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a9ae56f3-fb49-416f-bb83-a8f803cc4fae_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_9c6c7c66-373f-42d3-a549-2c48f56c4e53_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_0ca04916-e4aa-4f70-8f01-20fb7eedee71_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20220930.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9a07d43a-90fe-439b-97e7-2f925197ce12_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5bc863e-cedc-4401-8998-1af98f19f82b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9f6707d5-c5f1-4ffb-9360-f01afe1a8919_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6ee71a1f-7dbd-48fc-9a1b-19f56b6e7397_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_604192b4-543b-4771-bc2d-e836efea2717_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_363cbbc2-c98a-4568-9ceb-783b6f44c5aa_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_c41c8fbb-8abf-4511-aa9a-b3f10be74c8b_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_6f576dbe-2ea4-436e-bc84-e8069f7cfa8a_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:href="cah-20220930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:to="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_50af05f9-e02f-4e52-9779-882be423bab0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_3ba8b2f4-b9dd-4542-82a0-be529809697b_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_d0118516-6989-4342-8273-2470a4533799_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d402dc86-4a65-4ada-86d5-9128f792affd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_46ca6df1-d539-4533-81b2-079be9fe54d4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1019ebb1-c551-486a-ae85-3ea7f2985e66_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_e6b99f08-7550-4aa9-8367-194f3615a54c_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_05e5ee3e-0054-4f46-a0c1-86dfeb02e707_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_510fa158-016f-4830-9c3d-a3dd4c4357e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8ee65b8b-2edf-4c88-8d2a-ba0a5338fec6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_43b325ef-907c-4d22-831b-4ef6960f97cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c897d45d-895c-4368-a0b8-31fd886fe075_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0590be8d-dc5d-43e4-b6fb-87ae1a67c273_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9058a30-2df4-4815-aeca-028f1362949a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_42bc3054-2376-4562-b1fe-95011570f5d1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_bc67ef05-f098-4870-94b3-57b87a5f8b40_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_d8d092bc-86c3-4efb-bfb6-36f29ae2c1d8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_78eafc40-4209-4820-86e3-77d7865898cc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_348c27d7-a1ef-4764-96cd-46e12710a745_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a90715ac-dd6c-4aac-9752-4762fceb04db_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_8b0d630f-ba28-4508-990e-deb5e787d3ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_241fa169-26c4-4b15-bf76-f68546832ef5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_7d859ee4-dbf3-4215-acaf-56eef96ce4d1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_66b5a6bb-ca88-4a96-9832-804ecaf33a24_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20220930.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_57b5a1bf-69f1-4c25-b76a-5bf7880c3e77_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_7dcf5e70-946f-464e-93b0-d795f0348b11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_b5e537aa-3cf7-4b77-9d49-43b67faed0bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_95320b06-5d76-4460-9424-7660bac3b991_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_46df8a6b-edf1-4de8-819d-cfe8d7aac585_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_22fa1002-93c0-4cda-a721-e5381ff69c4e_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statement of Shareholders' Equity</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_79a78262-c9a1-413f-9312-3da1232f6953_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_43ad876c-4ac3-4180-ade5-8a79013a6471_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ac0f5112-be35-452a-9b4f-ef3d004bb97a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_2ac17197-a24a-4f63-992d-6b55b92cd00e_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20220930.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7f7936ad-5cf1-4b9f-80db-a36bb115a229_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_0d825dff-3d55-451e-9d1f-b56ef6d4c4c1_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20220930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3594601c-e6f8-4fcb-9332-52a80115e2c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_09639e16-e9e1-48af-8258-3e859b346be3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7e0e876f-ce16-4e05-b399-e9ea6e918787_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2b33e596-e033-4b84-b6f4-4ad9c4fab9a2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_1f9c7706-9f5c-4651-bbd3-f74accb4a654_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b4d86f0-6246-49a7-9152-63e9a6b45e8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_07d8cf07-7e7e-4b8c-b7f6-22584ba7b204_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1bac7f65-a3ca-45d7-a867-2a87989e6544_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_38323336-67be-417c-8198-15debdf11896_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_3c86efc5-f710-4011-b538-2af4ee0f5600_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_e44119e8-b0a5-46e8-aa87-9505b63bd28a_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_69bd0b0d-fdc3-42b2-b954-ba9655539cde_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_9ac3d518-b815-4e39-aaf4-fb5130f2dbb7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b4b40743-0762-4745-b154-b247d1bbca84_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_743b46a3-4cef-40f3-bca5-f066788149b6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f8ace67-33a6-4b5c-936f-a74fed1d993a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4ae98d2-b989-4256-af1a-62f20b50314d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_698a83c6-2298-4586-bf97-cb2158041794_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_17fc6391-e8f7-471a-9ec1-129cdf979c75_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_14d0ec1c-2baa-4f45-b781-bdd0a1810809_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c081b4e4-4d41-438f-a9a0-814ee4173e29_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7ee30056-b5d0-4ba9-85f6-a04959e900ae_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNet_00efd16e-f421-4287-b7d7-43831fa78a54_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets</link:label>
    <link:label id="lab_us-gaap_AssetsNet_label_en-US" xlink:label="lab_us-gaap_AssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNet" xlink:to="lab_us-gaap_AssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_3ae26b68-c225-4526-8c98-4bbab6347f6d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f8b7c505-6383-43c2-a3d3-349129b4a65a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_417bfc1e-04f4-41c8-ba4c-8c52c15e9ea9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_56023338-16f0-4699-a8dc-8f3b4f773658_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_3d312f6e-9496-485a-ba7d-563bfb2dd6fc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_29e8e33c-a4b7-46a0-a9dc-ea833183edd1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_90efa685-86dd-41ab-8acd-4da12d3a57f7_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a8f7c640-bf73-467c-8ef6-bf562f2c66d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_6f6f3501-ae81-462f-9b45-c45fa961fcd3_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_d9a2864f-19a0-40db-87f6-a9a63c5db337_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_bb203287-6455-4f67-b6c1-152f0adc8a34_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_df1c15b2-cee3-4c95-b38f-38ff01715810_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9ceaeb6f-c287-4024-89f7-e1ff6f6feaa5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_e69fa919-51ed-4b95-8208-54c79b82bb5f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9fa431f4-8231-43b5-8f4f-4b03e25a8216_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_4b895e02-d1a5-4dfd-8803-8b28a5a1ac5c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_a8b980b1-3df7-4bde-9bc7-63273ad96b0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_04790e30-bf4c-40b2-b931-92514bc135a2_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_856554dd-edae-46a0-8629-08dee51181d1_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NativeAmericanTribesMember_e0fbbec3-bfa6-4ac3-95f4-99a473626490_terseLabel_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes [Member]</link:label>
    <link:label id="lab_cah_NativeAmericanTribesMember_label_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes [Member]</link:label>
    <link:label id="lab_cah_NativeAmericanTribesMember_documentation_en-US" xlink:label="lab_cah_NativeAmericanTribesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American tribes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember" xlink:href="cah-20220930.xsd#cah_NativeAmericanTribesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NativeAmericanTribesMember" xlink:to="lab_cah_NativeAmericanTribesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_73f68069-461c-4ba6-ab85-586f5984d410_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_8c4b25b6-2363-40fb-ae1f-17e8fc039296_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_22083a4f-33fc-4300-9f18-f41a40351176_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3d457aa8-6757-415a-8a87-643195d240d6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3c1b323c-a949-459a-b583-b288bb5e2963_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_72206f5d-7b4e-4a21-b60a-0a3734900ea3_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20220930.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_9b70ba9e-c308-40c9-bc18-49c3e983e3f7_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20220930.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_OK_a8b4b610-211e-4927-8dfd-87c887d0b466_terseLabel_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:label id="lab_stpr_OK_label_en-US" xlink:label="lab_stpr_OK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OKLAHOMA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OK" xlink:to="lab_stpr_OK" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_44663b71-84d5-4099-830e-08cb0c8f6b33_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20220930.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c74c3cd9-56be-4fbd-8613-33fc803b5399_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_601f0c2a-d0b6-4135-93e9-af507d0d45b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_59083067-8540-4b55-9d19-4e6e6785a32a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_88c54aab-fa0f-446c-8475-92aa602e7f1b_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20220930.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_97bf9b33-3d4f-4833-baf4-95b624393daa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_86d5b056-1a77-4455-b3da-167f85eb948e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e30a7e4f-0345-49c3-ae36-5d9ff58ec4b1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_e0272a32-ed18-47da-b11e-a6664d21f7af_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_97223e29-1ca6-4755-8b65-f5e4a191cc20_verboseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_48499cc1-28ac-40d6-a0c0-ff65a9b998e1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DiscountRateFairValueInput_2f7d83b8-3c47-4cc2-b217-ebaa55de662f_terseLabel_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_label_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_documentation_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput" xlink:href="cah-20220930.xsd#cah_DiscountRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DiscountRateFairValueInput" xlink:to="lab_cah_DiscountRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_dbd2e41a-418e-4287-8e98-00b431e38f45_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2bab34cb-4a28-4a0c-88aa-45a5bbc14e0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_a0c68001-59ec-44a3-8aa6-47d163c93ad0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_94fd9db8-bb18-4c5b-9561-9f1ee64888a2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_9e3655d8-c342-4969-b3a4-3f12ccb9f43d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_add322d6-0fe2-4e96-84e9-898741a66970_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_724ebaeb-62a7-4cc1-ac4f-272709040f16_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9605a0d4-7736-4774-b5d9-5165b2733527_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0ede4926-73b6-4ef1-ac40-c347265f48d6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_307e5a59-931d-46b1-8679-35f38eb8b920_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_b80fdec1-0cd5-4cf8-b3eb-8d07ae797164_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7f1e11f9-ddb6-4d9b-a636-892efc51df19_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_31d8984e-1c67-4c2b-bcf9-4d9cfec0f03c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a166fd4a-95c0-4ef4-9acd-5af5f8228136_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_1e878599-c1db-4154-a940-e33402d3957c_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20220930.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_85dfca81-5f4b-4de0-89f5-d645e4cee1ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_edaf321c-d3d5-492e-b8c6-0276a6fa1535_terseLabel_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_label_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares excluded from calculation of diluted shares</link:label>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_documentation_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares excluded from calculation of diluted shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:href="cah-20220930.xsd#cah_Numberofsharesexcludedfromcalculationofdilutedshares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:to="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3b01eaee-b788-405a-a463-8abf300a952f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_80e8f596-431e-4855-b3bc-779d8e10a86e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_05b625b8-8128-4f50-b834-623307103104_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_574f8914-62bb-44fc-9540-90bd29534f6c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_b2fb4f99-caee-4999-be88-4ac0794c4f29_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_c46017c7-5f36-4dae-9a12-f5f8390defd0_terseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20220930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e48d7ca2-f921-41fa-8196-b351b4fc0ec2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e92fa096-028b-4b4e-a806-a9a4a36a1d41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d9ba5ded-7dfe-4548-a1ae-7666436c8571_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8bf7afa3-bea1-4848-95f3-83f20686bbd4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a395f408-6def-4bd6-9562-8aece3baf3d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_9cee2332-4f32-41f0-a06a-c03d446c1661_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_da424e98-30b8-4fbf-9f28-92e3343b8106_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_7f70694c-8404-4b6f-8734-c01e23a1a6a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c1acba3-d580-4cb8-a29f-6ad193c2e105_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_5f4b6cc6-fa23-4ac5-9d0f-c5d4168be57b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_adfeda5b-56a0-4c85-ba25-21927abba389_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_823f2b69-7636-4ba8-878a-cefc199770ad_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fdf121cb-84e6-462d-94ba-fadb0905ac21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_ed4b01ab-7635-491e-b728-26149aa91a10_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Domain]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_label_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Domain]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_documentation_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Pharmaceutical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalSegmentDomain" xlink:to="lab_cah_PharmaceuticalSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_2455e2bc-d04a-4888-a8b5-a284eafef2c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_74e95638-6069-4e09-aa03-f950a68f35fd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fa6bb20e-f444-429c-8c3d-2de4c76af7a9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5c43f382-ee4e-4c97-9d98-4436674bce7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a6b68259-6654-4fc7-8d2c-19ea761b301a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_62d061cc-e824-48ba-a203-97346197d157_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4aee6465-4fd0-460b-95d8-14c8ca153cf4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dce12f24-3095-4950-88ad-554bd3200842_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_f6bb9db9-710d-473a-9b39-3f5c67e95393_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_78d03038-2f83-421b-835f-4eb7f221a544_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_119f47c6-053a-4177-9cbc-dc941f598ddb_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">litigation settlement liability recorded</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_fecc3c3e-add6-401a-801b-a373114b4a0c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_13da9aac-cba3-4d16-81a2-3e126afcfc70_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bc093650-fe71-4c23-8cb4-ef9c14ce1f8b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f67b5f18-88f8-44d2-a8ef-4835a7cbc955_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_55477728-dbb5-484b-a923-184e0c085602_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f1e738fb-2cb5-4a46-92c0-d5b75746e966_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0b9b51ee-3850-447b-9409-555dc42f0a8d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_489a4206-258b-4e8f-85ab-c613ef676c6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_907ad6aa-91d1-4c69-8e58-d250eb719dcd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_59aafd13-3700-4848-be7d-ec15fa898ed6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9950c621-86ff-4eb3-b3f4-84ba75d6624d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_8028baaf-36c5-4653-90a2-9f0166b54e54_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_260e5a14-b6cd-44a1-ae29-d3a622ebdc2f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bb401102-a7d7-4a42-81d8-f1a64963d67e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f06a7d63-5076-4aae-8b74-70e00e9ee6df_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cah-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:964ac801-dd50-4cbf-978f-cd662ea3a8c6,g:8bda5b56-43aa-4d85-9f5e-cb52b0901382-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5848faca-5518-4219-a878-6ed95dffb4ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_DocumentType_5848faca-5518-4219-a878-6ed95dffb4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_daa44bcc-297c-47b1-8913-d98fbb2a5925" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_DocumentQuarterlyReport_daa44bcc-297c-47b1-8913-d98fbb2a5925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_688cef62-91d8-4178-94b3-d227f5f84ae2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_DocumentPeriodEndDate_688cef62-91d8-4178-94b3-d227f5f84ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_20b8593e-9922-4cc2-ad6b-0374b8ac600f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_DocumentTransitionReport_20b8593e-9922-4cc2-ad6b-0374b8ac600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_508fb2d9-ee19-4701-8b41-d3102f86ce04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityFileNumber_508fb2d9-ee19-4701-8b41-d3102f86ce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3dde56ce-d176-44cb-8fa8-21adf9239db8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityRegistrantName_3dde56ce-d176-44cb-8fa8-21adf9239db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_62ac6ddb-a1b9-4157-8bef-c20ac03838e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityCentralIndexKey_62ac6ddb-a1b9-4157-8bef-c20ac03838e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8a0e8f69-bfd7-4680-ba57-803f97477b33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_CurrentFiscalYearEndDate_8a0e8f69-bfd7-4680-ba57-803f97477b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_67e13230-b288-4c66-a1c8-33a2778477ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_DocumentFiscalYearFocus_67e13230-b288-4c66-a1c8-33a2778477ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c9d5a208-42bb-4573-8c21-61e6a7544e18" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c9d5a208-42bb-4573-8c21-61e6a7544e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6aebd85f-4195-4308-991d-f78b457fb3cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_AmendmentFlag_6aebd85f-4195-4308-991d-f78b457fb3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b9e83ec5-f73d-484a-b400-55746ee8a6b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b9e83ec5-f73d-484a-b400-55746ee8a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_57765e19-e568-4a65-8acd-e76defa384dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityTaxIdentificationNumber_57765e19-e568-4a65-8acd-e76defa384dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_94f64d83-24b2-4d05-a93b-e95045cf5189" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityAddressAddressLine1_94f64d83-24b2-4d05-a93b-e95045cf5189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_11b7b5bb-e370-450f-85c5-3497e0bdd802" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityAddressCityOrTown_11b7b5bb-e370-450f-85c5-3497e0bdd802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ff31ac9f-b419-4654-a885-bd1e2d91c219" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityAddressStateOrProvince_ff31ac9f-b419-4654-a885-bd1e2d91c219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_af961550-05df-4035-9293-0fca10f387ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityAddressPostalZipCode_af961550-05df-4035-9293-0fca10f387ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e7fd02a9-f970-4778-a5cb-42f24bf1fe42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_CityAreaCode_e7fd02a9-f970-4778-a5cb-42f24bf1fe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_22b9e816-27d5-4c39-8b8a-424e35bd645a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_LocalPhoneNumber_22b9e816-27d5-4c39-8b8a-424e35bd645a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_285f3aa3-a243-476f-ab8b-671bab80df66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityCurrentReportingStatus_285f3aa3-a243-476f-ab8b-671bab80df66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cae13ca2-a224-42d0-9d81-be5adcaa78c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityInteractiveDataCurrent_cae13ca2-a224-42d0-9d81-be5adcaa78c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8e1eb151-95d1-4e9f-8d66-ba9f5b1f7aa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityFilerCategory_8e1eb151-95d1-4e9f-8d66-ba9f5b1f7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_26589913-db3f-4d06-aab0-dbf2f13ab240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntitySmallBusiness_26589913-db3f-4d06-aab0-dbf2f13ab240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5fa3eb95-764e-47ff-bd85-5410814a3c6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityEmergingGrowthCompany_5fa3eb95-764e-47ff-bd85-5410814a3c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b517e8f9-d106-497f-9afe-e2109aab67c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityShellCompany_b517e8f9-d106-497f-9afe-e2109aab67c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_969b7366-7a82-47b7-bb66-80af73122a98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_Security12bTitle_969b7366-7a82-47b7-bb66-80af73122a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6eea46dd-555c-414f-aac2-8aee527822c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_TradingSymbol_6eea46dd-555c-414f-aac2-8aee527822c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c9465095-b78b-483e-975e-ca83522b9359" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_SecurityExchangeName_c9465095-b78b-483e-975e-ca83522b9359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7d46d9fe-3eb5-4472-a42b-4e0a3bab756f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f54f5d15-dd03-401b-9253-60bec5144193" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7d46d9fe-3eb5-4472-a42b-4e0a3bab756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_05166b7e-3fb4-43d0-84bc-5d5da87a1250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_Revenues_05166b7e-3fb4-43d0-84bc-5d5da87a1250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f26e3ba4-3092-445e-95c4-d6ed4e29a0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f26e3ba4-3092-445e-95c4-d6ed4e29a0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_80eeb131-de09-4bb5-a9cc-3d941fb34a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_GrossProfit_80eeb131-de09-4bb5-a9cc-3d941fb34a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_24ea6745-3a73-4b59-bc16-cf24bcf15fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_24ea6745-3a73-4b59-bc16-cf24bcf15fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a5e61fed-bcb7-44d5-8116-546d97811ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:to="loc_us-gaap_RestructuringCharges_a5e61fed-bcb7-44d5-8116-546d97811ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_dd44b514-a8e6-4c6f-99df-89bb357c4a7d" xlink:href="cah-20220930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_dd44b514-a8e6-4c6f-99df-89bb357c4a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_57763713-06aa-4512-8e56-40c172623984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_57763713-06aa-4512-8e56-40c172623984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_483eaf9e-4ab5-4a08-937c-ec79af965125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3f55026-0529-4183-b622-6b5af9688133" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_483eaf9e-4ab5-4a08-937c-ec79af965125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8b3e0a4d-3a12-4823-bb08-cad26db96434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_OperatingIncomeLoss_8b3e0a4d-3a12-4823-bb08-cad26db96434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ffabfba9-0a6a-43d7-93d5-edda017f3139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ffabfba9-0a6a-43d7-93d5-edda017f3139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_878f091e-227f-4b9c-a7d3-45ca033abf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_InterestExpense_878f091e-227f-4b9c-a7d3-45ca033abf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a9e4abc0-de1f-4d98-acc2-426f6666bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a9e4abc0-de1f-4d98-acc2-426f6666bd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d7b92ab-85a9-4dd3-a9f3-41bb4e558375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d7b92ab-85a9-4dd3-a9f3-41bb4e558375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_31b404a3-7003-4005-a004-5efef4f7a541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_31b404a3-7003-4005-a004-5efef4f7a541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ef4484da-2025-436e-a83b-cd1ecba25140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_ProfitLoss_ef4484da-2025-436e-a83b-cd1ecba25140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3dad70e6-167f-4870-9a8a-68d15cf80987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3dad70e6-167f-4870-9a8a-68d15cf80987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf857f98-6bea-48c0-bf4a-0532209f2d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_NetIncomeLoss_bf857f98-6bea-48c0-bf4a-0532209f2d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_594ec8b0-27b4-491a-a697-46699a79be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_594ec8b0-27b4-491a-a697-46699a79be7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0322670c-2d31-403d-9d62-8bf933021823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_594ec8b0-27b4-491a-a697-46699a79be7e" xlink:to="loc_us-gaap_EarningsPerShareBasic_0322670c-2d31-403d-9d62-8bf933021823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2ac6bbc5-50ea-45f3-ad3b-1890a13ed294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_594ec8b0-27b4-491a-a697-46699a79be7e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2ac6bbc5-50ea-45f3-ad3b-1890a13ed294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fa874c42-92f8-4cbf-a1c7-73c4ae5d5011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fa874c42-92f8-4cbf-a1c7-73c4ae5d5011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_66b9bd84-53a0-47e6-b157-3c2e3df6c972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fa874c42-92f8-4cbf-a1c7-73c4ae5d5011" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_66b9bd84-53a0-47e6-b157-3c2e3df6c972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80c0b273-5b01-461f-a840-a55569998d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fa874c42-92f8-4cbf-a1c7-73c4ae5d5011" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80c0b273-5b01-461f-a840-a55569998d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_71babc9d-f635-42fd-a8ab-82e7b5c314a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa545c1a-cce4-41ff-bd58-e80ce7c2a029" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_71babc9d-f635-42fd-a8ab-82e7b5c314a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18283ffd-d92e-475a-97c5-b7f51c07f982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cb278433-e031-454b-a6a5-5e4a4915d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18283ffd-d92e-475a-97c5-b7f51c07f982" xlink:to="loc_us-gaap_ProfitLoss_cb278433-e031-454b-a6a5-5e4a4915d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f577b434-3bb9-4e1e-a979-a367c2032a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18283ffd-d92e-475a-97c5-b7f51c07f982" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f577b434-3bb9-4e1e-a979-a367c2032a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cbd48610-1928-4044-bc48-c863e22b0c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f577b434-3bb9-4e1e-a979-a367c2032a19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cbd48610-1928-4044-bc48-c863e22b0c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0e2d354d-c027-4526-9aef-d9e6cfdc8cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f577b434-3bb9-4e1e-a979-a367c2032a19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0e2d354d-c027-4526-9aef-d9e6cfdc8cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fb5614ef-bdc5-46c5-bf7f-f2cc628ea373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f577b434-3bb9-4e1e-a979-a367c2032a19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fb5614ef-bdc5-46c5-bf7f-f2cc628ea373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_483751c6-fff7-4f46-8fde-cac0141bd012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18283ffd-d92e-475a-97c5-b7f51c07f982" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_483751c6-fff7-4f46-8fde-cac0141bd012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_29349304-660f-4440-b8bb-26e46a1251c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18283ffd-d92e-475a-97c5-b7f51c07f982" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_29349304-660f-4440-b8bb-26e46a1251c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1c07f64c-47a2-43b7-8cb6-3387a6f7c422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18283ffd-d92e-475a-97c5-b7f51c07f982" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1c07f64c-47a2-43b7-8cb6-3387a6f7c422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_92c1ce24-b057-40c7-b489-a409125217bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92c1ce24-b057-40c7-b489-a409125217bb" xlink:to="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:to="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b150f0e-8795-4796-ad90-f655f2f64e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b150f0e-8795-4796-ad90-f655f2f64e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_eb4199cd-e534-4e98-839a-6e497377d9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:to="loc_us-gaap_ReceivablesNetCurrent_eb4199cd-e534-4e98-839a-6e497377d9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9ad80dae-0036-42fc-ab5b-56e7e608324f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:to="loc_us-gaap_InventoryNet_9ad80dae-0036-42fc-ab5b-56e7e608324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_dd487f43-5e66-429f-b632-151e5fb6f383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:to="loc_us-gaap_OtherAssetsCurrent_dd487f43-5e66-429f-b632-151e5fb6f383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9a0f201-96a0-4a43-b992-6dfe09be508c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_987a0b05-21f0-4fc8-a238-edabc44e4c65" xlink:to="loc_us-gaap_AssetsCurrent_e9a0f201-96a0-4a43-b992-6dfe09be508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_98b1de19-1839-4508-b359-a275624b86e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_98b1de19-1839-4508-b359-a275624b86e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_6908154d-8c22-4922-83b0-60ce428dc596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_6908154d-8c22-4922-83b0-60ce428dc596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_82688406-9178-4179-8b89-30db617795a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_82688406-9178-4179-8b89-30db617795a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2688ee2e-88e9-47bd-9828-309f6b354cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9051fa84-be55-4642-ae75-277fc279e358" xlink:to="loc_us-gaap_Assets_2688ee2e-88e9-47bd-9828-309f6b354cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92c1ce24-b057-40c7-b489-a409125217bb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ed17d16b-7780-4592-9339-2246f2eefc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ed17d16b-7780-4592-9339-2246f2eefc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_47eac0c4-7be1-4e46-a051-21744c1d538f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ed17d16b-7780-4592-9339-2246f2eefc94" xlink:to="loc_us-gaap_AccountsPayableCurrent_47eac0c4-7be1-4e46-a051-21744c1d538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5c703a03-1000-4598-8e93-08fa528dabcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ed17d16b-7780-4592-9339-2246f2eefc94" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5c703a03-1000-4598-8e93-08fa528dabcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0370b36d-154b-4b0f-9340-01dd0b24f159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ed17d16b-7780-4592-9339-2246f2eefc94" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0370b36d-154b-4b0f-9340-01dd0b24f159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ffb83de1-0e8e-466b-bbd6-a26f47c242f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ed17d16b-7780-4592-9339-2246f2eefc94" xlink:to="loc_us-gaap_LiabilitiesCurrent_ffb83de1-0e8e-466b-bbd6-a26f47c242f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c55d97f1-73e1-461c-9f1c-a8c398915090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c55d97f1-73e1-461c-9f1c-a8c398915090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_b5fd725d-936f-472d-ac00-9e1195e6e23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_b5fd725d-936f-472d-ac00-9e1195e6e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9c709d0d-3136-4a98-8a9a-ba2242a219b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9c709d0d-3136-4a98-8a9a-ba2242a219b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_524c2f5c-56d8-482c-849f-e8f31923078c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_524c2f5c-56d8-482c-849f-e8f31923078c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1cd2694e-a2e9-49b1-a803-f00d5f6c7f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1cd2694e-a2e9-49b1-a803-f00d5f6c7f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7535c7e2-d905-45a1-b7b5-3ba6369be1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_PreferredStockValue_7535c7e2-d905-45a1-b7b5-3ba6369be1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0206a539-f96c-444e-9192-2a2c3067a76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0206a539-f96c-444e-9192-2a2c3067a76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f180ab81-c60b-4197-b534-d7fd7a961fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f180ab81-c60b-4197-b534-d7fd7a961fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c2d77f48-6ad0-4d44-b8c5-a7b269d3a805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_CommonStockSharesIssued_c2d77f48-6ad0-4d44-b8c5-a7b269d3a805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3fa8e04f-321a-4cdc-bed6-884f9ee2b63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_CommonStockValue_3fa8e04f-321a-4cdc-bed6-884f9ee2b63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c1dc218-18dd-41bc-b4ef-ec7acbba87a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c1dc218-18dd-41bc-b4ef-ec7acbba87a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d0d80461-3813-42b3-acf4-f6561d3aa484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_TreasuryStockValue_d0d80461-3813-42b3-acf4-f6561d3aa484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a5a899ec-410b-4f15-b9f6-8827bc4e8c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_TreasuryStockShares_a5a899ec-410b-4f15-b9f6-8827bc4e8c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5fd5363c-e8ce-41ac-b68d-277acf984f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5fd5363c-e8ce-41ac-b68d-277acf984f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0030a98-dd8b-4a4b-bb75-e1538b8f3166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_StockholdersEquity_b0030a98-dd8b-4a4b-bb75-e1538b8f3166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_21474b07-3a9a-4fec-a6c4-2a9351476b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_MinorityInterest_21474b07-3a9a-4fec-a6c4-2a9351476b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3046efd5-8c10-4095-947f-7a74040267cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0851f3ed-c79f-4214-9057-b837e9ff3753" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3046efd5-8c10-4095-947f-7a74040267cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4438173f-fc16-49af-af33-593da52ee379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04942749-a300-441a-a629-84098e187c08" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4438173f-fc16-49af-af33-593da52ee379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0d07b857-e0b1-4d16-b951-9b25f991b449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0d07b857-e0b1-4d16-b951-9b25f991b449" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a846e708-52d5-4585-a00d-8d08cb9ffeb8" xlink:to="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89011f21-56ad-4eab-bb67-c0f3f0b6386a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_CommonStockMember_89011f21-56ad-4eab-bb67-c0f3f0b6386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_241b5c79-fd82-40d2-ae5c-c6d20cd3d857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_RetainedEarningsMember_241b5c79-fd82-40d2-ae5c-c6d20cd3d857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_094b4de6-ae3e-42f3-b612-70a1fc94d042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_TreasuryStockMember_094b4de6-ae3e-42f3-b612-70a1fc94d042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c914afa0-f966-4d37-9f45-ace62c30d018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c914afa0-f966-4d37-9f45-ace62c30d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_57c80636-30ba-4845-ae38-86d66177e53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c721ed7d-d700-41a3-9cd5-24d5458fe8ac" xlink:to="loc_us-gaap_NoncontrollingInterestMember_57c80636-30ba-4845-ae38-86d66177e53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_8b038414-2392-4eef-b64c-c6dfbc38725f" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8d9d8725-d6bf-4cde-8b95-45117dd4f300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_CommonStockSharesIssued_8d9d8725-d6bf-4cde-8b95-45117dd4f300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f13a4e9-fe6e-4eda-8378-62a997c473d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f13a4e9-fe6e-4eda-8378-62a997c473d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5cec8493-34b7-4da3-b32d-20543234ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockShares_5cec8493-34b7-4da3-b32d-20543234ef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_dcb182dc-1da6-48ed-8ddf-568046d6c9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockValue_dcb182dc-1da6-48ed-8ddf-568046d6c9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0070757-db89-4399-8396-00c9a920f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_NetIncomeLoss_e0070757-db89-4399-8396-00c9a920f89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8a5a7006-2951-45da-9e98-bff9c6bb2e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_ProfitLoss_8a5a7006-2951-45da-9e98-bff9c6bb2e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d22a3ee1-7bb8-4797-b68b-dcbb5e32aa22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d22a3ee1-7bb8-4797-b68b-dcbb5e32aa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_06b4b412-cb97-4b86-a7a5-0915eedeb167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_06b4b412-cb97-4b86-a7a5-0915eedeb167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5ac9afe2-85cf-4144-a672-d61be163c101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5ac9afe2-85cf-4144-a672-d61be163c101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5bb4b2cc-07b7-4346-b2dd-ec53267c695d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5bb4b2cc-07b7-4346-b2dd-ec53267c695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_36cd31e6-2461-44f1-b6fc-26b69309eb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_36cd31e6-2461-44f1-b6fc-26b69309eb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_543c2fd2-7f97-4909-afde-d474fac16190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_543c2fd2-7f97-4909-afde-d474fac16190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_f1196d98-1b15-4a84-a7f2-cccf1a83965e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_Dividends_f1196d98-1b15-4a84-a7f2-cccf1a83965e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_6e2314ff-ecb8-4c16-9ccc-e54a880f72ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockholdersEquityOther_6e2314ff-ecb8-4c16-9ccc-e54a880f72ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4dda6366-9e47-41ce-9c6c-e8aecd6d9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_CommonStockSharesIssued_4dda6366-9e47-41ce-9c6c-e8aecd6d9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a2bd432-65cf-4904-bdeb-1e04dbdd8625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a2bd432-65cf-4904-bdeb-1e04dbdd8625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2339c8dd-25fd-4b32-9337-65080dffee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockShares_2339c8dd-25fd-4b32-9337-65080dffee2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6117d3ae-d851-4457-b22f-f065e5e1ec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_da742283-577a-4a90-a9df-98f1b7bb2f18" xlink:to="loc_us-gaap_TreasuryStockValue_6117d3ae-d851-4457-b22f-f065e5e1ec29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e680d3d6-1d8e-42b6-ae38-63f6e272da39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e680d3d6-1d8e-42b6-ae38-63f6e272da39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c816d5ce-f304-4515-9777-72bc02c88221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e680d3d6-1d8e-42b6-ae38-63f6e272da39" xlink:to="loc_us-gaap_ProfitLoss_c816d5ce-f304-4515-9777-72bc02c88221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e680d3d6-1d8e-42b6-ae38-63f6e272da39" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a5d6fd68-d66a-4422-9535-bbd190cc032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a5d6fd68-d66a-4422-9535-bbd190cc032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_04e5f8ee-08cf-426c-a130-0d9c48dc4f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_04e5f8ee-08cf-426c-a130-0d9c48dc4f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49ef6cd2-7254-4e92-af6d-cb767ae3cd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49ef6cd2-7254-4e92-af6d-cb767ae3cd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ca012ff1-60be-4b42-b2d9-e9efb56e37f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:to="loc_us-gaap_ShareBasedCompensation_ca012ff1-60be-4b42-b2d9-e9efb56e37f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_16da78a6-c1f2-42a2-bec0-ef4cd7ec5555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_16da78a6-c1f2-42a2-bec0-ef4cd7ec5555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15932166-0005-4236-bf1a-225e8f105c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f29d9984-1ad9-42c1-9aba-88ad584771d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15932166-0005-4236-bf1a-225e8f105c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_5385782d-7506-4b21-948c-566aab69514a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15932166-0005-4236-bf1a-225e8f105c11" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_5385782d-7506-4b21-948c-566aab69514a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_754da08d-cca8-47d4-b3c0-14e4bd1f6660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15932166-0005-4236-bf1a-225e8f105c11" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_754da08d-cca8-47d4-b3c0-14e4bd1f6660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2c03e8ca-4e3a-4115-a6c8-12848d596e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15932166-0005-4236-bf1a-225e8f105c11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2c03e8ca-4e3a-4115-a6c8-12848d596e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_224f0220-821f-45dc-8da1-a8eabc75e0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15932166-0005-4236-bf1a-225e8f105c11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_224f0220-821f-45dc-8da1-a8eabc75e0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8078d4fe-f155-45fa-96c6-114fd144b039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e680d3d6-1d8e-42b6-ae38-63f6e272da39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8078d4fe-f155-45fa-96c6-114fd144b039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_12ab2d13-e2af-43a2-a4ee-81313fb42719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_12ab2d13-e2af-43a2-a4ee-81313fb42719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45883197-bdbc-46ff-8b9a-27582c2d5564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45883197-bdbc-46ff-8b9a-27582c2d5564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_919a37ec-06be-494d-8ee5-1331e1769196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_919a37ec-06be-494d-8ee5-1331e1769196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_ead451b8-11b7-4674-a964-5e3a42efce91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_ead451b8-11b7-4674-a964-5e3a42efce91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_f7791958-cd6c-4858-94e7-7b42d1c4d1f1" xlink:href="cah-20220930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deadecc2-06b5-452d-ab02-dfa95f1fdbe6" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_f7791958-cd6c-4858-94e7-7b42d1c4d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15fafc1f-f07b-40f9-87c6-89ad38c2ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15fafc1f-f07b-40f9-87c6-89ad38c2ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_feeef95a-1aff-453a-968a-a578e806425f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_feeef95a-1aff-453a-968a-a578e806425f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_442bbb31-8324-4f01-ba7a-7e6d303fa823" xlink:href="cah-20220930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_442bbb31-8324-4f01-ba7a-7e6d303fa823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_4d525c1e-e3f8-4023-a32f-a832076024f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_4d525c1e-e3f8-4023-a32f-a832076024f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_16fadd89-0f28-4d2a-9db6-f29904be9426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_16fadd89-0f28-4d2a-9db6-f29904be9426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6add004-5990-44ef-ae08-bf9174ba26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6add004-5990-44ef-ae08-bf9174ba26a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36f9aeea-3105-40ab-86a9-ead35ac23e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb3ff397-a188-42eb-b44c-9105e3b91b45" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36f9aeea-3105-40ab-86a9-ead35ac23e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedFromAssetsHeldForSale_b42e988b-a723-4698-b383-142c3bf583f1" xlink:href="cah-20220930.xsd#cah_CashReclassifiedFromAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_cah_CashReclassifiedFromAssetsHeldForSale_b42e988b-a723-4698-b383-142c3bf583f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b04139b7-50fa-44f7-a232-266d06e803e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b04139b7-50fa-44f7-a232-266d06e803e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_849d87d9-cf37-4a61-9e41-e1442ae85c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_849d87d9-cf37-4a61-9e41-e1442ae85c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c840b25-ab8a-4c31-967c-c96c62d3e44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b59a304-92fc-44af-9f61-d18a93ab6ebb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c840b25-ab8a-4c31-967c-c96c62d3e44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf1a3021-8f9d-4e79-8405-907af85af198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b5772ff7-b140-41d7-af05-ab0f68609f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf1a3021-8f9d-4e79-8405-907af85af198" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b5772ff7-b140-41d7-af05-ab0f68609f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20220930.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_47316d33-4ff9-40c3-bd4d-e08e908dca83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_256cebce-5774-4dd5-97c3-5e9df9cefbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_47316d33-4ff9-40c3-bd4d-e08e908dca83" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_256cebce-5774-4dd5-97c3-5e9df9cefbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_49f257f8-1444-4fb5-8269-7bec776e0e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_df02d4ea-5544-4088-b628-96603a40ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_49f257f8-1444-4fb5-8269-7bec776e0e9b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_df02d4ea-5544-4088-b628-96603a40ce1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b81455bd-b5cd-4c69-b6ef-0e7269d3d911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4c54637d-49b6-4127-945d-6fdf8fe13316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b81455bd-b5cd-4c69-b6ef-0e7269d3d911" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4c54637d-49b6-4127-945d-6fdf8fe13316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20220930.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dab7cc1e-918a-4309-b4cb-f73efb25179b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d8a1833d-1e1f-499b-b79b-c0dcc194ce7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dab7cc1e-918a-4309-b4cb-f73efb25179b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d8a1833d-1e1f-499b-b79b-c0dcc194ce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20220930.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ad8eaba6-5573-41af-bd25-7fdbda70ffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a54783e6-fc06-4829-9338-a9db8e0af339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ad8eaba6-5573-41af-bd25-7fdbda70ffaf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a54783e6-fc06-4829-9338-a9db8e0af339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5bc28ea-c267-420b-bbe2-9aade3f5c4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3769c1e9-87ca-4a1a-a330-4643dfefb5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5bc28ea-c267-420b-bbe2-9aade3f5c4bc" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3769c1e9-87ca-4a1a-a330-4643dfefb5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8f558451-674f-407f-b517-bac710083efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_9f4ada53-d372-4e7d-9b09-05490eb4f9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8f558451-674f-407f-b517-bac710083efd" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_9f4ada53-d372-4e7d-9b09-05490eb4f9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20220930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1f62829-0fa5-4157-857d-419c44b85413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_3af8cd2b-5c21-4db8-b12f-20dcc1eb2a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1f62829-0fa5-4157-857d-419c44b85413" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_3af8cd2b-5c21-4db8-b12f-20dcc1eb2a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8bd07b21-e443-46cf-944b-438265e91ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a4200af4-ec29-47c5-b852-a67a0e31adef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8bd07b21-e443-46cf-944b-438265e91ed9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a4200af4-ec29-47c5-b852-a67a0e31adef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20220930.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0acfd863-15bf-4c73-92ed-e44e6f52c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_21728cb5-3728-42c6-9326-905ed26c695c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0acfd863-15bf-4c73-92ed-e44e6f52c174" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_21728cb5-3728-42c6-9326-905ed26c695c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ce1d6ffe-26c3-4d3f-a6a5-ecfb5ccc7e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3042d749-877e-4727-a01e-12634960c826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ce1d6ffe-26c3-4d3f-a6a5-ecfb5ccc7e38" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3042d749-877e-4727-a01e-12634960c826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_596edf6a-adea-4ec1-8090-76afc428199c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e69c2681-9419-4f0d-b7e2-a352e5234db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_596edf6a-adea-4ec1-8090-76afc428199c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e69c2681-9419-4f0d-b7e2-a352e5234db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4aed0efa-28e3-4add-9eea-272ca4d7ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ecb908a3-fefc-46f0-a4c2-a3bce0c76a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4aed0efa-28e3-4add-9eea-272ca4d7ab47" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ecb908a3-fefc-46f0-a4c2-a3bce0c76a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f2c89805-4637-4150-ab63-66c55459f46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4aed0efa-28e3-4add-9eea-272ca4d7ab47" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f2c89805-4637-4150-ab63-66c55459f46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresTables" xlink:type="simple" xlink:href="cah-20220930.xsd#DivestituresTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ce57aeb4-0d87-4ca1-9ce3-422fae675b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_905a0ce1-9c43-47a6-8d39-6b89b34b6a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_6dca539f-c0a9-4572-941e-b1ea02b712af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_905a0ce1-9c43-47a6-8d39-6b89b34b6a3f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_6dca539f-c0a9-4572-941e-b1ea02b712af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5b50c40d-8eb4-499b-9425-042cfd49363d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_905a0ce1-9c43-47a6-8d39-6b89b34b6a3f" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5b50c40d-8eb4-499b-9425-042cfd49363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_305ef2d0-3d90-4f2e-b2f7-e89e2febb5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0d400a91-e8b7-4624-99c8-e471f5efd6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_305ef2d0-3d90-4f2e-b2f7-e89e2febb5c2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0d400a91-e8b7-4624-99c8-e471f5efd6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_2a62419a-2e9e-4287-a141-d881e8ca1eaa" xlink:href="cah-20220930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_305ef2d0-3d90-4f2e-b2f7-e89e2febb5c2" xlink:to="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_2a62419a-2e9e-4287-a141-d881e8ca1eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2ca013d-207d-43c5-a417-7a89abe7cf80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cde9be28-441d-4e83-bcc0-94f3edc29ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2ca013d-207d-43c5-a417-7a89abe7cf80" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cde9be28-441d-4e83-bcc0-94f3edc29ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20220930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_13e7800d-0538-4b4d-8ab8-71130bed8b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_b0d6de7d-7c12-438e-bc4d-96ad8c454994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_13e7800d-0538-4b4d-8ab8-71130bed8b9d" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_b0d6de7d-7c12-438e-bc4d-96ad8c454994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2f3a499c-d3e8-4df0-b340-42600cb0cb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_386a0feb-8a57-4f14-ab05-cf096b8fd537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f3a499c-d3e8-4df0-b340-42600cb0cb55" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_386a0feb-8a57-4f14-ab05-cf096b8fd537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20220930.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c7b70d82-19e6-40c1-8215-05158a6554fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4a14b125-20e9-40d1-b066-2b549e0d866b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c7b70d82-19e6-40c1-8215-05158a6554fb" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4a14b125-20e9-40d1-b066-2b549e0d866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_97b4196d-945e-4e45-bd8b-cbdbcab0b90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_97b4196d-945e-4e45-bd8b-cbdbcab0b90d" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e07353b8-7af0-4201-b9fe-87f8a57844a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9d8d459f-8e82-44ff-ac29-3139b5a5fb7b" xlink:to="loc_srt_ConsolidationItemsDomain_e07353b8-7af0-4201-b9fe-87f8a57844a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70a59f0b-7945-4e37-92e0-e0237477c996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_39d0b151-d0dd-4391-b9cb-ebbef56dc8c3" xlink:to="loc_us-gaap_SegmentDomain_70a59f0b-7945-4e37-92e0-e0237477c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5849bc36-2685-4687-ae80-af2833bd5fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_c250c616-743f-44ad-90c7-ce88522a5e3d" xlink:to="loc_us-gaap_SubsegmentsDomain_5849bc36-2685-4687-ae80-af2833bd5fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_08bc7cde-00ae-4bc8-8947-6d6146f1b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ffdb7bb6-2595-4c3f-a823-a706f70d3c7f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_08bc7cde-00ae-4bc8-8947-6d6146f1b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_5470321d-80e2-4c7a-9755-bf34fd841296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc9d722b-8b0b-4526-9233-bd747c06cf72" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_5470321d-80e2-4c7a-9755-bf34fd841296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_60e1db06-f7fd-4320-8589-00dbe68de0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_5470321d-80e2-4c7a-9755-bf34fd841296" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_60e1db06-f7fd-4320-8589-00dbe68de0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3800395c-cdf2-49fc-89d4-1a15e9c46b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_97b4196d-945e-4e45-bd8b-cbdbcab0b90d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3800395c-cdf2-49fc-89d4-1a15e9c46b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_08810358-e7af-47fd-9072-1c7e25070966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_97b4196d-945e-4e45-bd8b-cbdbcab0b90d" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_08810358-e7af-47fd-9072-1c7e25070966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_12aa3ba3-fd5c-4eb5-b472-a3d03bcd2174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_97b4196d-945e-4e45-bd8b-cbdbcab0b90d" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_12aa3ba3-fd5c-4eb5-b472-a3d03bcd2174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee20319e-c85e-4ace-82b9-1643509e9772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_71693186-2ad6-4aa8-b278-7f50bc7884b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee20319e-c85e-4ace-82b9-1643509e9772" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_71693186-2ad6-4aa8-b278-7f50bc7884b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c4c8d15c-6258-47aa-9ec6-cea4ea10a435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee20319e-c85e-4ace-82b9-1643509e9772" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c4c8d15c-6258-47aa-9ec6-cea4ea10a435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_f8cc7da5-a4ed-4b16-bbf5-ed251f5bb697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee20319e-c85e-4ace-82b9-1643509e9772" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_f8cc7da5-a4ed-4b16-bbf5-ed251f5bb697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_90d12e47-a4aa-4eda-a30d-ae91c62f3836" xlink:href="cah-20220930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#DivestituresDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d908cb9d-c388-4281-90a8-769893e323c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d908cb9d-c388-4281-90a8-769893e323c2" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:href="cah-20220930.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:to="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_cdcde7ba-f299-47c0-8e64-9d921a033ca4" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_7ff4e8fb-fe8c-4768-9b60-ead2710aeaf5" xlink:to="loc_cah_CordisDivestitureDomain_cdcde7ba-f299-47c0-8e64-9d921a033ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_2276497b-d6cd-40ff-affe-b8ddeccfb9d8" xlink:href="cah-20220930.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_cdcde7ba-f299-47c0-8e64-9d921a033ca4" xlink:to="loc_cah_CordisDivestitureMember_2276497b-d6cd-40ff-affe-b8ddeccfb9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_e91fa4af-62bb-40e3-9c8e-395fa649d665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_4d224585-0721-468a-b60f-fd578b86ff58" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_e91fa4af-62bb-40e3-9c8e-395fa649d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_3f3de6e9-a8e2-45c3-a0ae-dfa665c58a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_e91fa4af-62bb-40e3-9c8e-395fa649d665" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_3f3de6e9-a8e2-45c3-a0ae-dfa665c58a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_b40a6831-a72d-40bb-bb28-d0c015977d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c2300332-5c7d-4a63-a3ea-3e4f4a5c45d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_b40a6831-a72d-40bb-bb28-d0c015977d5a" xlink:to="loc_us-gaap_SeveranceCosts1_c2300332-5c7d-4a63-a3ea-3e4f4a5c45d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_d9964932-d23a-4ce0-9c0f-d38746979f64" xlink:href="cah-20220930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_b40a6831-a72d-40bb-bb28-d0c015977d5a" xlink:to="loc_cah_FacilityExitAndOtherCosts_d9964932-d23a-4ce0-9c0f-d38746979f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_733609a6-b7b1-4293-a912-4340b27aee97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_b40a6831-a72d-40bb-bb28-d0c015977d5a" xlink:to="loc_us-gaap_RestructuringCharges_733609a6-b7b1-4293-a912-4340b27aee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_816044d1-b0ac-4e4d-86d4-5479fe22c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_816044d1-b0ac-4e4d-86d4-5479fe22c8e4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6ed6813d-a028-4e2e-99a5-260c8fcd05de" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_92f1748c-3397-4466-a47d-44d47394b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:to="loc_us-gaap_EmployeeSeveranceMember_92f1748c-3397-4466-a47d-44d47394b5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_899d3d7d-a9e3-4926-bc99-4b9da952895f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b86eade8-df05-43b9-9bdd-7f4354a4643c" xlink:to="loc_us-gaap_FacilityClosingMember_899d3d7d-a9e3-4926-bc99-4b9da952895f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b5254e18-bc36-43d5-8998-8bbe33929646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6146cf4d-6bb0-4c25-a73f-947c87962339" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b5254e18-bc36-43d5-8998-8bbe33929646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b5254e18-bc36-43d5-8998-8bbe33929646" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_03cfe05f-2e48-4295-8021-e9a9faee2a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_RestructuringReserve_03cfe05f-2e48-4295-8021-e9a9faee2a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_9bef8b62-321a-4ad0-95c5-e816db6c04ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_RestructuringCosts_9bef8b62-321a-4ad0-95c5-e816db6c04ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_cc597416-e3f3-4d5b-9b2c-148db945c24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_PaymentsForRestructuring_cc597416-e3f3-4d5b-9b2c-148db945c24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ce190ee6-f1d5-42ce-80ef-0ded602df159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d7575fb4-3786-44ad-9f12-a061985b4ae6" xlink:to="loc_us-gaap_RestructuringReserve_ce190ee6-f1d5-42ce-80ef-0ded602df159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a3aef5a8-8cac-4a4a-95b3-0ac74441b623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a3aef5a8-8cac-4a4a-95b3-0ac74441b623" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:to="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9e113077-12dd-4e68-b9f9-1f97bf58235e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_346d091b-f03c-4a43-b56f-822b01a638aa" xlink:to="loc_us-gaap_RestructuringPlanDomain_9e113077-12dd-4e68-b9f9-1f97bf58235e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84caba23-140f-4f08-9040-31ea6f50c4a3" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_44b0ebef-fd2a-4f71-b3ba-898bce14cff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:to="loc_us-gaap_SeveranceCosts1_44b0ebef-fd2a-4f71-b3ba-898bce14cff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_714914e0-38ed-49cc-89eb-4caf29de7440" xlink:href="cah-20220930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_45458b0d-80d0-451d-abd7-73c0d0f7a28f" xlink:to="loc_cah_FacilityExitAndOtherCosts_714914e0-38ed-49cc-89eb-4caf29de7440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1e282a94-0945-48a3-ad71-b004b2dc5052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1e282a94-0945-48a3-ad71-b004b2dc5052" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7dfe8b84-d777-4de9-96b1-0847182ac54e" xlink:to="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_50e13d2e-9235-4f42-b24f-f7b318635244" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:to="loc_cah_PharmaceuticalMember_50e13d2e-9235-4f42-b24f-f7b318635244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bab47b14-6489-4640-984d-a4a08e545387" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_11ffa478-72e2-4431-bb57-1c71e635eebc" xlink:to="loc_cah_MedicalMember_bab47b14-6489-4640-984d-a4a08e545387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_42557ffc-7d63-439e-b9b5-bf0030190a94" xlink:to="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:to="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_912438d8-1fcf-4ae0-a896-50d178b41cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_Goodwill_912438d8-1fcf-4ae0-a896-50d178b41cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_021a4f84-7543-4911-8cf3-f966051a34ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_021a4f84-7543-4911-8cf3-f966051a34ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_78048d25-78b9-49aa-9653-d7f345595015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_78048d25-78b9-49aa-9653-d7f345595015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4c3c95a7-224f-4395-b458-dfa8cf632f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_579e32e3-b730-42c5-b987-3fc46c68ca08" xlink:to="loc_us-gaap_Goodwill_4c3c95a7-224f-4395-b458-dfa8cf632f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b0f09430-c337-4a11-ad8b-19deb29fb08b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2c346827-8c6d-420d-92de-6f8a57b91de3" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b0f09430-c337-4a11-ad8b-19deb29fb08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61a8b937-6af5-4651-8349-4e15caa0598f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61a8b937-6af5-4651-8349-4e15caa0598f" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7c072b5a-f7dc-4e0f-ac8c-04fd32977423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_fb93dac8-67b6-49d6-bf3e-93b0a76497db" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7c072b5a-f7dc-4e0f-ac8c-04fd32977423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_6a671ad7-67f2-4511-8629-234ccc1e3a5d" xlink:href="cah-20220930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7c072b5a-f7dc-4e0f-ac8c-04fd32977423" xlink:to="loc_cah_IPRDTrademarksandOtherMember_6a671ad7-67f2-4511-8629-234ccc1e3a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_dad89d54-1c53-41ec-99d9-5aae2fe51667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d1750386-a314-4192-bf17-19ece92392af" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_dad89d54-1c53-41ec-99d9-5aae2fe51667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07573f97-7126-42bd-9aad-4a826879451e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_dad89d54-1c53-41ec-99d9-5aae2fe51667" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07573f97-7126-42bd-9aad-4a826879451e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61a8b937-6af5-4651-8349-4e15caa0598f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_483f9b64-0c77-4080-bb62-b896a1501224" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_5d4afed0-1e71-4eef-b3fd-69a3066fc120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:to="loc_us-gaap_CustomerRelationshipsMember_5d4afed0-1e71-4eef-b3fd-69a3066fc120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_52b23549-4a78-4ebb-9028-51176e1eb227" xlink:href="cah-20220930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:to="loc_cah_TrademarksAndPatentsMember_52b23549-4a78-4ebb-9028-51176e1eb227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1a26d55c-7dce-42a2-a64b-2e9066a6d078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_645abc28-1830-4548-8720-64811e974b31" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1a26d55c-7dce-42a2-a64b-2e9066a6d078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03b1b4a3-c848-4a7c-a4ab-f0f6617a2df8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2718a098-bfea-4e09-9ed4-8506c99e7f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2718a098-bfea-4e09-9ed4-8506c99e7f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d1a975ec-643c-4845-9f12-bf9817d3eec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d1a975ec-643c-4845-9f12-bf9817d3eec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5049747-6081-4df0-bb2e-414ccf4bb2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5049747-6081-4df0-bb2e-414ccf4bb2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e0ebdf68-ba3b-40a6-924f-b8169ffa8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a918b749-39eb-4b4a-ae39-c690bbe08662" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e0ebdf68-ba3b-40a6-924f-b8169ffa8b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5a2279b5-1709-4662-8896-c5bcbc0d448b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61a8b937-6af5-4651-8349-4e15caa0598f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5a2279b5-1709-4662-8896-c5bcbc0d448b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5d2e9a71-3125-4737-93ba-18ae5cf6559a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61a8b937-6af5-4651-8349-4e15caa0598f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5d2e9a71-3125-4737-93ba-18ae5cf6559a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5397d1f8-8a36-496a-8c97-c0e33cadb684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5397d1f8-8a36-496a-8c97-c0e33cadb684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ef31d002-ec2b-4eee-b937-d9d034365ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ef31d002-ec2b-4eee-b937-d9d034365ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_571f6da6-e62e-4738-8bd5-04e787daee6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_571f6da6-e62e-4738-8bd5-04e787daee6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2e86b7d4-7603-41e2-b25d-393a27f9e305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2e86b7d4-7603-41e2-b25d-393a27f9e305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d1594b5c-fc57-435f-8186-7e43869ed032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d1594b5c-fc57-435f-8186-7e43869ed032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1076c974-d1f8-4913-8507-f7787217bd29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1076c974-d1f8-4913-8507-f7787217bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f254b8-a440-457e-bd37-4e67992aec7c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_268ef1eb-888d-4b88-a6a5-dba518ff2ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_731270d2-914b-4034-8687-6e0f646c957f" xlink:to="loc_us-gaap_SegmentDomain_268ef1eb-888d-4b88-a6a5-dba518ff2ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_5ebb14d0-0a33-4c36-9a28-e170ea3e6dda" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_268ef1eb-888d-4b88-a6a5-dba518ff2ffe" xlink:to="loc_cah_MedicalMember_5ebb14d0-0a33-4c36-9a28-e170ea3e6dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:to="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_25c6b1f3-d8c6-4b73-9c42-e6cab05f419b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_26c93550-799b-40b5-98c7-6fa6b4ecd903" xlink:to="loc_us-gaap_ReportingUnitDomain_25c6b1f3-d8c6-4b73-9c42-e6cab05f419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_d39c45ab-9112-476b-b45e-3a8ae1330e99" xlink:href="cah-20220930.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_25c6b1f3-d8c6-4b73-9c42-e6cab05f419b" xlink:to="loc_cah_MedicalUnitMember_d39c45ab-9112-476b-b45e-3a8ae1330e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1cb295dc-ec5d-46d8-a740-b82d525bbdd4" xlink:to="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_3cedd16a-4527-4bc5-9617-8c4c71370733" xlink:href="cah-20220930.xsd#cah_DiscountRateFairValueInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_cah_DiscountRateFairValueInput_3cedd16a-4527-4bc5-9617-8c4c71370733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_b71f3401-600d-4a61-967e-c8f908488820" xlink:href="cah-20220930.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_b71f3401-600d-4a61-967e-c8f908488820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b5714540-0534-4e29-a433-491eff023043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b5714540-0534-4e29-a433-491eff023043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNet_08ce6472-6374-4a80-91d4-ab71fb16eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_AssetsNet_08ce6472-6374-4a80-91d4-ab71fb16eca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_21769695-b8ff-4373-98db-eb6b23bb518d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7cb1c1b6-4ae2-4f7d-b847-af50adc7a5b9" xlink:to="loc_us-gaap_Goodwill_21769695-b8ff-4373-98db-eb6b23bb518d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8632ee7-90b6-4479-ba9b-e7e9b7204a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8632ee7-90b6-4479-ba9b-e7e9b7204a4d" xlink:to="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1567a8c9-e976-4bf6-831d-076b1169bbc8" xlink:to="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8e8acd46-60b9-443c-9e07-b0fab92081ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:to="loc_us-gaap_CommercialPaperMember_8e8acd46-60b9-443c-9e07-b0fab92081ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_59890009-ee1b-48af-81eb-336ba4a70121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_59890009-ee1b-48af-81eb-336ba4a70121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_20114a0a-06cd-4a0c-b245-cf1e2842b0ce" xlink:href="cah-20220930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cade1a87-1d13-42b8-b505-70092eb6e260" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_20114a0a-06cd-4a0c-b245-cf1e2842b0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_45d00340-8907-49fc-adab-534fe44470e2" xlink:href="cah-20220930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_20114a0a-06cd-4a0c-b245-cf1e2842b0ce" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_45d00340-8907-49fc-adab-534fe44470e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_59c8aaa2-f62c-404f-847f-ffe8a5e64a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_464ba6cf-1276-430a-b117-5ed41a3a3e44" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_59c8aaa2-f62c-404f-847f-ffe8a5e64a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_17687641-087e-468a-99d7-632d83d00490" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_439603b3-ecf5-4b2b-82a5-2bfd3b3f1d73" xlink:href="cah-20220930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_439603b3-ecf5-4b2b-82a5-2bfd3b3f1d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_c30366fa-d899-4a31-9465-3741ddb7d24d" xlink:href="cah-20220930.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d340a48-7567-4b71-ad93-5a2fcfb16071" xlink:to="loc_cah_A2.616Notesdue2022Member_c30366fa-d899-4a31-9465-3741ddb7d24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8bd1e17f-38cf-49b5-859e-60a28aa59054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ea3ee7f5-cde2-45d6-8538-b191e368a362" xlink:to="loc_us-gaap_VariableRateDomain_8bd1e17f-38cf-49b5-859e-60a28aa59054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8126e665-8bc2-4b27-9423-b251940124c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9fd6a358-3f9b-433a-8ada-5423605eb505" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8126e665-8bc2-4b27-9423-b251940124c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f65a9c6a-1680-4b56-a4ac-fbef7f736046" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ef29c226-13fb-4862-9773-b628a4d2b10f" xlink:to="loc_srt_RangeMember_f65a9c6a-1680-4b56-a4ac-fbef7f736046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2d23bf9-7d90-44f6-93ab-c7945d0f9553" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fe280ae0-f9d7-4ebb-9032-954d2c63acd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fe280ae0-f9d7-4ebb-9032-954d2c63acd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_daf6c3d0-5978-4fb3-8ad0-ce7f7103d122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_daf6c3d0-5978-4fb3-8ad0-ce7f7103d122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_58b2923b-1cf7-4fd8-946e-33dcfc20f547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_58b2923b-1cf7-4fd8-946e-33dcfc20f547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0fd4ca1c-f402-48eb-81b7-cc18450b7f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0fd4ca1c-f402-48eb-81b7-cc18450b7f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_780316d7-4e1d-4ce0-a458-3d8a801f9d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_780316d7-4e1d-4ce0-a458-3d8a801f9d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_f200367f-9aa2-4736-9345-5b14bbd23e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8b2a73cb-277d-4a93-a08b-f3544f7d52b2" xlink:to="loc_us-gaap_OtherShortTermBorrowings_f200367f-9aa2-4736-9345-5b14bbd23e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ff71ea8-e863-42b9-967a-1ed0ec774bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ff71ea8-e863-42b9-967a-1ed0ec774bcb" xlink:to="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:href="cah-20220930.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:href="cah-20220930.xsd#cah_LitigationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_9b8cc954-c698-4b1b-8883-f350a03b4a7c" xlink:to="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_018a8dad-37b7-4eb8-a872-76aa11f2933e" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:to="loc_cah_ClassActionLawsuitsMember_018a8dad-37b7-4eb8-a872-76aa11f2933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_16a24596-490a-4203-b6e6-e32871bb2449" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_9b363521-de63-4538-afd1-f66eaa869da6" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_16a24596-490a-4203-b6e6-e32871bb2449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:href="cah-20220930.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_4cac7405-a186-4ce2-b420-b3efe2d720f8" xlink:to="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_a49fc956-ad80-4d15-8230-51ce41fb59bc" xlink:href="cah-20220930.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:to="loc_cah_PrivatePartiesMember_a49fc956-ad80-4d15-8230-51ce41fb59bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_edc32f24-b45f-40d3-b85b-6139c31c7d23" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_cd83406b-f0b0-4f6a-a8e8-d4a18114442d" xlink:to="loc_cah_ClassActionLawsuitsMember_edc32f24-b45f-40d3-b85b-6139c31c7d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6824013f-c98a-44c2-9e03-93a5f04091a2" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_f074f250-f0a8-4d4b-b28a-a69652c62e44" xlink:to="loc_cah_OpioidLitigationDomain_6824013f-c98a-44c2-9e03-93a5f04091a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_dadc14fe-1549-43f6-9b97-d264cc2679da" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_6824013f-c98a-44c2-9e03-93a5f04091a2" xlink:to="loc_cah_TotalOpioidLitigationMember_dadc14fe-1549-43f6-9b97-d264cc2679da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f9bebcd9-7a54-4d59-b7c9-9c5915f6f6a9" xlink:to="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_ad9a1d1c-90e7-48b2-b698-c23650073fca" xlink:href="cah-20220930.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_cah_AlamedaCountyMember_ad9a1d1c-90e7-48b2-b698-c23650073fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_2822d88e-2a4a-4974-809d-16bef18c3a71" xlink:href="cah-20220930.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_cah_OtherJurisdictionsMember_2822d88e-2a4a-4974-809d-16bef18c3a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WV_dadd4065-f896-4dcd-84ac-9e74871b1552" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_WV_dadd4065-f896-4dcd-84ac-9e74871b1552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_OK_e47a8a56-0af5-4958-9071-15346dbc38a1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_OK_e47a8a56-0af5-4958-9071-15346dbc38a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_a75409e7-03e5-4ba6-854a-7c5a1ef3a6d0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_WA_a75409e7-03e5-4ba6-854a-7c5a1ef3a6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_d2d3ef52-7af2-4c7b-b342-a17c4a601a36" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_stpr_GA_d2d3ef52-7af2-4c7b-b342-a17c4a601a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NativeAmericanTribesMember_727324e8-c753-4cc1-8a36-dc715cba2fdd" xlink:href="cah-20220930.xsd#cah_NativeAmericanTribesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e6505ebb-a8be-4aee-b586-6f9449a862e6" xlink:to="loc_cah_NativeAmericanTribesMember_727324e8-c753-4cc1-8a36-dc715cba2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ac3a55fe-a4cf-4f1d-8d74-0b6f99b2854a" xlink:to="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_85d14de8-d4fd-4627-abb9-bae20a8883b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:to="loc_srt_MinimumMember_85d14de8-d4fd-4627-abb9-bae20a8883b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_84330f5a-064e-4ca5-9c0b-1f03a2eee4a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0734fa11-ae7c-4882-bf33-fc9de424e54f" xlink:to="loc_srt_MaximumMember_84330f5a-064e-4ca5-9c0b-1f03a2eee4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_9db58ccd-f033-4166-89b9-819f08fec6eb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_499ea32f-94e3-44d8-bc1d-677d241e26e5" xlink:href="cah-20220930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:to="loc_cah_OpioidLawsuitsMember_499ea32f-94e3-44d8-bc1d-677d241e26e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_00c0fe68-8d3e-4098-91e7-300aa730a599" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_fa7ea527-2fbd-4ee3-a11e-df5d2f73cfc8" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_00c0fe68-8d3e-4098-91e7-300aa730a599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b8a085fd-94bc-4d4c-8ff3-7bcf1641908b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6c1dde3b-818e-428c-a60d-18aef6564345" xlink:to="loc_srt_NameOfMajorCustomerDomain_b8a085fd-94bc-4d4c-8ff3-7bcf1641908b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_03e269c5-fa27-4e52-a8c5-e93f47dc9d51" xlink:href="cah-20220930.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b8a085fd-94bc-4d4c-8ff3-7bcf1641908b" xlink:to="loc_cah_CVSHealthMember_03e269c5-fa27-4e52-a8c5-e93f47dc9d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_47e69d2a-06f0-44b0-b092-b7eb9674ea65" xlink:to="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_2553998c-4dba-4f61-ab41-f489f8f2afb5" xlink:href="cah-20220930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_OpioidLawsuitsMember_2553998c-4dba-4f61-ab41-f489f8f2afb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_03f252c7-e7f6-4fb0-a1ce-9776be50f811" xlink:href="cah-20220930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_ClassActionLawsuitsMember_03f252c7-e7f6-4fb0-a1ce-9776be50f811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_a34945fa-681b-459f-bbff-c566d6b7b470" xlink:href="cah-20220930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_a34945fa-681b-459f-bbff-c566d6b7b470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_ea96699e-30a6-48ba-9b76-0c4157f8126a" xlink:href="cah-20220930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7238b8b1-bba7-48e1-9fdd-8841cdc9424e" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_ea96699e-30a6-48ba-9b76-0c4157f8126a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dba265f1-a648-4903-8de5-3766fef09277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c71a5c71-1f5d-44af-af24-d00b4ff75cc4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dba265f1-a648-4903-8de5-3766fef09277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ee1d0741-6e2b-4628-b6be-2bd319d2cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dba265f1-a648-4903-8de5-3766fef09277" xlink:to="loc_us-gaap_SubsequentEventMember_ee1d0741-6e2b-4628-b6be-2bd319d2cf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3ae9ed2b-5e55-44ca-8591-119ee90b7570" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a6763a03-ee21-418b-ae8b-e3c316d04ac8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3ae9ed2b-5e55-44ca-8591-119ee90b7570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c53edacc-131b-450b-a9c2-cf22b55b0723" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3ae9ed2b-5e55-44ca-8591-119ee90b7570" xlink:to="loc_srt_ScenarioForecastMember_c53edacc-131b-450b-a9c2-cf22b55b0723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_163f6b81-fd0b-4a77-84de-8b26709382d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_63909bb9-09ac-4b6a-8a99-26924c85206d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_163f6b81-fd0b-4a77-84de-8b26709382d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_b6052862-8a56-4c9a-b675-0cfcbdd23fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_163f6b81-fd0b-4a77-84de-8b26709382d8" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_b6052862-8a56-4c9a-b675-0cfcbdd23fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_896264e8-eadb-4c55-8918-75d026cce448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_09f587c5-329a-45cd-8b0f-1a85badb702c" xlink:to="loc_us-gaap_SegmentDomain_896264e8-eadb-4c55-8918-75d026cce448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_2fd23223-2658-4b32-9454-a6359162495a" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_896264e8-eadb-4c55-8918-75d026cce448" xlink:to="loc_cah_PharmaceuticalMember_2fd23223-2658-4b32-9454-a6359162495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7722e54b-c2fe-4a39-ad6f-ee3f75bde89f" xlink:to="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_38a17058-f95a-43d2-99bf-08cdd6bf7367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_38a17058-f95a-43d2-99bf-08cdd6bf7367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_3b148519-57af-4306-ae5d-5c8678a588c4" xlink:href="cah-20220930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_LossContingencyLawsuitsNumber_3b148519-57af-4306-ae5d-5c8678a588c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_3d991efa-51a1-4a49-9449-da1d7024c547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LitigationReserve_3d991efa-51a1-4a49-9449-da1d7024c547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_170f5d41-f163-4a51-b96a-54383e420223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_170f5d41-f163-4a51-b96a-54383e420223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_8f16fb45-4df4-40e6-8ea6-b71171ba2df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_8f16fb45-4df4-40e6-8ea6-b71171ba2df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_729adc6d-cb9d-4d52-af63-6630ffbc1dc1" xlink:href="cah-20220930.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_AggregateAnnualAssessment_729adc6d-cb9d-4d52-af63-6630ffbc1dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_4dc5f4a7-eab7-4b4b-829a-54266f2ce797" xlink:href="cah-20220930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_4dc5f4a7-eab7-4b4b-829a-54266f2ce797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e43fe893-c8f8-4899-a4c3-f5d3895a5dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e43fe893-c8f8-4899-a4c3-f5d3895a5dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_76b61059-6654-42b7-a86e-4125b44a36cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_76b61059-6654-42b7-a86e-4125b44a36cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_0683d0e7-9eb1-4180-93ae-90ec963849d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_0683d0e7-9eb1-4180-93ae-90ec963849d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_9d44e8b2-bbf5-4a56-80d9-d1b0cc276bb1" xlink:href="cah-20220930.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_JudgmentForLostProfits_9d44e8b2-bbf5-4a56-80d9-d1b0cc276bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingStates_e1f238d9-9482-4745-92d6-65bd4c04e006" xlink:href="cah-20220930.xsd#cah_SettlingStates"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_SettlingStates_e1f238d9-9482-4745-92d6-65bd4c04e006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SettlingUSTerritories_71044a16-f4f0-4873-b3c8-39244d370bd4" xlink:href="cah-20220930.xsd#cah_SettlingUSTerritories"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_SettlingUSTerritories_71044a16-f4f0-4873-b3c8-39244d370bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_f0b26adb-19d7-422b-8a07-54cbeff6d265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_f0b26adb-19d7-422b-8a07-54cbeff6d265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IncomefromSettlementsofClassActionLawsuits_8d359897-91ce-4d09-b4bf-8085c9eb5d09" xlink:href="cah-20220930.xsd#cah_IncomefromSettlementsofClassActionLawsuits"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_IncomefromSettlementsofClassActionLawsuits_8d359897-91ce-4d09-b4bf-8085c9eb5d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_7b65dba7-f3b5-417f-bd41-513122c38d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_7b65dba7-f3b5-417f-bd41-513122c38d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyNumberOfEligibleStates_8536f454-3d6f-4ad3-8850-bbf1a993c996" xlink:href="cah-20220930.xsd#cah_LossContingencyNumberOfEligibleStates"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_cah_LossContingencyNumberOfEligibleStates_8536f454-3d6f-4ad3-8850-bbf1a993c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_a40bf5c5-5f3c-47dc-bbc5-88f9d36eb25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31a6878a-fadd-4010-8c97-1289511299f3" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_a40bf5c5-5f3c-47dc-bbc5-88f9d36eb25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb667b70-d971-4db2-b056-c9ffb655c34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb667b70-d971-4db2-b056-c9ffb655c34e" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:href="cah-20220930.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_d8f71994-666d-4591-a83a-c2a5f0ecb550" xlink:href="cah-20220930.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_0bec35f1-9848-4f2d-9c4a-013d9df4210f" xlink:to="loc_cah_TaxMatterDomain_d8f71994-666d-4591-a83a-c2a5f0ecb550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_b016c2dc-d46c-41ab-acf9-42e4a4acc1a8" xlink:href="cah-20220930.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_d8f71994-666d-4591-a83a-c2a5f0ecb550" xlink:to="loc_cah_CareFusionMember_b016c2dc-d46c-41ab-acf9-42e4a4acc1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_d160ac32-8eef-4e2b-894d-5d9c937aa4f4" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_7489877d-b143-48cd-aa41-66e87b747a8c" xlink:to="loc_cah_OpioidLitigationDomain_d160ac32-8eef-4e2b-894d-5d9c937aa4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_aba1ed75-837c-440c-966f-1c41e3d95db3" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_d160ac32-8eef-4e2b-894d-5d9c937aa4f4" xlink:to="loc_cah_TotalOpioidLitigationMember_aba1ed75-837c-440c-966f-1c41e3d95db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d873722-8e47-45d1-b2b4-283bc6c66de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3438e296-3d04-4375-b06c-511aab3590e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d873722-8e47-45d1-b2b4-283bc6c66de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_40a85828-4d84-4635-87d8-ccf687f84281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c4126f0f-7fe6-45a6-ba5f-2b667d52728e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_40a85828-4d84-4635-87d8-ccf687f84281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b64e4972-c311-4b49-a7c7-8e65c05c664e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_40a85828-4d84-4635-87d8-ccf687f84281" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b64e4972-c311-4b49-a7c7-8e65c05c664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bcf15956-0e0f-4024-8c6d-b7fb12eeef90" xlink:to="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f1bdd811-fd79-4b84-9332-f42776b41bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:to="loc_srt_MinimumMember_f1bdd811-fd79-4b84-9332-f42776b41bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_15fe2a4b-ada4-403c-801a-bc3fa6e1e6f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76e24b87-8330-400e-befc-76dec2da533f" xlink:to="loc_srt_MaximumMember_15fe2a4b-ada4-403c-801a-bc3fa6e1e6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_957b844c-caba-486c-bad6-c138299585eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f2b74685-c4de-423c-98d7-8cc1721a9d20" xlink:to="loc_srt_ScenarioUnspecifiedDomain_957b844c-caba-486c-bad6-c138299585eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_58e8df44-3957-4721-8fe9-b3ed61ed9a24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_957b844c-caba-486c-bad6-c138299585eb" xlink:to="loc_srt_ScenarioForecastMember_58e8df44-3957-4721-8fe9-b3ed61ed9a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:href="cah-20220930.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_3198a0a7-f334-4d13-be5d-21d2a5db3807" xlink:href="cah-20220930.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_e93fcb77-8394-4597-b3e6-a538d09941cb" xlink:to="loc_cah_CordisDivestitureDomain_3198a0a7-f334-4d13-be5d-21d2a5db3807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_8c6a8b3f-61e0-4292-8e71-728f6c12bab3" xlink:href="cah-20220930.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_3198a0a7-f334-4d13-be5d-21d2a5db3807" xlink:to="loc_cah_CordisDivestitureMember_8c6a8b3f-61e0-4292-8e71-728f6c12bab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_535741c6-c321-4358-a9ec-d2cd2709f454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f35f2f2c-77d3-4339-96bf-611d6f4a67d4" xlink:to="loc_us-gaap_SegmentDomain_535741c6-c321-4358-a9ec-d2cd2709f454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c7b90065-e118-43f0-8360-6deab1dd137e" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_535741c6-c321-4358-a9ec-d2cd2709f454" xlink:to="loc_cah_MedicalMember_c7b90065-e118-43f0-8360-6deab1dd137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_b3f3c01a-f1e3-41cc-99cf-4b7306e2f1b7" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_e0e00bb3-77c1-4259-aa17-b90d2b0d034c" xlink:to="loc_cah_GoodwillImpairmentDomain_b3f3c01a-f1e3-41cc-99cf-4b7306e2f1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentMedicalUnitMember_69c51c16-51b3-4c03-9463-05e255d2525a" xlink:href="cah-20220930.xsd#cah_GoodwillImpairmentMedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_b3f3c01a-f1e3-41cc-99cf-4b7306e2f1b7" xlink:to="loc_cah_GoodwillImpairmentMedicalUnitMember_69c51c16-51b3-4c03-9463-05e255d2525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_96cb3938-9c17-4aef-a291-d8b93477ec69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_404ef8b3-c811-436e-91a2-2b0294fb1b1a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_96cb3938-9c17-4aef-a291-d8b93477ec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_134cf63d-7c41-4b41-80c5-5e694593ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_96cb3938-9c17-4aef-a291-d8b93477ec69" xlink:to="loc_us-gaap_SubsequentEventMember_134cf63d-7c41-4b41-80c5-5e694593ecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_830afe26-b134-4c9e-a082-e457c14df833" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4eaaae45-f1ea-45e3-b6f3-bf4db4988f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4eaaae45-f1ea-45e3-b6f3-bf4db4988f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_012a660f-977f-4485-8476-2df0f6ffb92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_012a660f-977f-4485-8476-2df0f6ffb92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2cdc534a-0581-4d93-a5a7-20495470dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2cdc534a-0581-4d93-a5a7-20495470dcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0fcb1208-5117-4860-ae4f-a504f0c1ac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0fcb1208-5117-4860-ae4f-a504f0c1ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_230fbba8-e4c1-49d6-818b-89300268825d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_230fbba8-e4c1-49d6-818b-89300268825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6ce08036-2e87-4adf-abce-65cabe384ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6ce08036-2e87-4adf-abce-65cabe384ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_143462a3-34e8-4efd-8131-ef83c6ec7d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_OpenTaxYear_143462a3-34e8-4efd-8131-ef83c6ec7d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_bc649f05-a8b8-417c-b219-23173e6b2cff" xlink:href="cah-20220930.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_cah_IndemnificationReceivable_bc649f05-a8b8-417c-b219-23173e6b2cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d760b046-c6b0-47b8-baf5-48c3d32f3962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_50ff5b97-e8d7-4887-b08c-55b747b59b92" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d760b046-c6b0-47b8-baf5-48c3d32f3962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_815bf215-6484-4506-b181-6426fc23d8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_815bf215-6484-4506-b181-6426fc23d8f6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0cae14b-53c1-4609-9887-79c8c72dff77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63198e25-1111-4c75-b6a8-b1e5f4c00b37" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0cae14b-53c1-4609-9887-79c8c72dff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_154f6114-ea17-4e8c-bb8b-622dde07ad12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0cae14b-53c1-4609-9887-79c8c72dff77" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_154f6114-ea17-4e8c-bb8b-622dde07ad12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37866e23-6bc6-4098-ad9f-4b8bc2a46338" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_85edfd51-7f62-4f7f-8228-4701b40dd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_85edfd51-7f62-4f7f-8228-4701b40dd1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5279ce3f-130d-4690-beac-4f6c98131f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5279ce3f-130d-4690-beac-4f6c98131f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0c731a87-70c5-464f-a2b2-c297848ba70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0c731a87-70c5-464f-a2b2-c297848ba70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_fc3d8300-3e47-443d-8c5b-f1a5149b24e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c2937fc-db95-47f6-b762-e07fe8279e32" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_fc3d8300-3e47-443d-8c5b-f1a5149b24e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_48c9854d-b3b8-4b2d-a6d7-7c6f88f5e4cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9b1a9c5-34cf-465b-9faa-cf28574841ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9b1a9c5-34cf-465b-9faa-cf28574841ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64d3cfe0-ecb3-4a46-9d82-d3ffb6b1cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64d3cfe0-ecb3-4a46-9d82-d3ffb6b1cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6658d180-fc69-449c-b124-0db824d0558e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6658d180-fc69-449c-b124-0db824d0558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_7d3294d7-f1b9-44e3-9b91-f683bfc7dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_7d3294d7-f1b9-44e3-9b91-f683bfc7dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76876726-a914-4e91-9eb0-693f6a5bb74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7bb0742-f6c6-454d-a27f-9c392ba75450" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76876726-a914-4e91-9eb0-693f6a5bb74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_342662bd-e15e-441c-8b53-0cfaee7271fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c7d61b3-502e-4b46-b2b1-e15540fcf557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c7d61b3-502e-4b46-b2b1-e15540fcf557" xlink:to="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fdd286e7-fd30-4626-bf59-2fdfea7ca3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d499058d-aedf-4d36-883f-c78ecfba41e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fdd286e7-fd30-4626-bf59-2fdfea7ca3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_0d4379e1-92af-4814-a099-3cd7d45cda4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fdd286e7-fd30-4626-bf59-2fdfea7ca3ad" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_0d4379e1-92af-4814-a099-3cd7d45cda4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d59e316b-06a7-4f43-8998-ade76ff9cc73" xlink:to="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bc08e45c-cb70-4e73-9441-8b676afdde8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bc08e45c-cb70-4e73-9441-8b676afdde8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a70076ba-d8f1-4666-bf27-88ce6571417a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8e1c4049-ee51-4227-b5d6-91619c198605" xlink:to="loc_us-gaap_NondesignatedMember_a70076ba-d8f1-4666-bf27-88ce6571417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3afe03ad-6812-4feb-87a2-999310a36254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_eafc15bc-4e52-46cc-9d05-85ff3c580dcc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3afe03ad-6812-4feb-87a2-999310a36254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_02c3c9d3-380f-495a-ad83-475914c5d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3afe03ad-6812-4feb-87a2-999310a36254" xlink:to="loc_us-gaap_FairValueHedgingMember_02c3c9d3-380f-495a-ad83-475914c5d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_029e0d2a-9b15-4dae-b43a-eb19c4a19ff5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d943ec15-b684-4325-89ed-e5bee1e06ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d943ec15-b684-4325-89ed-e5bee1e06ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_99843438-c179-474a-92d0-0d2c5cdcf9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:to="loc_us-gaap_InterestRateSwapMember_99843438-c179-474a-92d0-0d2c5cdcf9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_27987426-ed8d-4cfd-aa6b-92a93fcb0114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f69c505-46eb-4a4e-aed4-a63580bc7adb" xlink:to="loc_us-gaap_CashFlowHedgingMember_27987426-ed8d-4cfd-aa6b-92a93fcb0114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2ad6c7fb-ad54-4053-80c8-c151052459ca" xlink:to="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e7ab71e5-147e-4b57-99b7-8eb2a932d5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e7ab71e5-147e-4b57-99b7-8eb2a932d5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_955c4ad9-d2fb-4cc6-a4b4-f3900941df56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_955c4ad9-d2fb-4cc6-a4b4-f3900941df56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_9be5a050-36ec-47d0-9d14-d084bf391fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_9be5a050-36ec-47d0-9d14-d084bf391fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_11a79878-250f-4efb-8a7e-f6de47c4c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_11a79878-250f-4efb-8a7e-f6de47c4c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_85919b8d-c277-4fdb-965e-62ee2817f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_85919b8d-c277-4fdb-965e-62ee2817f40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_13c954d9-0b43-4ba3-ab62-1be3e3e7210f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a210aaed-6442-4ea4-a2c5-3541a88d3403" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_13c954d9-0b43-4ba3-ab62-1be3e3e7210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df52a070-ed00-4bcb-b55c-f4e63892c4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df52a070-ed00-4bcb-b55c-f4e63892c4ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8118a82b-a0e0-484c-88a1-61917208bd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4bf796cf-268f-4b44-bc2f-ce32a5e15666" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8118a82b-a0e0-484c-88a1-61917208bd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_74b0c436-db24-441f-b937-887e90727645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8118a82b-a0e0-484c-88a1-61917208bd0c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_74b0c436-db24-441f-b937-887e90727645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_130de425-3ae5-4bc2-87eb-230e3bd4af83" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_034cb2df-1d98-4a4a-b409-df663a599003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:to="loc_us-gaap_DebtInstrumentFairValue_034cb2df-1d98-4a4a-b409-df663a599003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_5aaef7fc-46ae-40a5-a3f3-0ee03758a4ac" xlink:href="cah-20220930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_029d2b39-8207-4526-9780-e955bbde7703" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_5aaef7fc-46ae-40a5-a3f3-0ee03758a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d6d911b9-524d-4432-8f78-fcae3601062a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d6d911b9-524d-4432-8f78-fcae3601062a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c0e6e3ff-2e58-4b21-b265-85f83750145e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d19c5c71-4928-40dc-a193-62fbc3d2204f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c0e6e3ff-2e58-4b21-b265-85f83750145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3eb421e3-0b0d-4f03-89fa-c92a3d58015f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc557ba0-30ce-4dda-995e-c9aa4d7c0a15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3eb421e3-0b0d-4f03-89fa-c92a3d58015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_79296c7d-0b63-4e15-89bd-13fc6271ca88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3eb421e3-0b0d-4f03-89fa-c92a3d58015f" xlink:to="loc_us-gaap_SubsequentEventMember_79296c7d-0b63-4e15-89bd-13fc6271ca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9255ed27-e9f0-4537-886d-54fdc4e61f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5a984a1-af0d-4e63-8867-7fa9647b7088" xlink:to="loc_us-gaap_EquityComponentDomain_9255ed27-e9f0-4537-886d-54fdc4e61f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d34be578-aea7-4404-b657-fd0a49a28f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9255ed27-e9f0-4537-886d-54fdc4e61f57" xlink:to="loc_us-gaap_TreasuryStockMember_d34be578-aea7-4404-b657-fd0a49a28f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a1129d1-c5ff-4296-b4f5-3f54d42e7fe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_271f556e-293f-4000-8939-0f5c677afbdd" xlink:to="loc_srt_RangeMember_1a1129d1-c5ff-4296-b4f5-3f54d42e7fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5fe889db-c49f-4faf-ba34-c6183f86f2ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a1129d1-c5ff-4296-b4f5-3f54d42e7fe3" xlink:to="loc_srt_MinimumMember_5fe889db-c49f-4faf-ba34-c6183f86f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe0f970-14d9-4e4b-95c5-83d97db5f1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_972dda97-99d6-46e1-9bd8-8d7ac26f393a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe0f970-14d9-4e4b-95c5-83d97db5f1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7a2456d9-3fb8-435f-9fa2-1e099d08e4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbe0f970-14d9-4e4b-95c5-83d97db5f1f4" xlink:to="loc_us-gaap_PerformanceSharesMember_7a2456d9-3fb8-435f-9fa2-1e099d08e4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:href="cah-20220930.xsd#cah_ShareRepurchaseProgramAggregatePurchasePriceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis_354d63e0-9225-4171-aa05-4ca978fc15eb" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_1a04451c-ac40-4209-a17b-0e27b905833a" xlink:href="cah-20220930.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_1a04451c-ac40-4209-a17b-0e27b905833a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A1BillionShareRepurchaseProgramMember_22ca6d97-42e9-44a4-904f-c0ddd9e260ea" xlink:href="cah-20220930.xsd#cah_A1BillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePriceDomain_04d66b76-3622-4249-8023-a63de4f62ce6" xlink:to="loc_cah_A1BillionShareRepurchaseProgramMember_22ca6d97-42e9-44a4-904f-c0ddd9e260ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0958b203-d77f-400f-af2c-abc8a7820775" xlink:to="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af6dd79c-c219-40ae-b7b8-07f56d49f3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af6dd79c-c219-40ae-b7b8-07f56d49f3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f1f145dd-150d-415e-b7b8-e05ce07fa119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f1f145dd-150d-415e-b7b8-e05ce07fa119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_040eff69-907f-4fe5-ae1e-0537dd515a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_70f2241a-d9d9-4e51-9209-a683bfa2089b" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_040eff69-907f-4fe5-ae1e-0537dd515a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0391376d-3a24-4373-a377-2f7ffebb5bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0391376d-3a24-4373-a377-2f7ffebb5bc3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6bc0b48d-661e-4cde-944a-23b28146c3af" xlink:to="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_65f60d4a-5d25-4463-9bf9-ca793e84e87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_65f60d4a-5d25-4463-9bf9-ca793e84e87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_994096b5-53b7-469e-8557-d926e2770599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_994096b5-53b7-469e-8557-d926e2770599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7d5bdd0c-1702-4d78-94a0-1eb80e808959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_7d5bdd0c-1702-4d78-94a0-1eb80e808959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5465e975-6dc8-4916-9836-b8022749af4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0f6797de-7d7c-4b49-8fd0-46c26f243250" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5465e975-6dc8-4916-9836-b8022749af4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_52451b18-cd1c-4781-bfb0-08cad596b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee22efba-75b7-4c27-a3a5-bb8aa609304d" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_52451b18-cd1c-4781-bfb0-08cad596b16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_52451b18-cd1c-4781-bfb0-08cad596b16c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce38ff66-b39b-46b2-8612-2d2747b478c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce38ff66-b39b-46b2-8612-2d2747b478c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c56d3eb-1604-4b68-bdf0-3d075dc7655e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c56d3eb-1604-4b68-bdf0-3d075dc7655e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bd42eb9a-4a17-4754-9f36-8adb522168de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bd42eb9a-4a17-4754-9f36-8adb522168de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05aec8e-2feb-448b-9a38-f1cedef89d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05aec8e-2feb-448b-9a38-f1cedef89d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39119b0e-48b6-4f40-9041-7f022dec147b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39119b0e-48b6-4f40-9041-7f022dec147b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_0a3da7c4-7c68-457a-9778-71c4a14f6d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c443a75c-29eb-4a74-b310-8aef2ba5d98d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_0a3da7c4-7c68-457a-9778-71c4a14f6d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6cbdd431-adc6-48eb-8a47-d15999ecef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11c37ecd-6dfa-40d5-a312-3ca38a90b992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6cbdd431-adc6-48eb-8a47-d15999ecef51" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11c37ecd-6dfa-40d5-a312-3ca38a90b992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_6cefdfb7-d70f-4363-a0d4-262226f0702d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6cbdd431-adc6-48eb-8a47-d15999ecef51" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_6cefdfb7-d70f-4363-a0d4-262226f0702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_49f3d6e6-30dd-4e53-89c7-22d53132a7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6cbdd431-adc6-48eb-8a47-d15999ecef51" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_49f3d6e6-30dd-4e53-89c7-22d53132a7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0d956ca-e3fc-411b-bfc2-43ff3a9e7b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6cbdd431-adc6-48eb-8a47-d15999ecef51" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0d956ca-e3fc-411b-bfc2-43ff3a9e7b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f7380c24-32be-41ee-88d3-455c557c0be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares_712fe174-7d88-4e30-bfef-fe389ad5f4f2" xlink:href="cah-20220930.xsd#cah_Numberofsharesexcludedfromcalculationofdilutedshares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7380c24-32be-41ee-88d3-455c557c0be9" xlink:to="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares_712fe174-7d88-4e30-bfef-fe389ad5f4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d69247dd-379c-4599-b9c1-a125b37c6462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69247dd-379c-4599-b9c1-a125b37c6462" xlink:to="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:href="cah-20220930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:to="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_bd7c9db1-1c00-48bf-bc71-68968b18eb45" xlink:href="cah-20220930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_c29e279f-93b8-43cb-94c4-0aa715e9b267" xlink:to="loc_cah_OpioidLitigationDomain_bd7c9db1-1c00-48bf-bc71-68968b18eb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_066965f2-6c8f-4c49-8501-485103b31150" xlink:href="cah-20220930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_bd7c9db1-1c00-48bf-bc71-68968b18eb45" xlink:to="loc_cah_TotalOpioidLitigationMember_066965f2-6c8f-4c49-8501-485103b31150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9bfd827b-7dcc-49bf-ace6-7283b07c717c" xlink:to="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_280c4e32-e6a7-45dd-92b9-733202d89f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:to="loc_us-gaap_LitigationReserve_280c4e32-e6a7-45dd-92b9-733202d89f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5cdc11ee-8f89-4414-a587-ccbc0fd3c3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dae8b551-1334-417b-aec2-f1745aac6f7b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5cdc11ee-8f89-4414-a587-ccbc0fd3c3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_767d2959-4cab-44d7-ac8d-4ca5aabf90cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69247dd-379c-4599-b9c1-a125b37c6462" xlink:to="loc_us-gaap_NumberOfOperatingSegments_767d2959-4cab-44d7-ac8d-4ca5aabf90cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2f925a11-461d-45b4-8883-01a7712aab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69247dd-379c-4599-b9c1-a125b37c6462" xlink:to="loc_us-gaap_NumberOfReportableSegments_2f925a11-461d-45b4-8883-01a7712aab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_e1473912-b980-46e2-9884-2b2be0851ec6" xlink:href="cah-20220930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d69247dd-379c-4599-b9c1-a125b37c6462" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_e1473912-b980-46e2-9884-2b2be0851ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_65b0084c-a047-45ca-8e61-dfe0acd1f3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_65b0084c-a047-45ca-8e61-dfe0acd1f3da" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_6393481e-a14d-4fad-b710-eed563fcd166" xlink:to="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_faa6d23e-4c52-44e5-9491-3f1afef6bd28" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_faa6d23e-4c52-44e5-9491-3f1afef6bd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_33a02e47-86e6-4132-b98c-3fdc789b4fcc" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_33a02e47-86e6-4132-b98c-3fdc789b4fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_5753776b-d85b-4534-80ca-b691503879be" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_MedicaldistributionandproductsMember_5753776b-d85b-4534-80ca-b691503879be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember_452b2a3f-6214-46b5-b802-349e4c3681e7" xlink:href="cah-20220930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6664188a-5e1d-4ce7-93c6-66f3a83ab516" xlink:to="loc_cah_CardinalHealthAtHomeSolutionsMember_452b2a3f-6214-46b5-b802-349e4c3681e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_dc4d9b2c-c000-4dd6-afc2-1d368917ac3c" xlink:to="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_586b2e92-6a70-4720-b6ff-c0f02c2fa9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:to="loc_us-gaap_OperatingSegmentsMember_586b2e92-6a70-4720-b6ff-c0f02c2fa9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_fb00a924-a905-4f1f-b685-7b8ac86550d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_557b62f6-4ffd-4065-a3ab-c5fb5cc8d8c7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_fb00a924-a905-4f1f-b685-7b8ac86550d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_450e7469-e245-443d-88db-8153d3f7388c" xlink:to="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_317b0169-74d6-40ce-9024-bb4587fe8ced" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:to="loc_cah_PharmaceuticalMember_317b0169-74d6-40ce-9024-bb4587fe8ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_6eb163a5-3c7f-4815-9335-91255ce12342" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d373fc1f-a7c1-4377-b755-72cb11edacbd" xlink:to="loc_cah_MedicalMember_6eb163a5-3c7f-4815-9335-91255ce12342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8b078fe-1154-4124-b3b9-f1e2d8a2d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e9048fa0-8b4c-4981-a211-fac811ebc5c9" xlink:to="loc_us-gaap_EquityComponentDomain_f8b078fe-1154-4124-b3b9-f1e2d8a2d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_a0a54185-1ce4-432a-bed3-2bfdf36720e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8b078fe-1154-4124-b3b9-f1e2d8a2d76a" xlink:to="loc_us-gaap_TreasuryStockMember_a0a54185-1ce4-432a-bed3-2bfdf36720e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e80aed00-6709-43c0-a0e6-95bd494edebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_dc58591e-4d0d-4088-9e0f-e89cd9714832" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e80aed00-6709-43c0-a0e6-95bd494edebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7903e504-89e3-40db-b28c-c270e125bd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e80aed00-6709-43c0-a0e6-95bd494edebd" xlink:to="loc_us-gaap_Revenues_7903e504-89e3-40db-b28c-c270e125bd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_55185ad8-01f3-4ef3-8b4c-07fbac585cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_55185ad8-01f3-4ef3-8b4c-07fbac585cbe" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:to="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_28bf09a9-bcd3-4bab-ac2a-4ae52a86d1c3" xlink:to="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_80bb2cfd-e0b7-4d5a-908f-eb2aa18b7e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:to="loc_us-gaap_OperatingSegmentsMember_80bb2cfd-e0b7-4d5a-908f-eb2aa18b7e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f64cc75c-914c-48fd-9f72-a840dedfd573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e462a296-c393-4ecb-9a16-0823bad7e09d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f64cc75c-914c-48fd-9f72-a840dedfd573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d659ddaf-a4ca-4f13-be77-f8f4e0289371" xlink:to="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_fdac9ec9-cd05-41dc-b252-4baa6c4c74ba" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:to="loc_cah_PharmaceuticalMember_fdac9ec9-cd05-41dc-b252-4baa6c4c74ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_0a6a8f69-b922-4e49-b08f-a6461b5a3a36" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4347ece-c7b3-45b2-a6a2-7e1cae09e90e" xlink:to="loc_cah_MedicalMember_0a6a8f69-b922-4e49-b08f-a6461b5a3a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5bd7964f-05fa-49f9-a0c9-2d37286c1969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_0fb8ad51-dc3f-4d84-8456-c7e85429e675" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5bd7964f-05fa-49f9-a0c9-2d37286c1969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_634b6355-239c-418a-8e57-a9a2769e93ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_5bd7964f-05fa-49f9-a0c9-2d37286c1969" xlink:to="loc_us-gaap_OperatingIncomeLoss_634b6355-239c-418a-8e57-a9a2769e93ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f86f21f9-864b-4776-8938-265a8c963c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f86f21f9-864b-4776-8938-265a8c963c43" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:to="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_5269e093-a2ce-45b2-9b2d-f44cd79716f0" xlink:to="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9345e4b9-e3af-4f1b-a885-8443a0187365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:to="loc_us-gaap_OperatingSegmentsMember_9345e4b9-e3af-4f1b-a885-8443a0187365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d718fde1-dd51-478a-ace0-f29549c137ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_132d0aa3-2a9d-4b6b-b899-0f59fececd5f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d718fde1-dd51-478a-ace0-f29549c137ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_205fe949-f4e8-41ec-a920-e98f843d5586" xlink:to="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_18971703-6b15-4feb-93eb-c2ba58f7aef6" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:to="loc_cah_PharmaceuticalMember_18971703-6b15-4feb-93eb-c2ba58f7aef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c02459da-65e2-4f70-bd9e-70e75eb17461" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a7004527-b05b-4f28-93f2-d424ce774bad" xlink:to="loc_cah_MedicalMember_c02459da-65e2-4f70-bd9e-70e75eb17461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d0417443-be3a-4e8a-8225-fff16a4ebf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7b871893-0e93-4bed-a29d-19f0086606bb" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d0417443-be3a-4e8a-8225-fff16a4ebf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_df392adb-4911-43ba-b8ea-a1a02dcae9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d0417443-be3a-4e8a-8225-fff16a4ebf1b" xlink:to="loc_us-gaap_Assets_df392adb-4911-43ba-b8ea-a1a02dcae9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6b208a00-3ad9-4d3d-b2b8-9e2f3bf3e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6b208a00-3ad9-4d3d-b2b8-9e2f3bf3e88c" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:href="cah-20220930.xsd#cah_MedicalSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_34a5d235-d2af-4efa-b2ed-3310e49d9166" xlink:href="cah-20220930.xsd#cah_MedicalSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MedicalSegmentAxis_1752bec0-b05d-4c73-92c7-bf2a40510d0d" xlink:to="loc_cah_MedicalSegmentDomain_34a5d235-d2af-4efa-b2ed-3310e49d9166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_8aa4d485-39f6-4987-823f-2ca808ec5e49" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MedicalSegmentDomain_34a5d235-d2af-4efa-b2ed-3310e49d9166" xlink:to="loc_cah_MedicaldistributionandproductsMember_8aa4d485-39f6-4987-823f-2ca808ec5e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:href="cah-20220930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentAxis_6784efbc-e978-4a04-bdd6-995f8c0ec99f" xlink:to="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_968f2d6a-421d-4a7b-a8f4-20bd77b1c748" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_968f2d6a-421d-4a7b-a8f4-20bd77b1c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_07e8dc24-747a-4c4b-837e-d6e2b7d352db" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentDomain_a9942059-ed63-4ad1-a52f-76a431285a27" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_07e8dc24-747a-4c4b-837e-d6e2b7d352db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3bd476a9-3cef-43fd-b357-6a3d35f190a4" xlink:to="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0f2749b8-be99-4247-a2d4-190b5b17939d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:to="loc_us-gaap_OperatingSegmentsMember_0f2749b8-be99-4247-a2d4-190b5b17939d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c33fccbf-29ab-4176-88aa-83a387eb9224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_92c64508-e54f-47c2-a64d-292123107f2d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c33fccbf-29ab-4176-88aa-83a387eb9224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_94521b0e-4be1-474c-b38f-e8bd012693e6" xlink:to="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_e54e0a74-6606-4888-a735-642ad0c09f3e" xlink:href="cah-20220930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:to="loc_cah_PharmaceuticalMember_e54e0a74-6606-4888-a735-642ad0c09f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_49b0e090-0c1d-49ee-aa13-05dced4e91bc" xlink:href="cah-20220930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dbc44c56-5623-4075-ac7d-82491532299e" xlink:to="loc_cah_MedicalMember_49b0e090-0c1d-49ee-aa13-05dced4e91bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_7d56316f-2516-4b01-9ecf-8e6190863404" xlink:to="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_50aa2ee9-4624-403a-aa82-d2a371e1aad7" xlink:href="cah-20220930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:to="loc_cah_MedicaldistributionandproductsMember_50aa2ee9-4624-403a-aa82-d2a371e1aad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_7f516739-65a1-4835-8739-88c1368033d2" xlink:href="cah-20220930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_7f516739-65a1-4835-8739-88c1368033d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_73fea3c3-5805-4aee-975b-d82835ff23a9" xlink:href="cah-20220930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b62f6a1d-7431-4c74-95d6-ec64e10ce054" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_73fea3c3-5805-4aee-975b-d82835ff23a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_7f493ebf-febd-4a86-af47-b7eff8ccca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_ef70db7b-21b2-49d6-a34e-3ce2a3115e96" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_7f493ebf-febd-4a86-af47-b7eff8ccca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_457b66d8-22ec-4b6e-ab1f-cc4f6cf7bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f5ee9fd0-a9ad-44cd-a9fb-4feb46081348" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_457b66d8-22ec-4b6e-ab1f-cc4f6cf7bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_57f4e849-97e1-4e6c-98ca-5ba2299c472d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_457b66d8-22ec-4b6e-ab1f-cc4f6cf7bf78" xlink:to="loc_us-gaap_Revenues_57f4e849-97e1-4e6c-98ca-5ba2299c472d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9b6016dd-d478-4156-8638-dc9884c54834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:href="cah-20220930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9b6016dd-d478-4156-8638-dc9884c54834" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:to="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3a6e68b7-4464-41ec-92db-ce814c24d5ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_64b5b855-b9bc-474d-b503-62baf4843689" xlink:to="loc_srt_ConsolidationItemsDomain_3a6e68b7-4464-41ec-92db-ce814c24d5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4f5dd44e-98d8-473b-addd-59d8b3a5e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3a6e68b7-4464-41ec-92db-ce814c24d5ed" xlink:to="loc_us-gaap_OperatingSegmentsMember_4f5dd44e-98d8-473b-addd-59d8b3a5e86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_92928213-c2ed-4696-ba7f-b021930dd89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingSegmentsMember_4f5dd44e-98d8-473b-addd-59d8b3a5e86d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_92928213-c2ed-4696-ba7f-b021930dd89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:to="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_890e7835-db86-4a20-97fd-7132216eaf92" xlink:to="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bd449bd7-4e5b-4111-9875-012d7c40e5df" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:to="loc_country_US_bd449bd7-4e5b-4111-9875-012d7c40e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_395f267d-eb72-440e-86a0-882a54845066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_848f1bb7-46c0-4b22-aa77-7a756356fefc" xlink:to="loc_us-gaap_NonUsMember_395f267d-eb72-440e-86a0-882a54845066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_f82899b6-2267-45d3-850b-f7ad1d14490b" xlink:href="cah-20220930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_417c1c8a-28ce-49b8-a70b-b179b5deb9ee" xlink:to="loc_cah_SegmentRevenuebyGeographicLineItems_f82899b6-2267-45d3-850b-f7ad1d14490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_522dbdcd-5bef-448e-a3ec-ea4a8725c219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_f82899b6-2267-45d3-850b-f7ad1d14490b" xlink:to="loc_us-gaap_Revenues_522dbdcd-5bef-448e-a3ec-ea4a8725c219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f69b566-ba47-4a4a-9d82-c08994066095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f69b566-ba47-4a4a-9d82-c08994066095" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:to="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_efc3619c-f650-49bb-90f1-480db65ca839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3574eeca-777e-4b57-853b-fc2b1041b9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3574eeca-777e-4b57-853b-fc2b1041b9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9104f09c-6838-4c7b-a8cd-fcc265ef4f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e97d2f2c-e0fd-4111-b83c-ae0e1cfe6e3e" xlink:to="loc_us-gaap_PerformanceSharesMember_9104f09c-6838-4c7b-a8cd-fcc265ef4f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:to="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e5cb456-fc87-448e-90bc-e5d970248e57" xlink:to="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_10fdaf9a-6bb7-42fa-aa21-598bd08b2f31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:to="loc_srt_MinimumMember_10fdaf9a-6bb7-42fa-aa21-598bd08b2f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ceaef69d-3f0f-44da-8db1-734630fe821a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74c18546-b75a-41ee-8878-a796e841dc4b" xlink:to="loc_srt_MaximumMember_ceaef69d-3f0f-44da-8db1-734630fe821a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46b0ab43-df9f-44db-953e-9225d08218b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1aea6c9c-eded-4df2-8431-0054f2c16972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1aea6c9c-eded-4df2-8431-0054f2c16972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_956341e5-a8da-410c-a7db-1de4829d47c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_956341e5-a8da-410c-a7db-1de4829d47c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_874a7df8-90d0-4bc2-95af-4f27604fae9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_874a7df8-90d0-4bc2-95af-4f27604fae9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b4501ac-f556-45fd-83bc-e03ceac57921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8b4501ac-f556-45fd-83bc-e03ceac57921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e966495f-ec19-4339-b161-c924dcf24ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e966495f-ec19-4339-b161-c924dcf24ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_e3000393-fe98-49a5-9c83-04935cb22cdd" xlink:href="cah-20220930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_627c05fa-a567-4e75-86b6-3acecafd1079" xlink:to="loc_cah_VestingPeriodinyearsforShares_e3000393-fe98-49a5-9c83-04935cb22cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd2e22b3-5d8f-46c1-8d42-aab619ed2297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd2e22b3-5d8f-46c1-8d42-aab619ed2297" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:to="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fbe4a951-f68c-4982-8226-58314b5d80f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c6f538c0-31f1-4381-84ef-5199632ba05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c6f538c0-31f1-4381-84ef-5199632ba05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cd5d6c17-bc46-4753-bfaf-bb79277be280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc410582-0ba9-49b5-980f-374ff3fba462" xlink:to="loc_us-gaap_PerformanceSharesMember_cd5d6c17-bc46-4753-bfaf-bb79277be280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e0eb56b-9788-46a0-bc0d-dc6a5b20117a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0a1c117-d475-4ee9-b637-33baab5d07ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e0eb56b-9788-46a0-bc0d-dc6a5b20117a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4d02bfdf-3c0a-4b12-aa4f-d814988f38b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3e0eb56b-9788-46a0-bc0d-dc6a5b20117a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4d02bfdf-3c0a-4b12-aa4f-d814988f38b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5964370-3e68-411e-8929-75b1d0fcb4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5964370-3e68-411e-8929-75b1d0fcb4b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:to="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bd7a802-406e-4e39-a67d-a0ef91c6a06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05b60027-fdd6-458b-969a-478211046552" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bd7a802-406e-4e39-a67d-a0ef91c6a06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7544c3b8-01b4-47b1-ad5b-74dd4f46d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bd7a802-406e-4e39-a67d-a0ef91c6a06d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7544c3b8-01b4-47b1-ad5b-74dd4f46d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_66e3ba24-02cc-4e70-a3c2-1ccf45cb2bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_248d21ad-c0c4-4bd9-b7ac-a9079a4ab97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_248d21ad-c0c4-4bd9-b7ac-a9079a4ab97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ed926f0-9ec1-4209-a19d-e8c37207db94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ed926f0-9ec1-4209-a19d-e8c37207db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f57bce6b-fc9c-4e0f-8ee1-8994b04c85b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f57bce6b-fc9c-4e0f-8ee1-8994b04c85b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e938bea7-c716-4374-bb29-92ea5813ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e938bea7-c716-4374-bb29-92ea5813ea49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_860e4f35-9479-480a-9dea-f887ac0b0e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_860e4f35-9479-480a-9dea-f887ac0b0e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f26ec16a-e811-4871-a07d-3b77d90d37a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5ceafed0-a555-455e-a0f3-15850d5c52dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f26ec16a-e811-4871-a07d-3b77d90d37a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1096c1f-1e87-4617-ab96-2733276e4885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_451c3808-91ff-42e6-b802-d77f156e4ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_451c3808-91ff-42e6-b802-d77f156e4ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb71942-13f8-49b5-87e6-469787948e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb71942-13f8-49b5-87e6-469787948e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa396121-d1e0-4358-a581-780c5b4eb893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa396121-d1e0-4358-a581-780c5b4eb893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9885d64-d848-4ce7-8b11-cef72acc4015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9885d64-d848-4ce7-8b11-cef72acc4015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fddd60c5-73f4-4b6f-a7bf-7d8befc1aa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0b50029-8324-4c19-a51b-6ea13c469729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fddd60c5-73f4-4b6f-a7bf-7d8befc1aa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20220930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7855c850-8504-4e1f-8467-02a885e4555c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7855c850-8504-4e1f-8467-02a885e4555c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:to="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80842c22-40ca-4f97-92f1-0a2a6fa80896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d571fd98-b19a-45bf-8e81-6f055a3ab34f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80842c22-40ca-4f97-92f1-0a2a6fa80896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9590f57a-8e76-4c29-82d6-bf40d969c27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80842c22-40ca-4f97-92f1-0a2a6fa80896" xlink:to="loc_us-gaap_PerformanceSharesMember_9590f57a-8e76-4c29-82d6-bf40d969c27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ba2a48a-1497-4035-9830-eca5757e9a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_630844cf-6228-4896-8674-6771d27de8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_630844cf-6228-4896-8674-6771d27de8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa795a42-f03d-408a-9c8a-4a6652abe100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa795a42-f03d-408a-9c8a-4a6652abe100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19a168ac-bb67-4124-9cfa-24a44cd8119b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19a168ac-bb67-4124-9cfa-24a44cd8119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_65625f7b-f871-416b-bee1-e52fc77a7dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_65625f7b-f871-416b-bee1-e52fc77a7dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca43b552-7cd7-416d-8834-f0bbd87c0b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca43b552-7cd7-416d-8834-f0bbd87c0b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c9054df6-cd8f-4989-b3fc-0a15424b26e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c428dec7-3494-46f9-81c6-ee00962dd60f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c9054df6-cd8f-4989-b3fc-0a15424b26e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f222ec3-2d66-42be-820a-fc532579e395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7f222ec3-2d66-42be-820a-fc532579e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a758fac-b276-46bd-9d13-2c8d7249c107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a758fac-b276-46bd-9d13-2c8d7249c107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c2aae8-9489-47fe-9cc4-54baa82b30d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35c2aae8-9489-47fe-9cc4-54baa82b30d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365f6d9e-1f1b-4b80-a422-3ba80627c0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365f6d9e-1f1b-4b80-a422-3ba80627c0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45a69ca-a7be-41c6-b274-409a8988ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ccf84c8-ab77-48e1-bea8-c5e44cfbc43b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e45a69ca-a7be-41c6-b274-409a8988ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9ff9359b-e2f2-4904-808d-f17d9bd965a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9ff9359b-e2f2-4904-808d-f17d9bd965a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69c1002a-a1db-4990-8afb-822683b3ab85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67d05ce8-8b41-4e45-8a1e-6c63c0d330e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69c1002a-a1db-4990-8afb-822683b3ab85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cah-20220930_g1.jpg
<TEXT>
begin 644 cah-20220930_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^)WPV^)&E-'XJTS28)VC@EE@ABO+.XF@BE:T9YK>&[BG>-D+-LPVQA7[VT4
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MB>W2(R0@31.H+J,\>M?T >$HI(/"FF0S1LCII\*NC#!4B-<@CM6A10 4444
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MG^!VM^*_[)M()O#JV=OI< UC0/$%PJ06\=Q$TWEJ4DN;>4LDCKY;!EW_ ':
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MG^%=U96%S:W'A?3HY+Z5;N\CLU3R9Y8@KQSR;)$9U*&-QR5P0#Z9HKY^M/\
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MW@TNX8PRWVGQ[%D$^7^SW#2L[()5"E1,PK[[_P"#:7_@G5^U!_P3-_8?\7_
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MX)TW?AW3A\4&^"EWX;&FC5HC;?VA()-J?:,[-OS#YLXKR3]FS_@BE^T-J_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]1NM.U+1-:6-;W2KVW?#V\XC=T#%&BE7:QRDR'@D@ 'O%%%% !1110 4444
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M*NI/&;^#FN4U3['IU[9E1:B[0P[_ +6'SYKX\O'.<CV7_@H+_P $O;_]N/\
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M% !1110 4444 %%%% 'B'Q4_Y'_4?^NB?^BUKGJZ'XJ?\C_J/_71/_1:USU
M!1110 4444 %%%% !74?!W_D?[3_ *YR_P#HMJY>NH^#O_(_VG_7.7_T6U '
MM%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6V[V /N:NH^#O_(_VG_7.7_T6U<O74?!W_D?[3_KG+_Z+:@#VBBBB@ HHHH
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M?]<Y?_1;4 >T4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO67_  S#X[U_^W)K=]WV.VM?)\H2#&//DW9\SVQCOFO:/^&L/C9_T8_X[_\
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M-&\*_P#!:3X[GPMX.DL8[#P<MO9PV#V-JR;;'8F-L)C01X'13Q0!Z!_P4?\
MVW_B^OQ"L?\ @FM_P3XM(M5_: \=Z2;B^UR0%M/^&NA.?+DUW4'&<2 $BW@^
M]))M)!&Q)?>OV)?V2?AQ^PI^ROX,_91^%4UQ<:/X/TK[.+^]QY^H7,DCS7-W
M+CCS)IY)96 X!D(' %?'OC'_ ((.?%J[_:A^*?[4OP@_X*R?&/X>ZM\6?$IU
M7Q#:>%[*SC7RT+K:6GF'YY(K:%A#&&Z*.F2:^R/V0O@+X_\ V:_@;I_PF^)G
M[1_BGXKZO975S+/XT\9;/M]TLLK.L;[/EVQ@A%]E% 'IU%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20220930_g2.jpg
<TEXT>
begin 644 cah-20220930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K"^*4DD/PR\1RQ2,KKH-X593@@B%\$&MVL#XK?\
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M]A^"?_!7?_@F7^T;\75^ _P1_;9\ ^(O%LTS0V6C66L@/?2+G*6SN%2Z; )
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M[.'[0WQ/_82_8/\ #OPU^ WC/Q#J'AWP["GB"QT/PO=W<VF,-+T=2MPD4;-
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MX'_&KX<?\&Z_QD^&'Q"^$'BC0?$M^OCC[#X=UGP_<VM]<>;I$:1;()461][
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M_!)WQ+!\??"\T>A>&_&]UX%-XR6276]6>QFLI$N)!%F 2^88BA$N>/F^MO\
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M_P"T7J&LZKXA\2"1_#_@SPI:13ZC=11D*]PPEDCCAA5B%WNX+'(17*L!A_\
M!*__ (+K_L1_\%:;W5_!_P ";C7_  [XRT*S^V:AX,\8V<,%Y):;E0W4#0RR
MQSQ*[*K$,'0NNY%#*2 ?9]%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'X0_\ !\7_ ,DM_9U_[&#Q)_Z(
MT^OB#_@LS_P1W_;%_P""7&E^"?'?Q_\ VL_&'QE^#?B?68]/UW4M.U"ZLKBR
MG&)3:O#=37,4;21)(T,I+J6A8,JX7=^MO_!S]_P2I_;%_P""HG@7X/:%^R+X
M2TC5;CP=JVLW&N+JNO06(C2YBM%B*F4C?DPOG'3 ]:^\?VZ/V./AM^WO^R)X
MT_9)^+$*C3/%VB-;0WPB#OIMXF)+:\C!_CAG2.0#HVS:>&(H _.OX_:'^R-^
MRO\ \&IWC_Q+_P $O9[\>!?%/@**>+6+ZX#ZGJ$FIWUKI^HR7SH /M0C>6"5
M5 6/R?+4!445\&?L'?$W]IW6O^")-Y^Q)\*_^#?KQ%\3O#WQ$T76_,^,^FZ^
MJC4]2FN+A+?5%A_LV0F2R=88T'G];(?,N3C[B_X(P_\ !(;]OGX*?L:?'3_@
MEQ_P47\'Z4OPD^(.EW3^$]>T'Q1;WLNF7DZ^1<>7%G>H8B"ZBRH5)()"PS+B
MOG#PA_P35_X.EOV2/V=_$G_!+#]G$^$=8^#NM:A=0:=\1++Q1IUK+IMC=2E[
MA;=IKB.\M4E+.\B+!*RM+)Y;?,6(!V'PX_X)S?M5?$__ (-2O'O[+7[4?P9\
M0>&?'?PG\0ZKXH\ :+XBLBETEM9,NHDQ(<DB6*XU.! .\F!TQ7RK^TK^W3XT
M_P""E/\ P2>_87_X)@?#S7#<^-O$GC8>'?%4:MN: Z9,FE:49><LCV]XL[D]
M#;[B>,U_0M_P3G_9+\??L?\ [%7A']F[XY?&_6OBAXFT_3I?^$I\4>)=6N;\
MWMQ.[/)#$UTS.+6,,(8T./W<8)4%F%?EA_P23_X-L?CW^Q7_ ,%D-7_:=^*N
M@Z-_PJ/P1>Z]=_"JYBUJ*YN+QYW:VL/-MP=T3):3R2$M]V6%,9X- 'D__!T!
MHW_"K_VTOV)_V-O WP:NO''@;P1H&FP>'/AA;W7D_P#"1G^TK:R&EAPCA7FA
MLH+</L;;YQ(4Y(.!_P %//\ AZ-_P4 ^+OP6^.WPB_X($>/?@QXP^#>MQW=A
MK^C7HOY+VWBFMYK:V*QV%KL6"2 M'RP7S7 "[CG])_\ @X-_X(^_%?\ X*4?
M#_P%\:?V3/&%IH/QH^#^KR7_ (1FO;LVT>H0N\4K0"< ^3.DUO#+"[?(&#JQ
M42;T^9/@M^P__P ')G[?'[9OPN^)O_!2OXE'X+>!/A;*LEZOP[\:6UE=^(H_
M,BDGC":-=RYDN3#$DCRM&D<88QQY^1@#S[_@M'\(O GQW_X.K_V8/A5\3?#M
MKJ^@:GX3\-MJFE7T0D@O(H=5U><PRH>'C8QA64Y#*2""":M_\'*?PZ\$?#G_
M (+)_L/_ !"\">%M/T?5=0\4:5!>7>FV:0-*MGKUB;?=L SL\YPI/0$#H!7U
M)^W#_P $M_VO?CE_P<)_ ;_@H=\/?"FDW'PQ\ ^&],L_$>I7&NPQ7,4L-SJD
MD@2W8[Y %NH>0.<GT-)_P7'_ ."6W[7O[<_[>O[+/Q]_9Z\)Z3?^&_A5XCBO
M/&-Q?Z[#:R01+JEC<DQQR$-*?+@D.%[@#O0!\[_\%,76/_@[[_9:9S@'P;HP
MY]3<:V!^M)_P<V7$3?\ !8C]A"U5QO3QC8.RYY ;Q#IX!_\ '3^5>L_\' 7_
M  23_P""@/Q\_;/^$?\ P4V_X)E1Z=JGQ%^'6G6NGSZ!=ZI:6<H:TO9KNUNH
MS>NEO,A-S-'+'(ZY4( '#,%\&^,/_!&G_@NY^V1^V7^SW^WW^V5J_@K5_$?A
M[QMIL_B;PAH>K6MK:>#M#L-1L[F*.+#%;F>5FOI)!&TN-D8\QMP5 #R[_@HS
M\;/BS9?\'8NK>*-%_8PO_P!H?4/AEH>EQ>#?A;!J MS*@\.PW@N%9K>X&(+F
M]GN@/+/S@-P1FO0O@[X(_P""C7QU_P"#@SX1?\%&++_@D#XX_9_T&41:-\2(
MS/\ ;;2\$L-W;3ZC<3+:VP7,$\"%2C?-:J^XD_+],_\ !9__ ()$?MV^)/V[
MO!7_  5T_P""2^N:4OQ;\-V$=CX@\+ZI>P6W]J"**2!)HWN2L$@>VE:VFBE>
M,&-8RC;LTG_!+G]A3_@MO\2_^"B-[_P49_X*O?%ZZ\"V=CI;6>E_"#P=XR!T
M_4I/(:"(7%M87,MK]EB#O, \DDCS;6; 7D _62BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLOQQXU\*_#7P5
MK'Q%\=ZY!IFAZ!I=QJ.LZE=-B*TM8(VEEF<]E5%9C["OC+0/^"\G[,EU_P $
MQ[O_ (*O>+/@]\1-(^&L?B=M(TZS;3K.74]147BV0NHHOM*Q^4;@R)\T@8>4
M_'3(!]PT5P?[+_[1'@;]K7]GCP;^TS\,K+4K;P_XY\/V^L:/!K%ND5U';S(&
M02I&[JKX/(#,/<UWE !117RS_P %)_\ @KO^S#_P2QU+X=Z7^T;X;\9:A)\3
M=2O++P\?"6E6UR(I+8VHD,_G7,.Q2;N+!7=G#9 P,@'U-117RU_P4Z_X*Z_L
MP_\ !)O0?!GB+]I;PWXRU&#QSJ5S8Z.O@_2K:Z:.2!8V<RB>YAVKB5<%2W0\
M"@#ZEHKY:_;=_P""NO[,/[ O[1_PH_9>^-7AOQE>>(OC%J45CX5N/#NE6T]I
M#))>0VBFY>6YC:-?,G0DHC_*"<9&"?'3_@KK^S#^SY_P4/\  /\ P3-\;^&_
M&4WQ!^(VFVM]H-_INE6TFE11SRW4:":9[E9$;=:2Y"Q-P5Y.3@ ^I:*^6HO^
M"NO[,,W_  4_D_X)+IX;\9?\+,BTW[<VHG2K;^Q_+_LT:CCS_M/F[O)(&/)^
M_P 9Q\U?4M !1110 4444 %%97CKQ%?>$/!.L>+-,\,WFM7.EZ5<7=OHVG;?
MM%^\<3.MO%O(7S'*A%W$#+#) KQS_@G!_P %"O@A_P %.OV7--_:G^ ]OJ-E
MIMWJ-UIVI:)K2QK>Z5>V[X>WG$;N@8HT4J[6.4F0\$D  ]XHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S._P"#LO\
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MJE!^T/!H]O\ #'1;&PD\$/X6:=]1-O/?2[Q=_:5$6[[:!CRFQY><G=Q]VT4
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MOV(KCRDSYF<C;@_=M% 'PE<?\$8M3G_X+E0?\%C_ /AH> 6T.BFP_P"%??\
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MBB@ HHHH **** /$/BI_R/\ J/\ UT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ
M"BBB@ HHHH **** "NH^#O\ R/\ :?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\
MZ+:@#VBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *FO_\ ("O?^O23_P!!-?BM7[4Z_P#\@*]_
MZ])/_037XK4 %%%8/Q+^)_@#X.>"[WXB?$_Q5::+HNGH&N[^\<A$R0J@  EF
M)( 50220 ": -ZBO-OV=/VM/@;^U'X F^(GPJ\7)):V(_P")O:7VV&YTTX)
MG3<0@(5B&R5(4X)P</\ A#^US^S7\>_$U]X-^#_QBT?7M4TZ,R7-E9RL'\L-
MM,B;E E0$@%DW*-PYY&0#T:BLGQSX[\&_#/PG?>._B!XEL]'T?38O,OM1OYA
M'%"N0!DGN20 !R20 "2!7._!+]I/X%_M':;>:M\$OB5I_B"+3Y5COEM"ZR6Y
M;.W?'(JNH;#8)&#M."<&@#N**** /N7_ ((]?\@+Q[_U]Z=_Z#<5]GU\8?\
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M_D?[3_KG+_Z+:N7KJ/@[_P C_:?]<Y?_ $6U 'M%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M-?\ ^0%>_P#7I)_Z":_%:OVIU_\ Y 5[_P!>DG_H)K\5J "OGG_@I;\&OB5\
M8?@-I,_PJ\*P>(=3\(^-=/\ $4GABY(V:S!;B57M2I(#@B0,4_B"$#+$ _0U
M>0_MG?#/]H#XB?#/3[W]F3XB2Z#XM\/:_;:K:6[W\D%KJ\<6[?97&P@-&^0=
MK?*Q3:V Q( /FW_@F5<?LF?M ?"?Q/\ "*W^'6H^'O&]_P"$(=-^($9GEMWU
M6P(,:S1%'V[=KA2P5'^<9R&R8?#7@+P1\+_^"G?PT\"VGPN3X;:!X2\-W^E^
M#M3>V._QS,+8QMOE2-5W*)6<F0EF89SF50)_V'?V2?VAO%GPXUCXU^-/%UMX
M,U[6?A@GA/P(^B%UN-/@68SB[N">0YF5/E!SLW#Y>*WOA?\ LT?MT_%_XX?#
M+Q-^V$WAJRT7X/K+)I]_I%^UQ>>(KLHB+/(2QQGRHW8L$)(;Y<O\@!VG_!7;
M3-%U#]C/4)M7U^"U>SU_3[FPT^XBD==8N%E^6QVQ@L3("Q'& 4!. "P\]_X)
M]:O#XO\ VXOB5XQ\2?"6+X4Z[)X-TZ"#X9?9FCD>V!C+7Y(BBC8;A&@VKD>9
M@],MV7Q\_9S_ &O?VF_@#K&@>/-1\-Z?XO\ #/Q07Q!\.?LQ_P!&N+*V7%O'
M<$;L2,)9LY&-P3.!DB[^RU\"?VH-?_:DUO\ ;!_:PT7P_H&JR>$8_#>B>'/#
MUV9T2 3+,\TC[F'+*=HW$_O#D+M&0#Z@HHHH ^Y?^"/7_("\>_\ 7WIW_H-Q
M7V?7QA_P1Z_Y 7CW_K[T[_T&XK[/H **** "BBB@ HHHH **** "BBB@ HHH
MH \0^*G_ "/^H_\ 71/_ $6M<]70_%3_ )'_ %'_ *Z)_P"BUKGJ .,_:-\,
M?##QQ^S_ .-_ WQK\16ND>#]=\)ZAIGB?5+V_CM8K6PN+=X9Y&FD(2("-V.]
MN!U-?D'_ ,$]OC!^T]_P2S_;1LOV9->\:>&_B_\ !7X@^/O#'@S3/B/I<H^T
M)->:+;2:&\!21E:#[$\"D#S$*1'9(,+N_9+XG_#?P=\8_AOK_P )?B)HZ:AH
M/B?1KG2M:L78@3VMQ$T4J9'(RC$9'(ZCFOSV_84_X(%:'^S+^UA>_%#XE_&K
MQCXO\'> ?$%IJ'P?T'6M4C: S"PCB%W=1IUEM2#!#@1C$2, !\E 'YI?MA?\
M% ?V7OVP_B5J/[8OQ"^)%Q_PGQ^.OA^V\&>$I=&O&'AGP!IC7#O)YHB\HSW$
M\B3R1([,&'R_>91_13X.\7_#[]I#X):9X[\&ZI+?>%?'?A>&^TN]6%X'N+"]
MMP\<@210\9:*0'#*&&<$ C%>)_MG?\$M_P!G']L#P-X;\%'PYI'@W_A'?'&G
M^(_MWAWPQ9K+>?91*/LDGR#,4GF?,/\ 9'%=CX=_9 M_"W[9DO[66C?%G7H-
M-/PYC\)VGPV@81Z+:(D\<JW<<2G:LH6,1C"C"DB@#X?_ &5OV7_@9^Q[_P '
M!<7P)_9W\!6WAWPWI?[*!:*T@9G>:5M9CWSS2.2\TK$#+L2> .  !^HM>&0?
ML->%(/\ @H?-_P %#AXZU ZS-\,AX,/AW[-']E$'VM;G[1O^_ORNW'3%>YT
M%=1\'?\ D?[3_KG+_P"BVKEZZCX._P#(_P!I_P!<Y?\ T6U 'M%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 5-?_Y 5[_UZ2?^@FOQ6K]J=?\ ^0%>_P#7I)_Z":_%:@ HHHH
M**** "BBB@ HHHH ^Y?^"/7_ " O'O\ U]Z=_P"@W%?9]?&'_!'K_D!>/?\
MK[T[_P!!N*^SZ "BBB@ HHHH **** "BBB@ HHHH **** /$/BI_R/\ J/\
MUT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ "BBB@ HHHH **** "NH^#O\ R/\
M:?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\ Z+:@#VBBBB@ HHHH **** "BBB@
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M'?\ X3=M_P#)M'_#$GQL_P"B5>.__";MO_DVOU.HH _+'_AB3XV?]$J\=_\
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M_P"&L/C9_P!&/^.__ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\ XJO=** /"_\
MAK#XV?\ 1C_CO_P*MO\ XJC_ (:P^-G_ $8_X[_\"K;_ .*KW2B@#Y3\5?$O
MXV>)M?N=<_X9#\=P?:&4^5MMFVX4#KYHST]*S_\ A+OC9_T:;X[_ ._5M_\
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M\1Z5+X7L8)VGU,*BVMTWG<+);XE,; 9!G8]0* .)_P""?WP9^,OB+XJ^-_\
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MOV)?V2?AQ^PI^ROX,_91^%4UQ<:/X/TK[.+^]QY^H7,DCS7-W+CCS)IY)96
MX!D(' %?'OC'_@@Y\6KO]J'XI_M2_"#_ (*R?&/X>ZM\6?$IU7Q#:>%[*SC7
MRT+K:6GF'YY(K:%A#&&Z*.F2:^R/V0O@+X__ &:_@;I_PF^)G[1_BGXKZO97
M5S+/XT\9;/M]TLLK.L;[/EVQ@A%]E% 'IU%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20220930_g3.jpg
<TEXT>
begin 644 cah-20220930_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>A_"K7/$UFRKEHCI?B+P_?R,OU@@F4^SF@#])O\ @ZZ_:TUFV_X)D?#/P5\
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M:\4Z[XF_X,G+*+7-0EN?[+\=)8V;3.6*0+XJ9D3)[+O( [  #@"@#]P/"O\
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M6_@&U\/^'-2\9)\,5M!K/]L7][%?/L-W^Z*B\N"K%N?+7 Q@"@#]4OAS\1O
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MXM([J?PAX)LX9Y].@D&8Y+N2>6*.#>OS*FYI"I5M@5E8@'W/17R'_P $M_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA7YE?\'L>EZ=KD_[*FBZO>?9[2\\0^)X+JXR!Y4;G1E9LGT!)_"OUC_X)=?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "NH^#O_(_VG_7.7_T6U<O74?!W_D?[3_KG+_Z+:@#VBBBB@ HHHH ****
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M!]2T444 ?<O_  1Z_P"0%X]_Z^]._P#0;BOL^OC#_@CU_P @+Q[_ -?>G?\
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M[KP /@%\"OBHGC'2O'&E7C'5?$$5O//-;6GD;B8R3=3(VY$"*_#R&-=_ZYT
M%=1\'?\ D?[3_KG+_P"BVKEZZCX._P#(_P!I_P!<Y?\ T6U 'M%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 5-?_Y 5[_UZ2?^@FOQ6K]J=?\ ^0%>_P#7I)_Z":_%:@ HHHH
M**** "BBB@ HHHH ^Y?^"/7_ " O'O\ U]Z=_P"@W%?9]?&'_!'K_D!>/?\
MK[T[_P!!N*^SZ "BBB@ HHHH **** "BBB@ HHHH **** /$/BI_R/\ J/\
MUT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ "BBB@ HHHH **** "NH^#O\ R/\
M:?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\ Z+:@#VBBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *F
MO_\ ("O?^O23_P!!-?BM7[4Z_P#\@*]_Z])/_037XK4 %%%% !1110 4444
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M-G_1*O'?_A-VW_R;7ZG44 ?EC_PQ)\;/^B5>._\ PF[;_P"3:/\ AB3XV?\
M1*O'?_A-VW_R;7ZG44 ?$?['EI\;/V3['7K+_AF'QWK_ /;DUN^[[';6OD^4
M)!C'GR;L^9[8QWS7M'_#6'QL_P"C'_'?_@5;?_%5[I10!X7_ ,-8?&S_ *,?
M\=_^!5M_\51_PUA\;/\ HQ_QW_X%6W_Q5>Z44 >%_P##6'QL_P"C'_'?_@5;
M?_%4?\-8?&S_ *,?\=_^!5M_\57NE% 'A?\ PUA\;/\ HQ_QW_X%6W_Q5'_#
M6'QL_P"C'_'?_@5;?_%5[I10!X7_ ,-8?&S_ *,?\=_^!5M_\51_PUA\;/\
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MYB_?PSQ^'HH[B,DC(S)"-P[E!GH*=_P12_Y1'_LY?]D?T/\ ])$KV:V^'WQ
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M)[7QKX.TGQE8VTL$.KZ9!>PPSC#QK+&KA6'8@-@^]:=)'&D2+%$@55 "JHP
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MI=U%H.Q&AAOUB8Q3WBRM.'GC5/-&V1AYC.: /(O^"2G_ "<W^VW_ -G.S?\
MICTRLO\ X.:(9;G_ ((E_&2W@N6A>2]\**DRC)0GQ5I ##/IUKZ0_9@_8^\-
M_LP_$3XP?$30?&-]JDWQ?^(K^+M2MKN!$73YFL[>U\B(KRR;;=6RW.6-0?\
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M\./V%/V5_!G[*/PJFN+C1_!^E?9Q?WN//U"YDD>:YNY<<>9-/)+*P' ,A X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20220930_g4.jpg
<TEXT>
begin 644 cah-20220930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R[]M?]JCP5^Q%^R=X_\ VL/B#;-<:7X&\-SZD]E'
M($:]G "P6JL00K33-%$"> 9 37\^'[*/_!+[_@IA_P '.4.O_MT_M>?MGS>!
M_ EWKES:>$+.;2)]3MMT38>'3]-%S!%!:Q$^5YID+O(C[M[!W/ZG?\'5<&O3
M_P#!$#XK'1A(84U/PZVI!/\ GA_;=EU]O,,1_"JG_!$_XB^*O O_  ;:^"OB
M1^S3X1@\1>+/#?PK\47OAGP\MC+<C4==MKO4Y$M6A@99)3+=IM,:,KOOPI!(
M- 'Q+_P3$^$W_!7?_@BQ_P %<]!_8!\6_P#"=?%_X%>+XX!=ZOHFBW]]HNFV
M=R9(K?55)$BZ5)#/'LN$+A#&&)+CR9!^S/Q)_;[_ &+/@Y\8)O@#\5_VF_!W
MAWQE;Z#/K=QX>UC68[>XBTZ&WEN9;I@Y 6)8()I"Q. L;'M7XL>%_P#@Y?\
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M !1110 4444 ,NKJVLK:2]O;A(884+RRRN%5% R6)/  '.:X+]FK]J;]G_\
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MQ)Z &OS%O_\ @[N_X)06/[3'_"A%G\<SZ NJ_P!GR?%&'1(#H:R;]OG@>?\
M:6M@?^6HASCD(5^:O9_@A_P5J_8@_P""I_[*'[1<_P /](\?6_A#X=^%=2T[
MQ]<7.GV4-S<V<UA>>:^GLEQ,DC&&"4HTFT;BF003@ ^J/V??VF_V>OVK_!$_
MQ)_9I^,WASQUH%MJ4FGW&L>&-4CN[>.Z1(W>$O&2 X26-BO4!U/>NYK\L_\
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M:EKO@OX#0>)O#WB_PYIXO]2\)>,+"&&YDLS(L9NH'@EECEB61XT;YE=3(N5
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M\_MJ?#CP#;+<W?BK3UT+P^T\PC2>ZETG4HHU9S@*,S19)X ;- &%_P $K?\
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M8(K=65 -FU@  : /V7HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ)\$_$3Q1\*;+4O&GA'Q/\.M:?5=*NDM=3O;UEM;AXHFF;[#/=V^ HPYVC<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !17S#\=_P#DK.L?]=8__125R- 'V917
MQG10!]F45\9T4 ?9E%?&=% 'V917QG7<?LZ?\E9T_P#ZY3_^BFH ^E**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH K:U<36FC7=W;OMDBMI'1L9P0I(/-?DC_P] _;G_P"BX_\
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MT_Y*SI__ %RG_P#135P]=Q^SI_R5G3_^N4__ **:@#Z4HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4_$?_ "+U_P#]>4O_ * :_!>OWH\1_P#(O7__ %Y2_P#H!K\%
MZ "BBB@ HHHH **** "BBB@#]!_^"(/_ "+WQ&_Z_=,_] N:^[:^$O\ @B#_
M ,B]\1O^OW3/_0+FONV@ HHHH **** "BBB@ HHHH **** "BBB@#YA^._\
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MHH \+_X:P^-G_1C_ ([_ / JV_\ BJ/^&L/C9_T8_P"._P#P*MO_ (JO=**
M/!-1_:E^-FH:?/8?\,1^.T\^%H]_VFV.W<",XW<]:^#/^'=7QL_Z)]X[_P#"
M4MO_ )/K];J* /R1_P"'=7QL_P"B?>.__"4MO_D^C_AW5\;/^B?>._\ PE+;
M_P"3Z_6ZB@#\D?\ AW5\;/\ HGWCO_PE+;_Y/H_X=U?&S_HGWCO_ ,)2V_\
MD^OUNHH _)'_ (=U?&S_ *)]X[_\)2V_^3Z/^'=7QL_Z)]X[_P#"4MO_ )/K
M];J* /R1_P"'=7QL_P"B?>.__"4MO_D^C_AW5\;/^B?>._\ PE+;_P"3Z_6Z
MB@#X4_8@\,?&S]C73_$=A_PS7X[\2?\ "036LF_[!;6?D>2)1C'VB3=GS/;&
M.^>/=_\ AK#XV?\ 1C_CO_P*MO\ XJO=** /"_\ AK#XV?\ 1C_CO_P*MO\
MXJC_ (:P^-G_ $8_X[_\"K;_ .*KW2B@#PO_ (:P^-G_ $8_X[_\"K;_ .*H
M_P"&L/C9_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9_P!&/^.__ JV_P#BJ/\
MAK#XV?\ 1C_CO_P*MO\ XJO=** /"_\ AK#XV?\ 1C_CO_P*MO\ XJC_ (:P
M^-G_ $8_X[_\"K;_ .*KW2B@#PO_ (:P^-G_ $8_X[_\"K;_ .*H_P"&L/C9
M_P!&/^.__ JV_P#BJ]THH \+_P"&L/C9_P!&/^.__ JV_P#BJ/\ AK#XV?\
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M5[I10!X7_P -8?&S_HQ_QW_X%6W_ ,51_P -8?&S_HQ_QW_X%6W_ ,57NE%
M'GWP9^,?CWXFZG>V/B_X ^(?!T=K LD-SK4T3+<,6P4783R!SS7H-%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?*7
M_!4']MSXT?LX1_#C]FK]C_P9H_B#XY_''Q%<:-\/;3Q&[C3=+M[6$3ZCK%X(
M_G>"UA*L47EBZ\,%*-\\?&[QO_P6C_X)1^"XOVR_VD/VQ_"_[2WPJT>\MV^+
M/@^T^%%GX;U/PYIDLJ1RWVES6;G[9Y#.&99P"8U)PO+H ?II17RC_P %(_\
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MI_P2U>"_\-'5H3?6[ZG9RV6GO);[O,1);F:-$<C!;H217K'[<7[#OP1_;_\
M@?)\$/C=%JEK';ZG!JWASQ)X=OS::KX=U6 DV^H6-P 3#/&2V&P00S*002*^
M"OB__P &R_B+]H?QM;_&G]H?_@IEXU\=>/O"MI OPY\1:Y\/=$VV4UO/%-;C
M54$1;6H5:)08IG4$,W(W'(!];?"3X>Z]\.O^".7A3P9X^TPQ^)/#?[+UKI.J
M/<Q?OX9X_#T4=Q&21D9DA&X=R@ST%._X(I?\HC_V<O\ LC^A_P#I(E>S6WP^
M^('CS]FT?"SXY^)],N/%&M>"CI7BW6/#5B\%F][-:>5<S6L,KNR1[V=D5V)Q
M@$U2_9#_ &=-%_9$_9>\ _LO^'/$=UK%AX!\*V>AV>J7L2QS74=O$(UD=5^5
M6(&2!Q0!\*?\%G?A!\3_ ([_ /!5+]AGX8?!W]H?6OA7XAU"R^*+67CCP_IT
M%U=V CTC3)'5(I_D;S$1HCGH)"1R!7U'^Q#^QQ^U+^S'XGUW6_V@?^"C7C7X
MW6FJ6$4&G:9XJ\.6-C'IDBN6::-K;EF8':0W&!73?&K]C#PQ\:OVQ?@C^V+J
MGC2_LM2^",'B>+2M&M[=&@U,:U906DIE8_,GEK &7;U+'->T4 ?E#_P4#_86
M^'?CO_@NW\$_!DGB&_LO!'[06EW'B#XS^![5%%CXKOO!T:W.EO= _?4M<Q)(
MN,,EL!C+%A^BG[7/[67P2_8A^ &O_M)?M >)CIOAW0+<%U@C\RYOKASMAM+:
M+(,T\KE41!U)R2JAF&#\5_V,/#'Q6_;4^$O[:FH>-+^TU3X2Z+XAT[3M$AMT
M:WOTU:&&*1Y'/S*8Q""NWKN.:\X_X*C_ /!+Z?\ X*76WPUA7]J;Q9\-'^&?
MBF3Q'I4OA>Q@G:?4PJ+:W3>=PLEOB4QL!D&=CU H XG_ ()_?!GXR^(OBKXW
M_P""QW_!0_3X/ _BSQ3X._LKP;X%U"Z"Q?#?P/!(;SR;N1L#[9,ZBYN6;'EE
M0OR?-&GEO_!;?X4W?C/]GK1_^"OOP;_:AO/&'ACX10Z)X[\-_"75[N*Z\"^)
MX()5=+MHX@LCW+1W'F13F210R(!&-Q:O>/V2O^"9?Q]^ 'Q.NO%_QQ_X*>_%
MKXU^'+[0+O3+WP+X_CMWTV<3A5,CJG+$*&4 \$.<UYII/_! JR30-,_9F\7_
M +>GQ,U[]F/0]=CU/2OV>[ZRL1;E8[G[3%IUSJJQ_;+K3TEP5MG/"H@W;E#4
M ?>_@OQ/:^-?!VD^,K&VE@AU?3(+V&&<8>-98U<*P[$!L'WK3I(XTB18HD"J
MH 55& !Z"EH **** "BBB@ HHHH **** "BBB@ KX/\ ^#C_ $^]7_@F!JWC
M@V4MUI'@_P"(?A+7O$]M#&7+Z9;ZU:F<E!RRJ&#D=@A/:OO"LCQ]X#\&_%/P
M/K'PT^(OAJTUG0/$&F3Z=K6DW\0D@O+6:,QRPR*>JLC,I'H: ,[5_C?\&O#\
MOAB'7_BOX<L7\:R"/P<MYK4$1UQS%YP2TW,/M#&+YPL>XE?FZ<U\4?\ !OY%
MI7COX&?M!_&/2K:&[\(?$7]L3QWXI\"3F,-!<:8UY;QP3Q9XV^?:RLI'1ER.
M17GWQ._X-G]!^*/A+2_V;M>_X*+?%>?X"Z'JJ7GA[X7:KIFF:A=Z$JL&2WT_
M6+F)[BTB0#8JJI(C^4ELDG[ _P"":W[(_P 3OV%?V:+7]E3QM\5=&\7Z!X/U
M&2S^'6HZ=X832[J+0=B-##?K$QBGO%E:<//&J>:-LC#S&<T >1?\$E/^3F_V
MV_\ LYV;_P!,>F5E_P#!S1#+<_\ !$OXR6\%RT+R7OA14F49*$^*M( 89].M
M?2'[,'['WAO]F'XB?&#XB:#XQOM4F^+_ ,17\7:E;7<"(NGS-9V]KY$17EDV
MVZMEN<L:@_X*$?L8>&/^"@_[(OBG]D;QCXTO_#VG>*9]+EN-7TRW26> V6IV
MM^H57^4[FM50YZ!R1R* /&?V?_\ @F_^W=\)OC+X>^(_Q*_X+,?$WQ_H6D7X
MGU/P;K'@S2[>UU:/:1Y,DD0WHN2#E>>*\K_X.8?A)=P_L>^'OVROA7XYO_!O
MQ0^%?C"SL?"GC#1U'VF"RUV>/1K^V))'R/'=+)ZAH%P1N)K](J\7_;^_8P\,
M?M^_LSZC^S1XP\:7_A^QU'6M)U%]3TVW265'L-0@O40*_&&: *?0,2.: .E_
M9R^ GP>_8I_9H\,? #X96\&C>#O 'AQ+.VFNY5C"PQ(6EN9W.%WNWF322'&6
M=V/4U\3_  \U;Q7_ ,%P/VLO"?Q^L=*NM+_9-^!GC/\ MGP#<WD+1S?%+Q;9
ML\<.J(C %=+LW+F(G'G2YSGYDA^Q?VX_V7S^VG^R;XX_95?XGZMX-@\<Z/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744718320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,134,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745972656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 49,603<span></span>
</td>
<td class="nump">$ 43,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="nump">47,989<span></span>
</td>
<td class="nump">42,326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">153<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before income taxes</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in shares)</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in shares)</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4957<span></span>
</td>
<td class="nump">$ 0.4908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887747443648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744891040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 3,492<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">11,039<span></span>
</td>
<td class="nump">10,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">15,891<span></span>
</td>
<td class="nump">15,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">32,696<span></span>
</td>
<td class="nump">32,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,339<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">7,367<span></span>
</td>
<td class="nump">7,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,387<span></span>
</td>
<td class="nump">43,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">28,362<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,619<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,559<span></span>
</td>
<td class="nump">30,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">4,689<span></span>
</td>
<td class="nump">4,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 8,919<span></span>
</td>
<td class="nump">$ 9,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">$ 2,576<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">$ (3,880)<span></span>
</td>
<td class="num">$ (3,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (176)<span></span>
</td>
<td class="num">$ (114)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' deficit</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="num">(706)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; deficit</a></td>
<td class="nump">$ 43,387<span></span>
</td>
<td class="nump">$ 43,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887742312576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="num">$ (1,794)<span></span>
</td>
<td class="num">$ (2,806)<span></span>
</td>
<td class="num">$ (1,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Statement of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings/(Loss)</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2021</a></td>
<td class="num">$ (1,396)<span></span>
</td>
<td class="num">$ (2,666)<span></span>
</td>
<td class="num">(1,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2022</a></td>
<td class="nump">$ 706<span></span>
</td>
<td class="num">$ (2,813)<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2022</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2022</a></td>
<td class="num">$ (3,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Statement of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings/(Loss)</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2022</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2022</a></td>
<td class="nump">$ 1,780<span></span>
</td>
<td class="num">$ (2,576)<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2022</a></td>
<td class="num">(65,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2022</a></td>
<td class="num">$ (3,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745144816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">153<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="num">(926)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="num">(70)<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net tax withholdings from share-based compensation</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(1,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CashReclassifiedFromAssetsHeldForSale', window );">Cash Reclassified to Assets Held for Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and equivalents</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">4,717<span></span>
</td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">$ 3,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 3,492<span></span>
</td>
<td class="nump">$ 2,463<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedFromAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Reclassified from Assets Held for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedFromAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750919040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744717408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibd18cf751e3b4588bcfe40175c3f40a1_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750006704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September&#160;30, 2021, restructuring also included costs related to the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887749924848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"><tr><td style="width:1.0%"/><td style="width:44.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,002</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,675</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September&#160;30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September&#160;30, 2022 after recognizing the impairment charge was $6.7&#160;billion, of which $1.8&#160;billion was goodwill.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,206</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">361</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,789</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,681</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,800</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,692</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $71 million and $78 million for the three months ended September&#160;30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $212 million, $258 million, $233 million, $206 million, and $174 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887747456080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $28.4 billion and $27.1 billion at September 30, 2022 and June 30, 2022, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887828962704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $20&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this Settlement Agreement, we will pay up to approximately $6.0&#160;billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160&#160;million to the State of Washington and its participating subdivisions and approximately $95&#160;million to the </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of 49 states will then be subject to the Settlement Agreement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in resolution discussions with the Attorney General for the State of Alabama.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we made our second annual payment of $372&#160;million under the Settlement Agreement. In total, we have $6.03&#160;billion accrued at September&#160;30, 2022, of which $608&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 454 lawsuits as of October, 2022. Of these, 151 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September&#160;30, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 3, 2022, we are named as a defendant in 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,215 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 7 lawsuits involving similar claims by approximately 8 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, we had a total of $527&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07&#160;billion, net of estimated insurance </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div>In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $66 million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750848752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12&#160;million for fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September&#160;30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September&#160;30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22&#160;million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September&#160;30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September&#160;30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $940 million and $943 million of unrecognized tax benefits at September 30, 2022 and June&#160;30, 2022, respectively. Both the September 30, 2022 and June&#160;30, 2022 balances include $858 </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and June&#160;30, 2022, we had $49 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $75 million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2016 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $77 million and $75 million at September&#160;30, 2022 and June&#160;30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887829070048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750986496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September&#160;30, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September&#160;30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $100 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $4 million for the three months ended September&#160;30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $22&#160;million and a $5&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4&#160;million and $6&#160;million during the three months ended September&#160;30, 2022 and 2021, respectively.</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $6&#160;million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,838</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887749877488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit) </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program is expected to conclude in the second quarter of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(160)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(176)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750930272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share Attributable to Cardinal Health, Inc.</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings Per Share Attributable to Cardinal Health, Inc. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">273</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both </span></div>the three months ended September 30, 2022 and 2021 were 4 million<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887749934576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,547</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,614&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,822&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,140</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">638</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,129</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended September 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,253</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,338</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,796</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,387</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750886896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended September&#160;30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.62&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59.43</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $119 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887751038192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div>In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744702416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887749956912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"><tr><td style="width:1.0%"/><td style="width:44.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,002</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,675</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Definite and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,206</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">361</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,789</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,681</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,800</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,692</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887749637152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750928272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,838</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887750960192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7&#160;million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(160)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(176)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887749934576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">273</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745141968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,841&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,129</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,547</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,614&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,822&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,140</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">638</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div>(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,253</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,338</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,796</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,387</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887828228688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.62&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59.43</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744819824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestitures, net of cash sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745151600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744792720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744692384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887747342464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 5,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">3,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">3,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887742019440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,789<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,108<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,681<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">4,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">1,692<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,049<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887747397040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</a></td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Asset, Expected Amortization, Year One</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TerminalGrowthRateFairValueInput', window );">Terminal Growth Rate, Fair Value Input</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net Assets</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TerminalGrowthRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminal Growth Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TerminalGrowthRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744871040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, Long-term and Short-term, Combined Amount</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Early Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Early Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887738697920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>lawsuit </div>
<div>numberOfUSTerritories </div>
<div>plaintiff </div>
<div>states</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>lawsuit </div>
<div>states</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IncomefromSettlementsofClassActionLawsuits', window );">Income from Settlements of Class Action Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyNumberOfEligibleStates', window );">Loss Contingency, Number of Eligible States | states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number | lawsuit</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number | lawsuit</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product Liability Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember', window );">Alameda County [Member] | Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="nump">5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember', window );">Other Jurisdictions [Member] | Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WV', window );">WEST VIRGINIA | Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_OK', window );">OKLAHOMA | Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">WASHINGTON | Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember', window );">Native American tribes [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">litigation settlement liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">litigation settlement liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingStates', window );">Settling States | states</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SettlingUSTerritories', window );">Settling U.S Territories | numberOfUSTerritories</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember', window );">Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember', window );">Private Parties [Member] | GEORGIA | Opioid Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember', window );">Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IncomefromSettlementsofClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from Settlements of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IncomefromSettlementsofClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyNumberOfEligibleStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Eligible States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyNumberOfEligibleStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SettlingUSTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settling U.S Territories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SettlingUSTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_NativeAmericanTribesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887738445200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">26.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_GoodwillImpairmentAxis=cah_GoodwillImpairmentMedicalUnitMember', window );">Medical Unit Goodwill Impairment [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification receivable</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GoodwillImpairmentAxis=cah_GoodwillImpairmentMedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GoodwillImpairmentAxis=cah_GoodwillImpairmentMedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887742589824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Narrative (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward Contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887741977296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) | Not Designated as Hedging Instrument | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745979280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 5,267<span></span>
</td>
<td class="nump">$ 5,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 4,838<span></span>
</td>
<td class="nump">$ 5,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887742280432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember', window );">$500 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A1BillionShareRepurchaseProgramMember', window );">$1 billion share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $500 million share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="nump">$ 51.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $1 billion share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A1BillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePriceAxis=cah_A1BillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887741569040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">$ (706)<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other Comprehensive Income (Loss), Tax</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss, before reclassifications</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss, before reclassifications</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss, before reclassifications</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (176)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887747557776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745037584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_Numberofsharesexcludedfromcalculationofdilutedshares', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Numberofsharesexcludedfromcalculationofdilutedshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares excluded from calculation of diluted shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Numberofsharesexcludedfromcalculationofdilutedshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887828156848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project Costs On Investment And Other Spending</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">$ 6,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744794464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 49,603<span></span>
</td>
<td class="nump">$ 43,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">49,606<span></span>
</td>
<td class="nump">43,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">45,828<span></span>
</td>
<td class="nump">39,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">45,547<span></span>
</td>
<td class="nump">39,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember', window );">Cardinal Health At Home Solutions [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745115136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (286)<span></span>
</td>
<td class="num">$ (114)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887738380288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 43,387<span></span>
</td>
<td class="nump">$ 43,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">27,253<span></span>
</td>
<td class="nump">26,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,338<span></span>
</td>
<td class="nump">11,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 4,796<span></span>
</td>
<td class="nump">$ 5,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745057776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Disaggregated Revenue Within Reportable Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 49,603<span></span>
</td>
<td class="nump">$ 43,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">49,606<span></span>
</td>
<td class="nump">43,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">45,828<span></span>
</td>
<td class="nump">39,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">45,547<span></span>
</td>
<td class="nump">39,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical | Medical distribution and products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887747450048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue by Geographical Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 49,603<span></span>
</td>
<td class="nump">$ 43,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">48,477<span></span>
</td>
<td class="nump">42,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">49,606<span></span>
</td>
<td class="nump">43,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuebyGeographicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue by Geographic [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuebyGeographicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745936512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>Reportable_Segments</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares | Reportable_Segments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">234.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887744854704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887742578064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 46.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">69.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">49.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">54.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 59.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139887745943312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">76.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">59.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">57.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 72.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>cah-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20220930"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cah-20220930.xsd" xlink:type="simple"/>
    <context id="i2b05f6c142134569a5186e72d5061146_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97b6bf5e281846449637b671f8c5ea5f_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9365f443f224be298ffcc176e64bb3d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id865979318b34ac9a0006dc78693a91a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i61aa9535a0c549598a0d82a3c9b83b9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iebbccb601ed947409b53296af5ef77fe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ff6a8fdb0634005af68bc1212ab0bbe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i612187032ec943d394d68353bc74417b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a42960e2e7c47b3868bbc551995df2d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i698aacd651704977bb16df51d8070a30_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i18abcc7f15c143aab18a99234cb10114_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6785c932a3874568bb05dfea04d9946b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib19650c5a913416ca6588da34a348f22_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib26655c3a88e4720ab7d8bc05312c1b8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icad5885e711d42da835169aa6f388325_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i06e44ef25f8d4bd2bcd0d9afdb11ce46_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3061556bb3664f40a526ed65a094ef2e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0a06e509abb14275bd46ec4afb985d35_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i758e3844f8bd47929282bc88703ea8f0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibf460939e6f142618d8200a4e95a4733_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc85debed74f4b3faea2295133b498fa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib15ca96c683e4ba6865784ead9adbc78_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8bcede8d084d432d9ea4736241a37ba4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie41d7fe9babb47ad971ea568ec44ee4c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i853ff6add89c4a1ea84c989f618420fb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i490000f10c0b4b0682cb24d52cb388ad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idc43915a36234990a428483dd2251e18_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie32a5bd181674aac970917c2db9cf482_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i50701f17cc6d42238115a15492c656da_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6aa1095ca2d145a488a40d99cf500cbd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73291183b5c94c569731d6000358a035_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70aa8ba2fa76462a98de9c2a2a3b3eab_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id8df42a7b9384d7ba6a2b613756fc333_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd6f5954a39f4eaab401f0922f87e2b2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7336a5c8dffa4fed905779c7906e0698_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c4c7a1de55d4507ad5cbd581472af6f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i06c8e71b77e84415aa0fb3cf24c26850_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9cad212f102146228e0cd765ec3011f8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ied4f963e1258409697ad8f442ba79dc3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4be56105efe44fd58a9ef7c7851443fb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i056167140f4147eca75967688b8394b6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i51a3dd894882408790e569ecd7a0a0f6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9a322d3b1b71496d949f588cbc3e8c44_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7138c986208346caab693c394d3fc544_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6fb2d9aad92e4c598b91935a092f4aea_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6fbcc66fb7f548ae9276527dd4263120_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1bdbb7b08c494b6ea6bebbc41a301248_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5754d58acfdb4215a3917a18dd269e93_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2ec2ce0031f949829f8cff3fae7f33b8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i64c74d76f8974daeb64325a492d7cb0c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5001b8fecb8f4da89f5a3a06c330244d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5a2b097d758b45aa95ea584e855a2631_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if2e87b70e3bf41fa8effe5bef9f99d54_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8b18dbf515f4767a1d1688c18c6b7a1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i22fae5e1f8744690836ce67e2c6432cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ief8b6ae0c11d4c79addc75f5d463aad6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i27b66144fc554632a9c5a93bee338b1d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3bd0b96897d1470fb2329660c7d50e7d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2297365bf0cb4e03a98dbbb10ac1c343_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i64b8e59737824266b20b0bb162a7f6fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6f6b2710bce442e9c8a8211ae3d15b6_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a25416abfca4ca5a2c8a79563abdbf6_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ideb927b476ad43678e84b8626a1dccd8_I20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="id0676373b4634242b6227fe4aaa7279e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i78dcc5cdb1a34a3688e6c1ce718bb3d4_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="iad2e4f4027b649c8b68073da27cc75ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i39a78fb2810d4d5cb0d5270aa7494bd0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d26088d8851461e886dd938e1e01e06_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i05c064b32b7241f5861b32d00930b148_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:NativeAmericanTribesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i5a2674d9c4424aee92b083b06676b132_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if8c2e07a1122434fb48591c34c3b03e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if117a27e06074dd49394d4673002a60d_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i32f85e3cb646437cb5f56dcc696128e6_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i12caa08ddee14ac2a252cf36f1b23ea5_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i4a355aa72fe54940911ec0fc9eec1d71_I20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="i6de11675da4a46d1a1dd19d98e7d028f_D20221103-20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="i1eadbc725e9d4be693afcd2438eb9445_I20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="i91f3e424f456485faa3f18f61dbada6c_D20221103-20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="ibad30b04476e408b9b94106e5ec72041_D20210731-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ie89257f0029142808d8e517babd2e9ce_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5efb723c71ca43158a719af61d57c9fe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib3b381f73ed74b7c87202faa366ced15_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63acc3676d524a4cb1fe19ba5584d6a9_D20220701-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i9d5cab62da2c411d9384568354fcbb20_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7f63075f2d6941f88610dca064275c22_D20221001-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:GoodwillImpairmentMedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i2647f5df574a4790a972ae81d73483a7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i838c37506e6a4118b13af6b0e18e635e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if4a6ab707b7b48c3900375ae0fdf5bd0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4747655b789c466c9d320622352b10eb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i112c682ae8824132a82e463e2829fbde_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i409e7ac6eece4672b979373d4beb255a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8a28758bc65a4cb4af33498d26db24ac_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i49aba128f32b4dab86cb347514750422_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4d65960fd135483bb22e0f9214f5cc93_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iee5307df37214cb5856b80573d7cd236_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i387ff4bbab2845dabaeeca1215e98d4f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie5379f66427748ca8c43f633f07433f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id2ffadf1769b4b338c57b958d74314c6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id2ccafc16fb54194a171620229fdbe11_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i59e85c09481f4f09a7ccf2fe64711f33_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65825c4d85ac4f8d93a497d87be20ab0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8fdecbea244440c2ba6bf56b66b21f7d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib2c072105cd740018a1c9aeea1081994_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i03dbc97b506740c1ab99758d71d8644a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75e88d2441654c87afe085d4a0348bb9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9127505057a74be592b08798b91f4df4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic09ef0c511ae4237af07d4b591d9c579_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b51adfb3de843dc981ee6f67bb7126c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iad9bf46791af4b50b139fbccfcf7acb6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i804fad5b06b0439c81e19646ddce2790_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A1BillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib8fa2946d75244f5af4e048c4b6f80f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0ad50074ece84ece82376c3fa9fb7b8b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd1f58cfa53748e180e4ce356b89feb0_D20211004-20211004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePriceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="i6c5566f30ebc41c9a4c5aa210ea0d0a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7e0da40648754f7e8ebf900b3a6b20a7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7bca371c3eb7478a9a9c71b3235bd9da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i892094d14d894e958f90124c7fa6d265_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if7de5f4005fe40ad951ccbaf90fed316_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie2b8399010484b6095659918a1811fbe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5d06169bd4ac4fe1b8c2bc2c47eb44f6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i518c9f6c90a440a9b3e29e04e98d1fe2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i81ce1edc4ddb41989ad743f2322d6d0e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i49d63915083840a09569f5e9570a4c80_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i855d5c9c3f5e4418855a7294a17541ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if3044261be5249d9833e8961865fb32f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fbb9c3f242b449a93c375031cccfb0a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec9ffb10cd2a4f23ae074893f97a8ac8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i50162f37f7b7432489740885c70a6401_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if8e9a4dc61694a2cbe868bd038d8e96a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2f856b81cd0b4febbaa82e7ba3b7de3e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb884cfea93c4a6b9776a6eb15f99801_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if98a9f7800324334933b05a45c7c1081_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6964ebf21c6641d8a7d3c962e30215fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifdd40bf9e64d4e28aba32338f5e1c3f3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iab13212bf3f64da69caee3d568418629_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id23cd6cc579e4db1ac1517955232ea9e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i871bd2199ae14c3d8b2d85b00fa634dd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if915e60e430a448e95ac1d3210262b21_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae83bd29fad7455f842d7e87a827912f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad9bf49c924d4d84898b126cd4f6a3ff_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i015c85ec14f2406f8e7dffe472b4851c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65ff688f93904d2baa8f773161063474_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74b65aec35854386926330a8514839c9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i195c3e4a70d140e6a8c0d6fbd576c739_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if5d7926d786e4e449517abc30d8e145f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if2160ad80e344e7a85fc8a96deb9476c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie81002aafca94fc2b38566fff63f36b6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i28f690daefd04e45ba22e43204d3f8ce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a03688720b448f29df8a3a0536629e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8ead376383b64ae98d667697c55cf194_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8c8d1a31b74a43529c08389b432be66a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99c33230a00c486e83ac2a0e6d04febe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i24b600072fc640a2accf8530d5da12dc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i43ad627a1ffc43319b21b5b9c5ec5da3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22ab637b9b2d4e64a547c5de3c7224a8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic4a1eacea71a4285aadeba26a17758a0_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c7555e89f9a44c0be6b8791b103af9c_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iea97411b6d7641378c9eb6b952443d0d_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f28dc925abc41bb8cf3ce6828882c78_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1b0209d5fc294341b06b2c8dbf923e09_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f1fe6789c734a7cb6a29d3d8764b93b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2ada8d3d750f4d05bd88fb3b24af4514_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia8eb22db75ac48e3948c5833cc36811c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i217061d4807f455b88c7f795a4fa433d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="states">
        <measure>cah:states</measure>
    </unit>
    <unit id="numberofusterritories">
        <measure>cah:numberOfUSTerritories</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <unit id="reportable_segments">
        <measure>cah:Reportable_Segments</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF8yLTEtMS0xLTIwMDU3MQ_707cb9e9-547c-460b-9686-655d718a3435">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF8zLTEtMS0xLTIwMDU3MQ_958eec4f-0854-4d07-a3d4-2ffce74762da">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF80LTEtMS0xLTIwMDU3MQ_2f62f0e9-6943-43be-9014-e8e8e74e8805">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF81LTEtMS0xLTIwMDU3MQ_83bfba54-ff85-4347-89e2-56b6948fc4f8">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV80L2ZyYWc6NWMwZTljODY2MDY4NDNmMTlhNTJmMDJkMTdkMmIzMDMvdGFibGU6YjVjZTEyMjFkNWFiNGRlZTliNThiMDFmY2Q1YWFlZDAvdGFibGVyYW5nZTpiNWNlMTIyMWQ1YWI0ZGVlOWI1OGIwMWZjZDVhYWVkMF82LTEtMS0xLTIwMDU3MQ_ab423f01-4e9c-4a9a-839a-e5397140d43d">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN184NA_2bd5824e-ce5a-4493-bb1a-91ea8ee2bcd7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6M2Q2MWI3NWNlMjFkNDI1ODk4Njc2NzhmNDY1ZjI4ZjQvdGFibGVyYW5nZTozZDYxYjc1Y2UyMWQ0MjU4OTg2NzY3OGY0NjVmMjhmNF8wLTAtMS0xLTIwMDU3MQ_c14b92e0-58ea-4672-abfa-2e8b115f481c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xMjE_0f4b3615-524b-4869-b250-14439af82a7e">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NDAzOGU0OTg3NmViNGEzMjljYTVkNDI3YTE3NzExYmEvdGFibGVyYW5nZTo0MDM4ZTQ5ODc2ZWI0YTMyOWNhNWQ0MjdhMTc3MTFiYV8wLTAtMS0xLTIwMDU3MQ_592ba409-54a0-4856-90d0-687502c296fb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA4_ab80a66d-59fc-4b7a-8a87-a51828473600">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTAx_a980a02d-7eb4-4315-bd66-8d6b47d53ef8">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8wLTAtMS0xLTIwMDU3MQ_dbe1053f-0163-4994-8958-d2dd87e43014">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8wLTYtMS0xLTIwMDU3MQ_e13cfe86-2969-4b0b-a54a-2a29f54c3547">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTAtMS0xLTIwMDU3MQ_0fca447a-5ae7-4228-83f6-1a0c763f0e3f">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTItMS0xLTIwMDU3MQ_fd6abb01-c2a3-4725-82f7-15784843696d">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTQtMS0xLTIwMDU3MQ_3f687937-d30f-490b-a253-ae6b5bd8b2fc">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6YTY0MmU4ZWM2NmIwNDdlNmI0MmY1ZWExYTc3OTllZDYvdGFibGVyYW5nZTphNjQyZThlYzY2YjA0N2U2YjQyZjVlYTFhNzc5OWVkNl8zLTYtMS0xLTIwMDU3MQ_10cd1eda-2383-4cf0-9690-516ea9db4af5">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTAy_f6cd2820-c33e-4bd3-a184-c81587a47138">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTAz_5405e9ef-1d8c-428a-800f-2860f9326c9e">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6Mzk3Yzk5MjJkNzJmNGU1Yjg1ZjIxZDkzNTE4NjU0NmQvdGFibGVyYW5nZTozOTdjOTkyMmQ3MmY0ZTViODVmMjFkOTM1MTg2NTQ2ZF8yLTAtMS0xLTIwMDU3MQ_46672833-0e0c-43c9-8948-c5d56ead7792">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6Mzk3Yzk5MjJkNzJmNGU1Yjg1ZjIxZDkzNTE4NjU0NmQvdGFibGVyYW5nZTozOTdjOTkyMmQ3MmY0ZTViODVmMjFkOTM1MTg2NTQ2ZF8yLTEtMS0xLTIwMDU3MQ_f3359834-7a02-44d1-a0cd-0a1b99832da8">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6Mzk3Yzk5MjJkNzJmNGU1Yjg1ZjIxZDkzNTE4NjU0NmQvdGFibGVyYW5nZTozOTdjOTkyMmQ3MmY0ZTViODVmMjFkOTM1MTg2NTQ2ZF8yLTItMS0xLTIwMDU3MQ_62894aa7-319d-4c65-a775-ece94b3256bd">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA0_a1cc46b7-d565-42de-adfa-7f28b6fdfeb4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA1_5c2bee06-f18b-4013-9a00-f3c95ac2d58f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NWU4ZGVhMjgwYTc1NDAxODg3MmY2YWJkZWQ0ZGRiNjQvdGFibGVyYW5nZTo1ZThkZWEyODBhNzU0MDE4ODcyZjZhYmRlZDRkZGI2NF8wLTAtMS0xLTIwMDU3MQ_1cd5ba99-a21c-462e-b14a-e8a4247f1067">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NWU4ZGVhMjgwYTc1NDAxODg3MmY2YWJkZWQ0ZGRiNjQvdGFibGVyYW5nZTo1ZThkZWEyODBhNzU0MDE4ODcyZjZhYmRlZDRkZGI2NF8xLTQtMS0xLTIwMDU3MQ_63b96c89-889f-4492-aaa3-d0bcd7dcdad6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGFibGU6NWU4ZGVhMjgwYTc1NDAxODg3MmY2YWJkZWQ0ZGRiNjQvdGFibGVyYW5nZTo1ZThkZWEyODBhNzU0MDE4ODcyZjZhYmRlZDRkZGI2NF8yLTQtMS0xLTIwMDU3MQ_5855cab2-ef18-42cc-b66c-82c687a979d6">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xOTA2_42cf8aa6-d5c8-4ed0-b8de-50198ed8c394">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i97b6bf5e281846449637b671f8c5ea5f_I20221031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xL2ZyYWc6MjYzMWJmMmJjOTkwNDhiMGIyMDcwMWEyODcwOWI4MDcvdGV4dHJlZ2lvbjoyNjMxYmYyYmM5OTA0OGIwYjIwNzAxYTI4NzA5YjgwN18xODk5_60864d3f-af1d-408c-9b04-612185d9edfb"
      unitRef="shares">262134053</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMi0xLTEtMS0yMDA1NzE_e5ed5148-09bd-4c32-b5ea-49aa34f603b0"
      unitRef="usd">49603000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMi0zLTEtMS0yMDA1NzE_d7f3cf6c-68f8-44ba-9567-6f02c4e37d38"
      unitRef="usd">43968000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMy0xLTEtMS0yMDA1NzE_2cb3b534-be03-4b79-93b4-cedc6ce688fa"
      unitRef="usd">47989000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMy0zLTEtMS0yMDA1NzE_3b7a2d96-41c3-4a1d-913c-27cdadf291be"
      unitRef="usd">42326000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNC0xLTEtMS0yMDA1NzE_5579cef1-0d32-4871-a93d-c4dadfdd0101"
      unitRef="usd">1614000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNC0zLTEtMS0yMDA1NzE_a5c29626-6bf1-4032-a7b1-ef27019419df"
      unitRef="usd">1642000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNy0xLTEtMS0yMDA1NzE_11a56a55-6909-4a08-97f2-929c6f6a949e"
      unitRef="usd">1197000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfNy0zLTEtMS0yMDA1NzE_a4ec1650-d7ac-4e95-af7a-67f8a343091d"
      unitRef="usd">1114000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOC0xLTEtMS0yMDA1NzE_61f8e507-4ed2-4295-959c-bd9e6e8996a3"
      unitRef="usd">29000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOC0zLTEtMS0yMDA1NzE_4f44f422-61e5-4e7d-b9e5-a4b2af985028"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOS0xLTEtMS0yMDA1NzE_c5994da5-7090-462d-8322-70e048b0d5f1"
      unitRef="usd">71000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfOS0zLTEtMS0yMDA1NzE_4435b5d2-2671-44b3-98dd-bf54a5cde3f9"
      unitRef="usd">79000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTAtMS0xLTEtMjAwNTcx_ca548b5b-dc14-421b-af82-e73342587e03"
      unitRef="usd">-153000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTAtMy0xLTEtMjAwNTcx_f5f64fd5-781e-434c-99ac-2381e13ea848"
      unitRef="usd">2000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTEtMS0xLTEtMjAwNTcx_5c6b8e55-67a4-4773-9585-9c2af807ed8b"
      unitRef="usd">-27000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTEtMy0xLTEtMjAwNTcx_0337939b-9a4a-4025-93fa-4669adfe937b"
      unitRef="usd">-18000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTItMS0xLTEtMjAwNTcx_07d40fae-b28b-44d8-87e1-9ac389a9d386"
      unitRef="usd">137000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTItMy0xLTEtMjAwNTcx_83b03f9f-eb3b-45ea-8a12-140814aa1ac1"
      unitRef="usd">415000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTQtMS0xLTEtMjAwNTcx_553a2fc1-0da7-4e26-9872-d85210a35a3e"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTQtMy0xLTEtMjAwNTcx_3278ed90-c59b-404f-b113-cb5ca7589720"
      unitRef="usd">4000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTUtMS0xLTEtMjAwNTcx_c6d1d272-4b32-4ffb-aeef-3ad4b945b7a1"
      unitRef="usd">25000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTUtMy0xLTEtMjAwNTcx_993fa472-09bf-40c9-a523-204801bfcc4e"
      unitRef="usd">40000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTYtMS0xLTEtMjAwNTcx_b69fe7c8-3bbb-47c0-a6b5-536a36334247"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTYtMy0xLTEtMjAwNTcx_2ecce1c7-e87e-49b9-99d8-2505a0dd9f4b"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTctMS0xLTEtMjAwNTcx_1f75b542-3d10-49ad-a05e-19abe64641ec"
      unitRef="usd">110000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTctMy0xLTEtMjAwNTcx_dcc89a07-06b4-4a88-b91f-2f0ee9836312"
      unitRef="usd">369000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTktMS0xLTEtMjAwNTcx_fce2d702-9fc9-4f23-8033-20dc551bdd6d"
      unitRef="usd">-1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMTktMy0xLTEtMjAwNTcx_8da92d68-802c-4a28-a9c1-abb1d857a77d"
      unitRef="usd">97000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjAtMS0xLTEtMjAwNTcx_c553b429-dd4f-4f1c-8cc8-2e0641d78fb8"
      unitRef="usd">111000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjAtMy0xLTEtMjAwNTcx_cc1bcc6c-de9f-41d7-aaa1-1ef092b568c3"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjUtMS0xLTEtMjAwNTcx_571ce7b9-150a-4055-9030-297b7120a3fb"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjUtMy0xLTEtMjAwNTcx_e25be45a-c935-4f3c-b7f2-85ece05cd138"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjYtMS0xLTEtMjAwNTcx_f519ad54-badb-408a-abb4-11394f8ce628"
      unitRef="usd">110000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjYtMy0xLTEtMjAwNTcx_5363e2ab-e8ac-4087-9d9b-d2f112beae1e"
      unitRef="usd">271000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjktMS0xLTEtMjAwNTcx_0a06cfe8-4570-42db-bace-80825d5a2a18"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMjktMy0xLTEtMjAwNTcx_237d3e02-ceec-4d4d-88b7-9b45e8508d68"
      unitRef="usdPerShare">0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzAtMS0xLTEtMjAwNTcx_a2289947-bdaa-487b-8613-981fe659fc49"
      unitRef="usdPerShare">0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzAtMy0xLTEtMjAwNTcx_f238dafa-79b2-4286-8063-e21371b1836a"
      unitRef="usdPerShare">0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzMtMS0xLTEtMjAwNTcx_4e31e27f-d1da-48a2-846e-ed230b4a4f97"
      unitRef="shares">271000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzMtMy0xLTEtMjAwNTcx_7b4aa20a-758e-4611-a5fe-27bb66243b14"
      unitRef="shares">287000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzQtMS0xLTEtMjAwNTcx_41983acf-1981-4453-b77b-883937be6dbd"
      unitRef="shares">273000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzQtMy0xLTEtMjAwNTcx_dfe423b3-8f4f-4ee7-96f6-fa8c1b92d028"
      unitRef="shares">289000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzYtMS0xLTEtMjAwNTcx_e37d7db6-cb91-48df-809d-c3c067e7af62"
      unitRef="usdPerShare">0.4957</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV81OC9mcmFnOjQ5OGE3Y2UxMWYyODQ1MjU5ZmMwN2E1YTkxYmM1OWUwL3RhYmxlOjE5OTYwNmUyMDI2NDQxMGM4NDc0NzU5ZmQ4YTA5MWU4L3RhYmxlcmFuZ2U6MTk5NjA2ZTIwMjY0NDEwYzg0NzQ3NTlmZDhhMDkxZThfMzYtMy0xLTEtMjAwNTcx_5a47f662-9d72-4bd2-9f05-75ebf16b13ba"
      unitRef="usdPerShare">0.4908</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMi0xLTEtMS0yMDA1NzE_c553b429-dd4f-4f1c-8cc8-2e0641d78fb8"
      unitRef="usd">111000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMi0zLTEtMS0yMDA1NzE_cc1bcc6c-de9f-41d7-aaa1-1ef092b568c3"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNS0xLTEtMS0yMDA1NzE_fe47c038-0d36-4dd8-9dc7-b4bddba31d1a"
      unitRef="usd">-58000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNS0zLTEtMS0yMDA1NzE_3832e17b-c4eb-4b8e-87c4-5c431d151aed"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNi0xLTEtMS0yMDA1NzE_4e40a5e9-10af-4af4-a4d6-f0e2b4b61abf"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNi0zLTEtMS0yMDA1NzE_f9dc2dca-b347-4e3f-9d3b-ab26171698e0"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNy0xLTEtMS0yMDA1NzE_543d22c4-8dc2-4632-8616-b161c93ba610"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfNy0zLTEtMS0yMDA1NzE_b44df2e1-694d-45ce-9b44-c5a05c9436bf"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfOS0xLTEtMS0yMDA1NzE_7d115b6f-811e-4356-a172-720af493c3c4"
      unitRef="usd">49000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfOS0zLTEtMS0yMDA1NzE_fd2e2cf7-bf43-4d68-bf68-527e0b268ca2"
      unitRef="usd">245000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTEtMS0xLTEtMjAwNTcx_855e6acf-ffaf-4989-9031-fe272441fcf3"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTEtMy0xLTEtMjAwNTcx_27a0d7f7-0a64-405d-8429-bbc3df3b1e73"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTMtMS0xLTEtMjAwNTcx_327209c7-dcd6-4407-ac04-8d7dcc186305"
      unitRef="usd">48000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82MS9mcmFnOmNjMDEzMzczZTg2YzQxMzQ4Mzc0ZTU4M2I1MTE3MTg2L3RhYmxlOjIyMDg5ZDhhYTQ0ZDQ0ZDk5NjM1N2U5OGUzZTMyZmRkL3RhYmxlcmFuZ2U6MjIwODlkOGFhNDRkNDRkOTk2MzU3ZTk4ZTNlMzJmZGRfMTMtMy0xLTEtMjAwNTcx_8088d26d-8cc1-4189-aec3-275da1374e9f"
      unitRef="usd">244000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMy0xLTEtMS0yMDA1NzE_f702e366-da09-4837-b1bf-8a74d19881b7"
      unitRef="usd">3492000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMy0zLTEtMS0yMDA1NzE_0c383993-3ba9-407c-b354-f9623e0471bf"
      unitRef="usd">4717000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNC0xLTEtMS0yMDA1NzE_73d26048-3458-4985-a29f-f2d15b4a0e3c"
      unitRef="usd">11039000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNC0zLTEtMS0yMDA1NzE_33d76212-e78e-41cd-b84c-a975c88bf099"
      unitRef="usd">10561000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNS0xLTEtMS0yMDA1NzE_797373de-87eb-4bd1-977b-8518a9be1155"
      unitRef="usd">15891000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNS0zLTEtMS0yMDA1NzE_bd6d4df4-eb4a-40b1-8f59-e83084eb9443"
      unitRef="usd">15636000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNi0xLTEtMS0yMDA1NzE_2e7b39c6-e88f-4fd2-a1c5-b943b0101f17"
      unitRef="usd">2274000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfNi0zLTEtMS0yMDA1NzE_d01b082c-3c39-406d-902a-31133625b70f"
      unitRef="usd">2021000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfOC0xLTEtMS0yMDA1NzE_1e7ee306-2eea-4978-af01-666acd998ea8"
      unitRef="usd">32696000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfOC0zLTEtMS0yMDA1NzE_e32761c5-692d-4042-9836-8df0dca22b68"
      unitRef="usd">32935000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTAtMS0xLTEtMjAwNTcx_cf357b03-7e29-4b4f-b329-d535ee4877b8"
      unitRef="usd">2339000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTAtMy0xLTEtMjAwNTcx_fb89b407-91e6-4fd2-a155-ebf941400534"
      unitRef="usd">2361000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTEtMS0xLTEtMjAwNTcx_e83b65a0-d477-4ff1-a7a5-ae7044d76299"
      unitRef="usd">7367000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTEtMy0xLTEtMjAwNTcx_7171d65d-40a2-4cbb-b03b-be77970417b8"
      unitRef="usd">7629000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTMtMS0xLTEtMjAwNTcx_fcd6453a-14de-4eb6-a105-3cccf02eb652"
      unitRef="usd">985000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTMtMy0xLTEtMjAwNTcx_3ff1e721-4b48-4ab1-ba49-b2361511171f"
      unitRef="usd">953000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTQtMS0xLTEtMjAwNTcx_8c5bbf96-e0ce-4170-8674-8c6ab146e2a2"
      unitRef="usd">43387000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTQtMy0xLTEtMjAwNTcx_df853ee8-697c-4cb9-95d1-91eb97a897a8"
      unitRef="usd">43878000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTgtMS0xLTEtMjAwNTcx_71452653-91d0-4169-bcf8-8f57c3c264f4"
      unitRef="usd">28362000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTgtMy0xLTEtMjAwNTcx_a2ad989d-83a2-4f10-a5ad-0ff05592a38b"
      unitRef="usd">27128000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTktMS0xLTEtMjAwNTcx_e9a7fed1-b9de-4515-99bf-dfa065a08448"
      unitRef="usd">578000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMTktMy0xLTEtMjAwNTcx_88585c05-a233-4099-8cfa-80c05b03f7bc"
      unitRef="usd">580000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjAtMS0xLTEtMjAwNTcx_25bff129-7328-47a8-8266-490215d2991e"
      unitRef="usd">2619000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjAtMy0xLTEtMjAwNTcx_352aaa94-3a57-429a-98c0-be9657394a2a"
      unitRef="usd">2842000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjItMS0xLTEtMjAwNTcx_9cff57b7-176f-4346-bab2-0882279243ff"
      unitRef="usd">31559000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjItMy0xLTEtMjAwNTcx_a4c3cb5b-3c11-450d-b89e-d5cf198fb248"
      unitRef="usd">30550000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjQtMS0xLTEtMjAwNTcx_f08f5cfa-c1a7-4afa-9f8d-9f7c67f9ae0d"
      unitRef="usd">4689000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjQtMy0xLTEtMjAwNTcx_02d13acf-7b6a-44a3-9ee9-a221d35647ad"
      unitRef="usd">4735000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjUtMS0xLTEtMjAwNTcx_2e149a1f-ab05-4bf3-b35c-a2b8f3ded21a"
      unitRef="usd">8919000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjUtMy0xLTEtMjAwNTcx_adcc40ab-9f50-453f-bdf4-4b422f9caca2"
      unitRef="usd">9299000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMTU_7752af60-73f8-4b36-b07c-07b3babe857a"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMTU_7a197c2d-256d-4312-9521-d1d6f9e7c70e"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMzM_39945974-6cf7-4944-9166-35c48b5256d5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZDc1ZTA4YTY3YWFmNDY3ZGI1OGFmZDdjZjUzMDNjMTJfMzM_6f0b1ccc-210f-4f7c-a26f-25e7c8023811"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMS0xLTEtMjAwNTcx_9bdb4a2a-2bd4-41aa-a10f-00642f082bb5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMjktMy0xLTEtMjAwNTcx_146cc186-5469-48bd-bf0d-40a8ee9a237f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMTU_015d676b-f495-4383-9b16-26499382c77d"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMTU_eae56cd4-75a2-4f2d-8cfd-4e7ae0a833b2"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMzM_6815b59d-b787-46cf-a39d-f9a102c4a4f0"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246ZGM2ZDEwYjYzMzM3NGEwMGIyNzJhMjNkNjEwY2U2ODZfMzM_d2bb9aa8-39a0-4a36-b7ec-2dd34d6f8dd8"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMS0xLTEtMjAwNTcx_3d5c4578-2a21-4985-a6ec-d5e4454e7b64"
      unitRef="usd">2576000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzEtMy0xLTEtMjAwNTcx_2a0dc79c-fa21-41f1-aeaf-29c204cb874d"
      unitRef="usd">2813000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzItMS0xLTEtMjAwNTcx_0ef0d726-c824-4c8a-8262-48e3678f56ae"
      unitRef="usd">-301000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzItMy0xLTEtMjAwNTcx_847f041a-34cf-4681-91cc-f46beb8d3678"
      unitRef="usd">-280000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246MzU4NzlkOTAyMGI4NGE0MGJkY2M4ZDhiNDk0MmUzZDVfNDA_a739e05c-f118-4ab9-8e5e-684d8ff4f069"
      unitRef="shares">65000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMC0xLTEtMjAwNTcxL3RleHRyZWdpb246MzU4NzlkOTAyMGI4NGE0MGJkY2M4ZDhiNDk0MmUzZDVfNTQ_56a5a3ed-7652-4136-9fb5-3499cbdd7a6a"
      unitRef="shares">54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMS0xLTEtMjAwNTcx_9152b0b9-f072-4538-b98b-2c66dd407c02"
      unitRef="usd">3880000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzMtMy0xLTEtMjAwNTcx_338d0060-87bd-4b34-8945-d30cbdeda099"
      unitRef="usd">3128000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzQtMS0xLTEtMjAwNTcx_0f83cc64-4050-4183-85f1-f7b099f0f1b4"
      unitRef="usd">-176000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzQtMy0xLTEtMjAwNTcx_2fef7b1f-43f1-4982-baad-b9b2ee4707f4"
      unitRef="usd">-114000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzUtMS0xLTEtMjAwNTcx_bfe899fb-cd1a-409f-9a5b-794aabf9d29c"
      unitRef="usd">-1781000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzUtMy0xLTEtMjAwNTcx_70ab98bf-5a7f-41e2-be08-8dd97f39504b"
      unitRef="usd">-709000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzYtMS0xLTEtMjAwNTcx_fff5ec79-6acb-433e-a1c0-6be0dee6fbc2"
      unitRef="usd">1000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzYtMy0xLTEtMjAwNTcx_080f7bc2-ccb1-4a1e-86c1-169f8c952f44"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzctMS0xLTEtMjAwNTcx_ea958139-5a83-40e5-abcb-705d76e2feeb"
      unitRef="usd">-1780000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzctMy0xLTEtMjAwNTcx_2bfa7df6-106c-4325-b6a1-9ce75c580c13"
      unitRef="usd">-706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzgtMS0xLTEtMjAwNTcx_7bdff1e5-ee27-48e8-833f-1b6e936dd447"
      unitRef="usd">43387000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82NC9mcmFnOmIwYTU4MjI4ZGZmMzQzNWViNGI2OGI5YzE0NjJmNTc2L3RhYmxlOmQ3N2E1YTczY2NkYzQyNjc5NWU5MzBiNjE5M2JiZDk0L3RhYmxlcmFuZ2U6ZDc3YTVhNzNjY2RjNDI2Nzk1ZTkzMGI2MTkzYmJkOTRfMzgtMy0xLTEtMjAwNTcx_fb88b644-e42f-4389-a7ef-6589421a0176"
      unitRef="usd">43878000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i61aa9535a0c549598a0d82a3c9b83b9c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xLTEtMS0yMDA1NzE_704958a2-ea7b-47f9-bc5f-259a21d719b9"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61aa9535a0c549598a0d82a3c9b83b9c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0zLTEtMS0yMDA1NzE_9b22876b-34f1-4658-8836-4b5d93e0e1e8"
      unitRef="usd">2813000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebbccb601ed947409b53296af5ef77fe_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy01LTEtMS0yMDA1NzE_253b3e2c-1d75-4c83-bdb7-259300a2bfad"
      unitRef="usd">-280000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i1ff6a8fdb0634005af68bc1212ab0bbe_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy03LTEtMS0yMDA1NzE_6aec8792-612e-478e-b731-6e0dca520684"
      unitRef="shares">54000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i1ff6a8fdb0634005af68bc1212ab0bbe_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy05LTEtMS0yMDA1NzE_ef6bf6ff-a17e-4fdf-ac4e-02faa344e9d5"
      unitRef="usd">3128000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i612187032ec943d394d68353bc74417b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xMS0xLTEtMjAwNTcx_b2357266-31de-4f36-aa9a-d068d8032156"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a42960e2e7c47b3868bbc551995df2d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xMy0xLTEtMjAwNTcx_a8dbd1d6-6ecf-4741-b754-ad5bff2dd302"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMy0xNS0xLTEtMjAwNTcx_78d89be1-678b-407d-90cd-29a091994143"
      unitRef="usd">-706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNC01LTEtMS0yMDA1NzE_f519ad54-badb-408a-abb4-11394f8ce628"
      unitRef="usd">110000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNC0xMy0xLTEtMjAwNTcx_2d3444a8-b8f1-4988-9d73-0602a12a4eeb"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNC0xNS0xLTEtMjAwNTcx_1a864a55-287e-4e70-8f13-19ea1b8f06fc"
      unitRef="usd">111000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i698aacd651704977bb16df51d8070a30_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNS0xMS0xLTEtMjAwNTcx_758ea2ed-9779-4fbd-8b27-44f4aedb7a9e"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNS0xNS0xLTEtMjAwNTcx_e2f35c61-651d-4e8b-acb9-54924e29c667"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNi0xMy0xLTEtMjI2Mjg4_b493e259-a8a6-43c2-828b-f12e5bb89477"
      unitRef="usd">-2000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNi0xNS0xLTEtMjI3MTU0_8880761f-5549-448a-a5f2-a67b506a1c7c"
      unitRef="usd">-2000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy0xLTEtMS0yMDA1NzE_d559330b-b3f7-42e1-bbf4-9537727c4da5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy0zLTEtMS0yMDA1NzE_93fb11ea-806c-46ef-bc92-5dbdc8a11e4d"
      unitRef="usd">37000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy03LTEtMS0yMDA1NzE_f15e7e96-1c5f-4c76-88c2-35b4ca7b1437"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy05LTEtMS0yMDA1NzE_709b64e0-1a77-414a-99d4-459b02f0f1ce"
      unitRef="usd">48000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfNy0xNS0xLTEtMjAwNTcx_24a16655-9d0d-42d6-8aaa-b233ede3e946"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic3edbf0290804657bdb487095266bcc9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC0zLTEtMS0yMDA1NzE_11df2373-5132-423d-85fb-5fb395ef394a"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC03LTEtMS0yMDA1NzE_e6fe17be-5e4a-49d2-806b-1c466310191a"
      unitRef="shares">12000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2128efb82f01431e88a12de88a026cd3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC05LTEtMS0yMDA1NzE_7e98c836-1409-439a-9c3f-22cfebdbfec1"
      unitRef="usd">800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOC0xNS0xLTEtMjAwNTcx_6e64d7c5-cfa1-474d-86cf-3ffaddf12b00"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Dividends
      contextRef="i18abcc7f15c143aab18a99234cb10114_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOS01LTEtMS0yMDA1NzE_ab67c76f-27b5-4430-b65d-a82bfb17300d"
      unitRef="usd">131000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfOS0xNS0xLTEtMjAwNTcx_4ee00804-1aec-47b6-9c67-1b40e1acc330"
      unitRef="usd">131000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="icd68d22125c04ad2b1c36b3c00aaa599_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTAtMTMtMS0xLTIwMDU3MQ_a94fe0eb-af3d-4bf6-b63b-b8dcd848c1b9"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTAtMTUtMS0xLTIwMDU3MQ_fd9833f5-05d2-481b-b0b3-72aa0820e770"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6785c932a3874568bb05dfea04d9946b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMS0xLTEtMjAwNTcx_635f2a01-b35e-40f6-bb81-7c5a8028f684"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6785c932a3874568bb05dfea04d9946b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMy0xLTEtMjAwNTcx_d2231d66-603e-41ec-86ad-73b6a4f6a584"
      unitRef="usd">2576000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib19650c5a913416ca6588da34a348f22_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItNS0xLTEtMjAwNTcx_fbdf7da9-9899-4713-8189-a294e91df0aa"
      unitRef="usd">-301000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ib26655c3a88e4720ab7d8bc05312c1b8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItNy0xLTEtMjAwNTcx_a9e460d9-c9a2-429f-a7f8-328a453b4a04"
      unitRef="shares">65000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ib26655c3a88e4720ab7d8bc05312c1b8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItOS0xLTEtMjAwNTcx_adb8dad9-cd6a-47c3-b933-d5e722a7911c"
      unitRef="usd">3880000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icad5885e711d42da835169aa6f388325_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMTEtMS0xLTIwMDU3MQ_cd51abad-79c1-43a3-8756-80945e9fd948"
      unitRef="usd">-176000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06e44ef25f8d4bd2bcd0d9afdb11ce46_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMTMtMS0xLTIwMDU3MQ_dc160f7e-7f81-4160-83de-8a9d082f533c"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOmMxMGU1M2I2NjQwNDRiNDE4ZGQxYTA4NDVkOTgxYjU1L3RhYmxlcmFuZ2U6YzEwZTUzYjY2NDA0NGI0MThkZDFhMDg0NWQ5ODFiNTVfMTItMTUtMS0xLTIwMDU3MQ_3f9874f7-3f6a-411f-8de0-6e359a5a8c60"
      unitRef="usd">-1780000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3061556bb3664f40a526ed65a094ef2e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xLTEtMS0yMDA1NzE_0941e7c6-52d8-4a1b-8408-cc59d44760b7"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3061556bb3664f40a526ed65a094ef2e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0zLTEtMS0yMDA1NzE_6ef3fdf7-7985-49fe-952c-0e646490e9c5"
      unitRef="usd">2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a06e509abb14275bd46ec4afb985d35_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS01LTEtMS0yMDA1NzE_22f08986-3317-49ef-a8c4-62086d50fa47"
      unitRef="usd">1205000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i758e3844f8bd47929282bc88703ea8f0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS03LTEtMS0yMDA1NzE_8b6f1a1d-f67a-49e1-b294-fb25e2a60968"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i758e3844f8bd47929282bc88703ea8f0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS05LTEtMS0yMDA1NzE_c55bbc24-507f-4676-a811-7743ec4e4b31"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf460939e6f142618d8200a4e95a4733_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xMS0xLTEtMjAwNTcx_1427a977-f713-4980-a18e-4d3ce2da9b03"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc85debed74f4b3faea2295133b498fa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xMy0xLTEtMjAwNTcx_ac1701c9-819d-4e0f-b72b-f6985f39829f"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib15ca96c683e4ba6865784ead9adbc78_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMS0xNS0xLTEtMjAwNTcx_b38dbcd0-b02a-4055-8595-dcd0043d2606"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMi01LTEtMS0yMDA1NzE_e8768bb5-0b45-4942-a374-d6dbe72500b6"
      unitRef="usd">271000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i8bcede8d084d432d9ea4736241a37ba4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMi0xMy0xLTEtMjAwNTcx_43062ea0-72ae-417e-ab3a-9167183ff4ca"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMi0xNS0xLTEtMjAwNTcx_e7039fd0-73e0-4c75-b2b1-71dbbf2720f4"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMy0xMS0xLTEtMjAwNTcx_bb44c101-3ca0-40f1-904e-1a00ddad98ea"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMy0xNS0xLTEtMjAwNTcx_56b7393d-2235-4ff9-8d8d-302ca8298bf0"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS0xLTEtMS0yMDA1NzE_9649e3dc-d781-4116-ba54-ad9d8a15d377"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS0zLTEtMS0yMDA1NzE_7c5e5039-b175-4df6-a660-9494d0464110"
      unitRef="usd">40000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS03LTEtMS0yMDA1NzE_1a9b6e3d-56d8-4f44-bc4c-a66fd65d4eb3"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS05LTEtMS0yMDA1NzE_2e7045ff-38c0-48b9-b5bc-bf16daca6762"
      unitRef="usd">39000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNS0xNS0xLTEtMjAwNTcx_f31cd9ac-45d9-4b95-9842-f30edc4665c1"
      unitRef="usd">-1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibbab770fd0de40dbb9465ee16a0d0e22_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi0zLTEtMS0yMDA1NzE_fc30785b-0d8d-46c6-8ed0-db0446314c7a"
      unitRef="usd">100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi03LTEtMS0yMDA1NzE_d2befdd6-002f-4ca5-994f-e0dbe42d12a3"
      unitRef="shares">8000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id38d9933d67949d1a476f7b8a786e8d1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi05LTEtMS0yMDA1NzE_557a2aa0-0405-4dab-8162-f44352a68b95"
      unitRef="usd">400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNi0xNS0xLTEtMjAwNTcx_c0234c45-2c5e-4729-b7f6-14759e1d1904"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Dividends
      contextRef="ie41d7fe9babb47ad971ea568ec44ee4c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNy01LTEtMS0yMDA1NzE_5def6ab1-04fe-49bc-8fb2-121f078e4cab"
      unitRef="usd">141000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfNy0xNS0xLTEtMjAwNTcx_1946f3ce-84d0-4717-a71e-ce1a0c778188"
      unitRef="usd">141000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i8bcede8d084d432d9ea4736241a37ba4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfOC0xMy0xLTEtMjAwNTcx_c36d1634-9270-4c98-bcbf-adf20e3bd4e7"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfOC0xNS0xLTEtMjAwNTcx_7dda17a1-445a-4327-a559-949e0381b6bc"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i853ff6add89c4a1ea84c989f618420fb_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMS0xLTEtMjAwNTcx_2fcf2c0e-0e65-4ced-b698-5599239edde3"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i853ff6add89c4a1ea84c989f618420fb_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMy0xLTEtMjAwNTcx_09d31ef5-5540-497b-bc10-11dab6fed2c8"
      unitRef="usd">2666000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i490000f10c0b4b0682cb24d52cb388ad_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtNS0xLTEtMjAwNTcx_6c575bbb-619b-4c07-865c-fa63478e182e"
      unitRef="usd">1335000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="idc43915a36234990a428483dd2251e18_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtNy0xLTEtMjAwNTcx_ac706440-841d-4c13-ba6e-ba3488d787d4"
      unitRef="shares">43000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="idc43915a36234990a428483dd2251e18_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtOS0xLTEtMjAwNTcx_2352266c-95fb-43ff-8907-53ff62308576"
      unitRef="usd">2547000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie32a5bd181674aac970917c2db9cf482_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMTEtMS0xLTIwMDU3MQ_fd2b5a18-2675-4b5d-aec8-7f2afba587c8"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50701f17cc6d42238115a15492c656da_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMTMtMS0xLTIwMDU3MQ_2d965868-89f7-4bfe-ad78-aca4fb2d0984"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6aa1095ca2d145a488a40d99cf500cbd_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV82Ny9mcmFnOmRjOWU1ZGJlMDEzMjRlOGM4YmM2NzcwYTZmZDk0YjgyL3RhYmxlOjE2NWQyNTE5NDQ5ODQ3NmViZmZiNzMwOGYzNzgwZTQ4L3RhYmxlcmFuZ2U6MTY1ZDI1MTk0NDk4NDc2ZWJmZmI3MzA4ZjM3ODBlNDhfMTAtMTUtMS0xLTIwMDU3MQ_9b87f45f-bf0c-4f6e-a9ce-4c768a347709"
      unitRef="usd">1396000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMy0xLTEtMS0yMDA1NzE_c553b429-dd4f-4f1c-8cc8-2e0641d78fb8"
      unitRef="usd">111000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMy0zLTEtMS0yMDA1NzE_cc1bcc6c-de9f-41d7-aaa1-1ef092b568c3"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNi0xLTEtMS0yMDA1NzE_a3c434de-b0b1-463d-bd8b-b398ddd4c865"
      unitRef="usd">171000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNi0zLTEtMS0yMDA1NzE_c87d0a11-91ee-4e42-a69f-fad2839c26c9"
      unitRef="usd">168000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOC0xLTEtMS0yMDA1NzE_2b2817e9-b858-4ff1-b138-78f7bc4732b8"
      unitRef="usd">-153000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOC0zLTEtMS0yMDA1NzE_dbbe28b4-be37-440f-a45a-1de662075267"
      unitRef="usd">2000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOS0xLTEtMS0yMDA1NzE_e8daed7e-17d7-489e-a690-6af7bf2a44dc"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfOS0zLTEtMS0yMDA1NzE_b070260b-1701-41f8-a2b1-5f60f11d37c7"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTAtMS0xLTEtMjAwNTcx_34fbafe2-4aa4-4e6f-902b-a840d3ad8eda"
      unitRef="usd">23000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTAtMy0xLTEtMjAwNTcx_258c1aa3-929d-4523-80fa-74dbb6a3c5e5"
      unitRef="usd">24000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTEtMS0xLTEtMjAwNTcx_ab6f23c5-e691-4d0a-9e30-b1fa5faefb16"
      unitRef="usd">29000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTEtMy0xLTEtMjAwNTcx_de557848-1fea-47e9-a982-9169fe1b81ac"
      unitRef="usd">12000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTQtMS0xLTEtMjAwNTcx_7ce9e84d-0839-47e1-845e-5644ae187303"
      unitRef="usd">508000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTQtMy0xLTEtMjAwNTcx_097af0be-4466-498c-be11-96abbe672004"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTUtMS0xLTEtMjAwNTcx_14dc5996-2cd3-4434-b0ad-9997cd9ad4b3"
      unitRef="usd">264000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTUtMy0xLTEtMjAwNTcx_8fa1a487-5d5e-4538-8d79-faf23ada01dc"
      unitRef="usd">129000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTYtMS0xLTEtMjAwNTcx_b7074a62-26f3-4590-b99a-de7f341fa75c"
      unitRef="usd">1234000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTYtMy0xLTEtMjAwNTcx_87bda266-46cb-4214-b4b9-a8dfcac4c736"
      unitRef="usd">-292000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTctMS0xLTEtMjAwNTcx_c9417ce7-b07a-4320-9f87-bcdbee91e9ec"
      unitRef="usd">926000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTctMy0xLTEtMjAwNTcx_7381aded-8c08-4101-b940-d65767cc3440"
      unitRef="usd">495000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTgtMS0xLTEtMjAwNTcx_f563a5a8-8385-41d2-b97c-e255188a1aa5"
      unitRef="usd">23000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMTgtMy0xLTEtMjAwNTcx_edffe64e-ecab-48f7-b989-a4afe319aac1"
      unitRef="usd">-646000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjItMS0xLTEtMjAwNTcx_7ba81cd9-b51a-4c5a-a803-89fa37195890"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjItMy0xLTEtMjAwNTcx_b0e779ff-488c-4873-accd-6ccc27910bd5"
      unitRef="usd">927000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjMtMS0xLTEtMjAwNTcx_393372cf-071a-40d8-94a5-cfa5fbb53901"
      unitRef="usd">70000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjMtMy0xLTEtMjAwNTcx_e2d5e218-4853-4e23-8abf-d5da0805e4e0"
      unitRef="usd">67000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMS0xLTEtMjI0OTY1_f644e67f-ecd0-4a65-bd93-bb48eadfad88"
      unitRef="usd">2000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMy0xLTEtMjI0OTcz_6a49afc0-44dd-4d4c-9a24-7dd096a26c37"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMS0xLTEtMjAwNTcx_402508f8-266a-40e9-b4be-c8ded5e6e2d9"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjQtMy0xLTEtMjAwNTcx_005da0c0-87a5-4a69-99c7-a152843b8593"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireInvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjUtMS0xLTEtMjAwNTcx_dd328fb2-3648-4610-883a-3ddbcfc7d5e6"
      unitRef="usd">1000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjUtMy0xLTEtMjAwNTcx_40c90970-b80d-4b09-94d6-e1ed86fc0c5e"
      unitRef="usd">4000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjctMS0xLTEtMjAwNTcx_3793b85f-f42e-4b8e-b785-b0c5aa72f6aa"
      unitRef="usd">-70000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMjctMy0xLTEtMjAwNTcx_e46e3e2c-561e-4f33-9c1a-f9ca44de518b"
      unitRef="usd">862000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzItMS0xLTEtMjAwNTcx_3b78568b-cef9-42d9-9192-f77a4db8bda9"
      unitRef="usd">7000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzItMy0xLTEtMjAwNTcx_0e18231e-518d-453d-a0b3-765638a0da80"
      unitRef="usd">587000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzQtMS0xLTEtMjAwNTcx_e65acef5-f9c7-49e7-8a24-3bf9db3f0533"
      unitRef="usd">-14000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzQtMy0xLTEtMjAwNTcx_3f6e3901-c2df-486b-9cca-346645ec967e"
      unitRef="usd">-28000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzUtMS0xLTEtMjAwNTcx_d85d8027-4d9c-4655-9c1b-027f94d5ee52"
      unitRef="usd">142000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzUtMy0xLTEtMjAwNTcx_f0b80edc-95b8-4052-888d-fa2778467318"
      unitRef="usd">149000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzYtMS0xLTEtMjAwNTcx_0db4a6f5-238a-4dc0-8e16-148de281e91d"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzYtMy0xLTEtMjAwNTcx_a9df66d9-0de2-475c-8527-85364d90e0b0"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzctMS0xLTEtMjAwNTcx_65f3313f-fded-4e72-8af7-734f859a1d57"
      unitRef="usd">-1163000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzctMy0xLTEtMjAwNTcx_f5d461b0-bfd7-44f6-b22e-fb2879077e8c"
      unitRef="usd">-1264000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzktMS0xLTEtMjAwNTcx_4d8882db-fadf-43e2-b98c-323eec03e700"
      unitRef="usd">-15000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfMzktMy0xLTEtMjAwNTcx_36ef16d7-6482-400f-8788-89692d4cc688"
      unitRef="usd">-5000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cah:CashReclassifiedFromAssetsHeldForSale
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDAtMS0xLTEtMjAwNTcx_55418aa6-0e95-4785-aacf-9b9f06758d16"
      unitRef="usd">0</cah:CashReclassifiedFromAssetsHeldForSale>
    <cah:CashReclassifiedFromAssetsHeldForSale
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDAtMy0xLTEtMjAwNTcx_89a6fcb9-88aa-4f93-baca-b0d2a873431f"
      unitRef="usd">109000000</cah:CashReclassifiedFromAssetsHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDItMS0xLTEtMjAwNTcx_6ed926e5-4217-4730-baae-7c4b7662cb2a"
      unitRef="usd">-1225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDItMy0xLTEtMjAwNTcx_d22125ef-a7fe-44b9-aff3-a6a24f8b2d82"
      unitRef="usd">-944000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDMtMS0xLTEtMjAwNTcx_8ee909ab-b12e-472e-a13d-b17f9597be93"
      unitRef="usd">4717000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib15ca96c683e4ba6865784ead9adbc78_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDMtMy0xLTEtMjAwNTcx_90bb179e-fbf1-41d3-b2c3-581e10e16a79"
      unitRef="usd">3407000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDQtMS0xLTEtMjAwNTcx_0d4e9caf-6bfd-4923-8996-3cd378fc4a0f"
      unitRef="usd">3492000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6aa1095ca2d145a488a40d99cf500cbd_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83MC9mcmFnOjhmOTc2YzAxNDNkZDQwNDBiZGQ3Zjg2ODJjODJiMGNkL3RhYmxlOmYxNWYzZjc1MjAwNTQ4ZTQ4YWFkMjlhZWE2MGQ2Yzc4L3RhYmxlcmFuZ2U6ZjE1ZjNmNzUyMDA1NDhlNDhhYWQyOWFlYTYwZDZjNzhfNDQtMy0xLTEtMjAwNTcx_7eabec17-6d9f-410b-9ec6-40b2b00299c6"
      unitRef="usd">2463000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83Ni9mcmFnOjVhNGM4OWJiOWU3OTQwNTc5YTNhMmJlYzg0ZTRlMTEwL3RleHRyZWdpb246NWE0Yzg5YmI5ZTc5NDA1NzlhM2EyYmVjODRlNGUxMTBfMzEzMA_0bd52747-4f5f-4e66-9374-1267a28949d7">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the three months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83Ni9mcmFnOjVhNGM4OWJiOWU3OTQwNTc5YTNhMmJlYzg0ZTRlMTEwL3RleHRyZWdpb246NWE0Yzg5YmI5ZTc5NDA1NzlhM2EyYmVjODRlNGUxMTBfMzEyNg_3cc0af61-54c6-46f0-87d5-f6be5f86a4d7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83Ni9mcmFnOjVhNGM4OWJiOWU3OTQwNTc5YTNhMmJlYzg0ZTRlMTEwL3RleHRyZWdpb246NWE0Yzg5YmI5ZTc5NDA1NzlhM2EyYmVjODRlNGUxMTBfMzEyMw_b823eec1-6192-49d9-8a47-66d603cff97e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the three months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83OS9mcmFnOjE4ZjU4NTc4MGY1NDQyMTJiNjc1YzE5MGVjODY5NTc5L3RleHRyZWdpb246MThmNTg1NzgwZjU0NDIxMmI2NzVjMTkwZWM4Njk1NzlfNTc1_259a5622-a4e1-4904-a07d-5e4053d199ea">&lt;div style="text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we sold the Cordis business to Hellman &amp;amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ibd18cf751e3b4588bcfe40175c3f40a1_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Cordis business operated within our Medical segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i73291183b5c94c569731d6000358a035_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV83OS9mcmFnOjE4ZjU4NTc4MGY1NDQyMTJiNjc1YzE5MGVjODY5NTc5L3RleHRyZWdpb246MThmNTg1NzgwZjU0NDIxMmI2NzVjMTkwZWM4Njk1NzlfOTA_87e6989b-391e-4287-8efe-1ca13c6f0ecb"
      unitRef="usd">923000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RleHRyZWdpb246N2VjYmFjZTNlOTE1NDVjMWIxZDQ2OTU0OTIxZDA1ZjRfOTk3_ef61c98f-9c2b-4237-9650-b2231670a005">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September&#160;30, 2021, restructuring also included costs related to the divestiture of the Cordis business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RleHRyZWdpb246N2VjYmFjZTNlOTE1NDVjMWIxZDQ2OTU0OTIxZDA1ZjRfMTAyMw_6dcd6080-66e6-4623-967b-bdcc866ac1af">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMi0xLTEtMS0yMDA1NzE_24055499-fc95-4a77-a53e-1bbdaff0dcd6"
      unitRef="usd">19000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMi0zLTEtMS0yMDA1NzE_1c16554b-44b0-4812-8e68-6abdec23b5aa"
      unitRef="usd">8000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMy0xLTEtMS0yMDA1NzE_31e0a153-0dc8-4c5c-9178-c2b950e9a2b8"
      unitRef="usd">10000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfMy0zLTEtMS0yMDA1NzE_20d1734a-22d1-4fce-bf40-4afd553e72b7"
      unitRef="usd">10000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfNC0xLTEtMS0yMDA1NzE_61f8e507-4ed2-4295-959c-bd9e6e8996a3"
      unitRef="usd">29000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOjczOGE2ZWQ1YTU1NTQwNjY4NzQ3NzgxZGY0MzVhNzAzL3RhYmxlcmFuZ2U6NzM4YTZlZDVhNTU1NDA2Njg3NDc3ODFkZjQzNWE3MDNfNC0zLTEtMS0yMDA1NzE_4f44f422-61e5-4e7d-b9e5-a4b2af985028"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RleHRyZWdpb246N2VjYmFjZTNlOTE1NDVjMWIxZDQ2OTU0OTIxZDA1ZjRfMTAwOA_bd483dce-7842-45b4-aa71-2b1d6ec01ce6">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i70aa8ba2fa76462a98de9c2a2a3b3eab_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMS0xLTEtMS0yMDA1NzE_1aa25fd0-4705-401e-8c02-ba87f6f98a39"
      unitRef="usd">56000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id8df42a7b9384d7ba6a2b613756fc333_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMS0zLTEtMS0yMDA1NzE_9bae4777-f35f-4bd6-91e0-4b7be3961e2b"
      unitRef="usd">10000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMS01LTEtMS0yMDA1NzE_c2590a88-791b-4fb9-994e-59704a9de4f5"
      unitRef="usd">66000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="idd6f5954a39f4eaab401f0922f87e2b2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMi0xLTEtMS0yMDA1NzE_fe4a4bb8-2f47-46c4-b90f-f44f669269ff"
      unitRef="usd">20000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i7336a5c8dffa4fed905779c7906e0698_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMi0zLTEtMS0yMDA1NzE_730759ac-a6fc-4eae-8ec0-01df70e1021f"
      unitRef="usd">3000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMi01LTEtMS0yMDA1NzE_6e59bd62-7021-4d18-a571-038989d7cd81"
      unitRef="usd">23000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="idd6f5954a39f4eaab401f0922f87e2b2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMy0xLTEtMS0yMDA1NzE_bef50a5a-9d69-476a-b72b-50353a3278fe"
      unitRef="usd">11000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i7336a5c8dffa4fed905779c7906e0698_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMy0zLTEtMS0yMDA1NzE_13d5c15c-714f-4cb7-a8b4-2425f41b8021"
      unitRef="usd">10000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfMy01LTEtMS0yMDA1NzE_3297d4bd-4576-49c4-8248-b9c8ffe0a98b"
      unitRef="usd">21000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i7c4c7a1de55d4507ad5cbd581472af6f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfNC0xLTEtMS0yMDA1NzE_f19e0cd1-e456-4ecb-b377-601a00b59018"
      unitRef="usd">65000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i06c8e71b77e84415aa0fb3cf24c26850_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfNC0zLTEtMS0yMDA1NzE_98e42593-d3ff-4b6e-8da6-742f771bd654"
      unitRef="usd">3000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84Mi9mcmFnOjdlY2JhY2UzZTkxNTQ1YzFiMWQ0Njk1NDkyMWQwNWY0L3RhYmxlOmMxOWU2ZWU2YjExNDQ2MzNhYTIyNTA4OTA1OGQ0YjI0L3RhYmxlcmFuZ2U6YzE5ZTZlZTZiMTE0NDYzM2FhMjI1MDg5MDU4ZDRiMjRfNC01LTEtMS0yMDA1NzE_086b3c12-844c-49dd-bd41-46a05f51a520"
      unitRef="usd">68000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjc0ODc3OTA3MjQxOA_e076bce8-baf1-4946-9132-3fce74451042">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,002&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September&#160;30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September&#160;30, 2022 after recognizing the impairment charge was $6.7&#160;billion, of which $1.8&#160;billion was goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,037&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,692&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $71 million and $78 million for the three months ended September&#160;30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $212 million, $258 million, $233 million, $206 million, and $174 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjc0ODc3OTA3MjQxOQ_e6adf1b4-6e9c-4158-b10b-b85396374fa1">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,002&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i9cad212f102146228e0cd765ec3011f8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMS0xLTEtMS0yMDA1NzE_5a795d40-b5f2-4c16-a18b-e6e2db53b0c1"
      unitRef="usd">2673000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ied4f963e1258409697ad8f442ba79dc3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMS0zLTEtMS0yMDA1NzE_8cafb136-50b9-4443-b276-265639bcbed2"
      unitRef="usd">3182000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMS01LTEtMS0yMDA1NzE_fa18b809-fd49-4398-8dd6-c2474225fe1c"
      unitRef="usd">5855000000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4be56105efe44fd58a9ef7c7851443fb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMy0xLTEtMS0yMDA1NzE_2c789466-4179-4c53-800f-78380f7af8d2"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMy0zLTEtMS0yMDA1NzE_73ef3454-682b-4ffd-919d-0838b609dc94"
      unitRef="usd">26000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfMy01LTEtMS0yMDA1NzE_41cff5ed-159e-4402-ba00-8f28d10dad36"
      unitRef="usd">26000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4be56105efe44fd58a9ef7c7851443fb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0xLTEtMS0yMTA3NzQ_02f8ad52-99dd-42c7-b06e-931810acb186"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0zLTEtMS0yMTA3Nzg_1577684a-8074-4c6f-a629-d14c8003cdf4"
      unitRef="usd">154000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC01LTEtMS0yMTA3ODI_5b4400b0-b869-49a2-bfdf-7cce540e131e"
      unitRef="usd">154000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i51a3dd894882408790e569ecd7a0a0f6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0xLTEtMS0yMDA1NzE_af51aeae-b2c0-44fa-8082-7dc97f00201b"
      unitRef="usd">2673000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9a322d3b1b71496d949f588cbc3e8c44_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC0zLTEtMS0yMDA1NzE_c8c34d56-36b2-422b-9432-4255e90c6821"
      unitRef="usd">3002000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkwODA5N2VlYWIyMzQ2NzJiNjU4MjQ2MzMyYjQ2MTFkL3RhYmxlcmFuZ2U6OTA4MDk3ZWVhYjIzNDY3MmI2NTgyNDYzMzJiNDYxMWRfNC01LTEtMS0yMDA1NzE_f30c1041-9e32-4042-b408-6bca17e811d3"
      unitRef="usd">5675000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i9a322d3b1b71496d949f588cbc3e8c44_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NjkxMA_679ab43b-ddbc-405e-ad9b-ce2e5ada753a"
      unitRef="usd">3600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <cah:DiscountRateFairValueInput
      contextRef="i7138c986208346caab693c394d3fc544_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzMwMQ_04cd1db4-79f3-4491-9b53-d67d13aca075"
      unitRef="number">0.105</cah:DiscountRateFairValueInput>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="i7138c986208346caab693c394d3fc544_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzMxNg_7b9d718d-4e0b-4e61-b740-5c5c2851560d"
      unitRef="number">0.02</cah:TerminalGrowthRateFairValueInput>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjc0ODc3OTA3MTk3Ng_1577684a-8074-4c6f-a629-d14c8003cdf4"
      unitRef="usd">154000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AssetsNet
      contextRef="i6fb2d9aad92e4c598b91935a092f4aea_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzMzMg_1031c363-7368-40a2-8816-910d2b942b3a"
      unitRef="usd">6700000000</us-gaap:AssetsNet>
    <us-gaap:Goodwill
      contextRef="i6fb2d9aad92e4c598b91935a092f4aea_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNzY5NjU4MTM5NzM1OA_5e98f5e8-477b-43ef-8262-065f5c3f098e"
      unitRef="usd">1800000000</us-gaap:Goodwill>
    <cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDgx_a00b6119-9df4-4344-b29c-85d6cb111174">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,037&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,692&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6fbcc66fb7f548ae9276527dd4263120_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMy0xLTEtMS0yMDA1NzE_be4f99cd-8646-4884-8148-d9fca893592c"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6fbcc66fb7f548ae9276527dd4263120_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMy01LTEtMS0yMDA1NzE_5262666b-67a8-412a-ab1d-f2992ceee174"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNC0xLTEtMS0yMDA1NzE_4c62a6a6-0dc5-46b5-8027-352e87f2cd38"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNC01LTEtMS0yMDA1NzE_52758476-574f-4b83-b45a-04cbe9d2a05f"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy0xLTEtMS0yMDA1NzE_1db54d90-3bbf-49f3-8473-4b585ff7366e"
      unitRef="usd">3206000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy0zLTEtMS0yMDA1NzE_4e071840-c664-49fd-9281-ab88f8ca0552"
      unitRef="usd">2157000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1a8e3e496d314c1d8e6fc7af91dc33cc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy01LTEtMS0yMDA1NzE_0d6bb9d3-e266-41c7-9b72-983d3c7d7ff5"
      unitRef="usd">1049000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i1bdbb7b08c494b6ea6bebbc41a301248_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfNy03LTEtMS0yMDA1NzE_b8f39b6d-9938-40fb-a6d0-41a9cb334849">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC0xLTEtMS0yMDA1NzE_f282b59f-9f5e-4d22-a5b4-adbef9d4762e"
      unitRef="usd">546000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC0zLTEtMS0yMDA1NzE_e36c1190-8d3b-489b-8b40-35da78c9389c"
      unitRef="usd">361000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3e2fe9414cca4e25add5fde0a9e3ed10_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC01LTEtMS0yMDA1NzE_4e3bb0f6-73a9-4e60-aecb-9322ebbcac72"
      unitRef="usd">185000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i5754d58acfdb4215a3917a18dd269e93_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOC03LTEtMS0yMDA1NzE_ba27efa4-212d-4784-b4f3-cb7f8f4445ec">P8Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS0xLTEtMS0yMDA1NzE_a21ac8a7-98da-4081-b2ca-ccc05bfc85d5"
      unitRef="usd">1037000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS0zLTEtMS0yMDA1NzE_28bf10ee-3327-476f-bb21-1088ad92d01e"
      unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i53f90edf3f164b6dbc7f24d8c50fde3a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS01LTEtMS0yMDA1NzE_a03bbecc-c82e-4fc7-a2f7-5cd29c21b2ff"
      unitRef="usd">447000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i2ec2ce0031f949829f8cff3fae7f33b8_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfOS03LTEtMS0yMDA1NzE_1859de81-e15b-4aa2-95d0-0b8f7b00dc15">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtMS0xLTEtMjAwNTcx_ebead3c5-d3f6-4952-b5cb-4d967e788ecf"
      unitRef="usd">4789000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtMy0xLTEtMjAwNTcx_a3e82b81-47c9-492b-bf88-8317bb98a380"
      unitRef="usd">3108000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtNS0xLTEtMjAwNTcx_950729b9-7752-40f1-a0f2-b19c81f9824f"
      unitRef="usd">1681000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTAtNy0xLTEtMjAwNTcx_f901ef1d-ba41-4aab-9825-fdc22db54701">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTEtMS0xLTEtMjAwNTcx_4080695f-33ca-4856-8fee-1b7b41647d39"
      unitRef="usd">4800000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTEtMy0xLTEtMjAwNTcx_e1d54057-1ae5-4238-9d3c-755e7e1aa701"
      unitRef="usd">3108000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOmE5NTBmZWJhZjFiZTQ2M2M4NTY1NzZlMjk2ZGJjMDdlL3RhYmxlcmFuZ2U6YTk1MGZlYmFmMWJlNDYzYzg1NjU3NmUyOTZkYmMwN2VfMTEtNS0xLTEtMjAwNTcx_d621c9dd-03f2-4a89-a721-37fdd529ade3"
      unitRef="usd">1692000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i64c74d76f8974daeb64325a492d7cb0c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMy0xLTEtMS0yMDA1NzE_24f15e3b-abd9-40dc-bf5c-d3d980ef537f"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i64c74d76f8974daeb64325a492d7cb0c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMy01LTEtMS0yMDA1NzE_8a450642-fae2-4ea0-a523-5a7ee85f0bfd"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNC0xLTEtMS0yMDA1NzE_696c93e4-4496-46e7-a830-94995942fed8"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNC01LTEtMS0yMDA1NzE_a9c8800e-8795-4c83-b023-6eb6c76ee04d"
      unitRef="usd">11000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5001b8fecb8f4da89f5a3a06c330244d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNy0xLTEtMS0yMDA1NzE_0b09730a-05cf-496d-b9d4-218ec46d812e"
      unitRef="usd">3272000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5001b8fecb8f4da89f5a3a06c330244d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNy0zLTEtMS0yMDA1NzE_0c533d1b-1d57-41a1-837f-a5f6b6b5142c"
      unitRef="usd">2165000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5001b8fecb8f4da89f5a3a06c330244d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfNy01LTEtMS0yMDA1NzE_81d63a91-af45-4b6b-9903-dddb6f786a6c"
      unitRef="usd">1107000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a2b097d758b45aa95ea584e855a2631_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOC0xLTEtMS0yMDA1NzE_455d5ea1-84f2-4a89-b659-4ea3cda7a909"
      unitRef="usd">552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a2b097d758b45aa95ea584e855a2631_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOC0zLTEtMS0yMDA1NzE_fcd89550-6e39-450a-b811-9bd5510ca871"
      unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a2b097d758b45aa95ea584e855a2631_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOC01LTEtMS0yMDA1NzE_a6eb9138-1d7e-4af4-9197-53c229386a60"
      unitRef="usd">192000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOS0xLTEtMS0yMDA1NzE_72893b2f-cf91-465b-872a-15745fba7e2d"
      unitRef="usd">1038000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOS0zLTEtMS0yMDA1NzE_caea8c68-ffdc-44f2-8b3a-4736ea290f30"
      unitRef="usd">574000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2c6734c317d54b76a588bc63a4ce2c4f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfOS01LTEtMS0yMDA1NzE_16849799-18ff-4bb2-93b7-0e2acbd5878d"
      unitRef="usd">464000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTAtMS0xLTEtMjAwNTcx_c942db14-3d0d-42e9-89bf-f289ca87c1e7"
      unitRef="usd">4862000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTAtMy0xLTEtMjAwNTcx_6ef1251a-ba0b-49d5-88e6-1f23f0613595"
      unitRef="usd">3099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTAtNS0xLTEtMjAwNTcx_bfac82d0-3360-4418-856a-3cd6759dd472"
      unitRef="usd">1763000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTEtMS0xLTEtMjAwNTcx_cdefbf51-6e23-4de2-bb7b-89862d2f8a6c"
      unitRef="usd">4873000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTEtMy0xLTEtMjAwNTcx_e8309544-57a1-45e5-a3d3-94145076ec53"
      unitRef="usd">3099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RhYmxlOjkyNDVkNGZhZGRkZTRkM2M4NGQwZmZmYWU1ZjcyZGI3L3RhYmxlcmFuZ2U6OTI0NWQ0ZmFkZGRlNGQzYzg0ZDBmZmZhZTVmNzJkYjdfMTEtNS0xLTEtMjAwNTcx_2f90c030-ba88-4582-996e-d86492713998"
      unitRef="usd">1774000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjYy_4e320dbf-7dad-4ab0-9f8f-e9a4d69cc539"
      unitRef="usd">71000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfMjY5_3e7d2ff0-a06f-486a-8c10-33c119e58cd3"
      unitRef="usd">78000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDMy_e3cbdb98-dd05-44e8-bdf6-e882c59c281f"
      unitRef="usd">212000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDM2_1e55baa8-1e65-4d37-8998-2f8ce439dcd9"
      unitRef="usd">258000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDQw_86456a4c-0dc7-4977-a2e2-7527f55bfe2a"
      unitRef="usd">233000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDQ0_5b7f2c13-ffd7-4f5d-8acf-8cb4fbbaa19f"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV84NS9mcmFnOjA3MGI3ZmY2NmE2NjRiODY5NGExNGJkYWVhZTAwZWUyL3RleHRyZWdpb246MDcwYjdmZjY2YTY2NGI4Njk0YTE0YmRhZWFlMDBlZTJfNDUy_90855683-e106-4e82-ae9f-0033a5d3bd0c"
      unitRef="usd">174000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMjMxMg_7e3b195b-a9d3-4ccf-8cfc-f899ce843e6d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $28.4 billion and $27.1 billion at September 30, 2022 and June 30, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTI2_2013c7e6-d8c6-43d2-bbd9-a8a31d07defa"
      unitRef="usd">5300000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTI2_b7a03e0f-128b-4d3f-87c8-5c0efb00f536"
      unitRef="usd">5300000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTE5_8321ac99-3928-4e31-95a0-0e0466cf3923"
      unitRef="usd">28400000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTI2_8becfc69-0dd0-4fc9-957d-bb1dace8fa28"
      unitRef="usd">27100000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="if2e87b70e3bf41fa8effe5bef9f99d54_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTQ5NzU1ODE2MzI5_265027b9-2519-42b1-9c28-9c293d5880f4"
      unitRef="usd">572000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if2e87b70e3bf41fa8effe5bef9f99d54_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfNTQ5NzU1ODE2NTc2_4f8bc9be-1754-4e6f-8752-e4ed4d55739e"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic8b18dbf515f4767a1d1688c18c6b7a1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTE5OA_c807ebf1-15bc-4f07-9483-0b91fc64e8c2"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i22fae5e1f8744690836ce67e2c6432cb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTIzOA_42c1d948-828a-4485-b434-5659abd2484f"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ief8b6ae0c11d4c79addc75f5d463aad6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTI4Mw_a8f267fb-5c29-495b-a597-fb030c1956f6"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i27b66144fc554632a9c5a93bee338b1d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85NC9mcmFnOmUzMWZhYmQ3ZmU0NDRlZTk5YmE1OGEwMDk5NjIzMzJjL3RleHRyZWdpb246ZTMxZmFiZDdmZTQ0NGVlOTliYTU4YTAwOTk2MjMzMmNfMTMzOA_e73f4fd5-1757-4223-9a7e-22b9aac61d10"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTQzNQ_082645ce-6fa5-4f16-8d16-1c140388237e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $20&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;National Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this Settlement Agreement, we will pay up to approximately $6.0&#160;billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors&#x2019; controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Settlements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124&#160;million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160&#160;million to the State of Washington and its participating subdivisions and approximately $95&#160;million to the &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of 49 states will then be subject to the Settlement Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged in resolution discussions with the Attorney General for the State of Alabama.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136&#160;million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2022, we made our second annual payment of $372&#160;million under the Settlement Agreement. In total, we have $6.03&#160;billion accrued at September&#160;30, 2022, of which $608&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 454 lawsuits as of October, 2022. Of these, 151 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of November 3, 2022, we are named as a defendant in 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,215 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 7 lawsuits involving similar claims by approximately 8 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, we had a total of $527&#160;million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07&#160;billion, net of estimated insurance &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust Litigation Proceeds&lt;/span&gt;&lt;/div&gt;In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $66 million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i3bd0b96897d1470fb2329660c7d50e7d_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMjUz_bfee9e07-ad2d-4de1-9a9c-cb2e2655d8f6">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment
      contextRef="i2297365bf0cb4e03a98dbbb10ac1c343_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzA5_aaba906f-9f8c-4c7f-bbe1-d3f3191effd9"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i64b8e59737824266b20b0bb162a7f6fd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTkzNg_e8d5bc15-b8b5-49f2-949d-c64ffd44b501"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="id6f6b2710bce442e9c8a8211ae3d15b6_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM2Mg_690f3231-96b3-4705-b198-475559a9748f"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i2297365bf0cb4e03a98dbbb10ac1c343_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM0OQ_04e37c55-052d-429a-8f94-62686d6c50c8"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <cah:JudgmentForLostProfits
      contextRef="i3a25416abfca4ca5a2c8a79563abdbf6_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM3OA_49227bb0-31cd-4f9d-baaa-ccced99ca621"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <cah:SettlingStates
      contextRef="ideb927b476ad43678e84b8626a1dccd8_I20221103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc0NTc4NA_14cbc7de-d414-4d28-8db7-1fa5f63424cc"
      unitRef="states">46</cah:SettlingStates>
    <cah:SettlingUSTerritories
      contextRef="ideb927b476ad43678e84b8626a1dccd8_I20221103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc0NTc5MA_8071340f-3377-41bd-875b-8406a6709ae4"
      unitRef="numberofusterritories">5</cah:SettlingUSTerritories>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="id0676373b4634242b6227fe4aaa7279e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfOTU4Mg_eda76d46-4371-448a-b0db-63e598b3944c"
      unitRef="usd">6000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i78dcc5cdb1a34a3688e6c1ce718bb3d4_I20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc2NjgwMg_ae3b7ab0-101b-4857-bfb6-f9dce0b3a041"
      unitRef="usd">124000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="iad2e4f4027b649c8b68073da27cc75ac_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzE0NjgyNTY2NzY2NQ_863b0712-edb2-4c0e-9b7b-5bff89a8f68c"
      unitRef="usd">160000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i39a78fb2810d4d5cb0d5270aa7494bd0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc2NjgyOA_1747006b-0b79-4bad-b15b-e0e8e9f5fae1"
      unitRef="usd">95000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <cah:LossContingencyNumberOfEligibleStates
      contextRef="i2d26088d8851461e886dd938e1e01e06_I20221031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTMxOTQxMzk2MjQyOTc_6bb6deef-7af1-49ab-a3bb-3b614edf8b70"
      unitRef="states">49</cah:LossContingencyNumberOfEligibleStates>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i05c064b32b7241f5861b32d00930b148_I20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTQyMg_c162eef2-7445-414f-901b-526a77b45186"
      unitRef="usd">136000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i5a2674d9c4424aee92b083b06676b132_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfODcyNTM_2c79c1e4-a579-4794-9c0c-b3bd33998517"
      unitRef="usd">372000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationReserve
      contextRef="id0676373b4634242b6227fe4aaa7279e_I20220930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTI2MjI_696e0685-758d-4fb1-9728-f7bba8d63fa0"
      unitRef="usd">6030000000.00</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="if8c2e07a1122434fb48591c34c3b03e8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTI2NDk_0e78af67-3a1f-47fa-aa7f-c8ec10e6361b"
      unitRef="usd">608000000</us-gaap:LitigationReserve>
    <cah:LossContingencyLawsuitsNumber
      contextRef="if117a27e06074dd49394d4673002a60d_I20221031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfNzY5NjU4MTQ4NTM5MQ_6392d90e-a7d1-4a2d-9609-95e74a21cea6"
      unitRef="lawsuit">454</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i32f85e3cb646437cb5f56dcc696128e6_I20221031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTQ3NDA_6f5f7988-e313-4a2f-bef5-8ace79ace0a3"
      unitRef="lawsuit">151</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i12caa08ddee14ac2a252cf36f1b23ea5_D20220701-20220731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDczMTM0Mg_030fb0e3-8b77-480e-9da9-7fd66fe8448c"
      unitRef="plaintiff">21</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4a355aa72fe54940911ec0fc9eec1d71_I20221103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTU4NDk_d989c952-014a-43f4-afe9-dad3a8528815"
      unitRef="lawsuit">450</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i6de11675da4a46d1a1dd19d98e7d028f_D20221103-20221103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTU5NzI_060deb77-ec30-4bbd-8700-afef64572f98"
      unitRef="plaintiff">5215</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1eadbc725e9d4be693afcd2438eb9445_I20221103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTYxMjM_9c28a928-d402-41bb-b50a-a400dd09af77"
      unitRef="lawsuit">7</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i91f3e424f456485faa3f18f61dbada6c_D20221103-20221103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTYxNzc_3cfa57a2-b772-48ae-b319-e7d4d07ea5f0"
      unitRef="plaintiff">8</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="ibad30b04476e408b9b94106e5ec72041_D20210731-20210731"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTYzNzc_609ce6f1-d790-41d1-b80c-691cc0ca1ff3"
      unitRef="lawsuit">1300</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ie89257f0029142808d8e517babd2e9ce_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTY2MDI_20e8d2fd-7dea-4e57-991d-f974bb77730f"
      unitRef="usd">527000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i5efb723c71ca43158a719af61d57c9fe_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMTcwNTg_0ff918c0-0121-4895-aff1-dc53ce4168ba"
      unitRef="usd">1070000000.00</us-gaap:LossContingencyAccrualAtCarryingValue>
    <cah:IncomefromSettlementsofClassActionLawsuits
      contextRef="ib3b381f73ed74b7c87202faa366ced15_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV85Ny9mcmFnOjY1NDk1ZmI2MjE5YzQ5ZjFhZjllMjJhM2U2YWYxM2VlL3RleHRyZWdpb246NjU0OTVmYjYyMTljNDlmMWFmOWUyMmEzZTZhZjEzZWVfMzg0ODI5MDc3MjQ1MA_8c235602-d7a1-4d73-8f06-3b752dfad1c6"
      unitRef="usd">66000000</cah:IncomefromSettlementsofClassActionLawsuits>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzQ0MTA_cbddd5ce-c478-4b83-8b00-8c609d76bdb6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Goodwill Impairment Charge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12&#160;million for fiscal 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effect of the goodwill impairment charge during the three months ended September&#160;30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September&#160;30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22&#160;million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September&#160;30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September&#160;30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $940 million and $943 million of unrecognized tax benefits at September 30, 2022 and June&#160;30, 2022, respectively. Both the September 30, 2022 and June&#160;30, 2022 balances include $858 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022 and June&#160;30, 2022, we had $49 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $75 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2016 through the current fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $77 million and $75 million at September&#160;30, 2022 and June&#160;30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i056167140f4147eca75967688b8394b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2MjQ_1577684a-8074-4c6f-a629-d14c8003cdf4"
      unitRef="usd">154000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i63acc3676d524a4cb1fe19ba5584d6a9_D20220701-20230630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2Mzk_2c3308a2-a253-49cf-9903-5e0c51508fc9"
      unitRef="usd">12000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OpenTaxYear
      contextRef="i9d5cab62da2c411d9384568354fcbb20_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2NjQ_f06fd986-b585-448a-8a0b-61ba626b2261">2023</us-gaap:OpenTaxYear>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7f63075f2d6941f88610dca064275c22_D20221001-20230630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI3NDg3NzkwODE2NTc_a3322c78-b65f-407d-97c5-f4bb88ecc110"
      unitRef="usd">-22000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzE4OTY_6b2fa008-f7a7-4c7b-8d08-a1bcee9dbc91"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzE5MTE_09b53d8e-d0e9-404a-850a-d9cef3e42807"
      unitRef="number">0.263</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzIxODQ_37ada235-5f6f-451e-8db3-8ce31e171128"
      unitRef="usd">940000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzIxOTE_91f04c10-38d9-402a-b091-0e2e51ef2d61"
      unitRef="usd">943000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzIyODI_27962e8b-085f-4b2e-a2a4-7a5df4315d46"
      unitRef="usd">858000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI0MjY_cd012c71-2e20-424e-8e8a-dc3334d581b4"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzI0MzM_ae459edf-aeb3-4eb3-aed1-03b86c020d79"
      unitRef="usd">48000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i2647f5df574a4790a972ae81d73483a7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzMzMDI_1860afce-1b05-4076-8dfc-bb7570de186c"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i838c37506e6a4118b13af6b0e18e635e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzMzMjc_de5f0d06-afd3-40d0-9e70-31a855b08be2"
      unitRef="usd">75000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OpenTaxYear
      contextRef="if4a6ab707b7b48c3900375ae0fdf5bd0_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzQ0MDI_1a281da7-f5fa-4532-a8fa-264891ae7f61">2016</us-gaap:OpenTaxYear>
    <cah:IndemnificationReceivable
      contextRef="i4747655b789c466c9d320622352b10eb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzM5Njc_54bdf021-ec18-4759-8f06-d677921c4666"
      unitRef="usd">77000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i112c682ae8824132a82e463e2829fbde_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDAvZnJhZzo1YjJkNmYzMGUyZjI0YTIxYmJiYjQwMTQ5MWNhMTk5ZS90ZXh0cmVnaW9uOjViMmQ2ZjMwZTJmMjRhMjFiYmJiNDAxNDkxY2ExOTllXzU0OTc1NTgxODQ0NQ_2b41e6fb-2331-4ff3-88e7-2b795da22158"
      unitRef="usd">75000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90ZXh0cmVnaW9uOjQxZTlmMzFjZGU0ZTRhMTU4MDljY2I2NDVmNzc2ZWRkXzEyMjI_98715589-da0e-40bd-a3e6-40e496122a14">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90ZXh0cmVnaW9uOjQxZTlmMzFjZGU0ZTRhMTU4MDljY2I2NDVmNzc2ZWRkXzEyMzU_9ed9b4d9-ec60-4b8f-a17d-9b58adccd774">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i409e7ac6eece4672b979373d4beb255a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtMS0xLTEtMjAwNTcx_e1d7953c-bba7-4f26-9d59-159c9dc0b941"
      unitRef="usd">1477000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a28758bc65a4cb4af33498d26db24ac_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtMy0xLTEtMjAwNTcx_0e93cd71-da80-4c2d-ac67-9e8830d8ae9a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i49aba128f32b4dab86cb347514750422_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtNS0xLTEtMjAwNTcx_d3c6c5f4-6e88-4eb0-805c-1bad4a7e7f81"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d65960fd135483bb22e0f9214f5cc93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzMtNy0xLTEtMjAwNTcx_dbb360fc-071e-47c5-90a4-16a329136076"
      unitRef="usd">1477000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i409e7ac6eece4672b979373d4beb255a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtMS0xLTEtMjAwNTcx_f96bd46b-697b-46f6-be5e-9018726a275e"
      unitRef="usd">88000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8a28758bc65a4cb4af33498d26db24ac_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtMy0xLTEtMjAwNTcx_62fda9d5-9f35-4915-a64a-a2e56de727aa"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i49aba128f32b4dab86cb347514750422_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtNS0xLTEtMjAwNTcx_cc70819f-838d-48d4-adeb-8ee72c133d44"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iee5307df37214cb5856b80573d7cd236_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzQtNy0xLTEtMjAwNTcx_db5265a4-8839-403d-a1d2-e5910a09781c"
      unitRef="usd">88000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i409e7ac6eece4672b979373d4beb255a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtMS0xLTEtMjAwNTcx_2772ca72-b5d9-4253-8fa4-6019dd8a4654"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i8a28758bc65a4cb4af33498d26db24ac_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtMy0xLTEtMjAwNTcx_d9f30c23-0c74-45b2-adb2-910129a78594"
      unitRef="usd">-5000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i49aba128f32b4dab86cb347514750422_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtNS0xLTEtMjAwNTcx_f86821b4-7571-4768-b083-2e1d26fb63ae"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="iee5307df37214cb5856b80573d7cd236_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTowNWRkMDlkMjEwYzA0NzYxYTU4MDk0N2ZhOWE5NGNmYS90YWJsZXJhbmdlOjA1ZGQwOWQyMTBjMDQ3NjFhNTgwOTQ3ZmE5YTk0Y2ZhXzgtNy0xLTEtMjAwNTcx_e99dca6a-4f6c-4a5b-92cf-227a77a7916d"
      unitRef="usd">-5000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i387ff4bbab2845dabaeeca1215e98d4f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtMS0xLTEtMjAwNTcx_403d5ebf-fd38-4b57-ae3e-135b0b3b8993"
      unitRef="usd">2425000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie5379f66427748ca8c43f633f07433f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtMy0xLTEtMjAwNTcx_7ec50c9d-f529-4f9d-89ab-09db2f30e8d0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id2ffadf1769b4b338c57b958d74314c6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtNS0xLTEtMjAwNTcx_95c3db15-4ebf-45e3-a897-c5b33d4706e1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id2ccafc16fb54194a171620229fdbe11_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzMtNy0xLTEtMjAwNTcx_3aa52770-13e5-4fa1-8968-b970da0a96c1"
      unitRef="usd">2425000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i387ff4bbab2845dabaeeca1215e98d4f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtMS0xLTEtMjAwNTcx_2ee45f91-1bc5-4652-8249-b2f6f6f58491"
      unitRef="usd">97000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie5379f66427748ca8c43f633f07433f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtMy0xLTEtMjAwNTcx_de280e7c-8349-40af-9201-00bbf979b699"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id2ffadf1769b4b338c57b958d74314c6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtNS0xLTEtMjAwNTcx_faba7c5d-44fa-4051-8293-2dffb7f6eba6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i59e85c09481f4f09a7ccf2fe64711f33_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzQtNy0xLTEtMjAwNTcx_14db19ab-09aa-48f2-9731-9918c69c5b97"
      unitRef="usd">97000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i387ff4bbab2845dabaeeca1215e98d4f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtMS0xLTEtMjAwNTcx_fe984381-ad01-4977-b361-afff9c7552c5"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ie5379f66427748ca8c43f633f07433f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtMy0xLTEtMjAwNTcx_460c7c2d-8def-42c3-b106-b3e0b24ed54e"
      unitRef="usd">15000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="id2ffadf1769b4b338c57b958d74314c6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtNS0xLTEtMjAwNTcx_ea5064de-a608-446e-ab64-cbfb5f657318"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i59e85c09481f4f09a7ccf2fe64711f33_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDMvZnJhZzo0MWU5ZjMxY2RlNGU0YTE1ODA5Y2NiNjQ1Zjc3NmVkZC90YWJsZTozYmNhYjk5OTA4ZGU0ZWVjYmRiYjM0NTUwYzAzZTNhYi90YWJsZXJhbmdlOjNiY2FiOTk5MDhkZTRlZWNiZGJiMzQ1NTBjMDNlM2FiXzYtNy0xLTEtMjAwNTcx_d83b2516-b943-4619-8704-3a03231c63f1"
      unitRef="usd">15000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzM4NDgyOTA3MDkwOTI_8a4e1574-778b-4cdc-9a70-0b15713cf667">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September&#160;30, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During three months ended September&#160;30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $100 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains recognized in other comprehensive loss were $4 million for the three months ended September&#160;30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $22&#160;million and a $5&#160;million for the three months ended September&#160;30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4&#160;million and $6&#160;million during the three months ended September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $6&#160;million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzMyODY_18475af6-1fa0-4762-a7db-98629fb3cd3c"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i65825c4d85ac4f8d93a497d87be20ab0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzM1NjM_5db279b3-8a7a-4316-81b9-92cec317d22a"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i8fdecbea244440c2ba6bf56b66b21f7d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzM4NDgyOTA3MDkwOTU_d80bb0cd-65f9-43c2-9145-1ddad0439be2"
      unitRef="usd">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib2c072105cd740018a1c9aeea1081994_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzQ5NDc4MDIzMzM1ODk_c2c531af-a2c0-4e5d-b92f-17b4b27022ac"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i03dbc97b506740c1ab99758d71d8644a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzU3NTM_cea6ac7f-9d63-4618-a274-231c0df1ae19"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i75e88d2441654c87afe085d4a0348bb9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzU3Njc_a5e5e082-1a6c-4cfe-b887-41a2956da89c"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i03dbc97b506740c1ab99758d71d8644a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzYwMzQ_59128fa3-aea8-4b24-821a-ab53339e18ae"
      unitRef="usd">4000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i75e88d2441654c87afe085d4a0348bb9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzYwNDE_04d863a5-cbe6-4e63-93e2-830909477447"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i9127505057a74be592b08798b91f4df4_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzQ5NDc4MDIzMzU4MTY_9703787d-9642-431d-85a8-080378481b3d"
      unitRef="usd">-6000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90ZXh0cmVnaW9uOjMxMTAxMmE1NjkzNzQ0Zjc4MDk5NTM5MDJkMDZkNGNmXzc3MTY_47f9b3ea-a885-4513-bec5-d51d8b067683">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,838&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic09ef0c511ae4237af07d4b591d9c579_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzEtMS0xLTEtMjAwNTcx_5102cd9b-d882-416f-8c71-e04a7d1bc8e3"
      unitRef="usd">4838000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7b51adfb3de843dc981ee6f67bb7126c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzEtMy0xLTEtMjAwNTcx_db40a41f-b929-4663-9e08-714612e238fe"
      unitRef="usd">5049000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzItMS0xLTEtMjAwNTcx_35d21790-a582-43e3-8adf-5559157ec35e"
      unitRef="usd">5267000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDYvZnJhZzozMTEwMTJhNTY5Mzc0NGY3ODA5OTUzOTAyZDA2ZDRjZi90YWJsZTphZDVlYTc0NjM1YTI0ZjBiODE4Y2Y4ZmE4ZTRiYjhmNC90YWJsZXJhbmdlOmFkNWVhNzQ2MzVhMjRmMGI4MThjZjhmYThlNGJiOGY0XzItMy0xLTEtMjAwNTcx_e7fac206-13b5-4edd-8f01-e5219aa763c7"
      unitRef="usd">5315000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzcyMw_d7c844a1-6960-4a01-a391-8b972cd04d7d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity/(Deficit) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program is expected to conclude in the second quarter of fiscal 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iad9bf46791af4b50b139fbccfcf7acb6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzE3MA_76d65e55-470e-46fc-9004-746bd3dd7af9"
      unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i804fad5b06b0439c81e19646ddce2790_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEyNDM_36afa354-92da-496c-a392-af1f4faa584b"
      unitRef="shares">12000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i804fad5b06b0439c81e19646ddce2790_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEyNDk_8c6468a0-bf13-44f1-a710-68fbd3cc5877"
      unitRef="usdPerShare">66.74</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib8fa2946d75244f5af4e048c4b6f80f0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEyNjY_05f72c0c-f90f-4aa8-baa0-db4943003fa5"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0ad50074ece84ece82376c3fa9fb7b8b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzI3NDg3NzkwNzEzMTk_a38c996f-0469-4492-a2a8-8d21ef5d8741"
      unitRef="shares">7800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i0ad50074ece84ece82376c3fa9fb7b8b_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0Xzc2OTY1ODEzOTYzMTU_3dd1ff93-86e2-4815-8c44-d837464c97d8"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ibd1f58cfa53748e180e4ce356b89feb0_D20211004-20211004"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0Xzc2OTY1ODEzOTYzMjM_e32070c8-4034-4b2b-b40d-6b8ce10deab8"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibd1f58cfa53748e180e4ce356b89feb0_D20211004-20211004"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0Xzc2OTY1ODEzOTYzMzE_17aa40f3-934d-4f9f-ba12-7001c0079438"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90ZXh0cmVnaW9uOmM2NWFlYWRlMjg5NDRmZjg5NjZhODY3MjRiOGRmMDY0XzcyMg_af864f57-510c-48db-a314-69a63cd78e66">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c5566f30ebc41c9a4c5aa210ea0d0a1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzEtMS0xLTEtMjAwNTcx_cf0abaf5-c2db-430d-accf-49f39210ce2a"
      unitRef="usd">-102000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0da40648754f7e8ebf900b3a6b20a7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzEtMy0xLTEtMjAwNTcx_3c3e0450-0ecb-46c2-b994-a1f3864e9b44"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bca371c3eb7478a9a9c71b3235bd9da_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzEtNS0xLTEtMjAwNTcx_20c6655c-5367-4f1c-b358-3ec53def3ec4"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzItMS0xLTEtMjAwNTcx_90002e1b-d774-4512-b055-d4d867a1189d"
      unitRef="usd">-58000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i892094d14d894e958f90124c7fa6d265_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzItMy0xLTEtMjAwNTcx_af171695-b597-400a-91e6-e1857661a0fd"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i698aacd651704977bb16df51d8070a30_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzItNS0xLTEtMjAwNTcx_b363f34e-8bdf-4d9b-92d5-a7c38de37c78"
      unitRef="usd">-60000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzMtMS0xLTEtMjAwNTcx_dcf7b61f-bc1e-45e5-b418-78fcc505f2b5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i892094d14d894e958f90124c7fa6d265_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzMtMy0xLTEtMjAwNTcx_1487960b-bcab-43f5-979c-367ca406a1fb"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i698aacd651704977bb16df51d8070a30_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzMtNS0xLTEtMjAwNTcx_59cf2a77-69bf-483a-9bb2-0173dea56bec"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtMC0xLTEtMjMwOTE2L3RleHRyZWdpb246NzYzYzE4N2Y5YmVmNDQ3ZDg3OGJiZDIyNGE3NmRkNWNfMjc0ODc3OTA2OTU1Ng_9900cca2-bf8d-4abc-b48f-dc863229fc34"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e08cfb0128f4d48b17b9b608f785ca0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtMS0xLTEtMjAwNTcx_57b47143-8794-4ef2-b427-fb53fbd68898"
      unitRef="usd">-58000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i892094d14d894e958f90124c7fa6d265_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtMy0xLTEtMjAwNTcx_68d756b4-dbdb-449b-bcc6-1e742abdc97f"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7de5f4005fe40ad951ccbaf90fed316_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzQtNS0xLTEtMjAwNTcx_690a28fd-8740-49c3-9614-95e768f33cb8"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2b8399010484b6095659918a1811fbe_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzUtMS0xLTEtMjAwNTcx_923ecbef-0cef-47fe-a2dd-c5b60cf7c70c"
      unitRef="usd">-160000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d06169bd4ac4fe1b8c2bc2c47eb44f6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzUtMy0xLTEtMjAwNTcx_48cda0e1-2532-4a2d-bba3-50f442522566"
      unitRef="usd">-16000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i518c9f6c90a440a9b3e29e04e98d1fe2_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpjMDM2YzFkYTBiNWU0YTIxOTIxZTQ3Y2UxZTI3NjA4Ny90YWJsZXJhbmdlOmMwMzZjMWRhMGI1ZTRhMjE5MjFlNDdjZTFlMjc2MDg3XzUtNS0xLTEtMjAwNTcx_fd608725-86e4-4972-ade9-4553cc090371"
      unitRef="usd">-176000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81ce1edc4ddb41989ad743f2322d6d0e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzEtMS0xLTEtMjExOTg3_4464ff9d-51f1-443f-b9ad-3c7d702515aa"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49d63915083840a09569f5e9570a4c80_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzEtMy0xLTEtMjExOTg3_88850260-4f3a-4eac-af88-1f09021950b8"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i855d5c9c3f5e4418855a7294a17541ef_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzEtNS0xLTEtMjExOTg3_6013989c-e4d3-4746-8337-e49c77b9f797"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzItMS0xLTEtMjExOTg3_7c8d3aed-0a23-42f1-b0a1-00ce5ca492c5"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if3044261be5249d9833e8961865fb32f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzItMy0xLTEtMjExOTg3_c3faf665-b7e6-4026-ba9e-9aa8eae22c2a"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzItNS0xLTEtMjExOTg3_981c6332-a963-4901-9c8b-9d9291392bbd"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzMtMS0xLTEtMjExOTg3_ed1f44c5-b551-4502-8cf2-9be86739cae5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if3044261be5249d9833e8961865fb32f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzMtMy0xLTEtMjExOTg3_1917d6f1-4f29-433d-a556-57bdedb0b6fb"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1912eeb240dd4c66bb2db0ff2d1bb68e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzMtNS0xLTEtMjExOTg3_815fe4e8-3052-49bd-b961-538680850f12"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i69bd045d82024be1a538d4d502c01f1a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzQtMS0xLTEtMjExOTg3_ef50170d-6d3d-4661-b19b-0430e223db35"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if3044261be5249d9833e8961865fb32f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzQtMy0xLTEtMjExOTg3_a7f0b749-12d5-446d-8acf-032c2aff5aa5"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2fbb9c3f242b449a93c375031cccfb0a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzQtNS0xLTEtMjExOTg3_b3c5b265-5ad9-47fa-846a-48cdcc60e2df"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec9ffb10cd2a4f23ae074893f97a8ac8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzUtMS0xLTEtMjExOTg3_45df0160-7f7c-40f3-82f8-e832f6a9daf4"
      unitRef="usd">-71000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50162f37f7b7432489740885c70a6401_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzUtMy0xLTEtMjExOTg3_c6d6f327-e3e8-46b3-8afb-682dee780073"
      unitRef="usd">10000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8e9a4dc61694a2cbe868bd038d8e96a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMDkvZnJhZzpjNjVhZWFkZTI4OTQ0ZmY4OTY2YTg2NzI0YjhkZjA2NC90YWJsZTpmMjAyYmQzMzRhZjE0ZDc1OTYwNTU3ZWU5YTM3MDEyZS90YWJsZXJhbmdlOmYyMDJiZDMzNGFmMTRkNzU5NjA1NTdlZTlhMzcwMTJlXzUtNS0xLTEtMjExOTg3_a702da3e-e328-42d1-a794-7f1e50a0fd49"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzU3OA_c65ebfd2-55b1-4d6c-90c6-5b23262aa50d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings Per Share Attributable to Cardinal Health, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both &lt;/span&gt;&lt;/div&gt;the three months ended September 30, 2022 and 2021 were 4 million</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzU4NQ_f7ba8e12-23ee-4820-ac3e-38a09269957d">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzItMS0xLTEtMjAwNTcx_c282a7b5-f5b6-4607-ba0d-f5f4749d249b"
      unitRef="shares">271000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzItMy0xLTEtMjAwNTcx_dee91834-3820-48bf-a87f-b5e9357bb078"
      unitRef="shares">287000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzQtMS0xLTEtMjAwNTcx_0ab790e2-2f88-4861-96d5-4883239a71ea"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzQtMy0xLTEtMjAwNTcx_c54c84de-4021-4649-844f-04bdeb8fd969"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzUtMS0xLTEtMjAwNTcx_10571865-cd1c-4434-8638-8770772f4b73"
      unitRef="shares">273000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90YWJsZTo0ZmQ2ZDI2YmFhZDE0NjQyYjUzNzllY2FhYjY1MDRjOC90YWJsZXJhbmdlOjRmZDZkMjZiYWFkMTQ2NDJiNTM3OWVjYWFiNjUwNGM4XzUtMy0xLTEtMjAwNTcx_85995d90-cf6b-4ae6-8756-ead9ae0ba6e7"
      unitRef="shares">289000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <cah:Numberofsharesexcludedfromcalculationofdilutedshares
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzMyMQ_3547cf7c-4fd6-4fa1-8805-c50d056445e6"
      unitRef="shares">4000000</cah:Numberofsharesexcludedfromcalculationofdilutedshares>
    <cah:Numberofsharesexcludedfromcalculationofdilutedshares
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTIvZnJhZzo0ZjA3NGE5NTAyMzM0Mjc4ODQzYWMwMjlkMGFkNzMyMi90ZXh0cmVnaW9uOjRmMDc0YTk1MDIzMzQyNzg4NDNhYzAyOWQwYWQ3MzIyXzMyMQ_f9f0605a-c627-4b37-b6d3-4bf52bef3eda"
      unitRef="shares">4000000</cah:Numberofsharesexcludedfromcalculationofdilutedshares>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MzY_831111f9-db03-475a-b455-0835b4f5d264">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,828&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;surgical gown recall costs/(income);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;shareholder cooperation agreement costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;(gain)/loss on sale of equity interest in naviHealth; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for/(benefit from) income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,796&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzEwMg_29f01f1a-5eaa-430d-ae97-d186014f2ee5"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzEwMg_546a5816-5f18-43cc-b25e-3a15cf7f1b26"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzI3NDg3NzkwNzY5MDk_0c790f17-517d-4834-af88-a9ab47e78974">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,828&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,140&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i2f856b81cd0b4febbaa82e7ba3b7de3e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzItMS0xLTEtMjAwNTcx_4542e5a3-2df1-4f44-b3e5-64a60826ffb9"
      unitRef="usd">45547000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb884cfea93c4a6b9776a6eb15f99801_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzItMy0xLTEtMjAwNTcx_f1c8b9ac-9d78-4ab2-be66-a7ec31d32de1"
      unitRef="usd">39614000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if98a9f7800324334933b05a45c7c1081_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzMtMS0xLTEtMjAwNTcx_b4a990f8-5cae-4fcd-baff-29b91b18f348"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6964ebf21c6641d8a7d3c962e30215fc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzMtMy0xLTEtMjAwNTcx_c5e180e0-4598-4eed-b6dc-de5cdb99547f"
      unitRef="usd">208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdd40bf9e64d4e28aba32338f5e1c3f3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzQtMS0xLTEtMjAwNTcx_2525c37c-4ab4-4a27-907a-2138b040bab6"
      unitRef="usd">45828000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab13212bf3f64da69caee3d568418629_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzQtMy0xLTEtMjAwNTcx_85d8a81b-d3b9-4de4-962d-9c7fce400a91"
      unitRef="usd">39822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id23cd6cc579e4db1ac1517955232ea9e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzUtMS0xLTEtMjAwNTcx_ba7e92f3-d646-4207-98fa-e2f07de02170"
      unitRef="usd">3140000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i871bd2199ae14c3d8b2d85b00fa634dd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzUtMy0xLTEtMjAwNTcx_a89198d3-3922-43f9-9e82-7aa89dda44c1"
      unitRef="usd">3567000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if915e60e430a448e95ac1d3210262b21_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzYtMS0xLTEtMjAwNTcx_afdba632-449d-4fe2-a87f-7c6945a68d9e"
      unitRef="usd">638000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae83bd29fad7455f842d7e87a827912f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzYtMy0xLTEtMjAwNTcx_fbaa7c6c-2d62-413f-8f83-1875c079aacf"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad9bf49c924d4d84898b126cd4f6a3ff_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzctMS0xLTEtMjAwNTcx_19fbb5fe-bb90-466f-bd7e-04fe79c1ca36"
      unitRef="usd">3778000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i015c85ec14f2406f8e7dffe472b4851c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzctMy0xLTEtMjAwNTcx_1f789b55-122f-4e49-bf83-1d2e27358280"
      unitRef="usd">4149000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzgtMS0xLTEtMjAwNTcx_9b8d9d7d-c1a3-4ccb-bccb-89fe7b0e3772"
      unitRef="usd">49606000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzgtMy0xLTEtMjAwNTcx_0b0f55d3-231d-4d71-87a0-1b431fc0c70a"
      unitRef="usd">43971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65ff688f93904d2baa8f773161063474_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzktMS0xLTEtMjAwNTcx_57e55933-f3fd-4cf8-9469-998823bcdc02"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzktMy0xLTEtMjAwNTcx_0fec5bd6-9b21-4282-9010-f328f555dbea"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzEwLTEtMS0xLTIwMDU3MQ_e5ed5148-09bd-4c32-b5ea-49aa34f603b0"
      unitRef="usd">49603000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5NjBlZWIwYTBjY2U0OTI0OGRmNzM5ODk0MmViYmIwZi90YWJsZXJhbmdlOjk2MGVlYjBhMGNjZTQ5MjQ4ZGY3Mzk4OTQyZWJiYjBmXzEwLTMtMS0xLTIwMDU3MQ_78173c52-9a43-4a20-b553-7ddf74b7b91b"
      unitRef="usd">43968000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MzI_116aba3d-1cd4-42de-b125-8a25b0103e28">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,603&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i74b65aec35854386926330a8514839c9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzItMS0xLTEtMjAwNTcx_d68d6649-da26-4106-93d4-fc4d2c510275"
      unitRef="usd">48477000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i195c3e4a70d140e6a8c0d6fbd576c739_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzItMy0xLTEtMjAwNTcx_79201032-f3e9-423a-b407-8a5cdd7f791a"
      unitRef="usd">42841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5d7926d786e4e449517abc30d8e145f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzMtMS0xLTEtMjAwNTcx_cbb62fe0-9a32-4049-bb38-096eae655b74"
      unitRef="usd">1129000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2160ad80e344e7a85fc8a96deb9476c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzMtMy0xLTEtMjAwNTcx_0a4eea7e-221a-454d-ab9a-38cd9c8ad667"
      unitRef="usd">1130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzQtMS0xLTEtMjAwNTcx_9b8d9d7d-c1a3-4ccb-bccb-89fe7b0e3772"
      unitRef="usd">49606000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzQtMy0xLTEtMjAwNTcx_8d59aa7a-e0f8-4239-af4a-5b6bca8bf2ae"
      unitRef="usd">43971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65ff688f93904d2baa8f773161063474_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzUtMS0xLTEtMjAwNTcx_57e55933-f3fd-4cf8-9469-998823bcdc02"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzUtMy0xLTEtMjAwNTcx_9f068f11-3995-483a-90c5-fd905b4a3662"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzYtMS0xLTEtMjAwNTcx_e5ed5148-09bd-4c32-b5ea-49aa34f603b0"
      unitRef="usd">49603000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpmNDUwMDFjODM1NTY0ODczOTk5OWJkNGQwY2NkN2E5Yi90YWJsZXJhbmdlOmY0NTAwMWM4MzU1NjQ4NzM5OTk5YmQ0ZDBjY2Q3YTliXzYtMy0xLTEtMjAwNTcx_2210778b-0be5-4e0a-a007-ca0aee6387be"
      unitRef="usd">43968000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQzNzY_8713025a-3767-4808-a8d1-d33d8feeea20"
      unitRef="usd">6000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQzODM_2562991e-7b23-43b1-8695-1e2c512afab1"
      unitRef="usd">7000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MjM_29715fe1-9bc1-4df8-b2c8-e977b36ccffa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifdd40bf9e64d4e28aba32338f5e1c3f3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzItMS0xLTEtMjAwNTcx_78436ec1-474e-4ab0-9c4f-840d57734d78"
      unitRef="usd">431000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iab13212bf3f64da69caee3d568418629_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzItMy0xLTEtMjAwNTcx_36eb2741-4818-466d-94cb-35bdee8b6bcb"
      unitRef="usd">406000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iad9bf49c924d4d84898b126cd4f6a3ff_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzMtMS0xLTEtMjAwNTcx_4923493d-efe4-4422-9eff-6ac0afcfa3ac"
      unitRef="usd">-8000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i015c85ec14f2406f8e7dffe472b4851c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzMtMy0xLTEtMjAwNTcx_15d404aa-0b87-4eee-a64c-db4df7ba1f73"
      unitRef="usd">123000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzQtMS0xLTEtMjAwNTcx_5f172d0c-d9dc-443a-8e7c-ed1a5e75f6ae"
      unitRef="usd">423000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie64d2318949545f78a6514d6e2a7c0a1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzQtMy0xLTEtMjAwNTcx_a6182ee9-d0b4-42ad-abad-bdcab699cad1"
      unitRef="usd">529000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65ff688f93904d2baa8f773161063474_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzUtMS0xLTEtMjAwNTcx_10afff6b-aff3-48ef-9aab-4962f20fce64"
      unitRef="usd">-286000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1289f8c1f72343758713233ac0fd6d08_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzUtMy0xLTEtMjAwNTcx_0c7b00a8-fbac-4f40-8a45-8903aefda8dd"
      unitRef="usd">-114000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzYtMS0xLTEtMjAwNTcx_07d40fae-b28b-44d8-87e1-9ac389a9d386"
      unitRef="usd">137000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTpiNjI5MzRjOGFmYmQ0ZDZkYjM1MDc1MTI5NWRiOWVmYy90YWJsZXJhbmdlOmI2MjkzNGM4YWZiZDRkNmRiMzUwNzUxMjk1ZGI5ZWZjXzYtMy0xLTEtMjAwNTcx_e3de778d-9ff3-40af-b63f-029c34b61e9f"
      unitRef="usd">415000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90ZXh0cmVnaW9uOjMyOWEwZGM5NTc4OTQ5YmM5YzgzZTQ5NjU3MDJkYmY3XzQ5MzE_0c93bd15-49dc-424f-a330-fbeb9bbcfc1e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,796&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="ie81002aafca94fc2b38566fff63f36b6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzEtMS0xLTEtMjAwNTcx_48de397c-78ac-4350-87a3-66248ec27807"
      unitRef="usd">27253000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i28f690daefd04e45ba22e43204d3f8ce_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzEtMy0xLTEtMjAwNTcx_8188d2b1-1b6e-4d80-86a7-9a4dd62491a7"
      unitRef="usd">26409000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2a03688720b448f29df8a3a0536629e2_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzItMS0xLTEtMjAwNTcx_bfabd72a-2cfb-41d2-8e21-33b4f321bc5f"
      unitRef="usd">11338000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8ead376383b64ae98d667697c55cf194_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzItMy0xLTEtMjAwNTcx_08ac1dc2-8184-437c-b830-ea8fbc327265"
      unitRef="usd">11632000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8c8d1a31b74a43529c08389b432be66a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzMtMS0xLTEtMjAwNTcx_ed279996-03c1-4272-a23c-c7c9b8021225"
      unitRef="usd">4796000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i99c33230a00c486e83ac2a0e6d04febe_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzMtMy0xLTEtMjAwNTcx_9385c091-fec0-4f49-8c70-5168c3866802"
      unitRef="usd">5837000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic9365f443f224be298ffcc176e64bb3d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzQtMS0xLTEtMjAwNTcx_8c5bbf96-e0ce-4170-8674-8c6ab146e2a2"
      unitRef="usd">43387000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id865979318b34ac9a0006dc78693a91a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTUvZnJhZzozMjlhMGRjOTU3ODk0OWJjOWM4M2U0OTY1NzAyZGJmNy90YWJsZTo5ZTE5YzA0Y2QxNzQ0MjZkOGI5MGFjZDBhYTc3ZWRiMy90YWJsZXJhbmdlOjllMTljMDRjZDE3NDQyNmQ4YjkwYWNkMGFhNzdlZGIzXzQtMy0xLTEtMjAwNTcx_6d7e68bc-74ad-4cc6-8849-e44108178839"
      unitRef="usd">43878000000</us-gaap:Assets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI0NDE_6d934825-2601-4e3a-b6ed-9e4c7312b269">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59.43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $119 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI0MTI_1c5210be-7dd6-4161-b47a-edec0c5e6f31">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzItMS0xLTEtMjAwNTcx_34519fee-67c4-444e-9987-44295c79cc84"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24b600072fc640a2accf8530d5da12dc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzItMy0xLTEtMjAwNTcx_74039a6b-1851-4cf4-866a-e801dc9617be"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzQtMS0xLTEtMjAwNTcx_6842f611-784f-47ba-89eb-16b109611558"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i43ad627a1ffc43319b21b5b9c5ec5da3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzQtMy0xLTEtMjAwNTcx_687747d4-669c-4112-8ed7-f9c42902f344"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzUtMS0xLTEtMjAwNTcx_d9cecabb-0a38-467d-80aa-a4f72840f0ad"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTphMTY0YjJjMzNlMzc0MTFhOTMxZjg0MTAyMjM5MjZjMi90YWJsZXJhbmdlOmExNjRiMmMzM2UzNzQxMWE5MzFmODQxMDIyMzkyNmMyXzUtMy0xLTEtMjAwNTcx_ab45beb7-28ee-497b-b35c-d00a0544fe2b"
      unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI5MQ_0a9e02a8-d2c4-4fb9-8fb3-05a7532f7724"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ib5540d97c8e94418a71568830cef4eb7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzU0OTc1NTgxNjM0NA_85d4e2ca-823d-41dd-af35-b19fe4cd7998"
      unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzQ2OQ_0b36de9d-5be5-4a37-8a57-277254c67674">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzIzODg_ed188e50-e518-46ca-9700-c3c6c9c2c667">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59.43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i22ab637b9b2d4e64a547c5de3c7224a8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzEtMS0xLTEtMjAwNTcx_07bbcd85-1433-4d20-b456-da557fdd8ef5"
      unitRef="shares">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i22ab637b9b2d4e64a547c5de3c7224a8_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzEtMy0xLTEtMjAwNTcx_c0255b58-ee0d-4255-9a19-2a2cf24f7d0f"
      unitRef="usdPerShare">46.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzItMS0xLTEtMjAwNTcx_62e4d12e-ec7b-4466-be89-0df030386d3e"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzItMy0xLTEtMjAwNTcx_ff491ad4-3674-4aa2-a4c5-032820eaf3c4"
      unitRef="usdPerShare">69.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzMtMS0xLTEtMjAwNTcx_bfe74c68-cfb4-4040-a2b5-eee1d575c43c"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzMtMy0xLTEtMjAwNTcx_a74692a5-e5b2-40e3-9e69-8048ed3d24b4"
      unitRef="usdPerShare">49.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzQtMS0xLTEtMjAwNTcx_5acd6826-bfe5-493d-8e2b-ae5ba79c7033"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzQtMy0xLTEtMjAwNTcx_bae439b8-b497-4ee3-9bd1-9c5d4fa778b6"
      unitRef="usdPerShare">54.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzUtMS0xLTEtMjAwNTcx_930c826b-05eb-41d6-9dfa-4da3530afa4b"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTo2ZGRmMjcwYTM4MDY0OWUzODY2MjJlYmMzZGEwZGEyOS90YWJsZXJhbmdlOjZkZGYyNzBhMzgwNjQ5ZTM4NjYyMmViYzNkYTBkYTI5XzUtMy0xLTEtMjAwNTcx_77dc5995-cf46-48da-b837-e1443acf624b"
      unitRef="usdPerShare">59.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if63fbb11d1d74abd8bdf47907e4d63f6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzgxNg_fd189f71-bd02-4058-b062-38b5949bc81b"
      unitRef="usd">119000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzg4OQ_29c70fc8-d21e-4f6f-944c-791096a01d7f">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE2MTQ_37d10fac-6266-43b3-ac5d-0baa6ddc165a"
      unitRef="reportable_segments">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic4a1eacea71a4285aadeba26a17758a0_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3Nzc_799800f1-2d4d-4879-826e-03c5a0cd34e7"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8c7555e89f9a44c0be6b8791b103af9c_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3Nzc_db54ca3f-d3d2-4a9b-b808-f01cc3d48616"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iea97411b6d7641378c9eb6b952443d0d_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3ODM_34ecb77e-458a-46d3-b09f-8facb42a7e1c"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9f28dc925abc41bb8cf3ce6828882c78_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE3ODM_5dd068a3-80e2-4b9b-91d3-be61783516c3"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1b0209d5fc294341b06b2c8dbf923e09_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTM_0f4a2e12-d05a-45cd-9e4d-4503341af023"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1f1fe6789c734a7cb6a29d3d8764b93b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTM_189c78dd-b906-468a-9b88-cfd5cd861da9"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2ada8d3d750f4d05bd88fb3b24af4514_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTk_1ae150bf-ffd7-4e5a-afa5-8ce6b0928c85"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia8eb22db75ac48e3948c5833cc36811c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzE4NTk_77456e6f-d8e5-4e28-8741-ea07a276a7c3"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i2b05f6c142134569a5186e72d5061146_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzI0MjQ_0b0e95d7-dd47-48fe-a339-409c7048ba71">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i217061d4807f455b88c7f795a4fa433d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzEtMS0xLTEtMjAwNTcx_4dc86c00-157d-42a2-9480-9ff6f41fd73e"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i217061d4807f455b88c7f795a4fa433d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzEtMy0xLTEtMjAwNTcx_051d538d-331e-4177-ab15-ab48cd69b67c"
      unitRef="usdPerShare">54.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzItMS0xLTEtMjAwNTcx_18237de7-cd46-48e4-9c01-7f70a242679d"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzItMy0xLTEtMjAwNTcx_ff1932ad-72ef-4428-ad9c-89a654a4acde"
      unitRef="usdPerShare">76.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzMtMS0xLTEtMjAwNTcx_7fc4aeaa-547f-4ca9-bb6f-2b1fd33b5ca1"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzMtMy0xLTEtMjAwNTcx_269305bd-31f9-4c0e-a551-1d4a02720060"
      unitRef="usdPerShare">59.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzQtMS0xLTEtMjAwNTcx_1bed27e2-95ac-416c-af4b-2261b14c1657"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzQtMy0xLTEtMjAwNTcx_f8690270-b62f-44fe-90a8-df342514a8e7"
      unitRef="usdPerShare">57.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzUtMS0xLTEtMjAwNTcx_1c449910-f5b0-4657-808a-20cafcf7413f"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90YWJsZTpiOTZkMWQ5ODA4YmI0MmU0ODBkYTI2NjE3ZGE3YzBiZi90YWJsZXJhbmdlOmI5NmQxZDk4MDhiYjQyZTQ4MGRhMjY2MTdkYTdjMGJmXzUtMy0xLTEtMjAwNTcx_725455b3-9ddf-4097-923d-2088343edb01"
      unitRef="usdPerShare">72.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1d9ddb47d76d4c8dab48d4435d5dcb92_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzIyNjc_d5ee7db7-9370-452d-b325-09d734442ff5"
      unitRef="usd">28000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6786ddf7023f42559db1005ec9e8ab6b_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMThjZjc1MWUzYjQ1ODhiY2ZlNDAxNzVjM2Y0MGExL3NlYzpiZDE4Y2Y3NTFlM2I0NTg4YmNmZTQwMTc1YzNmNDBhMV8xMTgvZnJhZzozNmRhY2NmZGIwMmQ0ZjM0OGI5MmVjMTNiY2ViYTg2Mi90ZXh0cmVnaW9uOjM2ZGFjY2ZkYjAyZDRmMzQ4YjkyZWMxM2JjZWJhODYyXzIzNDA_b95a03a7-9d75-49a4-89f9-c8ec1dcfb91b">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'CC]*M3]PEZ_P]YM'HL,ZM"2?ZX62DM,Y']=P2J-#=S&3'6?JPV+X;*'Y:M
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M[(4+=T#/A/*);Z;G-_1\*[T[P78T@3%^V)53758#SM66"1-17Z. <3 ?\#2
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M5+9!!R1K(5E>#581Y+0H/_%C1<3. .7'/0!5 Y ](#HP(*P&A/: P8$!437
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M>VC9@+X7QOC=@!WT[\?EOU!+ P04    " ![2615$< 5D=4&  #H$0  &0
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M89E+I*1E CQ?&^/;#2OH/NY<_Q=02P,$%     @ >TED5=T/=SNX!0  <PT
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M>BN<'(F7H?PD1(02D)JM6#C.Z"^279\%;I.&.H.W215#+3<Q1> =54 V9++
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MYZGWG9=U@52*E@[)1$Y*5HXY"%1I\-E36O#L6=!EGJ,G8A9?-4EDKN",\DM
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M%UMY2ENRNPWM"KOG>?#LHW1S4,?U.=WH4L]2PJXS)*R47+ZBRW7KMBJYBEG
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M<VAE970Q-"YX;6RM5FUOVS80_BL'=2@2(+!LV6X\US:0I"NVHD&#IFL_%/M
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MA:>Y#OOU3&PZ%1U#UD%%AFE!*%#4@.>[IW[S^?&YY.N2"<0N8]I/H7Y0.:7
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M;;3G893D4OL<(;>L(F8O6?W:& ;@SZEJER*+TX@JII/*Z1]6T#9AP;<7WPL
MF1^VHZ\%,MC%W'\R^;RR#VVQG;[1O+5R29W2;*[ :L8>$]81Y?OA?(ABY@TJ
M( 0+E)>W^5J9%=.EK2KMX_;[*)N_O$1%M<'<:]J60J:?:\??%4^L\5Z_:Y..
M$=T> RGGI?6-U*\M9$&+;3<7A+/:P8&N47=:L6&'CH_O18!]T[TW6N[F0@&V
MH^R7V>P*:$6[<2+H:H\H%Y'"=VKY1%'"A.ZZ9V8)ZX(=0DWL28B=^)K(1J4^
M,K$/NA(< _JO*5:M,&3Z>)Q\ZI:ZM0JDEDO4N)]*"=>W39+H/V\'G]!F+! ,
ML5N'!BN[$)7:@G.$=?WL\3O$_8 <TI&=Z%F_$ST[NA-=<PYH]*J'N[>1HE"F
MP%3PAW:FKW$+#;P!G8!\W#_];@/]C;/MK+!1,!]8ZM -$25/I? :Q.5I[KLN
M@$X!]K3H>[?0J-A_(?B%Q1_D^&HVOX <16 /[&3E:8,3J_Q+A9R\;NHBRAR"
M@W9OM&U\FU.T&9#&SF2V@U1BNYN%<:YUS?E;5#_FU49^C#V<9\L!%+D_)*-Z
M-QJXXJ11.VR)QV_(5&9RRWM7JB^0>Q>]P?F_1W$P%=6Z;;LKK!TS5>GL>=^F
M-CS4!Z.]TW;%;A6_*3S%D.G@W3_M/UMFZ;2^6YZ^>=XJM\)(I9*7,!T/?X#V
M7?J.2#?!UO'LOK !7P+Q<HU/+W:R .^7%GW>WDB _F-N^C]02P,$%     @
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MW)DBE-R'@"CB#P7?@C"S-<TT<C-SM0Z?IN;8YTKHIU3KE!]HUZ6B:BU0PFF
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M=Z"L@_F^E!*W&_N#]@)-_@)02P,$%     @ >TED580BZ)IH P  !0T  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULM5==;]LX$/PKA%H4*=!&HAPK
M=LX68.<#/:#!!3':>SC< R.M+;:4J)*TG?S[(RE%<LX2:[C-BTU2VMG9%6=$
M3;9<?)<9@$*/.2ODU,N4*B]\7R89Y$2>\A(*?67)14Z4GHJ5+TL!)+5!.?/#
M((C\G-#"BR=V[4[$$[Y6C!9P)Y!<YSD13W-@?#OUL/>\<$]7F3(+?CPIR0H6
MH+Z4=T+/_ 8EI3D4DO(""5A.O1F^F..Q";!W?*6PE3MC9$IYX/R[F?R93KW
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MTR0/$=1X[_7__^K]G9-I#F)ES]\2)7Q=J.J0VJPV9_Q9=;)M;Z\^$&Z)T'M
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M F]B<4=WOY'"(3>S-Z<QS_^"72%K#\!\PP5-"F6)((G2_7_\O0C$@8*THU=
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MMF0P_?DGZ-F_Z+SOR5@E%L,R%D.3]>D?LELI]W6N[O6]7#]K3-LIA&-K>^B
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MPPV0 'CR@+J_8DP^GR0)BDV^Z?]02P,$%     @ >TED51\2IPK:!   $1T
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M^5UOJ&Q1U:C>9TIE2?5Q+KB>()<'Z.]G6::>-\H&FLKKR7]02P,$%     @
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MZ0S"G'$9Q"-_-M?Q2)56<(ES#:;,<Z9_3E&H[3CH!KN#![[.K#L(XU'!UKA
M^Z&8:]J%#4O*<Y2&*PD:5^-@TKV>#9V]-_C(<6OVUN"4+)7ZYC9OTW'0<0ZA
MP,0Z!D:/#<Y0"$=$;GRO.8/FDPZXO]ZQO_':2<N2&9PI\8FG-AL'5P&DN&*E
ML ]J>X>UGK[C2Y0P_A>VM6TG@*0T5N4UF#S(N:R>[$<=AST \;0#HAH0'0,N
M_P+HU8">%UIYYF7=,,OBD59;T,Z:V-S"Q\:C20V7+HL+J^DM)YR-;YF67*X-
MS%'#(F,:86*MYLO2LJ5 L IF3*=<,@%WR(3-7L!;F5S V0,F2B9<<.;SH58P
M4WE.*\]BX(/!U,-57I068<H,3X#)%&ZXH(,4;N>+<SB[0<NX,.?P$DR%K!]<
MPCT7@LC-*+2DU7D<)K6N::4K^HNN'MPK:3,#MS+%]! ?4HR:0$6[0$VCDX0+
M+"Z@UWD!42>*6OR9/1[>/>%.K\E;S_/U'I^WSY.EL9KNQ9>V<%5TE^UTKE=<
MFX(E. ZH&1C4&PSBY\^Z@\[K-JU/1':@_+)1?GF*/?[D;R:F+]D&-34:2*JR
MJZKF^;.KJ-M]O?3%=L9WQ^=M(:F^T_??<=UN$T=#RLUF7VF+S=6PL3D0T&\$
M]$^G;K6B'N8N3.HN G4Q,)B4FEN.YKK-T?Y3YNZ)R ZD#QKI@T?E#B9U[MZ5
M^9(*>-<1ZM;QOK3&4J>@ H=)^I6Z(,T-VQ:9P9_I.4K@*8L##<-&P_#_ZR^M
M!?VC H<M%=@[$M!B<_7J2$*X-P!RU&L_%PUY5DI;M;CFM!F]$S]QCLZG-)*K
M"?J;IIKG]TRON30@<$64G8LA>:2K&5EMK"K\F%DJ2T/++S/Z6X':&=#[E5)V
MMW$?:/ZHQ+\ 4$L#!!0    ( 'M)9%6O5P.Z?P(  /<%   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;*U4P6[;, S]%<(#A@WH8L=.NZ%+#"1IA_;0
M+FBP]3#LH-B,K566/(E.NK^?)#M>6J1!#[M8(L7WQ$>+'&^5?C E(L%C):29
M!"51?1Z&)BNQ8F:@:I3V9*UTQ<B:N@A-K9'E'E2),(ZBL[!B7 ;IV/L6.AVK
MA@27N-!@FJIB^L\,A=I.@F&P<]SQHB3G"--QS0I<(GVK%]I:8<^2\PJEX4J"
MQO4DF [/YR,7[P.^<]R:O3TX)2NE'IQQG4^"R"6$ C-R#,PN&YRC$([(IO&[
MXPSZ*QUP?[]C_^*U6RTK9G"NQ#W/J9P$GP+(<<T:07=J>X6=GE/'EREA_!>V
M76P40-884E4'MAE47+8K>^SJL >P/(<!<0>(GP-&+P"2#I!XH6UF7M8%(Y:.
MM=J"=M&6S6U\;3S:JN'2_<4E:7O*+8[22Z8EEX6!!6I8EDPC3(DT7S7$5@*!
M%,R9SKED JZ0"2I/X%IF [AE6C/W"^#=!1+CPKR'#V <@]DM7,(-%\+^+C,.
MR6;K[@RS+K-9FUG\0F8)W"A)I8%+F6/^%!]:E;W4>"=U%A\E7&(]@"0Z@3B*
MXP/YS%\/'QY))^DKGWB^Y/65_S%=&=+V9?\\5*Z6;G28SG7[N:E9AI/ MK-!
MO<$@??MF>!9]/J3U/Y$]43[JE8^.L:?WOK<PA^D&M1T5<-M4*UN$"RX:YUZV
MK^=K0X:8M&^O@&G^R_:"G1YTJ#+M=:?^.C>V-NEH'&[VY1Z+:#6$>SU4H2[\
M:#&0J492^\9Z;S^]IKYIG_EG=JJU0^@?33L2;Y@NN#0@<&TIH\%'FX]NQTQK
MD*I]IZX4V;[WV]).9M0NP)ZOE:*=X2[H9WWZ%U!+ P04    " ![2615YA$A
M)@P#   +"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RM5FUOVC 0
M_BNGK)I::6M"PILZB%1HMU4J+8)U^S#M@R$'>'7LS#;02OOQLQW(4@I9-^U+
M8CMWSSW/V;Y+9RWDO5H@:GA(&5==;Z%U=N;[:KK E*A3D2$W7V9"ID2;J9S[
M*I-($N>4,C\,@J:?$LJ]N./6AC+NB*5FE.-0@EJF*9&//61BW?5JWG9A1.<+
M;1?\N).1.8Y1WV5#:69^@9+0%+FB@H/$6=<[KYWUV];>&7RFN%:E,5@E$R'N
M[>0JZ7J!)80,I]HB$/-:81\9LT"&QH\-IE>$M([E\1;]O=-NM$R(PKY@7VBB
M%UVO[4&",[)D>B36'W&CIV'QIH(I]X1U;MNH>S!=*BW2C;-AD%*>O\G#)@\E
MAR@XX!!N',(=AS \X!!M'"(G-&?F9%T03>*.%&N0UMJ@V8'+C?,V:BBWNSC6
MTGREQD_'8YR;/=%PQ?,385-[0Z0D-KMP?(&:4*9.X @HAP%ES!BHCJ]-: O@
M3S=A>GF8\$"8" :"ZX6"2YY@\M3?-Y0+WN&6=R^L!!QC=@I1\ ;"( SA;GP!
MQT<GH'(U>_CU7PY7V\)5T(R*]$8.MWX ]X.Y1W!\+91)X0@9T9B %G!--9WG
MR3;W1#,\P+J7HS<=NKV0J_AMV.KXJ[*R/3:U=F'SA':]H%VOI'VS3"<H0<S
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MBKOMPVH?QG!CHP6&#F-[(_7'[_ 1\& \B9OQ2P+XWL.]YQ[P\<QX2]FW? 7
MT?<D3O.)L>(\NS3-/%A!0O(+FD$J/GFB+"%<G+*EF6<,2%@F);&)+<LS$Q*E
MQG1<7GM@TS%=\SA*X8&A?)TDA#U?0TRW$\,V7BX\1LL5+RZ8TW%&EC '_CE[
M8.+,;%#"*($TCVB*&#Q-C"O[<H;](J&,^#N";;YSC(I6%I1^*T[NPHEA%15!
M# $O((CXMX$9Q'&!).KXMP8UFGL6B;O'+^B_E\V+9A8DAQF-_XE"OIH8OH%"
M>"+KF#_2[2W4#0T*O(#&>?D7;>M8RT#!.N<TJ9-%!4F45O_)]YJ(G02!TY^
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MS>P&)60)I#GC*1+P-+?>XNLE&14)9<0G!OO\8(R*5M:<?RTF=^'<<HJ*((9
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MT>N&Z$<(>!HPE1&A.PD)^O*'2BZ'^5]#3%8[><,[%<^!ZSRC <PM]4'/0>S
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MG'-]D]S;7E/VQ!<  CU'(>$=8R%$?&F:?+* "/,+&@.15V:415C()9N;/&:
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MJ0!Y?4:IV"S4#?)AW_\+4$L#!!0    ( 'M)9%6A=S P/P4  ,,G   9
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;,6:;6_J-A3'OXJ574V]4M<\\-"6
M 5(AB7:G]:HJMW<OIFDRB8'H)C'7-J6=]N%G)R$/-+@P'8TWA3@^OV/[?_S
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MN^CK_TIDW6$V43RU#=:"*]VNV6&L.VH0)D!_7W*N]A.S0=&C!W\ 4$L#!!0
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M<I0J'M]%Q\B->_ NI*'GLVNNZ8,%E5U \TLIS;%C-R@_@2;_ 5!+ P04
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MJ&UVJUG.ETU_F7<&,/4^KDZK2JP^"E[(DKG)OSCA>$37O&"N-/]ELT&IS&R
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
M+AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*
M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC
M)8QQ8K3^-8+)#^Q^ %!+ P04    " ![2615:-V]WX0$  #L)   #P   'AL
M+W=O<FMB;V]K+GAM;,6:36_;.!! _PJAR[; =FWK(VV#ND :)]T V<:(@UP+
M6AK;1"G22]).TU^_(SEN*$0>[&7BDRV*EI\H<=YPI$\/UOV86_M#_*RU\>-D
M%<+Z=##PY0IJZ?^R:S"X9V%=+0-NNN7 KQW(RJ\ 0JT'Z7!X,JBE,LGG3_MC
M3=T@WK !RJ"LP<:FX5[!@W_>WVR*K?)JKK0*C^.D_:XA$;4RJE:_H!HGPT3X
ME7WXVSKURYH@]:QT5NMQ,MKMN <75/FB>=9 WLFY;UN"G-]*!!DG)T,\X$(Y
M']H>[?$E,FX!.^^V-L%>*AW 362 K\YNULHLF\/@60RBTVC'8?^Y&\13]W^&
MT2X6JH2)+3<UF+ ;1P>Z 31^I=8^$4;6,$[.[1:<F,HE-">%_W)5[4XP(%DT
M7.Y4X0YW5;6,G#RF N.A$OC-6ZTJY*C$K,'!GT:0*0&9'A'R>QI!9@1D=A3(
M+U)+4X*((',",C_F2&819$% %L>$S"/($P+RA!?RB_3*"[L04P<>N[8]A#3(
MN:EK&4&^)R#?\T)., CZH,(&&2.B#P31!UZB6^1QFQ*), *WPW51K[5]!! S
MV,9!\2,!^9$7\JNUU8/2NN6["2N,V%=XA<VRP1!G<>0>4J%[R(MY;<WRW1VX
M6MS,M5KN.CPSQYBD8=@54]<J-)W\G\V,#GCE<4-<*]ED"3$FY9@1LV2N3&EK
M$'?R9V>NC"BEC)B=<BF5$_=2;T#\ ]+C-&Z',<:C9#)BMLFE,N@V)35.CV9:
MOX"C)#)BMLAL)1VLK*[ ^3_$Q;\;S$=C-LH=(V9Y7$AG<!9X,<70TH**LQ"<
MFF\PK=6=U)"RQXA9'S-8-CWPZNY^COMC-$HC(V:/M(/V#B7<9@DU'LF_X*,,
M,F)6")D>=%+6E%)(RJP04L==3$HA*;-"2"%W,<EE"K-"#H1K\>:NF=5Q9$PI
MJZ3<5ND+VWO(MS$E)9>462Y]\;L7DI),RBP9,I!W;TS*-RFS;WH">>]04K))
MN65S(*(_@<:8E'A29O'$2RKQ9@)!*MT=1$H[*;-VZ'@>K^\S2CO94;43K_ S
M2CL9LW9HS"+&I+23,6N'MF/GHI/U,6;MT)B=BTYY)V/V#HW9N>B4>3)F\Y"+
M_VY-E#)/QFP><O'?Q:3DDS'+)U[\BV_2.=D\/_@=WV-,2CX9LWP.)9A/Q#$F
M9:&,V4+]">;O88U+X92%<F8+'<B#V_JM>^Q4["D+Y<P6ZDV$G^_1&).R4,YL
MH?Y\_7R%D1/G5'QOYI2%<F8+T1E[+,N<?$[#;"$:,Y9E3EDHYRZR]2PLHO 9
M8U(6RH^Q_KF%+1B,I/.X+)A3%LI?O]Z&X>BI<1H7]'/*0CEW[:T/\\Q[P.@Y
M[\9-RD(YLX7Z,"?*R^72 >9+\;-.RD(%LX7Z,)]OS7@T"\I"Q6M8J&]YOION
M,29EH>(U+-1;19CAT:L8D[)0P6PA$K.3%A>4A8K7J,$=Q.R\+D"^+]!::+!_
MNZ:"A3)0?<._\-A>2EU.G6@^=@\!\Z(IW2\V6I]CVXVYMK+:OZRS?]'H\W]0
M2P,$%     @ >TED5;P!UL'@ 0  ["   !H   !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<\W:.T[#0!2%X:U$7@"3^YCP4$)%0XO8@!4F#Y'$EF<0R>Z)
M0A&.14&#YE36V/+UW_B397O^DG9MV7:'O-GV>7+<[PYYT6Q*Z1]"R,M-VK?Y
MINO3X7QDU0W[MIR7PSKT[?*]7:>@T^DL##]G-(_SGS,GKZ<^_65BMUIME^FI
M6W[LTZ'\,CA\=L-[WJ14FLEK.ZQ3633AN+ONSN&RD9OSY&;R_+9HAN<W:4+M
M((4@K1]D$&3U@QR"O'Y0A*!8/V@&0;/Z0;<0=%L_Z Z"[NH'W4/0??T@F:*,
M4X*D$=8$6@MR+01>"X(M!&(+DBT$9@NB+01J"[(M!&X+PBT$<@O2+01V"^(M
M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]
ME4!O1;V50&]#O8U ;T.]C4!O0[V-0&\;O2PAT-M0;R/0VU!O(]#;4&\CT-M0
M;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;46\GT-M1;R?0VT<ONPGT=M3;"?1V
MU-L)]';4VPGT=M3;"?1VU-L)](ZH=R30.Z+>D4#OB'I' KTCZAT)](ZH=R30
M.XX^5OZGWKF<=BE?>[[7>/W_I+J<STW7RU^6WSM'-]0%YP _-SQ^ 5!+ P04
M    " ![2615%-1QY- !  "M(   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-
MVLENPC 4!=!?0=E6Q'@('01LVFY;%OT!-WE 1!);MJ'P]W7"(+6BJ(A*O1LB
M8OO=%ULZFV3TMK7D>YNZ:OPX681@'QCS^8)J[5-CJ8DC,^-J'>)?-V=6YTL]
M)R8&@R'+31.H"?W0UD@FHR>:Z545>L^;>-N7IADGCBJ?]!YW$]NL<:*MK<I<
MASC.UDWQ+:6_3TCCRFZ.7Y36W\0)"3N9T([\'+!?][HFY\J">E/MPHNNXRRV
MJ9@/VXI\>K[$B1[-;%;F5)A\5<<EJ;>.=.$71*&NTEW1F_/)(>XP[7[YU?E=
MF7.!<>;4&>OCB3FZ/.YP).WJOHV%R(7R_",>$V/IJY^/VM,NJ/AE=MS>#^.6
MW7EXUEVNW^.O9WRL?V$? J0/"=*' NDC ^EC"-+'+4@?=R!]W(/TP0<HC:"(
MRE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM D56@
MR"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K0I%5
MH<BJ4&15*+(J%%D5BJP*15:%(FN&(FN&(FN&(FN&(FN&(FOVG[*^&[/\ZQ?H
M[36M==D<\EGWE<+D$U!+ 0(4 Q0    ( 'I)9%4'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ >DED
M5; )&,?N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ >DED59E<G",0!@  G"<  !,              ( !
MS $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !Z26154;$8XL(%
M  #!'@  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ >DED56571EG:!0  3!<  !@              ("!
M!0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( 'I)9%72
M\?:NB0,  #T+   8              " @144  !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"% ,4    " !Z26158QUJ7R0&   .&P  &
M    @('4%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M>TED55OINW#Q"   %TX  !@              ("!+AX  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( 'M)9%7^7 99C <  -LF   8
M          " @54G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " ![2615%[#1SR@&  !J$   &               @($7+P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ >TED5;8$MEXY P  Q 8
M !@              ("!=34  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( 'M)9%5P481_(@0  $L*   8              " @>0X  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " ![2615$< 5D=4&
M  #H$0  &0              @($\/0  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( 'M)9%7=#W<[N 4  ',-   9              "
M@4A$  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ >TED
M52CP-V'>&0  4TL  !D              ("!-TH  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " ![2615S8#W5O,'  #G%0  &0
M        @(%,9   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( 'M)9%7;@N)[@@,  $H(   9              " @79L  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ >TED5>P]K8]6"P  F"0
M !D              ("!+W   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " ![2615XBEP;HL$  ##"P  &0              @(&\>P
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( 'M)9%5[=?],
M_@(  %D'   9              " @7Z   !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ >TED56K;E-NM"@  #!T  !D
M ("!LX,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " ![
M2615WD;%9T8%  "##@  &0              @(&7C@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( 'M)9%7\H[5C304  -@-   9
M          " @124  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ >TED533JY<$7 P  ^P<  !D              ("!F)D  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " ![2615'V2V/T$$   9
M"P  &0              @('FG   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( 'M)9%75J?7+E ,  %\(   9              " @5ZA
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ >TED5;L,
M&[?< @  708  !D              ("!*:4  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " ![2615;T+LSE$#  !A"   &0
M    @($\J   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M 'M)9%5S+)[$\@(  +P&   9              " @<2K  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ >TED58 6^LZ%!0  "@\  !D
M             ("![:X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " ![2615\>((UK4#  !/"@  &0              @(&IM   >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( 'M)9%4P=P]PX (
M - *   9              " @96X  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ >TED5;T?F,"Z @  3 <  !D              ("!
MK+L  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " ![2615
MA"+HFF@#   %#0  &0              @(&=O@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( 'M)9%7%,#""@@(  &8&   9
M      " @3S"  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ >TED57D8^Y27 P  GPT  !D              ("!]<0  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " ![2615^I %/CT%  "D'
M&0              @('#R   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( 'M)9%7=W72 PP0  / ;   9              " @3?.  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ >TED51\2IPK:
M!   $1T  !D              ("!,=,  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " ![2615<4Y&7\</  !S\P  &0
M@(%"V   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( 'M)
M9%4RI![WO 8  (4]   9              " @4#H  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ >TED5:(?SXJ= P  #1,  !D
M         ("!,^\  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " ![2615E<BZM2L$  "@$@  &0              @($'\P  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( 'M)9%43YX=EX (  (0(
M   9              " @6GW  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ >TED51)X9O&1!   *1T  !D              ("!@/H
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " ![2615FD^9
M7D4%  #X&P  &0              @(%(_P  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( 'M)9%4)4"02% ,  +0(   9
M  " @<0$ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M>TED5:]7 [I_ @  ]P4  !D              ("!#P@! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " ![2615YA$A)@P#   +"0  &0
M            @('%"@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( 'M)9%43ZAM@J@0  )@;   9              " @0@. 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ >TED5<_*!-Z> P
MIA$  !D              ("!Z1(! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " ![2615+[TCW08#  #S#   &0              @(&^
M%@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( 'M)9%7P
M<Q'W;@0  !@9   9              " @?L9 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ >TED5<OEL"IO P  ^ \  !D
M     ("!H!X! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'M)9%6CRMS"- ,  ,X3   -              "
M 10S 0!X;"]S='EL97,N>&UL4$L! A0#%     @ >TED59>*NQS     $P(
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9>&UL4$L%!@     _ #\ ,!$  "9  0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>184</ContextCount>
  <ElementCount>234</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DivestituresDetails</Role>
      <ShortName>Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/Divestitures</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Restructuring and Employee Severance Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Income Taxes Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Shareholders' Equity Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Segment Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails</Role>
      <ShortName>Segment Information Disaggregated Revenue Within Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails</Role>
      <ShortName>Segment Information Revenue by Geographical Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Share-Based Compensation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20220930.htm">cah-20220930.htm</File>
    <File>a23q1_10qx093022xex3113.htm</File>
    <File>a23q1_10qx093022xex3123.htm</File>
    <File>a23q1_10qx093022xex3213.htm</File>
    <File>a23q1_10qx093022xex9911.htm</File>
    <File>cah-20220930.xsd</File>
    <File>cah-20220930_cal.xml</File>
    <File>cah-20220930_def.xml</File>
    <File>cah-20220930_lab.xml</File>
    <File>cah-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20220930_g1.jpg</File>
    <File>cah-20220930_g2.jpg</File>
    <File>cah-20220930_g3.jpg</File>
    <File>cah-20220930_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="555">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20220930.htm": {
   "axisCustom": 7,
   "axisStandard": 26,
   "contextCount": 184,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 465,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 21,
   "keyStandard": 213,
   "memberCustom": 27,
   "memberStandard": 42,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Restructuring and Employee Severance (Tables)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Divestitures (Details)",
     "role": "http://www.cardinal.com/role/DivestituresDetails",
     "shortName": "Divestitures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i73291183b5c94c569731d6000358a035_D20210701-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Restructuring and Employee Severance Narrative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails",
     "shortName": "Restructuring and Employee Severance Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i3a25416abfca4ca5a2c8a79563abdbf6_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cah:JudgmentForLostProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Income Taxes Narrative (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "iee5307df37214cb5856b80573d7cd236_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurements Narrative (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "iee5307df37214cb5856b80573d7cd236_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments Narrative (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Shareholders' Equity Narrative (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ib8fa2946d75244f5af4e048c4b6f80f0_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
       "ix:continuation",
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
       "ix:continuation",
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Segment Information Narrative (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "if915e60e430a448e95ac1d3210262b21_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "ie81002aafca94fc2b38566fff63f36b6_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i3061556bb3664f40a526ed65a094ef2e_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
     "shortName": "Condensed Consolidated Statement of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i3061556bb3664f40a526ed65a094ef2e_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
     "shortName": "Segment Information Disaggregated Revenue Within Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Segment Information Revenue by Geographical Segments (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
     "shortName": "Segment Information Revenue by Geographical Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i74b65aec35854386926330a8514839c9_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Share-Based Compensation Narrative (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i22ab637b9b2d4e64a547c5de3c7224a8_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i217061d4807f455b88c7f795a4fa433d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i217061d4807f455b88c7f795a4fa433d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Divestitures",
     "role": "http://www.cardinal.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20220930.htm",
      "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "cah_A1BillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$1 billion share repurchase program",
        "label": "$1 billion share repurchase program [Member]",
        "terseLabel": "$1 billion share repurchase program"
       }
      }
     },
     "localname": "A1BillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A500MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$500 million share repurchase program [Domain]",
        "label": "$500 million share repurchase program [Member]",
        "terseLabel": "$500 million share repurchase program"
       }
      }
     },
     "localname": "A500MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home Solutions [Member]",
        "label": "Cardinal Health At Home Solutions [Member]",
        "terseLabel": "Cardinal Health At Home Solutions [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeSolutionsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedFromAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reclassified from Assets Held for Sale",
        "label": "Cash Reclassified from Assets Held for Sale",
        "terseLabel": "Cash Reclassified to Assets Held for Sale"
       }
      }
     },
     "localname": "CashReclassifiedFromAssetsHeldForSale",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture [Member]"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DiscountRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Rate, Fair Value Input",
        "label": "Discount Rate, Fair Value Input",
        "terseLabel": "Discount Rate, Fair Value Input"
       }
      }
     },
     "localname": "DiscountRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_GoodwillImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment",
        "label": "Goodwill Impairment [Axis]",
        "terseLabel": "Goodwill Impairment [Axis]"
       }
      }
     },
     "localname": "GoodwillImpairmentAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GoodwillImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment",
        "label": "Goodwill Impairment [Domain]",
        "terseLabel": "Goodwill Impairment [Domain]"
       }
      }
     },
     "localname": "GoodwillImpairmentDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GoodwillImpairmentMedicalUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment - Medical Unit",
        "label": "Goodwill Impairment - Medical Unit [Member]",
        "terseLabel": "Medical Unit Goodwill Impairment [Member]"
       }
      }
     },
     "localname": "GoodwillImpairmentMedicalUnitMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "Trademarks and patents"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IncomefromSettlementsofClassActionLawsuits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from Settlements of Class Action Lawsuits",
        "label": "Income from Settlements of Class Action Lawsuits",
        "terseLabel": "Income from Settlements of Class Action Lawsuits"
       }
      }
     },
     "localname": "IncomefromSettlementsofClassActionLawsuits",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_JudgmentForLostProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment for lost profits",
        "label": "Judgment for lost profits",
        "terseLabel": "Judgment for lost profits"
       }
      }
     },
     "localname": "JudgmentForLostProfits",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LitigationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Litigation Type [Axis]",
        "label": "Litigation Type [Domain]",
        "terseLabel": "Litigation Type [Domain]"
       }
      }
     },
     "localname": "LitigationTypeDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "terseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_LossContingencyNumberOfEligibleStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Eligible States",
        "label": "Loss Contingency, Number of Eligible States",
        "terseLabel": "Loss Contingency, Number of Eligible States"
       }
      }
     },
     "localname": "LossContingencyNumberOfEligibleStates",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Segment [Axis]",
        "label": "Medical Segment [Axis]",
        "terseLabel": "Medical Segment [Axis]"
       }
      }
     },
     "localname": "MedicalSegmentAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_MedicalSegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Medical Segment [Axis]",
        "label": "Medical Segment [Domain]",
        "terseLabel": "Medical Segment [Domain]"
       }
      }
     },
     "localname": "MedicalSegmentDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit",
        "label": "Medical Unit [Member]",
        "terseLabel": "Medical Unit [Member]"
       }
      }
     },
     "localname": "MedicalUnitMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NativeAmericanTribesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Native American tribes",
        "label": "Native American tribes [Member]",
        "terseLabel": "Native American tribes [Member]"
       }
      }
     },
     "localname": "NativeAmericanTribesMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net tax withholdings from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NuclearPrecisionHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Services [Member]",
        "label": "Nuclear Precision Health Services [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthServicesMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Numberofsharesexcludedfromcalculationofdilutedshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares excluded from calculation of diluted shares",
        "label": "Number of shares excluded from calculation of diluted shares",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "Numberofsharesexcludedfromcalculationofdilutedshares",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Segment [Axis]",
        "label": "Pharmaceutical Segment [Axis]",
        "terseLabel": "Pharmaceutical Segment [Axis]"
       }
      }
     },
     "localname": "PharmaceuticalSegmentAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PharmaceuticalSegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Pharmaceutical Segment [Axis]",
        "label": "Pharmaceutical Segment [Domain]",
        "terseLabel": "Pharmaceutical Segment [Domain]"
       }
      }
     },
     "localname": "PharmaceuticalSegmentDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits [Member]"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project Costs On Investment And Other Spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "label": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Definite and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_SegmentRevenuebyGeographicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Line Items]",
        "terseLabel": "Segment Revenue by Geographic [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuebyGeographicLineItems",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuebyGeographicTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Table]",
        "terseLabel": "Segment Revenue by Geographic [Table]"
       }
      }
     },
     "localname": "SegmentRevenuebyGeographicTable",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SettlingStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling States",
        "label": "Settling States",
        "terseLabel": "Settling States"
       }
      }
     },
     "localname": "SettlingStates",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_SettlingUSTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settling U.S Territories",
        "label": "Settling U.S Territories",
        "terseLabel": "Settling U.S Territories"
       }
      }
     },
     "localname": "SettlingUSTerritories",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePriceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program aggregate purchase price",
        "label": "Share repurchase program aggregate purchase price [Axis]",
        "terseLabel": "Share repurchase program aggregate purchase price [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAggregatePurchasePriceAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePriceDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program aggregate purchase price [Domain]",
        "label": "Share repurchase program aggregate purchase price [Domain]",
        "terseLabel": "Share repurchase program aggregate purchase price [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAggregatePurchasePriceDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TerminalGrowthRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminal Growth Rate, Fair Value Input",
        "label": "Terminal Growth Rate, Fair Value Input",
        "terseLabel": "Terminal Growth Rate, Fair Value Input"
       }
      }
     },
     "localname": "TerminalGrowthRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20220930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r95",
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r153",
      "r157",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r95",
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r153",
      "r157",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r165",
      "r318",
      "r320",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r228",
      "r230",
      "r231",
      "r232",
      "r256",
      "r293",
      "r330",
      "r332",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r534",
      "r537",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r228",
      "r230",
      "r231",
      "r232",
      "r256",
      "r293",
      "r330",
      "r332",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r534",
      "r537",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r165",
      "r318",
      "r320",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r204",
      "r228",
      "r230",
      "r231",
      "r232",
      "r256",
      "r293",
      "r321",
      "r330",
      "r332",
      "r360",
      "r361",
      "r362",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r534",
      "r537",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r204",
      "r228",
      "r230",
      "r231",
      "r232",
      "r256",
      "r293",
      "r321",
      "r330",
      "r332",
      "r360",
      "r361",
      "r362",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r534",
      "r537",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r105",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r105",
      "r110",
      "r226",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r95",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Condensed Consolidated Statement of Shareholders' Equity"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r318",
      "r319",
      "r535",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r318",
      "r319",
      "r535",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r105",
      "r110",
      "r226",
      "r331",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OKLAHOMA",
        "terseLabel": "OKLAHOMA"
       }
      }
     },
     "localname": "OK",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA",
        "terseLabel": "WEST VIRGINIA"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts Payable, Current"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r504",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r42",
      "r48",
      "r55",
      "r56",
      "r57",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r43",
      "r48",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r45",
      "r47",
      "r48",
      "r519",
      "r542",
      "r543"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r48",
      "r55",
      "r56",
      "r57",
      "r97",
      "r98",
      "r99",
      "r412",
      "r478",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r84",
      "r186",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r44",
      "r48",
      "r55",
      "r56",
      "r57",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r92",
      "r141",
      "r148",
      "r155",
      "r168",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r406",
      "r413",
      "r462",
      "r479",
      "r481",
      "r499",
      "r518"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r29",
      "r92",
      "r168",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r406",
      "r413",
      "r462",
      "r479",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r6",
      "r544",
      "r545",
      "r547",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "Net Assets",
        "terseLabel": "Net Assets"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r428",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r11",
      "r86"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r86",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r463"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r233",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54",
      "r65",
      "r509",
      "r529"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r53",
      "r64",
      "r402",
      "r417",
      "r508",
      "r528"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate",
        "verboseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r494"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r270",
      "r277",
      "r278",
      "r280",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r91",
      "r95",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r281",
      "r282",
      "r283",
      "r284",
      "r476",
      "r500",
      "r501",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r268",
      "r281",
      "r282",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r35",
      "r91",
      "r95",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r281",
      "r282",
      "r283",
      "r284",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r35",
      "r91",
      "r95",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r308",
      "r311",
      "r312",
      "r313",
      "r473",
      "r474",
      "r476",
      "r477",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Debt, Long-term and Short-term, Combined Amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r136"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward Contract"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r40",
      "r429",
      "r431",
      "r436",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r426",
      "r429",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r420",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r419",
      "r422",
      "r423",
      "r426",
      "r427",
      "r433",
      "r436",
      "r443",
      "r444",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r366",
      "r367",
      "r369",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r5",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r314",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r111",
      "r113",
      "r115",
      "r116",
      "r117",
      "r122",
      "r123",
      "r451",
      "r452",
      "r510",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r113",
      "r115",
      "r116",
      "r117",
      "r122",
      "r123",
      "r451",
      "r452",
      "r510",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r125",
      "r169",
      "r307",
      "r314",
      "r370",
      "r371",
      "r372",
      "r386",
      "r387",
      "r450",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r478",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r453",
      "r454",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r268",
      "r281",
      "r282",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r454",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r268",
      "r322",
      "r323",
      "r328",
      "r329",
      "r454",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r268",
      "r281",
      "r282",
      "r322",
      "r323",
      "r328",
      "r329",
      "r454",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r268",
      "r281",
      "r282",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r454",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r268",
      "r281",
      "r282",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments Disclosure"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r13",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r196",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r192",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r187",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r192",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r40",
      "r322",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net",
        "terseLabel": "Gain (Loss) Related to Litigation Settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r84",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on Early Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r12",
      "r171",
      "r173",
      "r180",
      "r184",
      "r481",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r173",
      "r180",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r84",
      "r172",
      "r177",
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r68",
      "r92",
      "r141",
      "r147",
      "r151",
      "r154",
      "r157",
      "r168",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r462"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r426",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r141",
      "r147",
      "r151",
      "r154",
      "r157",
      "r497",
      "r505",
      "r512",
      "r531"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r200",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r377",
      "r383",
      "r384",
      "r388",
      "r390",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax Disclosure"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r139",
      "r375",
      "r389",
      "r392",
      "r532"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for/(benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase/(decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r185",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r135",
      "r472",
      "r475",
      "r511"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r27",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r92",
      "r168",
      "r462",
      "r481",
      "r503",
      "r522"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r34",
      "r92",
      "r168",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r407",
      "r413",
      "r414",
      "r462",
      "r479",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r36",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability",
        "verboseLabel": "litigation settlement liability recorded"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-Lived Assets Held-for-sale [Line Items]",
        "terseLabel": "Long Lived Assets Held-for-sale [Line Items]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r35",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r228",
      "r230",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss Contingency, Pending Claims, Number"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r92",
      "r168",
      "r238",
      "r243",
      "r244",
      "r245",
      "r251",
      "r252",
      "r462",
      "r502",
      "r521"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r314",
      "r404",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "terseLabel": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by/(used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r4",
      "r49",
      "r52",
      "r57",
      "r62",
      "r85",
      "r92",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r114",
      "r141",
      "r147",
      "r151",
      "r154",
      "r157",
      "r168",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r452",
      "r462",
      "r506",
      "r526"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Earnings/(Loss)",
        "totalLabel": "Net earnings attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r52",
      "r57",
      "r108",
      "r109",
      "r409",
      "r416"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: comprehensive income attributable to noncontrolling interests",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r314",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r141",
      "r147",
      "r151",
      "r154",
      "r157"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r28",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r48",
      "r55",
      "r56",
      "r58",
      "r464",
      "r466",
      "r470"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other comprehensive loss, before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r43",
      "r45",
      "r430",
      "r434",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r50",
      "r53",
      "r55",
      "r56",
      "r58",
      "r63",
      "r307",
      "r464",
      "r469",
      "r470",
      "r507",
      "r527"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r50",
      "r53",
      "r402",
      "r403",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r46",
      "r55",
      "r63",
      "r375",
      "r391",
      "r393",
      "r464",
      "r467",
      "r470",
      "r507",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-Term Borrowings",
        "terseLabel": "Other Short-term Borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for Legal Settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r78",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value, Issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestitures, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r4",
      "r49",
      "r52",
      "r57",
      "r79",
      "r92",
      "r100",
      "r108",
      "r109",
      "r141",
      "r147",
      "r151",
      "r154",
      "r157",
      "r168",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r402",
      "r408",
      "r410",
      "r416",
      "r417",
      "r452",
      "r462",
      "r512"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r199",
      "r481",
      "r513",
      "r524"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r67",
      "r170"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r481",
      "r523",
      "r546"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r55",
      "r56",
      "r58",
      "r464",
      "r468",
      "r470"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Amounts reclassified to earnings"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r148",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r147",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r147",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r208",
      "r211",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r84",
      "r205",
      "r214",
      "r217"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "totalLabel": "Total restructuring and employee severance",
        "verboseLabel": "Restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r208",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r314",
      "r481",
      "r520",
      "r541",
      "r543"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r169",
      "r370",
      "r371",
      "r372",
      "r386",
      "r387",
      "r450",
      "r538",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r92",
      "r132",
      "r133",
      "r146",
      "r152",
      "r153",
      "r160",
      "r161",
      "r165",
      "r168",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r247",
      "r249",
      "r251",
      "r252",
      "r462",
      "r512"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r48",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r187",
      "r191",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": {
     "auth_ref": [
      "r3",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Schedule of Long-Lived Assets Held-for-sale [Table]",
        "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]"
       }
      }
     },
     "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r208",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r141",
      "r144",
      "r150",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r89",
      "r126",
      "r127",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r300",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r128",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r165",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r210",
      "r219",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r130",
      "r131",
      "r141",
      "r145",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r164",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r128",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r165",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r201",
      "r210",
      "r219",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r55",
      "r56",
      "r57",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r125",
      "r169",
      "r307",
      "r314",
      "r370",
      "r371",
      "r372",
      "r386",
      "r387",
      "r450",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r478",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r125",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r307",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r314",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Employee stock plans activity, net of shares withheld for employee taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r92",
      "r167",
      "r168",
      "r462",
      "r481"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r56",
      "r92",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r168",
      "r169",
      "r314",
      "r370",
      "r371",
      "r372",
      "r386",
      "r387",
      "r400",
      "r401",
      "r415",
      "r450",
      "r462",
      "r464",
      "r465",
      "r470",
      "r478",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedPeriodEndLabel": "Balance at end of period",
        "negatedPeriodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r314",
      "r317",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Stockholders' Equity, Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items [Axis]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items [Domain]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r471",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r471",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r471",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r37",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r37",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r21",
      "r307",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury shares acquired (using cost method), shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r37",
      "r315",
      "r316"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period",
        "negatedTerseLabel": "Treasury Stock, Value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r111",
      "r117"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r565": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r566": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r567": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0000721371-22-000133-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-22-000133-xbrl.zip
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M]2<'MHZM3"4WDCH@@SKP&:(D3[6EC.U7J?7IW?.GM@(!.? U5:HX;<EJ; A
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M-I;?]U=@.K5Q4B7UY79B=SNN<MK.QIE,G+6=2>VG+8@$):0I@@%(J95?O^\
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M L'"S"E)KT U,ZW#P6O01DC&T=]ME<.?5JZ3&0QJ2<K.O01 X:K+Z8S6"=Q
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M@4&FLV:!,5/6JNI25B2-&GG'VP%F0^O#504)DIX0Q<W8%HD5^MN8M.$*;Q@
M<S.3V1U*K95V-"#;V?C&[<MWK]^+EUGCM5R:T[MWNJ<^P'K@F9%ZCH]Z$'EN
M?2A6B3>@\,Q)[WH9U;-(#V^+0K,J]*:BJ"B@U7^@UPTY>;'#5N < <*,[]NE
MK,1[95<PQ .J&&HH&(#=H:)XW8M=.>BQ ;3F6U:108"Z2:=V/*"?C'AX2#P<
M!@$P8M6IB$'#"%J%5T*Z<'L(<!.#!8AB##L8CS LZMT-Q0KD?>H_ELCO'"./
M83\,>?7,MHGIM9+.3AX1YJ (@_!?P$,$,,>.!O3P$KR(/001?:<V(H/]-$O
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MQ=DV/>.7TO/H7/20]XU*696S:CGBWQ'9 1JC4]2<MNM*3FGTO8RYP4O8"TH
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MI0:^73)LAU6^[[_GV)CIPSUQ-V& PMBUM/FT-.8.R9UJ,=E7$0;U21RUDG?
M%5!)CWTT\M#+MGL-3$%,/ 8;E.-*8"(:;RGT'K.J\)U\0:6G&$0((&$13JMS
MU.\FZ1O4.;#!A=+ I-_3F2^9;6&64_&K2LR RB1MBRC5N<Y]HP:K5MKQ$: /
M?#[:RZIN0JP-<!Y3ZGR]$)T=V6^JMI]\CJ:$^VQF\@W\LVB6Y8O_ 5!+ P04
M    " ![2615<-6Y.:#* 0 6OQ0 $    &-A:"TR,#(R,#DS,"YH=&WLO6M7
MVTC6*/S]_ J]/'.>DZR%B>HF5:5[<A8=2"9S&I(&TCGD2Z^Z8A';\D@VEZSS
MX]]=DFQL,(D!&TMN9Z8!6U*IJO9]U[[\^K^ONIW@PF9YDO;^N85VPJW@?[_Y
M]?]KM?[O;T>_!WNI'G9M;Q"\S:P<6!-<)H-V\,78_%O@LK0;?$FS;\F%;+6*
M9]ZF_>LL.6L/ AQB?.MB]EI$5&H>HI8Q+&Q1K5Q+Q-RUM(DB;"617$?;9Z^Y
M,I(I%K4HD;)%#6<MX9AM:<6P"D6(",?;YK4RB&L7,V2)HHQSI9VE(8J9)HZ&
M$OG7M@>P.EAA+W]]I;*.2?ZYU1X,^J]?O?(?=]+L[!4.P^A5>7&KNE6GP]X@
MNYZ^-[=ZYRR]>%5=?.57.'I@F+?.I.R/'W R5\7@U86IF_-!/YL]M+\R=6MR
M-1C?>7EYN3.>=-+K)#WK0?1JD,E>[M*L*P< 0O]XV IQ"XT'\0\ELX>!M1,8
M*Q_(GK8W+[WO9D0F7CP>'K[X-O7$)2GN1T*(5\75T:UW[IR>B+^L9#Z:R/UC
M>JB.9YNG%*/X1^LK[YC8TQ9L^-0#(P#\:%L1:X6\1=!H'&.3V5"$"U- O,J3
M64N!N:%7__?@]V/=MEW9N@T%+=M33VF9F:0G.SLZ[1;#AX*$8Y3*!G=Q#[Z\
MF<?KCNR=_7/+]EJ?C[> +JPT;W[MVH$,_&,M^Y]A<O'/K;=I;P#4WCJY[L-$
M=/GIGUL#>S5X56SZJS?_XW_\CU\'R:!CW\ ,6Z.)_/JJ_.[75^7(*C77;WXU
MR460#ZX[]I];)LG['7G]NI?V++P_N7KM;[19^6=BC.T5?\+U0^ X6:++UU\-
MCJS[YU8"A,]<I!% DE 6"<D0CVR,@9%$"-'HK[UB*C$PEYO-Z<FN?[5-7N_W
M8'[7;V$UF>Q\Z!E[]7_L]5:0&!C:D#^OU5YZ\3L^NC@E!T-SOG_Q];TX_]C]
M][>#D_;YUW.-#KY\_GYZ_@?ZN-=.3O'7SN'>[M7A]S_/#_!I>/!^_^IW<M@Y
M_=Y/ON[MTU-\2@Y/WG4.\(?P\.2,GG8/NU]/_K@\.-'H]/MA]W#OM_;!GSS\
M'7^]/OVBH\,O!Y=?3SKG'_=.\<'>*3W<.^P>G'3:AR?_[A[L^3F8;P?=#]\/
M]@XNS/MWB7K_.3H]__/\Z\G^]<'YNV^'7]XEA^^/.C!&<GC23@[VWG5/\1_H
M],N[SM>]W>J9/^%=K/?UI)\<?CGL')Q\N#[XXN_Y$'Y]_V?GXY</Z./[#Y<'
M7[Z>?]W[LWWZY<]O!^_X]>\G^X.#X_#J]Q.XMO>9'/SQ5QS&6@DK6HS&ND6C
M4+5$Q*-6Q)B)$9>$$K;U)H1_,< J1K^^F@+K,J'\=IAE .)W2:YEY]3*;+]G
M]D!L;0#],T!_GP%HP;BUFCI@>XR"& [CEB2&MK!SVL8TCK"16V]:K3!J>0;P
M;% >Z20W8'X'W^0;(/\,R.$,(&,781<"-4>"$E"XE&V!@D5;EL/_8FHY#X&:
M 0QD91#^!..G9@/CN6",9L"8$^64!!IV#E1I2FC<XL+B%HL40)T[H'&^]>:/
MY^34NP!>4X"X(\\V4/T95/$,J$I%,7&PO]0*D,-2R!8G\,,R(F)$0T.)V7KC
M9">W=P#[:EKIRJRS(#BUS6>HBEXK?YT72BJ /B@4^M<#4!#_N94GW7[':ZS%
M=^W,8\:D5KASE<,4?GTU/43Y^IMW5E/(TV%6?"KLE=<5MI6H\1AL&PUD"]5O
M]"DQ_K-+;!84$[(S[8"W'_[/M IS^^$WHZ^F1^\7K&KT"13Z;.#U#\\_<0OD
M9S@>ZN;:>)IFXE91B-3I*Z//HY>\FMJHF?LF8A4I,)TQ1YQ&E(J(P#<Q<EPS
M*YG[ZX-_'0K!JEG]=I46T*#< 12"J34>J+HRWPX,>TFY_+PM :W&*^M:F0\S
M^Z8"0'%Q-,3HVNBS'^/.>,,"FZ<?J(S+UY^/]^89:PHZBC$@4Q%K;@6EH#K'
MB$6<DU!;1ZV*"ZQ&(ZQ&=<1J-#]6HZ=@]20,0!\X]L ;[P68F;"&R5L+1B<'
M:?9(<-UYWG^Y9WMI%TSP&</.BU)30[R:GOW/L$4+$C%'*7$84V6QX*"':Q1'
M-J)*$5/2<DV09(J6I^#^,%J>V@'#(R9B01!7A$HM),PR,CKFD2!2(%GM0%3#
M'8@6LP,1DE(PPF2H&15,<!D:CB710H&2)_3S[4"%\?;,*W'E1P,ON^IW$IT,
M#FQ7P2M, E=+QW+E"'U]/ "B]\_L_V?H/3)IMY_VX&.^>Y4 JQ[=!M]WT][Q
M(-7?RK%^?37S%>-=&\]D5:"Q2FFMHA!9(VA,0Z$8P2*2('U='#N[-J YL@.9
M]*S9EUDOZ9WE#8$/<BZ2W!D%(*!AR*2+N-(((RQ5J-3ZP.<D*P3/=9.()P(X
M\#@DV&H!9@L1U$2<,*)T#(I1K-8&.+M:#[O#CC]*^SAHV\S?E]FV'^W"?NCI
MM&L; C(L*;"WT&(;:QHKPH&<E&8,"<&,PV9M0':8]OS"L[0#9NS9!]@"4/(&
M#8&2!CHR8.%AID,J#59(DT@1'8922B;$"@SG-0'7ZHW["-0_"0!F* ZIB&.E
M4&0<0X8#/"4)UP^V*^&>JP>T)M8H%V(1\I!&+%9&49"6@N$H J5S#8EXJ>K_
MZ@$*_)A;ISAV(:($6<XEPL;_"G&D#5D_@"Y9*5T]2!&70(JQ0TPC'[:DX LA
M,*%:H1 ANGX@7;X=N'JH1C%G6A L"8\I\QIN",JME2$U0M!(/9_/K<D,=RG.
M0(5$Q$+-I$"$HDC+B'%N)*'P?^XP7AO0/+>_95'P >6$,4TDYY;&.)0J-ESI
MD!&$-5)\;>#SK/Z6!0%'2P/4PFR,D*'82$X8BH24D2.<$\S6!C@U\+<L"&1A
M9"FU#C/'#55@R6L3&B&=40AI2Z.U =EJ_"T+@A()(\18I!2)(NJCT,%&LV"B
MRU!XX)5>9K0&7K'G4AC0PEQAH0028J&02B&*8Z8,C:RFTBG!F2%L;4#SK K#
MXN 3,VX)I]1Q@$PLL, <F!SWQP)6<A>N#7R>3V%8''"4HQ'(%F$C!\03(6XX
M#D-)K6"2QH2L#7!6K3 L#F1& UNSRIH8!)$B3EJ)L6"($$4%=W)M0+8"A6&!
MA(68EB+2$2>6*AGQB,6<6@FJG5$ZYL\'I57M !B%UEAN0DX-)=@(ZSE*A"F2
M)%:2KB *;DT0=B61>M->48&PM0K3T!BJ(]"+L5&A<]@@I2)NUP^VJS^B6@F@
ME9(JCD,'-JD%8"LE:,2L19$,36@Q7C] /]\1U4H :@@W0A!BHEA081#PY,C%
MBLN81\"LT?H!]#F/J%8"4DN1B9T50*J*QJ!AQ,A*!EQ84VHMU>L'TF<^HEH)
M5#DC/K+1&"XTE0!13K7@PH&-1G'H5*5 -A^8S^AQ6I SD J_80Z%.E14A1''
M&E0AP^ 7X5R:M0'-<WN<%I5/H"D1B$DP-@@5(I04<\J),1@S9!%?&_@\J\=I
M0<"Q!$OF2[R@**92:A&' L4:[ >A'>5X;8!3 X_3@D#&O.[@ $@Z,A1CPA$0
M%V)48!VQR,BU =EJ/$X+@E(D)<" :0E&.&62@B3R68A 52P,M7I&J;2J'8@)
M%@AQHI@65+-(Q 29"*9*&)?P8UH1KF4,NY9M4(@RD^1[P"5RF-,PLR62SKQ4
M'\WW5FS[$S3?.)22*XF=C",:82FXL4)CB251Q,H&)(T< 7BRH08  1MYF^:#
MW9Z![VQV8:<9SGZWWTFOK3VV%S;S5:(:DGY@N'$4RU@)PJF)E8PD5A%L(XN<
M)M6QT7J Z)W42<?+C$Z:PZU- 9")'!.,2B(<M5(J"A(\%!@['ENL<(/"5NM$
M3*N/7(T)B2330'].4F>-"%D<"QV+,+)A)/@Z G;I)%@#L&JJ8XF,9<Q0T+>E
M8:"R,8YHC*6+7/VCP.I$IDL*U-/<QDC%L>64@@4D0Z>(=IAJ''$6KA&(GEGF
M+0A 0DN#$78(]%;0&S&WH39QQ*PF(4*.UU\I&9NIOPUAWVV>'Y=#Y#<6P*>V
MS+I2V^$@T;+3$&W$&NI$1"S"C--0@&$F#7>48B5C870#U,4Y('-@38- 0I5E
M$0J9=992!Y)&"NMB'7.&?"D:U2 ]H@94LWH%(@1H1KX\G*.@,U@M8R:B..)<
M<2*H6D4EM2;2VNH!R9 D_M"/<HYIR$&Q!T(5%B29#$'C:%(^0%VDV*+T"TDP
M-D2!"HBHB(R@PC'.M=+$<DWI6D#FF:38HCR^B' M>(1#3FBDI521(-J7F2%.
M,]JD[-PCVT^S 6C;GWO)X X\_)=KPNW&)?]Z0S_Q>\HX]N'/T0!S%UZ,G,)&
M2&D$ME0SP95 PE=5$]A1:67]*7056+ 4R@10:!W!S]@QRJ45&"PQ'!M#<400
M;H"U[+L)N 1VW/Z>7%CSH0=;<9:HCMW-<SO(?[L^D.=I]K8C\PGV^>'3T=Y)
M)HWMRNQ;+GOET6]#8(8DM\1ZT480U<AP&SD=2R<0V&A$Z_K#[-U#X#4.0!KF
M@[1KLR/;*7J"Y.VDWY1L;*2,4K$*0?_P6KZ5D?(%"WV,?8@P;9([N,ZP6[U9
M0"QV5H!MI[6D%C-I#'/&AF"V$VM0 _CI@^#K>>D-']WMF4_2MZQI"EFRF%'O
M4]'.*(I]*)I L43<& RVG&A2(:":@FWU%,F( ]O<..)0!*S79W4Y3 W7+ 3"
M) U0-A_%<??LA>VD?6M.K&[WTDYZ=GWD.\,UA32QU5C;,"3(@0'/L7!<.^?3
M*&-'B%I[B?F,\%L]C494Q]3$D>,"?DNK(DI =E*!3:Q5V("ZV@VR0A9T,L'"
M$"GNK(8? #,N'(A/&49@@H28T@84H*VS)KL<D$G?OS,V,>.*,E_*WDK&J>4,
MKH"YOV8@6Y5RNJ@*SSJ*"=4$Q891%4>RZ+$:$4FUQ9JZ-8/6RA67!8'-8<MC
M%8>6*$>1D]PZ9YFR3C@A )(-2O/;LVKPH>>#4?R#-T2UBW<B%!VF YN;H?6[
M5Y_XYL5E]FFNP!)4CB'F:!SYL"\4<:X1UY&"3_4W'-YFUB2#4930W70^F^E$
M=C[)?F-<GQB# < L<CRF-!(A)Y&V40S\T&N,N@$%07\$DR-[D78N?-#7U$T-
M@8UU7$72AMH7-=2QD,;HF#EF*,@L:1IP(CX+-I[?';?3;'!BL^[4#8G]F4AZ
M,J/U1)H,!M8<66V3"PGB,S^6\&,TQT]9>I;);D,P!,<JBA"E3C,&2(&E\/5C
MB;*6$&"VS]A"JRX84A?($&5")2(POPVB<>@4]LV3HE"#[AG:V#3 VY)G@]>E
M3EE9:!-6P-L_C_]E96?07D?G"<8B)A%3+M2*VI#X1"RE% JE1II04E^J\B#[
M'<CDK+"DW\I\(H7NT%Z>IMFWC_TD3<SQP%[*S'A;>U<WYFB=*FX9P";FF/I6
M$3CTG:Y0A&7L(F<:8 C4!D"KMP9,Y "",0J5MI1B*S27'",D+3&(58&;"(45
M-!%>?D_7=8$F"N>&)L(3;6F?<DPK,:,HDLII2;5D$@,X8\% 4U5@\C4!FC4*
MXUP]/(U5 K1+,-.EH22*N>7 ?2,<@=&NM:ER2@"@I+9@'*K<_F<(#^U?P(^3
MZ_ZM9)];-SS5]/!X45+[#4N8<)NF ]FY?7G)<A<!LR:/D[LW+:<],=QM.>V7
M5%X:#3!7P^DR\C%UH%#:+$L&:9;<,WAYYT?W^?CDYLYYWC6-Q6$41R0F"HPC
M"CJ#BC".G:52RAC'PM97DZL?-BTL=)D# V':*%3T-HDXMQ'HU39&W'=]'D63
MQ_43$%[<CX7#>^L=!?VV%P E8/)!/WO]Y<_'<Y ?J1,5L.5E/DR6[[F/']VK
M?@K4TF#KFP9X-P4%_4Y%'.!J)(ZUCIFL\2GT7*#>70=0+^B0A@@9<Z<P1Z&A
M/H<[- S[@B:QC\\T8;-!_?'_;$!]XQXQ. HY-]RG3$:^V5]DC"#<(AO"_RNW
M-&B&M6/@JU(-:X,"8$@LA+&'3(<1502K&%/D&(\0?#"AUZ04HKR^*/ 3:B\L
M=X#2A=WMPG9HV3O)$K6X<XD-YCT1\WQ<34R-T!3T>6FMP"KD1(41*/H*D2;4
M]UDE3%;O7'=<8QO&$B&,*:%.4<Z$=ZMK@"*Q#6BC]YOL^.HMQVUK![^G>L(T
MFZB F0TMF&92+>A<<WW-08=0# 8!Z TAT+6APB>QTB@F88AE%)KZBI)5.IH^
M=63B)^YNWE9\G2470)>?@) 7@'3K(#S&KJ=..=69SJ;JVH/=2P0[SBS18-U&
ME,1:,<<BHW4D(M\0>Z,)KPYW_8@5=DZ_I@R0U!ZCY\3>OP6=3"=78BUER(VQ
M%E'I*Y RK!V)'%*86,EN*UDU]-4]*Y/\F?O@?4,]14_0%N-''T.-.79_!+Z9
M/'M\]<%<FTK"F#\ <)9104.!D-6AT\):C4R,-D=;][WW]S3/W\)6)KTSV]-
M/+]=@[$,F_[1W7Q]/4EIJ1GJP4@/OGXN-OCX<Z_I>!-C$8IB9B25-#)((F.0
M,(+;V(28NY(->D1I;3!FI1CS5"Y=Q.!W9-<:^38=]I81(7R+ET[AZ(]YZ=2M
M3^E=9XL.C)A98:BRD2#2:0-&.+=*4,HV?.\ALK?AO$T@1RS%U%$64<Z<E,0A
M[B)DE#0RTAO>]A1>4J2=_GN8);E)"E-CJ3;&\Z'BZID88"<)54AI'%D:<B6
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MY9JJR/'0A0VP-YZ :RP,#U;(759BA83 6F#[J=4@^_T/T-8B39P$F1(KKAH
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M$BH*N8LYT[()5NW:,NG5VZ%< ,2I0=1P0:U@'/@YPE3'3D8&1W<*D:\5=C2
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M\_)CVTI3S,<D%V]^A1_C9NE@T,4,6:(HXUQIW^H0Q4P31WWZ&MJ:?"8?7'<
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MXY;?2LQI3*(PW'J#6@B1F-17!\-T+L_>TI'IR)[YW@.R-SB$*W\_A+KZ2PI
MJ!";5FP5;5$"ZKXR4=3B)O+G^HQ8QX'DJ[KA05DX?#OXT-,[]46O\5%>,=KK
M9 !OTG/@VXO]*ZD'!9;XP[ELC!V!S(/<]X1T"=BH22](!GF@VX4%^_)Q[O-Z
M6 XLBG8P*\^V9EL.4R>,TQ<I ZOC!]=_^/"/+M(EC4O03LR:-&&^O!U>SD;@
M.)Y_Y-DGK8C=.6I%;![MN22AVSC?38SIV%6HT$N77L"$JX(<H(L5)6[>EB4J
MWX(]>]<VS/T=_2R]\.,TU*-56H>G)_#>[F?Z]<L!/NR"=-LS'?@-WYVBKU_
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MWU.@K$_MM/>W#93Y_A>C(;/"NA8R7+<HYK+%0U",,(]")PB.M !^$[.XQ8
M'QO*L/RH^D>PL9+T;T);_ON_.$;Q+WDPL!W;]V@1] J\V Y ('2&GE4'$D@Y
MT%-LKXGA##0<'3\_/)Q!\%$HQ((/Q8$3+&ODA\SY'MT'W]%]1*T$^9S*_#&H
M-%DR2&Q>Q>W8S)J@/\SRH0_@&:0!W%&<&R#\0KWT"I$/V]S5@]?S:(B/]'VO
M8)<>J.^<)(.R%(&5NAWHCLSSISDY&K#D3!8\[_BZJ]+.BP=IOXU<\&$5T%:
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M#,HX]3FT,9^RV3&C;,VD-[FA,WCZ<^0'+6ZD>H0!+V/QC5$4-X' -0C@?>9
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M090_:M0?7V-$_-WGRN:;SU-#U1";QP0N\?T9E(7Y&L6=%&<#!^79P/[TV4!
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MUW++WEI6?UMK#0_Z=:@U#;_/#</O36GX/1L)U3AUYD75"V/A<#-&Y>_S!]0
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MM\6XL&;O(R[LV+O',3+TH;EF@UL9%WZ&<>$/\=^S.$1L432^WI!)C';F9UJ
M]1_0+D2(EW).EGAB._HXZ^7)KTF?OOB2_JR\<<D-!J%BBGZ/2S(=@#F-%C:&
MWJY(G#!I'(CYYN5\E4-6[  772(]6-0M&X_C*>MIE],0_0HD0+1:A!869G[V
MC0;S+=394Z(DNV;NRTL"@R A!:M[VO;2:09V.3SI.LN_\[OY%2FE8?&J,2&$
M\ SB">^P)RYBWH60]298>6W9I0![Q5]/13''#U@;S 5XA5Z':4Z"*?-C^8D
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MZSOVS6$,SR[+4W'M9ERXL]I1^H-OO9G_3>20U!N.0^7-)MBFA113%M+)8\H
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M.UY5?>_N',MB7(Q,U7]A!Z26851(*<VF>B5DRBM1E+/NTWH(3K.6#"^UU46
M#$P:G#)%?2K2N!98:3 G=6G=^16;2UU5$$SSZNZFDA6%Y<+9A-ZC-!S@W2E%
M=&*2WPR:8B:N!<^RN$&%'>:$:MC\?#A.SHHIE?W0.#XA)SJ?)Y))6 VU91/P
M,P I+Z@(HFDE39C%D16LLR.\$^;)D 5%\ZIJ!@,.-<)31Z[X*U-ZP<:*BU<1
MEB$67E)V-#[$R=6A?;%>GF93'"CKJO6=V]U;YFHN-AEEGMLXG7&UIVD(A[RI
M6FV6EU9EHV(H3J.$;1'TKI9='YG0_W0"##DN0>8G><SPP96W\[8GO[@R8 7>
M5!/BMZ!SSRT;ZC5:8?<QK:P'_(7+HT;(6*SO'BIYK%OBK*CZ=C(O ,]Z+3N9
M@@@K<V/]FPDIN,1LBM5:'^><P;7-]=1,9/@R8##?*;=WVQ=/FU)BSYU9MRG+
M<QLW+AHM'U!1]1>>Q'M#JOPBEEB,%0:'&/D X3V_>'B/K@WMN:;T1!'C2\K&
M"N6E1GG=T4!XS+ QP,*KT'EU7*6G)C>\U6V!YR0K4N#T$5"_KE:]6LB'<GPE
MPC:B-RIC.-<R./WUI<LO9G#8(IV5R<R',Y[;(>E-=0N.\[;;&HT0Q#W< %HX
M[X1=)2RKYOG,[=5F*U!2-19=;O+* ,-M:ZYC\^(:5T47I&AVS=V^YF>AW7$]
M*N%0O0 A?/1+DL&^A2&A=,L*U,HCT=&3X\#748KU^XR6/3R7Z(!SJZ&46^3[
M/)_"20+,%F-E"S]*6NY8(;H6EG/USKJE6I8E],RU>"WA[)=G]6)49^\C@)Q8
MS!?ZT*W*(_"Z4MK)#/^=9?B[MDCPM_J>WU]575=1K2XIW&N6IE_&"9I-E1TE
M%#N0*;/QA-O9O!2X$49A!Q">)+#CF7;!6H"CMZX]O,,%?*,<HE1@@QK$'GU
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M13;Q!)Y%M;1#],4=@IAV/DTI$JNIRW)0.31#>=,XEF!<98^B2C%4OK#D7-$
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M?T-.&Y7I;$,C)S NP,*'FB/GX ^VA2SP'F!UUT,Q> NJ;LH]KQWFS/:Q_]9
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MY3G/D2PG6>Y!9VPX>D=Y3FH7<ML]V6VG#3U+[KLNK,32OI/Y^/+*W>3C=V_
M\LJ.LLJ3:#;YW'JN]"_TW;YNNGN[*O(8&L=.>F;)!=I?0LA3H>T=:K@D[3W8
MMBNTE7)EE16J]7Z)GGI06C;*Z!'.7?L2.EM&DKJ"-B=71\)^;A5;V#*T("E[
M%V7M.PP"*5$>5ZTRM'ZOSYI9G5W7G>[7LJ!C>M$V&E3/-L[ARI*S_6V,#>23
MI.:=!VS?2*2OA.J0-!(TNEW5D!MS*[>+V26B/G47RCIHXD_HT'\J:O1=48^N
M*]%R=:1QOX>(E"3LON)14J \LE:T9:%35];GB7A-/@CW""5Y<J/ (&'0L[BX
M1#\*NDI"ZC\E=:EGV^3_^R_7T(U77;(?G@1=]=M=MM(=4-;%23*M%564&_1Y
M>TVZ??S)*Q_RRGOB]K?"M6Q7>],I1?.9(/G?9_F>;NW>O:C2W5/*-NY7PWW/
MO?Z D'\[9^MN+>2A;F\+"/C :_C0E-D6'%7*P6<D!RWO?K@"CR0')2M+5F[I
M7B]96;+R4V!ETS'ZR,I2.UW63K>&JY;:J92#SUT.ZD.CEV>Z%(323-].$#(7
M]"]3XB<4_@WCJ]?_A+\6 APJRJR7NCN_X-]FQ32.;OA'<1K2=/I2Q8O$I%[_
MT\]_>5V];:?/W@W![*%KWT4S0_OO5Y.,5]2^9!6U\15]A6R@FD,=;U\$[B8%
MQ2> -.&B9/GOW?<5\=:8QL'KX^DTC_T96VUEFBEO2 Y+ ,_^%R7)]'*@O$^#
MX3->,*-K"_8NRY7I):P5PV0?9PR3G;9CLAL#)5ZOKJE8*&Q2XC1(9B&%FY1)
M3M4I^:%<9%EX'2=)XYD*SXO&FU_HMJ7 7!/,G2[+S(&A<*RG-$3B*@6]P+N&
MBH*SB.("/X1QF@-V&;X77^33E$;Q=/XI<='R7OCPA6Y4K\4)XG5\[/!SRIY+
MTG0&+Z)11 -<>?:2'!X]5(YQ@CDM9LF4CX&,X11@N4O-D42;$!W?GU/@H% A
MDTF>_8C'\*[D1O%O8"C\6YP$#.F%L31X^F,"H^2S+A_$W@U/NHH+O!)' U]E
M8S836*.0PRCA5?!H@GLM9U. #P25;RC)][2/[Q#J8UBI."V/4+/UV3N5"+JV
MUD8Z!^(4LW%))R#G)$NK?1* 0 !"LH]!.J+D*)0QN0$"1PDLD,*T!09>%>(D
MV Y;3>"N$N%/BCP*O'E%\AO&0V)K %/1">4SS/@VBH'/_U$H*9G.<LJ(A!=_
M ]XK8'NSFHGK2YKCA6(7SO*<AJN)LI($=W#4MO==Q^'T$E6>H<;4GN9W9=PV
M3AF1_"0+OB^>"G!@O.+/L-RAH5L+C]A@C=L&NC3<UB&-R0^5C\$<VH[^WZ_&
M\$K^@<$_6![TP;H/OWV^]G\?K!SKMDNR3\$C&-TQX*G+IW_%# NK*)9/JV\A
M/FCVL^GJ6^ZY\)L_B6MKU8"9%0+B(B&3@KXL?WBUL,3LIE?S;VA1?=@+^=>O
MEC:,2$R9WT]#]M6"125XU!@:IKGR:VVHK_SNL1YKK?78]L9G]GI]SQK&(J6&
M8UA;]&5ZA.?LKG_3AEE'5=^C=H'#FR4]\.G)]L."L:3<8A,(PMY[(.U=^?YO
M]];(FB10?M<?;=:WT7N_LWY7FRYHRHP575-_7SC.'XK]F2MIO]R_HAVJUS+C
MVYU'.U&1ZJ?&X?\<Q'ZHNT'DV#HU?<MV73^(J*7ICAV8D:41_7]-I]);+O-Z
M#2Y ZP'KZKM*(A ?+TER36Z*@U_FQPN#;:H1:VL 6Q[W?3K;#7,XLHR='\*.
M-=1M=Y-#>/U<66KID6FO=NJ*[[?=GRT[,&)_]K4#/R*^WQHIL>M.>/FXG]_)
M#VU1;:Q&KR<0+&VU(=,GHVM[I\*6Y[)Q)ULRI\+O,Y).XRFSLYB? #Y(RM_?
MPM&99,4LIX5R[&>SJ7)*\N]TJGR.B^^]\Y^<,X?')8&)^92F2IHIZ.QCSP\N
M27I!B](+^?<B5?YN4&7,:9 ##= G6U&HZ<K,9CEW/:.3D?]4ZA[_3RG@2NXG
MI C\&0F_W^(-TTL0B!>7_)?*=<E_+?V7+0Z;-?>5V<;TRTLG/D'38[0J&K!?
M#GT#5^0@)]DZ?,JS@(9([@ZQG[G6/$ZN2#+C<"6PY/764KH_P;7]DY3/D88#
MY3H&(XOYP@G*S'A231WVAC+)80_ 9XE"?]!@QO95%D5Q@!BX0(;Z^PB,-OB1
MP;FQ[[GOOPH0I+0HRJ?6NQ%.U@91)Q51E4."WE)X*-^GGV>@P.DF477[D!XI
M,^:-Q^=_@5'E\32&6TY^<.F@' <LV*![IJ4<XD4'S:\.CHX4PH:R:J\JO[)
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M!HJM[5+5 B&H$CNBJN'X_FAD6*:O6["AW-6]/I^8]K2=X^M^4Y4GZMT"0*S
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M'WJ-[RV6[XU8O7-</#[6XS0\KY?RN%I),,T_1N?DASSI-SCIS[XL&T@1M9Q
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M[,L!QXX*#JGCRJ2S2M)]H$7QLE5W76H!GL[)%[B*"YC51=Q]3DSIA)MS_F"
M4Z!V7DC1O^L,<B[VY\'=7-NF(\1,CR*,SWJNIWJ:J:L1J^2W]"B(S(/7RW4W
M,J^LDVK= _LDY?9]X.V[U%S8(5KH@.JFD9&E6IH=JB[6T?E^8(:1Z>O4Z<[V
MO4/3*)$I8)ST]AW_4%=NF]IV%WQE?]V#*] :5KH'EU2L!3"X 2*T#)4M"Y'N
M3^ NU2?NMJQ[![3IPC'7*V^K/,\V.L]:VN*9H'5J7N"H81".5,O2')4$&D;B
MG3 (8.5,S3YX;2W7.?3$=;JO V+/F8X[&>^61>9/2\COM@C]B0CY7KFHI9#?
M5,@O&BVNYKJA,0H1XT-78;D\E=# 5 W'#HEN.A;U,)O"NG<+\JY(VSF$Q36W
MT7D\IH5R1J^5S]F8I/>#C:\5[&>+<[\S\%D)F/_H )(2,+\#0/<2,']?N.D2
M,%\"YC]CP'R[)X#YUL%K"9@O ?,E8+X$S.\78/ZO) &R4^7+):4-@J\-CK^>
ML'D:4/7&4-?W@/YN#&UO]=<=@ZK7AX:]GOR52.SKS[AC8.MS\/K*FM#KNS'.
M.@:@_N]92MN)L(=4R8YQP7%1T/7.X%TD]W:8$&T]61X)_'/SX-K3@61J7QP.
M2C95".-6B0?:U]1LQ&IA6)_T[UE\19(V_?_>"9J=XMR-VX5W+E9[[X2<P#-'
M=F199F08ED\-SXVB(-"=$1U9OF^&__M^S3P<8)[C-,1_3FKV.9Z^@=G< ,G^
M0Y(9/5"B+!^3*;SWQ_1E.ANK8<9T.WQL9R*Y9V5K\/'[ZZ\8L?WVWOKKM[_&
MIS]__WGVYW_BL]_>&Q]_>V]__7FBG7W[]_CL/*@CN>/?3=XV//CYU3C[_O7G
M[S=GWP+[[,\_[-.?O\9GWT[L4^/?,)[OVF(D]Z^W@?GU_#^79S_/OGTU/G\[
MP];B/[_K?YU__WD*[SR%?[_"W#^>?XY.6X R(D<SJ#D:J2'1/-5R34?U=3]2
M7>)8H>ZYKNX[!Z_-@>4M8V7T)&&G>]GK?16(]\U\Z:I O'?R2NB.;,_Q3-WU
M38L$'H%1C<+ <4>>23R="($XD@*Q:P)QJ9)2"TS7]#Q3-7T" E%S M4W;4N-
MO)%A4LUR=(9V.'#T9:B0QQ-,3\=<6(%>D9.0*CD-*&P*/Z$<W^P9X;(^@G;V
MN:;V&9T*@TT*GUT)G[,W+; 39FB,-,M53<MVL93/5HGA16IDA+KM6T2C9H!-
MM ::V5OHB1U"04JPUP[J,%)L[%ML+*/-FZ$S,G1#I8Y+54L/0M5WK4 EGF,'
MKNM'FN>!V- &]FBYCO#QMN]3]XV]3Z^ ];,\OH^ZTO4BYLZH*R6U;T#J2'&S
M,W'3!H[E.29H*MC2@C6W"'75<QQ?=6W=)9Y/==VV0=S8 ]?K;;?/[CF-GH2T
MZ(R6(J7%GJ3%,O!J. JM,+)4"@:,:FF^KKJ1[:G4-377HKX'HI])BY$YDAZ5
M!]MSGW(Z(7&HT!\3S"^[;\.^KIM'G5%3&-@SS]&0MM&NQ4]+]QJ#.K[I!2.0
M-R[V)0\-E>B!K8+<,7U-U_1(=PY>&P/#6:Y5[(FN(CTJ3UM7D2)CKR)C26,)
M-=W77"-0S<#$$- H5#W-(*JIZZ8Y,FS?T;"X>: 9/?*F/ %HIKN2Z;J-NW0K
M+/M<-MQ> -F[*V<[HYI)$;L7$?NQ)="E4X=24QNI!J5@%'J.JY)(T]71:$2"
MT/-<2MR#UZ8Q&'G+1F%/U+*MQ-5C :SO%UV]N\*G,TJ>%#[[$CY+^ATU#6>$
M-N#(,T+0[RQ#]5QSI+IAI(4!,0Q_Q(6/9^X=+UV"I<N,_%T[]K()#.6FRLJ?
M8%&N#$#N77TL"?\I(>GT. U/2MK+$,,N<S;/CY<Q)X/(M!U?,U4'ED^U?"M2
M?1-^"FW3IM1R'<=WT6(W^YLV)0.23UO_D]+CP:3'(IAAY+N>CSBUGDY'98C
MME7J1YZE X?8IL6DQ_VSIV2 <NT]^%N6A==QDM2!2>SF0M*+6.9_/U!"54EM
M;IORWA"\MU>Y.%(R[4XRM;1VH:[ICVRBJ:'E.""9(ETE#K%50AW-LC#I$Q,[
M'9!,R\4H/=%K9/#R:>LU4HH\N!19U&\<W='#D8VN+F*H5N#[*MA*\!=U' \$
MB<ZL(V< TD3&,Q\^GMD7A8RE(>P@1-E9F=D9S:N1\(%=M\J8@)2#&\C!ELXD
M41".+-LDJFZ%5+6HCTV=-5LU061%F@&_V\;!:\]==OKW1)>2/J*GK4M)N; 3
MN;"H'YE@5U''T-%Q[*H6\775)Y:G^H8YTFU=!_4I KE@FT_ ^_,T^]:U*R4[
MHT67,%AVVV*N)]V%.J.9<>$K[=7=R>/?6QH:![;O1]Y(I5J Y<R.IKHCQU+=
M8 2RV1I1 YO96^; =/ON]NIHE[B]=('KEYS=;9>WGLC9SFBZ4L[N0<XNZKUA
MY-HFI:XZ\IP _8*>ZME8S*U3WW.(B_\Q.>LZR]TZ.RKO=I(*MYRTM]QQ;L>P
MP,_F!7L(6W<,=_I#3/PXB?]_]MZUJ:TD61O]*PKV>_;IB:#HNE^Z)XB@C>UQ
MGP;:-FX'_N*HJY$M)$82QA#OCS]92Q(721@)"5B"VGO:QD@JU:JJ?/+)K+ST
MF\.DVO>'MAL/.RU8J-[__H^F1/W>V(ZIZ9LW7V"7(,NZ\("?EZ]N7>[UW6I8
MS^H_>\PQGGJDR9;W,/M^KW%LSW+=JD5NN^I$89?D*J@=2ZV/-V!X</X>G)N2
MO+%TUOIETCN@"!=4"@8T-6#$B33(^:1S41'EF:>2IQRMI]>97-F2U?4+BEE5
M#%R2&5\[#*R/I5XP\/XQ<-QRM]0&HTU FN6(GD0PLL(&A%/"0AAJF7: @6J=
MT&59[J7@X^WB-[(*CCO=2OPZJ='JM+\@L$Z/&AT'DZNZD5VIM=3H'<)[!V\
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M72^N[L2;JDKC7[ =N[&_E_;MCX)&<Z'1E +'.&GFO>2(XURHBVB&M$@$)>4
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M%<RQ2#T"RBAR"UF&7' JTTB&L<W%"<*2&E(^"4Q\KL;CS5@QU7HD*4FK4W"
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M);]T02U*?MGR.NDXBD;[W/F%<&P09\8BXUE"E/H4@:6EZ,G:IBY*_GF,L<H
M5HM8O?D!K%0Y7QJZ3;J09)0\*"^03Y;D(I9@PTB?$$L)CG$BL.,8Z,@ZK@O
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MY]&GHS=LYWR+?_JZP_:V_X!G/$P7F2M7*F/!-I"HO$2"!HVX)0YICC7R7IC
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M="$X#D9Y'0WG1%M%A-2:81\3CTY5_17(J+\"N3T)$XX@8'GG*/[5Z94KG+E
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MA%$K7"":2,6M]49A0Y2GP1F?N*8WP^O,01AW,Z +_,[GNASDJ0 $OSG=V?[
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M>WAAK>2E[P&F=)+];INMG!X,MDG^32_ZDVX5)6;;H9/S?9H%B>Z(1%,J&H7
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MZ@L'+U\^\ 8>//30XAU^\_#EC>JE,>D8O,;H!F7LQI?Q!KGQM<<:EL\T[/0
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M^MWD=<0N-K(4PA&'0S,2$OAP;/7B*6B1>*$;+T1M,-/>B3^\-MT,H)FXP'D
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M76Y+5X: \&*[&5<-^VA2,VYG'"L!#JAQQI0FDY8CR)77A?'&6$YUGE'&Y0T
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M\KNT2%X@-7$37O-*KYKWK&3\RQN=/L8X7]H6^LM;)L_<E*46KH_L DPPMGH
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M?'9AXY$ZA^DS+(,8IF_"EP8]K)/HI"KV2! 1?RB&\J;3FOPQ9=3UD9"G)0U
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M\&]>'\^^ICE_/']QL'\BLY+F/ LDS\N2<&H<XF8;(GE6Z*+,E/:(';]\_+%
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MCSR!M;A:! #=G6\0/D3+HDX]3I?XK,IWCT53G1#!>[&'[&[KK#^\P.UN#:^
M"W67'XI(OPCGT781@[?& /-U[1X&S%Q"YD/!FGK*#H;]A$2+K'2O]><"8NEL
M3?>\^_-:(ZF2S8N&$J6E9B68<UG)G>,J5]SQHLRSC.DB<W</[-2P/BG \\,&
M=!:@I,3!JY,B5\RIS!-=.DJX9HZH(E-$"5_";]1Z7>P\X6*Y/F=&L9J-Q5;
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M-V9==PG-9<J7VA;>6\^+DAE,"BYSQXTW3 B];FH/$LY^S^%_GD_)9^)&FWJ
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M(IRB8WG16";?ADDLNUX$0^602)ECEXG<$4T=(UXHFNE,E9+:QC)9Q^]25^K
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M# CTUED,!_;;]1L'5UR.4^7X*$XZO;-&'T99+D'!:9GZ:LU&JYC5=<&.P:.
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M,-\XT])0R1BV.A^\,N--=3Q^QTG)&3SGTT5]Y]WI_DZ=[!T<XOT=?[5_\%7
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M=#WLC7D??G<I;7%K*>TY2F,_;PKIFZ+PU5C6:)4T.DH:O7H+YK5A+A"!>'$
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M$]\J&[KQK-,MY/*77CPNM,[E%E$?<;6W)[_>*%#1:!=DDP8-0WO3# BX/V+
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M^.NV[^FSRI[Q2+9W9&.OKD]V9V.O<EG 1NZ.,:9;M+='&M/@2J$8Z-LX!8L
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M2\AM!Z?W??)?H'_]9>A\.ZJC.WF+XN[_WN)_%P.J!5^S_W8Q0 ?], /+N,_
MB1;)X=B&1%!4DH@H<HK2!>IC9<%,R,YE25^ [4X7M_#[T.$,^V+K,Y3Y\&RR
M/>7-=_$:GB\/];,[MOOEX>'X3-(@(>??+S-O%?0-[68J_Q2L*(0Z:$9"7W\Y
M*G/#2U@ "FK&I7;!:$XD^$RDMI0XG0/),5EKLV.2NDF0>(V455#$OZ&(/!\8
MK2?U:A#X:X?LG#(V"TPHIZ,CBE(D(!I9W \TH\Y(K9CDUN?*:K_P^G4Y^0#'
ML%A"/U.*::<A$B^+>^25)$$8]**B#D Y2U'79N/\W9LTZ3U4LU?A^B"Y5L/G
M;ML/>_FO;9OZG47Z"-UQ$Z'_V,[3C%E&10)/1# ,I\SHB151$Q8ISUQ#\*JV
MO;R=FHV:J&JIOI+P*]NK:0QP3"Y;@?.X"E3B%(R3N5,*T:VD<)[B).S\<_6^
M[B_I,Q+* \]IG'F#)BB(1% LJ'(5'+&)H<"HRCZ"TL*;RA*Z@8Q-FF(W!8]7
MQ^VZVJLV8/>& ^B0P?8R06>.SPS5+:D/AE!AD::@%'$\!&(DIUYE$:Q2M1'U
M78KN.8O_9X*KGDXK&H93QLZ)R%SHB'X)B9*C>VY31$<]<L)L, $LU<;9ZI/Y
M)1)609)X+']@4Z&TCMKJ14"^6?1%-M#O+9!M9&[9] =E56POOX(P8+!'97:4
MDD =.KZ<!>*B$T0(FAU&>L:FZG'1742M@B_Y'SY3U=5L/:-X@W46"&_M9+'.
M9?DG(?PM$Q'9M,"XDTQ9^MB^U7J+"5QF84&B:$U&CEBFQ*4()$L-2GB7G:CM
M+=ZZF/"T7N*Z^KX&ZP=*N1J /\(X1O\*"V1LCI'A3CIL%DT_%#:/OWH"&82B
M7EN2@M X=)4E/NI, )QCP)6Q5E9&P&J4;52L7AL=$RBG&G ^X(S>+>.P[)#"
MW0/?[4,_HY;IH+0C-.$/2:TC/J##"(Y& .\!*:R^7'>=CHURV&J#8FW!KPV!
MZ ]F.X=M-S3_-PK +U); @D?_XTVN2F7.IB7/<G8]D,_X\BJPDF-8 "!=M\H
M3T+B F,)&ZC6$H"&._97[_G*>WI4SP, 4XJ]J@=>.-Q;?/1S]-7R#KIL0UER
M'/]X>WCDFZYX;>?(95&I8)TB*DI+I,R*!*8,8<[F9 .GTM8.[^Y+XRIH4L_5
M 9E27]51]>$4WY_:=PCW_5%>'V$8YF/>PRQ8':Q*# T?"D,"MQAR(NJS3X8Z
MY[0R,!&4ODO8*OC1SQP_]313#31_1_A^8U(:G0Q3B>3@(H:'"%GOM"$J"<ZE
MRMSQVE'9)0+6Y>;"AK5 RVXM<E'B!1R""?6%5W!VAX#Q@^:<U0[';LNZ>=IH
M[.$:O@KC!TIW&JSN#$/7A.7@PQP^M;<LIB0IM'+ B:),$.G1XPL9)/Y@PBBA
MJ?*U([)[$[E1P5D]L$RKK"N8^GG[JO#>X>?)<B!WV\.C#@[P'@PP3[F<(AWR
MIM<\2F;DG?Q52I*\X3T(F[W\R7^9<>Z2B]D19= [ERXR8A&.)(,U"GTHHS*K
MGNQP*SGK9W7<^FC\-%^6C.OW)6K!8;_*6&%19@& OH*R.%9X '0PN2=,2QZ%
M99SZ]'C2>0@+FV0B:^'P>CK)TVG]":TN4(:6PS@2-4I+IB"(5U2CJPR1HQ\;
M(=;.+'G>5G<J_$VKNHHI;W6'"3A#(XV:."DUD5HS$JC.),2@C69<9UY[^W+2
MR7&M.,@G[R0$143RJ%$;T*L"% 9/S B>:610.^5D,^.@IT39=R*I^^BG;IK2
M#0(I%'V=>:*F004>2.3%'T\T$1<X4L8-.*Y%%M4CZ%7HVJ24I4W"5'6=/B[:
M,)94U((@,0E)I#"&6.Z1=6N85Y*GQ"=)C;L7VNKR_J;M$*2+W677P2*>?.K\
MHO=Q!,LBC9_.@)W^M>R'$IM]E9:C+.CL/'H%18^66F)%\,3PF!6G6>A'E=;#
M.=DD"U$=I_<9HH\$AD<9U+N^/W@S;S__!FD?SA>_=S).<A\@SGW?-[DY+8 M
MO(T<4.$E0WFJLCDOBMMIK"8!*>=<TQQ%[1+)FO1ODDEZ4A!/JOC'7_-[Z>>E
M<OOC <!0K>#Y\D,G6\_[#NV55N\^#FW\XZ"=([S[U_]>-L/)@WP>254TT7 B
M>,G*L!Z(UP%=DJA=\* -KU[55(?RM;/*KE$QT]E3X90C27E*I!2<!,X (W[N
M#7IHQM':^_S7J=@DD_P$&+N67[:>FJH9W+\UB[8;!7#&5#!1.)DX<=%;].5E
MF<15),+QX&/.UJO:1<M7:=@DP[<!4%E+1=6 \J[QH9DW0P-C$>-U^"H3'3>6
M$@-<%?A*X@3R21/G"LUQTJ+V+',7315Y/O6@AQF/3"47+(G>CPT&''$^"T*5
MD=[I9)FK'2)=IV*3YM*JN+@*_3454 _\[6+_$W2'I=H!N=SU1\W@Y^_ ][ 7
MYF=)-_T,AZ),(M!2%PC%^73$THA,6X!HJ&:65Q\"*U&V23/JM("IKZAJ('H%
M&1##)4)!TL: YX(LBN$X@SCU!D" (4GZB/.[3L1*I4@6+&?GHD3B*\-H5=KN
MF=[]?($TB;+JE8[4\4J<\2@*9XGF 8-EZ0+Q4O/" .,L"BYM[6R(*8*DIRW;
MFQ2&3Z#H*3S&K\;;&:U4!L(5\-+O1V&(@Q2Q:"R7D0;TDA_9>[H_7SLQMLO%
MT+_W)T7H7WEC/D<1#1$YE4WNA"Y^]BCHC!+.(D%PH3)O-U.RH=[A0S!P=3A4
M$/TC^X3G)%(=#$B%S@8M7:DH"!Q\%/GG7F65=(BT>MQP'P(WU$.L 9KI%%5W
MVP/!W2TAW<"] PF)RT2$<CA])Y=) (/1C^+),V8CK1YT?I^B#74#:Z"EHBJJ
MP>.T,.B<!&E L. ,R0QL:6^+W#E)"0-AHW,F@ZY=:W.)@/7+5R,TQV7^+EM'
M7P4KI(V,!Y)+RUD<=R5=P494H>%*4M0;KVT^;R1DDZSGP_5^O7)U79G7R\OS
M_<$X#?<'Q:,]]O.2'KXS[/JN.T&G]7_]? DSE81ECF8".%J)=-F2$#C#C]%#
M3,)K4[O&8B7"-LE.UH-'?9U4-HV7.+7>IU!JV'16@4A@E'C.!5'<."MY B.J
M=_FX1L4FF<!Z0%A3VA4[41WCN]ON!&>K6;#1@HF11!<2D0Q?[A-SQ&NNH]%&
MF0EZ"GY[_R8M-M33](,E/.$BU@R8-4:4?3%;&O@::LH,XXB*5#"GF ZB=A.+
M^KM&[[NSM</QT:=3)VB1,_A$W%CG&XPGWDM!$CB?/(])JMI+NC>0L4F^S9K:
MOY[[O)[0:Y8='+:+"U0D?)=2*A$;2XM7JSCQ)CJB0](I!>UP=JU?-W")ADUR
M6BKK?2UQ5^S(,_AF >G\\ >,'Y>'R[$L_Q7D)C;#S&L/WB(8A49;*FDTQ"8
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MZ%)F4$YTD)241"UT,3(/U?.U:Q_\^:?!4SU-U<L#1O3"2S\NC1^68_5.ITY
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MSE9ZV2:E[CP#-$ZCQ$E+Q$>)+>.P[% ,?I%>'Q[-VQ. CW",GO8BPIFI./D
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M/%6]Z2KQ^TK JRK!W_WX"BY2#,SR% E+'B--"XG8A"M4VE*IDXXN;G$1Z^E
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M)0LJ&D=RLFCO:.+$@VKL':<Q"?2^:Q_0;D?R%$BO(..^"T-7D*B302;0"$0
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M$XP^3EY<S68PB=\^S/QD/FYNE?^.XGDUG<\O*&=>9BN)4;)DJ!E#C<ZBF5Q
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M\S&2[[\9;PLPWVL?YJ.(VM^5]P0I]TX]8SE[:2PQO+3#D8*1$)0A+!H&6BB
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M&VJ4$=D98AC7&+8%#-M\F4SN+=>VC#-@M0.28S$.OW_VKF&;7DROM/7:5/$
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MH-D'QZEEU2=2;@4RO!/8G:--TCL+N)<RB2_3\9>2_[R;'5W5<#CK*"Z- +"
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M?>;,)H:GXMYUDFT/)3VW\:S4N0VBGMRZ^VC.X]!U8VD/Y1U$W/.'OD)F0V+
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M>QTL3?.KZ>0C:O;EFS >?5P&9'Z2FNJ!]Y^FLT7YM^?3V6SZ)RY[7O=&:P_
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MK=)#37KTQ^Y#:=>T_\Z6#I$&:1/1FJ']B F(D](3+@*W3.HH?/6[[P_QTNN
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M#\5D<K$%XC8EP['%E-0L53^7DIJCIT534D49=*D2>,=&! D*<DT,07%PG'5
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MUJN@O-5!J;T)H-/%.SH#5+:D<H4CQ(Q:MBDZB*09?/&VJ&JMXKB55XR_C&*
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MUEEF=LRE;R%'J8P$"OEF])<_>G^*NM.I6(6%;9B&NF-\F#M4!B8RC@>HX_1
M\@7PS/)MU 98*H: ^81%TZ?XG:][]V-M+D<%/2N.R9EV#$LI/G!P7Y?$O<]
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MKN7D)Q$\V/X=I&7Q@-]9A 0> /EX@<RH[SR #QW* \836&4#$?74\1+6;22
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MB\+!\\@NF0C'MYN$NV99:E $T=A%2B*!^<H+#QT<1\^H.A$,B9/A/_O&UWA
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M<2(D*=8$N\Y??5IO5GMD;F&7?OJXJG+ ]LV;^%[PSV;O03G"?7@E,SMKCMX
MT9#*V3UB:V3Z9##I4_VW(]'NTSX_]UN5 ^EDJPR[[^(,\ YJ_<TZ2:PETKB$
M2SM!(O1>L TG/.(_P F;3=]I-E[7\^RBFM8^=&S]Q_8<E_R;Y.-3I1RYRZR;
MS.XE7?;F;[ M],#<A>#E-SF?]^#WQ><FLV2#X7QQ0.AN]>)I1<D]  WKPJQH
MIRK8:0>3ZH(Z,Q.NM5R+;),PNSV#C::-+S^(6&%7>!:'O2MZV-H;6MVIU_7C
M<IK&8T.!%2/GH?-1Z=94]T%3]["PLN-AL=E/;K>:OV!I)9QP%VG#R\2 G3Q
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M[\I]EJ<_*N.G?H /XPGQ,:WB2@L+AOS5B8_G[53ZC3E616-/JS+P(1KU#^K
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M4OLX]%_D$O]__.\/ZN+X/P%02P,$%     @ >TED51L4(;991   1%,  !,
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MS2R8*>FQ#[H^;!_WUW:79L%[_V\NM?E[*YH>I\A=/+N#SF>C":!&)3M(MWF
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M;4;-ES^@JFS4;RD^^O%ZPR'4P\=?Q;PEN89#EJB;5# ,O4AG'\$Y<A/(%WB
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MU'BUW9!)>4^4%^G'V!/8?A+['&$>XZ^NR3?)"ZOKH78I#%S9L'R JXV8.9Y
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M04/7*OO2<SWF<<6M!RXJN:Q3DVK,ZDN;11^$/2HD\H UM5'=!0)D8) 4$:,
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M<CVM,:%TC2WQ-W\8'619#\H3*W)N;$X?W;S/*5A_K0"7>(,^3?8&:0NPU8(
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M^AJZS>]84IKG$?^O!\V#4S$G;[_\].1TE[Q+=]Q,73Y7.8*]@==LVBAGRS[
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MPGL!((REWT42R@,0\EJ1F9Q()IU#=SZ-ZQH]4U64N4#8#/&XN>0CFVYZU)<
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MT!%2/:B5!YYQU?F4]+7(X^ [4\F/[H0"WQS^S$QM1CHV>F:"Z,DKL0N:=1,
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ME^:^<>;I<KX?YAX<N=S@ZM.9M;<X-BKKB^@",@=);X$*T3@5(6>$EP-[V/_
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MJ&\.QKC@$48;2[&M)+I9O*I+;?+(H;Y'.OF]]E^'W'[,F33M?7$Y_$]. M*
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M\(0RL)QCS0T :-E<>_,GNM^X)B^<XK9\@AG*-URZYBJ@XMRQ->LF.AT).--
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MMQE^,2\Q[I+_I5Q0NK>^.>7:VPS)N,D>=MR<5VY0G_>EI)(.006!/_<"<$?
M&/IR%D+:[@!0.+,SJR@WE7N\S&]>=8FH+=-\.G9O@YFC*T6@_)J_]5P;A)Z)
MCZ'BBT)>@(,ZA9EVNG3:1'@[WO[KR]:0*C__>4,Z4W5H7FZ?CF/4[M(%N2I3
M(YA4=YSBJDL*Y-H*"M3!OW[6<_XY%C,KDBW?<OK=UU:UBX/.\--:T_^\WB\G
MZY5"^2E'Y$NI\9[C96@@$5(.BQ#]%K[)(B3B5< F!KFQU9CMSKGVNOG<R4^M
M[OJ_'I&U3+WB*\[?U Y+0C\A H>1$!FBD$ =VF*MZ"(5*$:WCKZ,7'.SP"B
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MVG3&/@&C-=H[A%$:=],IB$BD%P;XI <'N.DD>()0I8FZ$R@''!3#'$1!#H=
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M>^]:]_YX5S+OVC-K9K^[/,^\LW?E+&QY#,Z5SWKU7F3BGE/O=?M_\A/^"3.
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M@K9,\N&<;CX@VA;N4^UR!'XW=&OI[BO>O1$MNR5NIEL>?O797L3)(@RK9'Z
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MKXO*.4 W9.ROBF;!&-T84SMS11R6%)0^U9Y*1QX*H R"2*?>P=7MTY#F.L]
M9]V=76Y)!C@9?" Q'!T(J2T:TN%6/>**.>Y_J2AXEK69T=<[^''<CJF>R-F'
M2.=8\X$-Z\?J0MA"C?B,STF6>UA))KYO6;VFWW!(/I#P#)S@ Y9PZ+IB37R
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M@9@1Y=$86?(B@I37@Y>$4?')WDR-+(-;<Q<*RD<Z2TA3)@6=KT.23@4*'RG
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MC#N]CFB(6)C9BQ1A.ZSX ,3$4F:98GV\#560,8 -*>>Y16;(AWDI\V&'W>S
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MDHH'CL<80R$[S:'&KD*EB<_]7%5>J(KK-F(/";:E@3 4@*-OW^V^2O?5T@:
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M1VRJ&HS3C)Q;Y<;!@&XK\WAY)]/5A!P,D"<%)(=KU7VEW-2:>_,]-?G_FLN
MHBP681C1,$Y\&$4L@LCS!*0)HY!*SCCSF/*XM7/CV5[FMJYM"R(:2?=B51VR
MS[6CVKT@#8+5V$?E8\-DOQH, M=$)+^%36Y@JQWYJKR0X#Y/[VB>+A_USZLB
M+<K*%Y!SN309%S3S"WF?2YY60EXU+]&BR,RO])^_I>4M>*#<9.91=4^I+*YT
MNYF21:%?HLOJI[])7H([NJ)-MJ"=(";Y9\HE4%(6H,Q L;XW^1V V,6:Z 8?
MY$ID.2ASJL6L#CK,\[NFC?CK994CHOZ#Z8#+O#1WTW5'>PT^S8XYD"-CYU?1
MLB*=?W>RA:93_/WUH_OA'M&/-!>I_E[^+.FRO+TN_YS=R2_9<EW%\#<G]2JF
M,5:FIH:G.$1Q&$*2! 0JA D6BBH>6*4UL.QO;DO%1F10RPRN2V"D!ENQ^\0
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M;5Y'"]-=U=FI\N0>SO*5(9+#;NOI<HE#A0C6QAY/H/X'A302&++0HU&4A+Y
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M69J=??$8V]*TAL+=B#RE\E!VXY.VIS453ZEU9!V>?.A2AXZ?LTQ\2Y?+VDF
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MSG.YXH_7XF^Z'[.ET.O7<BTJ/X.\BL;;6_"^9J=/"IJ(!1D+@5GDPSCB!*)
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MPM^GE)EKR<>W6?Y!?ONO+/_]XWV:I9I I3&$35VQ:UXN$AR'/I488K^B-)Q
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MQ9VL.[OJ"MC"Z+Q1MX9FH/UY=W^3;LNMU3_<C=N_V#/I&BUN3;(C_1]SY_1
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M:?SF!T?3CJT'06AD@M[*:**P5[ 1<X2$CIU@#.5><;:?:7TLNM0]<K3H?&&
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M:["!Y(%'(C.IJZ=!C24/E8]-)I]7(DM9;UP0W\]_/*U7'_1//<L+NRU#[1U
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MH#B$ !N[\ HM"%!:860QE0:*]L-X.U?_QW\6&QT&^BBT71K^C_H</(^CQCC
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M\H?V2OC7Z>S)_JRV!5>?GM8K9UPXET_UOY]6Z[I\1UL3?%*6=FR+7(+2U<C
M)5: 8\Z +$I3&%26W 2E:+U1GK&QWUMCM*S]FY73P66D66GYM*P+J_];F*UV
MZU#YF6X##D#/=+O1)&M5V0L:;Q3)]C2YRUH=[[*=4MD?&[426G>) $YD[-TJ
MS:"V7R+HCDW!5,V&6X:_+1;J3[OQWI6$;/T:-(&,:6. +IW#*I(<4*PX$*JL
M%*](67&O7/==G8R-*S=R[A= #7<4N0CI==,Q!5 ]<UK/&/G;E"FP&LBV/(-9
M&MOR&@8=-N;%5P>S-:\)OV]S7GTVH>WYR9Q0;DO%OTY7<K98/2V; B-;NZ8B
M1!48Y4#AL@18* H8-!#8?;0JM"0Y*NG-)FBP6&-CUXU6@+?6T'QK#<G%]^^;
M(_A5MMAIF,) #1_/&^S47D=I3.9J]D6[.3Z=35L7P:$,U6B$^[17PX5Z>;,U
M&D@OZS6^]8AT>UL_2Q?=M?$!AY2KDBN 984!UCD"E*D*(*9@@8V"1'K[@)_K
M8&STNN>N6\<:AAME9V&\;K3>"D[/K-83+@$Y[V[$9R C=8-+9A;+[ 2T1+4<
MKN'1E<GNW&O#):[K$/H@3UW7<W%&ZL;VG1"-"200 E6Y?*%0$2!R4X+2B$H1
MS40I<5OC_NN:+]=^QN:F^9!/\KB3_K[*U_IA.G=^R9G@]A<RL%#"'G:Z-(10
MH!5QI\2F ERX\A,ED4I"4>%"M=B]G:N^D=MTT>.Q;V.DW0::R!6N<I,#719V
M'>5%#D2E*V HQDI R,HBZ&@]!K ASWTB8?+;+L0H/]!93CJ+_5C)1#;WMME!
MK>9C98[MWI/?1R87<=ZJ3\OGK^N%_,_&:)Y HDJ)"@XXRJWQF@N[:\ZQ!G8%
M8+K"U))84(+X,WV,;1)N1,QJ&>_:+6=@(I$S4'(CE2YR8;'CW+DZ$$ U,J""
M=CT0&"E<F(VK_^?0Q3,6UT,W_^-N^P?Y;K,R9'R=B>T::W?ZS0*5O9INCF,N
MQ[QX#T&EM5*5_7PE1\SNQTH)F'*!\R0O<DG*'"-Q. 3>:W#* >A_53X+OW;9
MIOH!WF]ENI$<>EZD GDA/&'.9>U3I<HYT\.P27(NJWB2'J?CT<BLVMOKRM6W
MQ>;04'_4ZUVHU[?%&[YZ_+Q<_)PJK5X__[YR%:2V,6'W<CW]6?LK;$]H905+
M*D0.B*008&5IA:K<KH_$*,@YUU+D00FX>Q!R; OLGHXNL?1RHV4VU^MM]*?[
MC?NWM+HZ#_A:V4P\_^NK)ZMO-IW_LA<RRK<Z!Y[3]_)-^)'=2X]TSVQY-,A;
M!3.KX6$HJ_NUTS/[O!OE[-7OFU'>!<#N].WED+_/ 4F5LKP/$8?-;MXCR">)
MT/OLZ[8CM/OY267"W6W$+L0 8R&,4*5=3J K(9@K0*D1@ I&M5%<E +'G'OX
M=3^V=6/KO>#2HIZ4WLQV&L0=GWB.2=@A2WJD!SJ*N0IR]D<O$1]QP"4^WO'L
M_$4.@<* N714%-A*=.H#R[/?^%]M#</7>J[-=#TA)$>Z+!6 4E* (>/ I44'
MA5"HP(15[B0D@-8N]#,V_JJ7F=JQWRR6__I*-%)F;JA=X'YM$JWY7Q$I#\ZB
M;""4O"PTD'G.W'D3!<S0 D!"4,&YA$BCN-02T6"_2%()!ZL5=U/_-'O52AQX
MK'$)9K_U(,$GVC/Q1R$5DT>B"X=T&23.]C)T[H@N5<]DC>A\/(R"5\OUY*M^
M<,;O;]H%+O]XG$H^VZ8ES&ENE "%Q-BE Q9 <)6#4D&J.4*88*^R89V]C(U^
M]R4,=+[H1K.; 9)AU+?A%P2/]\3W4K]KVML&]J:\_==NNG>W/<AD]U)O,]7]
M'K[%UJK+#QZ$.D%6<5-2"$I:N@13UNH2E;6ZI"JTKI@Q)*S"\X5^QC;9V]5L
M*Z?/B5$0KB'+_DUH#;/L!P$5N>I?A"'IJG_:RPNL^A=5/;_J7WX\C@Q^U<OI
MS[IZ_/NYJR]0GX']9DG&G7F]?OZ;5@_3^<,7/:L=Q%:/TQ_.K6Y"I> 65 PD
MRA7 #"+ *"^!*5E!BSK72%#X0)P88Z.25LQL7\YK?H@I1\6/:?K'NF<BBH$Y
MF(AN0RD13T4*,2B-W0;4,<O=V%H<";YN/!N^/FJ]=IG>]W)EHZI QF .B!8"
M8.@RY'&.0%7FN,JQ*V$:=*Y^N:NQD5DK:5:+FFUDC2R7U(&P'VFEP:UG8HJ%
M+)B<KJ.1B( Z.AJ49*XK?$PD'F_$5TUZ-UVY>A"U^],[^[/5!)6,&XP)* RD
M )<P!W;'5 &("HV0S+D456C9I)->QD81VZI C:19(VI6RQI>.>D4U&YJ2 95
MSZP0A5)4]:2+*-Q4/NFTU<'K)UU4[%P!I<L/QUD';UL_H\^N3"-?ZM=\-97;
MW;VJ8 Y%50$E40&P+ A@1<Y!44%%)"_<#5:(@=#9V]@(8".L\P0]B(C.^'J]
MG(JG-7<WPK7;SE)-Y_;K_YOFL_7CG7/L^9= %ZSN@?"S(Y+!VS-I;)']7)=T
MM9+>9;6LO9RZ>*&2R*3H[FM0J\)+[6/#PN^E.*IYLUBM/QEW\[ZZGZNO>OES
M*O7JZV*F)H)3QA"K ,)&6I[!"-"2*<LSO$!(TY+RH(W(Y:[&1C).4N=M7LM:
M.YMLI,V<N&$<TH&P'X&DP:UG]HB%+)@XKJ.1B#4Z.AJ4,JXK?,P7'F_<>G3[
M83IO$A-,.(-E29@$!.(28$,58+E2@!-D+'T4KBQ0W+GLMH^QT<-.Q.P/)V16
M2QE]X+K#,O0T-0JAOO<>@>#<<$QZHG[R,]!=#R]TP'FBXN73R]-'DZ9[NI1H
M;X*A4=J:"D!AER69D@(PJ 4HA<N'1[D1TLM?([+_T9%#(V=\B%HH_A135U %
M@I)18_''+G13"J KY\>(5$Y@'E+<KD_\!RA\=Y) ZR!MUC__$RWR_-_5T(/D
MQ^P]0M\SZ\<E<>T]"=8UY/K-=G6Q]S&DM;H&C6?^JJO-Q"U"[N[MS:).^J_G
M\ODC7S\M-TF%6%G(O$ %((H(@ G#@#-9 8R$9,0H4XH@#^V.OL:VN#A1LSU9
M[[)&VL@[LBZ4_1@K$78]LU,\;,%$Y %((M+IZFE0@O%0^9A,?%ZY=8O:!(Y\
MF'(QG35A<NMW?+K\#SY[<G%V$UT(6 FN !3&THAE%&"-50Z@IK+2)4)EF-WJ
MW?/82.7=8ODG7ZIZ@K@3Q=A][#7 0W>W"6$<;L_;AJ*]VA/[ESN7P,*)GM6R
MW[DPXS[VPYZ )=\E7^OWA?;.GG!<WE'[-A">B_/O6CGGZM_GTW5;)@8+J.L-
M'.0( <PA!P+1$B!9<5XP(6GIE47L;.MC8YQ6P,Q)&%%CYQ2];FJY&9.>Z2,Y
M'/YI-V^"9:"<F_OPI$FN>5'KCLR:I^\,EE;SHKC[.34O/Y1B!V;);W=,S2 M
MD0O>+',E 39V[\6QL-0%1<$HX[3,@RRGRUV-C;B.-A)UMH_H&X .A&,V7[&X
M#;OW\H;LQIW7.31ZV7@==/2"^ZYS"G=ON\Z^$4<6AVGN/YEMDI+/RX69KEV_
M[ZS\;7R9RVRRF*\6LZFJ0ZV=Q\Y$0L0YDPC($CJO)E<B'%4ET#Q'REI!!!.O
M8HOI1!H;^1S5$EB8O?1#C5*;I$7N6\DVFM6^4'NZ97_4V@6258(1]B.U8<>M
M9_(;:LB"R3(=RHE(-8% @Y)O.@"/23IAR^$;T\^/?/G=?LM/ZSKX=[IJ?"JM
M('RNOO[0KI[U^GFS9T5:\IP80$VI ,:Y HS9C6M)%9.DX-9.]"X>$=+QV(CY
M4/9L7_C&$VHC?L3F+FA KF^#^X*Y9QX=#<+^.^N^D!YHTYT0\:"M>0QL';OV
MH.8&V]#'*+F_UX]Z/]8_V'E/U(ENZW//">00FI*4@&):M>4.L*@ E B712Y@
MP7B85_!A!V,C]T:^35[E]@#__6KUU.&^X(>DGSU\"SX]LW(,-!'^ON?U3^;E
M>]3\P+Z]YY4[]>B]\%SL):E8[X*=/]HA;B_]"U@Q7%0*:)>('O.*  J5 8HI
MBG)=L%P%.O.>[VALD]S)F>T$=?X!WV.=*BZ"ZWO_>3MDO5]W1J$5<;/9#46R
MB\P+W0Q\;]FM[.DUY97GXZAA$V"DE>4<E^NMMC/OETO[ =198%X_[Q[YS)_K
MQ##.?>#M?SU-U\][*10^K1_U\MLCGW_Z42=.^,TVL5Z]GS=ADD?N9/4O?[4[
MV.T%ZR3/E5"X8J!PIX)8YP:P$A> 58QHIBO+5$'A1Z/1;&SD5TO8.L,^K50=
M65D[Q0;ZQ(X&8$^F'8V\(Z+V6F%0:YSMHY+MP>)2X.\_UT*3U=C<90TZ>^O#
M*JOQR=86H*Q%Z"YK,,KL-]>@=)>=^!#7CV0.JCWOF73+R^C&/]%Z-AZ]!EU
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M&,9,E78KZ6<<7.EG;$30Q$,TLNX5H0Q,XGP-W.O;P$20]<P(PZ#EOXE+A-I
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M"BKW?_*E:D)7=M*M:H/EVR.??ZIE=&56C)ZNM7K?RCM1&!9*TA)@7A+[A^*
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M_[Y#F?T4^%V/Q:W:_TM/'QY=O4UW7O6@#].Q?7I:K]9\KEH_$CFAAMIQ+BN
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MD%PK@(6U,V@!*2!85DS00@ABPGS6DLDV-@/E6+5LIUNV>%K7UW\[];):O^Q
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M&>"&0+LO49B(H%!0GT['1DN-S* 6.CN93G[9G^)'P(^44N/:,RFE@#3<#SL
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M.^LFO#Y@DPEUBKH<0DNPL[<@9X.E&W4-0VAD6FH9MXAJ\T:1W#QQ/;S(9M/
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M, R0X^[:W#)B#ILZCD Y[OFX/JVW1L^J6'VJ#JK;@\UIG*N,9130%$J ,(>
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MR)\]Z\JB^K:U/#K2E*\NL7U^\LOC.RH4H@:&Z)L&B&_;<J,-&*6P7:UU%_
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M:[*,SQ;+;Q.''"/7'#QQ!A22=>RR,1"#+SKR8D-HE51SO>AN@.@^QGDX([O
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M-&X(8""$-11"!Y!Z9 >E1"<SZ6.&#FLSJ @Q9M+,PA1EDU"BM Y,'@B=P4(
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M;NG*G9I&ZI*U-#(!;01ICX$4J7&Y%@G0 ?%T6[/63X)[DCCR:-Z!H#:DG#J
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MD=Z/=5#NB0#X#)7CWM&G!F(K<76@"=_CYTN+XVUYLYB??<3E^287LB!B\3H
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M7W(^OYV_KV.%JPVZB5#?.QPIHX]8<Z,4KRU%G828$B/[LTC,27A,K?L -=U
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MA?0BM&;'?A3VX3.VQ];3KY_-Y=:!"??"GG[Z]K?P;XOEZUE8;=]R"K$QA^3
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M_ASFP:"R.R2/EEL7&?.O+U;KQ3DN-Z7!=03RI^GGU566;U:A8&; T7*Z2K!
ME"6#\4$R8TKBHO4+\C/D= NXXX&P&$8F(T=B;F(#9,.\"^M:>W"U"Q&%U-4^
M";8V*X\1?&U;KCFW!CE&(79)PWYZA7%MMU. I2&'.[@??\8O.%M\KLE3Z=-\
M,5N<?7L_/?MTO1T>A,E:U[3EA.0"!0'!J @"/:$^F,QL:T?A!9+&S7TZI3IJ
M*9LN[KQGF'?CX0?/7;1T@.2FR)QL6@@H/23C68S(G#&M2WEWH:N78-Y8CL!A
M NI PSVSI]^6-=U'6.X"\PYBP5##\!X\9@5.,Y.\1UMTZVCR2S1U:W(=B(+=
M8;:_2/J&V*TLLU?GB^5Z^I\;,4XR#]YJ3%#'-(!R2F\;?L;B';=9(J83^IE/
M4-FM,3<X#%N(K6]@_H'K"6JFR 2Q8)@CGR:7ZJ +,B6X2JDH^CJUGE7P/$7=
MVG:# VY?<?0-KO=8C=_:^^S6X7FW2;#F$V08<ZE=\(*L@^V# 5_SNJ/CQI<2
M7&2MLZ8.)'7<=/HQX=A,@!W@]%$3X^%CGP[DF=>*7&Y9K;TV ERMCTLZIIA8
M5JIY'OYNE/51[#/\<]@ <NH0?:3H']E3)I\]6 Z2"V*;)0;ZVGR/K&#4J1BM
M?>O:Q5WHZJ.<Z/3(.UI&WVM52(-F^GLO<9*:CY.TTM\3L*((K:*#H%2-#%J$
MF&N]$1KKO0B8;.LF22<M\;AM.;Q]4&HST=+;S(L#%^K(+V\"N.0M)(92II"C
M<:V?_9^GZ+LJX=@#._>574.Y='"]/N?#W]KH+U\_XWR%6[.6)%GCJ*L49O\;
MPW*"1?+,F !,(M:GO=J:A;B9?6922:-+.:$;O"O9WU66U!%X/;6$OSM0_T'7
MU\<_<?8%_[:8KS_1$;:\F$Q>&9H:/;"R#E+,&IA"ZVP.B":/BN?[%']7'L[)
MH'R47+\[%-=S^O'/Q42@,]%F!=:P38)O[7"G,T@O@[#%HV2M>VP<1.AWY1N=
M#+.'2/'[A"IAKQ9-Z#I-/4%)FM@I=0''G0&+2CKCD6Z7$[Y5/T?J3G#5_T?"
M=6])?I> _75QL9QP9@T9\PHV%K[R7-8G50O%T@4BN(U9M)ZJ<1BE.\'5_)\(
MU[WEV %:G^J)R5,47N=$9CG=#<IDXJ$E'D8GLA8ZQIQ[ZEYOOW^\M9!$#X!Z
MOL6VY,*R+,!S5=^GI )GG 6#K!A%!T?;YMU"OK_N]7N)?+_N]7OPOP<PW6GD
M+(S#PC&"<X[8$AVQQ00-.0;-72FBE.:C#[Z;WO7["/;9WO7[<+FK/N8:8^0J
M,V!!DF.3I $?A /DEF&0Y('G>R]UC?J8GZA;_5Z">;*/^3Y<ZD #; <;3>=G
M_TS6V ;I@L LM69 -VI%>M3@72*DEV"BPI0]:S_K^!X1O60<M[LVCN-S;T"Y
M.C$ZF<B+A.R2H1-C)?BD!*!)(3)=%/>M\T8>(6/L:85'"?8YF!S Y3XNC$K\
MI3K,DFC5(=*]R04H:V+M7XH@@PO(I63H_>Z7QLT'=R3T0\3T\/HXD&<=:(:'
MO4IMBCSQVB4JU(D@Q6;2D<I"*)J%G&S0L76LY;!1&(,]K QQA1S'YY$U0W7F
M%Q?S]7LRLG\-T^6_A-D%_C[_?+&>R(0Y<Q/(GQ?DRL=$^M+PVNA6)<NE95;*
M'53$TROTD=YPH-@6S7DX=HDN+L]K!M-OR\6?ZT^/["5:TJ**<3",U88SAM->
M+$)RQ3.GR#J_7P+^>*'N"^OTD41P/"J:\K.CZ^1^9VIMN=*D*IDFWUNA\!"4
MW,Q5P%*8D$P--5ZIQP$$Q^&F(:\[0,Q-&0ES"8VR HRTJO:J8F1#906AGH'(
M#:;0^E%ROP*>P5_%V^#B,(YV (7KE&7!K?&F3DMPI<Y-J-:XRQ$PFBADC)J[
MUHE >Z6.#_[>W%9![,7/7E/ WRSF9_6V?!MGT[-MEY.KI.D/G\B?JW_WTV))
M]RAY=BT2PH]<L$EZ>,M--TH6_QGC^I''O>B,%(@6/*M@5=9##)X@9M%'*Y@*
MJO61?9R2XQN+Q/7O<_JLBWJC;AT_%)F.2?%@LV>TN6+ 2W+Q4VVEF%GQ6K<V
M7QXA8UQ/J('<'_8).8[5'5Q9KVG)Z?K7D*:SZ?K;)H+(M;'!)0_H;0TET0Z<
MY!F8-9%SXV-,K3O//*1B?*P<)=C[_:V.XW)W.+D,.J:0D0=G@6<N:YM6!U$S
M#98Q+^AN1F&:MTM[A(YQL7*L;)^%R@&,[@$LB_-S7*9IF+T+GZ\;I#MT(65E
MP+ Z5J[V<?#(+$160O2".=Y\3N2CA/0$ET/D>Q\P1S.[ \2\QR^+V1>R >^R
MY^I5VSO/B!6 R",H%VJ.*$:0TL2@@F5<M.[9\BQ!XP;OFB.H'?-'#NY>NQ1W
M-C+%J[YM@G&N @O 3*JQ2)8@"J4A%8["$=-8>LFIVF&9<4-TS=#1FJ$C8Z.J
MR>EZC?D])IQ^J2;=ZD.@/ZY8]6ZY.%N&\\N=59..2<6 P&]!^9(@9++VM%0%
M%;D)#,4.4-EOU7%NIN:"7IR$ZQW<6C6Z09]V7MV%C_1OMLV7C8K!I )<5.-/
M$M/(Z+.@,2L>9)"TD<:7U6-TC'M'M7:@CN9TAVBYU,W:)Q="$%",2*"8HOM5
MV0*ED FGT=2H]\!XZ<&-.E["+T#F '9W )J[!VGK75KCK%$<F+,(RKA0)[%8
M,%)D)TF!*M\:, ^I&-?(::U>CN1R=SBYU0=99[I/@W)@M:FY&;;.5/82=! E
MU3<T9EO[3D_1TE-,;W\9/PN9 QG^G=G$TALFHP1,M=-3%!&<"!I$+)E^7'BV
MNZ1*?0\V<5LI'V$0[\'RD<'T2OS5<//'8HVK?(%5ZI=[2)))8TJ ['SMSB\Y
M>&4T2*MXSM%F<?]E[5'8//7Y/1FZ#0#2A(T=7$C_$I;3BNZ:$K91MK7\I/:/
MAI1K(H#.!IR6C@PZSU&:VO6H=7;,?1K&39)I;;0<Q>'.$')Y:%S,'#E9X]*1
MT:]JLTFG/8)A09#5KCW3K7WGAU2,>^,<)]5G('( BSL R=U#\QXSGG^^:8F[
M89 OV02I'=2A5^0DR@ NY !:"6F8QAKI'-3"?8RJ<=.PAO6/CI9"][BZ.BM<
M&#1TQ[J81+6^+%VY0M:..MPKQH5J/BM@%[IZ,HF/Q\)>4#M ,".";;5<3]Z'
M^=FE(B_")R$,<%GJ0YH1X*TEH@TI7I5%Y&RG[@CTJ;>01-_=H.C.@N.V<FFE
M@@[G80^"O[3=B]'!)Q. &T<;C]K4T4 )2L1BBZ5#H79J=+F+Z,=TFX\0UGUQ
M'\"Y[JZ5-]=9T"Z*8&6*(*RM[V?D" ;F(A2I5<V)KL/K!KU)WNQ5F3A8PYUA
M#9/#^-T!;"KA;\N]](OP=7I^<9,=_3I\IK]9?YL4%(X%9%!JK/)RT*&DLZ7I
M3"4C0\JMN^;N0U]/ULF!@+C_DC24=#I 7N77U4O9JWG>Y '4KU\OSB-MNPYA
MNIBO)SD4DV1FH'T=KEFBK!8=@T2>J>5,9BZ&T%\O4]93]*\-V@:02 <X>X^?
MP[=-0Z.W91/<?!>^;;2_)EYYTO_ 4Z'S4K*K84T$*7,J2;"B5>LA@$_1TM.;
M9ALL->%Z!^AYE3:EYU?DO[Y85H[2Z?AC,4_;;R:L9)4")]-0,?()76VEQ*.%
ME+A3FD5;5.LPT YD]11R;H.IUK+H %Z_A>E\56N/<?5V_LO7VEKE8KKZ5'GV
MME0>3JQCDIO-A<Z)88GN]Z!J@".[X!BGN]ZT#DR_2%1/(<8VT&HKAPZ ]52A
MXZ34U8PMX&LJDK*U3YM4&G3D*D;RA[ YGIZBI:<P41L8->%ZKV7$VP2"S9W^
M>C&O1V3#MQ O$W;#/+^A+[;%M@VJB(];KTD1<<,M-ZHAOD4177S71"4BYI$2
M4UO((L?@ )W99-_[V@(E ,?,,%FK8FK=J&XO H]/;%VM[BRQC>M8*P1J%2&)
M@C5AP4/(I@"B+%;'C,ZW[@;\."4C%WP-AI6'&:]'RV'D'*(WX<_5Q?0F_]='
MEY+7JDY5)2<W\DU[5%EO 1:8C"K<']7V:.K0O8\=.]'Y>"DMVK!L;&E?*^U;
M^=D^2B.UX)"Q'H":Z1!*YE",P1"<\3F8743^R&>/5UYSE) 6#3DV=L+I+*Q6
MK]+&!-BRY*K B'$RX'/((&W<A$UI$\X*L"8$SHOP4NY2FO?D B/*_FB9+5HS
M<&04O%LN\D6ZMN"^W=L)-T$H[>L,1!;H"F3UQ1 -H!3.\AB%4KLT;7U^E7'B
MQLWQT)"58X-B1GQ83TNY*?Y)(5G%-(0Z#XA\?0&1M@!1$G4B6\&*VP4']S]X
MW">#QM?_<6SK2>97I<K92<4,>?HL,E#%!-)CZ" KV@_G2BFQ2[;X(Q\]WA5P
MI)">$O<!'!M;X,OIE[#&=V%YJ[8XU#I?7Q,[<DWQR%R#$Y*!Y@D5+U'[N(N1
M_]AG=R+R0P2U:,BU;JT^S$F*(E3M,%Y L4SWD],1#)<^29YL%CM5%!UE]0UR
MR[>4?QO^C0R"MY^GB^FM.-U&#19F51&:$4<"^4&9[K\H'+'%>*-%,N)!K?RC
M\G_LL\=]S&U\RQ_-O,Z$?WD@C!.*<5D@>:);J21JDR)9T[]T88IY?K]A[D[B
M'_NZ/UY:SXC^ -:-W7)]L0ZS^]NX&C81<N**S@+7RH.2-?<O>@M9&)62,-;O
M--7IF27Z@<$ADENT9^/(:='7@\Y^PUKH^OE3'3^R/2$^8DS9@PU:T0G1'J)-
M'GS2GNMBZ+[<:6['"TG23Q(P;JI&PQNC'9O'QLIV0MKM+5P>(C2ZUI%$,J!B
M90LB1$V>E"E>*1\<J=,6"?5/$C!>>GTCP2Y:<WGLZO-9.,<<7M?4I*O.=2'[
MP#-/X!E:4"Z2DUWC[4E(VABSLMQO./EXX?G#CQY1_&V$M6C'N;%-RYKL\3\N
MEM-5GFY<I.N694Z([!R""(KNV3JTV3&?@9N(A;LDP_W&)X\;ET]\_CBNY3 0
M:,+#,>^*]>?EY%__I9I!F1QL#<75F'=.&5PM%O)H58UW<ZV?RU)?8?KKV>++
MC_7CMK="_>K6C;!=9AS/LKWD#^':V$)^^S\GJ&QP01M@H;9$\=J1EK*<3%^I
M3(Y)NO!<4>Y.0G[[/\<Q!@<2\IY<&UO(__IJ$JPF3XCN'B:Q]KT)M>D!J2";
M=.!89##YN1YGNYWD5^-DT YUDO?CVMA"_NW5)(LLL6A!!FL1H)*-$*42$+A-
M*AC&@WS.B-])R+_M)N3F^:T#"7E/KHULF_VQ2<1\=8Y+VOO\XW(:KY\OK+!2
M*"23TNHZJ#IQJ)U,("?+=8I!E+S+,]_3*XQ3YSJ,?=:(CST4Q&\\U4"&H]8%
M(:C:@Z9PLC@RV98L$B=\%%5I-?#>]^N$,%BE1./(SF%L[$'V5YE*5JH2.(>
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MOI9'Y_PS0M5.#QD=SD1K0!HAR/55'AP3LL[0RZB*$0E-8UQ->8..CX #H7:
M."8&VRO-V#]FY^<DL?L/>A5<,:4T)\U,BM&1F(? ;02&PL:ZL$_>C2SN1=C
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M]* 9BS0[XK0VZY@S2\ M$Z"R=73/!@8<HV/HF//-]Y <1_&TB:H1$'TZ^?6
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MLO5;QV&4=OIRL ^"[NFJ&UMD711:OK^(J]UYMB,LI9?*T0$"5[GNG<T0+6>
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MVX?A'>#FX5>E3":W9*2HNH;6RE)($1(R*,)KY1.7%EL/2W].3WG'8*<-TSM
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M>#,Q,3,N:'1M4$L! A0#%     @ >TED53]V26#^!P  1R<  !L
M     ( !+P@  &$R,W$Q7S$P<7@P.3,P,C)X97@S,3(S+FAT;5!+ 0(4 Q0
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ML0  $               @ &(_ $ 8V%H+3(P,C(P.3,P+GAS9%!+ 0(4 Q0
M   ( 'M)9%5 6L1XT!4  "_)   4              "  ;4, @!C86@M,C R
M,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( 'M)9%6)IXGS:6<  #:?!  4
M          "  ;<B @!C86@M,C R,C Y,S!?9&5F+GAM;%!+ 0(4 Q0    (
M 'M)9%4.;M[%6$X  ,M<   3              "  5** @!C86@M,C R,C Y
M,S!?9S$N:G!G4$L! A0#%     @ >TED51L4(;991   1%,  !,
M     ( !V]@" &-A:"TR,#(R,#DS,%]G,BYJ<&=02P$"% ,4    " ![2615
M7RTT;E(V  ")10  $P              @ %E'0, 8V%H+3(P,C(P.3,P7V<S
M+FIP9U!+ 0(4 Q0    ( 'M)9%6\!B)O?UH  ,9I   3              "
M >A3 P!C86@M,C R,C Y,S!?9S0N:G!G4$L! A0#%     @ >TED558YAZP!
MV   D-@( !0              ( !F*X# &-A:"TR,#(R,#DS,%]L86(N>&UL
M4$L! A0#%     @ >TED54<<W8N6D0  $9L& !0              ( !RX8$
K &-A:"TR,#(R,#DS,%]P<F4N>&UL4$L%!@     .  X K ,  ),8!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
